CodeList |
CodeListItem |
NCI attributes |
OID | Name (CDISC Submission Value) | DataType Extensible | NCI Code | CDISC Synonym | CDISC Definition | Preferred Term |
---|---|---|---|---|---|---|
CDISC Submission Value [ODM:CodedValue] | ||||||
CL.C66767.ACN | Action Taken with Study Treatment (ACN) | text Extensible: No | C66767 | Action Taken with Study Treatment | Action Taken with Study Treatment | CDISC SDTM Action Taken with Study Treatment Terminology |
DOSE INCREASED | C49503 | An indication that a medication schedule was modified by addition; either by changing the frequency, strength or amount. (NCI) | Dose Increased | |||
DOSE NOT CHANGED | C49504 | An indication that a medication schedule was maintained. (NCI) | Dose Not Changed | |||
DOSE REDUCED | C49505 | An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount. (NCI) | Dose Reduced | |||
DRUG INTERRUPTED | C49501 | An indication that a medication schedule was modified by temporarily terminating a prescribed regimen of medication. (NCI) | Drug Interrupted | |||
DRUG WITHDRAWN | C49502 | An indication that a medication schedule was modified through termination of a prescribed regimen of medication. (NCI) | Drug Withdrawn | |||
NOT APPLICABLE | C48660 | NA;Not Applicable | Determination of a value is not relevant in the current context. (NCI) | Not Applicable | ||
UNKNOWN | C17998 | U;Unknown | Not known, not observed, not recorded, or refused. (NCI) | Unknown | ||
Back to top | ||||||
CL.C66768.OUT | Outcome of Event (OUT) | text Extensible: No | C66768 | Outcome of Event | A condition or event that is attributed to the adverse event and is the result or conclusion of the adverse event. (NCI) | CDISC SDTM Adverse Event Outcome Terminology |
FATAL | C48275 | Grade 5;5;FATAL | The termination of life as a result of an adverse event. (NCI) | Death Related to Adverse Event | ||
NOT RECOVERED/NOT RESOLVED | C49494 | One of the possible results of an adverse event outcome that indicates that the event has not improved or recuperated. (NCI) | Not Recovered or Not Resolved | |||
RECOVERED/RESOLVED | C49498 | One of the possible results of an adverse event outcome that indicates that the event has improved or recuperated. (NCI) | Recovered or Resolved | |||
RECOVERED/RESOLVED WITH SEQUELAE | C49495 | One of the possible results of an adverse event outcome where the subject recuperated but retained pathological conditions resulting from the prior disease or injury. (NCI) | Recovered or Resolved with Sequelae | |||
RECOVERING/RESOLVING | C49496 | One of the possible results of an adverse event outcome that indicates that the event is improving. (NCI) | Recovering or Resolving | |||
UNKNOWN | C17998 | U;Unknown | Not known, not observed, not recorded, or refused. (NCI) | Unknown | ||
Back to top | ||||||
CL.C66780.AGESPAN | Age Span (AGESPAN) | text Extensible: Yes | C66780 | Age Span | Subgroups of populations based on age. (NCI) | CDISC SDTM Age Group Terminology |
ADOLESCENT (12-17 YEARS) | C27954 | A juvenile between the onset of puberty and maturity; in the state of development between puberty and maturity. (NCI) | Adolescent | |||
ADULT (18-65) | C49685 | A person from 18 years to 65 years of age. (NCI) | Adult 18-65 Years Old | |||
CHILDREN (2-11 YEARS) | C49683 | A person from 2 years to 11 years of age. (NCI) | Children 2-11 Years Old | |||
ELDERLY (> 65) | C16268 | An age group comprised by people 65 years of age and older. (NCI) | Elderly | |||
IN UTERO | C49641 | The period of time during which the embryo or fetus is present in the uterus of the female. Also describes the location of the embryo or fetus as being in the uterus in contrast to outside the uterus (ex utero). (NCI) | In Utero | |||
INFANT AND TODDLER (28 DAYS - 23 MONTHS) | C49643 | A person from 28 days to 23 months of age. (NCI) | Infant And Toddler | |||
NEWBORN (0-27 DAYS) | C16731 | An infant during the first month after birth. (NCI) | Newborn | |||
PRETERM NEWBORN INFANTS | C49642 | An infant born prior to completion of the normal gestation period. (NCI) | Preterm Newborn Infant | |||
Back to top | ||||||
CL.C66781.AGEU | Age Unit (AGEU) | text Extensible: No | C66781 | Age Unit | Those units of time that are routinely used to express the age of a subject. | CDISC SDTM Age Unit Terminology |
DAYS | C25301 | The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours. This also refers to a specific day. (NCI) | Day | |||
HOURS | C25529 | Hour;hr | A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day. (NCI) | Hour | ||
MONTHS | C29846 | One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks. (NCI) | Month | |||
WEEKS | C29844 | Any period of seven consecutive days. (NCI) | Week | |||
YEARS | C29848 | The period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period. (NCI) | Year | |||
Back to top | ||||||
CL.C66797.IECAT | Category for Inclusion/Exclusion (IECAT) | text Extensible: No | C66797 | Category for Inclusion/Exclusion | A collection of criteria on which subjects are evaluated and that must be met by all study subjects. (NCI) | CDISC SDTM Category for Inclusion And Or Exclusion Terminology |
EXCLUSION | C25370 | List of characteristics in a protocol, any one of which may exclude a potential subject from participation in a study. (CDISC glossary) | Exclusion Criteria | |||
INCLUSION | C25532 | The criteria in a protocol that prospective subjects must meet to be eligible for participation in a study. NOTE: Exclusion and inclusion criteria define the study population. See also exclusion criteria. (CDISC glossary) | Inclusion Criteria | |||
Back to top | ||||||
CL.C66783.SOC | CDISC System Organ Class (SOC) | text Extensible: No | C66783 | CDISC System Organ Class | Terms at the highest level of the CDISC system organ class terminology. | CDISC SDTM System Organ Class Terminology |
BLOOD AND LYMPHATIC SYSTEM DISORDERS | C35814 | Any deviation from the normal structure or function of the blood or lymphatic system that is manifested by a characteristic set of symptoms and signs. (NCI) | Hematopoietic and Lymphoid System Disorder | |||
CARDIAC DISORDERS | C3079 | Any deviation from the normal structure or function of the cardiac system that is manifested by a characteristic set of symptoms and signs. (NCI) | Heart Disorder | |||
CONGENITAL, FAMILIAL AND GENETIC DISORDERS | C49399 | A class of disorders that encompasses conditions resulting from a congenital, familial hereditary trait or genetic abnormality as is manifested by a characteristic set of symptoms and signs. (NCI) | Congenital, Familial and Genetic Disorder Class | |||
EAR AND LABYRINTH DISORDERS | C49400 | Any deviation from the normal structure or function of the ear or labyrinth that is manifested by a characteristic set of symptoms and signs. (NCI) | Ear and Labyrinth Disorder Class | |||
ENDOCRINE DISORDERS | C3009 | Any deviation from the normal structure or function of the endocrine system that is manifested by a characteristic set of symptoms and signs. (NCI) | Endocrine Disorder | |||
EYE DISORDERS | C26767 | Any deviation from the normal structure or function of the eye that is manifested by a characteristic set of symptoms and signs. (NCI) | Eye Disorder | |||
GASTROINTESTINAL DISORDERS | C2990 | Diseases of the digestive tract (oral cavity to anus) and associated organs (salivary glands, liver, pancreas). (NCI) | Gastrointestinal Disorder | |||
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | C49401 | A class of disorders that encompasses conditions of a general kind that result from a disease, the treatment of disease or administration of treatment at a particular site and are manifested by a characteristic set of symptoms and signs. (NCI) | General Disorders and Administration Site Conditions Class | |||
HEPATOBILIARY DISORDERS | C3959 | Any deviation from the normal structure or function of the liver or biliary tract that is manifested by a characteristic set of symptoms and signs. (NCI) | Hepatobiliary Disorder | |||
IMMUNE SYSTEM DISORDERS | C3507 | A disorder resulting from an abnormality in the immune system. -- 2003 (NCI) | Immune System Disorder | |||
INFECTIONS AND INFESTATIONS | C26726 | A disorder resulting from the presence and activity of a microbial, viral, or parasitic agent. It can be transmitted by direct or indirect contact. -- 2003 (NCI) | Infectious Disorder | |||
INJURY, POISONING AND PROCEDURAL COMPLICATIONS | C49402 | A class of disorders that encompasses conditions resulting from an injury, poisoning or procedure. (NCI) | Injury, Poisoning and Procedural Complication Class | |||
INVESTIGATIONS | C41198 | The act or process of a systematic and thorough examination; research, study; the process of inquiring into or following up, intended to develop facts. (NCI) | Investigation | |||
METABOLISM AND NUTRITION DISORDERS | C49403 | A class of disorders that encompasses conditions occurring as a result of metabolic dysfunction or deviation from the normal nutritional requirements. (NCI) | Metabolism and Nutrition Disorder Class | |||
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | C27574 | Any deviation from the normal structure or function of the musculoskeletal or connective tissue that is manifested by a characteristic set of symptoms and signs. (NCI) | Connective and Soft Tissue Disorder | |||
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) | C3262 | An abnormal tissue growth resulted from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant ones exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias. -- 2004 (NCI) | Neoplasm | |||
NERVOUS SYSTEM DISORDERS | C26835 | Any deviation from the normal structure or function of the nervous system that is manifested by a characteristic set of symptoms and signs. (NCI) | Nervous System Disorder | |||
PREGNANCY, PUERPERIUM AND PERINATAL CONDITIONS | C49404 | A class of conditions associated with pregnancy, puerperium and perinatal status. (NCI) | Pregnancy, Puerperium and Perinatal Condition Class | |||
PSYCHIATRIC DISORDERS | C2893 | Any deviation from the normal structure or function of the brain and a psychiatric condition, that results in an impairment of an individual's normal cognitive, emotional, or behavioral functioning, and is caused by physiological or psychosocial factors. (NCI) | Psychiatric Disorder | |||
RENAL AND URINARY DISORDERS | C3430 | Disorders of any part of the urologic system. (NCI) | Urinary System Disorder | |||
REPRODUCTIVE SYSTEM AND BREAST DISORDERS | C49405 | Any deviation from the normal structure or function of the reproductive system or breast that is manifested by a characteristic set of symptoms and signs. (NCI) | Reproductive System and Breast Disorder Class | |||
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | C27669 | Any deviation from the normal structure or function of the respiratory system including the thorax and mediastinum that is manifested by a characteristic set of symptoms and signs. (NCI) | Respiratory and Thoracic Disorder | |||
SKIN AND SUBCUTANEOUS TISSUE DISORDERS | C3371 | Any deviation from the normal structure or function of the skin or subcutaneous tissue that is manifested by a characteristic set of symptoms and signs.(NCI) | Skin Disorder | |||
SOCIAL CIRCUMSTANCES | C20188 | A set of concepts that results from or is influenced by criteria or activities associated with the social environment of a person. (NCI) | Social Circumstances | |||
SURGICAL AND MEDICAL PROCEDURES | C25218 | A particular course of action intended to achieve a result. (NCI) | Intervention or Procedure | |||
VASCULAR DISORDERS | C35117 | Any deviation from the normal structure or function of the vascular system that is manifested by a characteristic set of symptoms and signs. (NCI) | Vascular Disorder | |||
Back to top | ||||||
CL.C66784.TOXGR | Common Terminology Criteria for Adverse Events (TOXGR) | text Extensible: No | C66784 | Common Terminology Criteria for Adverse Events | A standard terminology developed to report adverse events occurring in cancer clinical trials. Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration. The CTCAE contain a grading scale for each adverse event term representing the severity of the event. (NCI) | CDISC SDTM Common Terminology Criteria for Adverse Event Grade Terminology |
1 | C41338 | Grade 1;1 | A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. | Mild Adverse Event | ||
2 | C41339 | Grade 2;2 | A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. | Moderate Adverse Event | ||
3 | C41340 | Grade 3;3 | A type of adverse event that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. | Severe Adverse Event | ||
4 | C41337 | Grade 4;4;LIFE THREATENING | An adverse event, and/or its immediate sequelae, which is associated with an imminent risk of death or which is associated with physical or mental disabilities that affect or limit the ability of a person to perform activities of daily living (eating, ambulation, toileting, etc.) See NCI Common Terminology Criteria for Adverse Events. | Life Threatening or Disabling Adverse Event | ||
5 | C48275 | Grade 5;5;FATAL | The termination of life as a result of an adverse event. (NCI) | Death Related to Adverse Event | ||
Back to top | ||||||
CL.C87162.TOXGR | Common Terminology Criteria for Adverse Events V4.0 (TOXGR) | text Extensible: No | C87162 | Common Terminology Criteria for Adverse Events V4.0 | The version 4.0 standard terminology developed to report adverse events occurring in cancer clinical trials. Common terminology criteria for adverse events (CTCAE) are used to study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration. The CTCAE contain a grading scale for each adverse event term representing the severity of the event. (NCI) | CDISC SDTM Common Terminology Criteria for Adverse Event Grade Terminology Version 4.0 |
0 | C75533 | ABSENT;Grade 0;0 | Grade 0 is universally defined as absence of Adverse Events or within normal limits or values. | Absent Adverse Event | ||
1 | C84263 | MILD;Grade 1;1 | An adverse event that is asymptomatic; or involves mild or minor symptoms; or is of marginal clinical relevance; or consists of clinical or diagnostic observations alone; or for which intervention is not indicated; or for which only non-prescription intervention is indicated. | Mild Adverse Event | ||
2 | C84264 | MODERATE;Grade 2;2 | An adverse event for which only minimal, local, or noninvasive intervention (e.g. packing, cautery) is indicated; or that limits instrumental activities of daily living (ADLs, e.g., shopping, laundry, transportation, or ability to conduct finances). | Moderate Adverse Event | ||
3 | C84265 | SEVERE;Grade 3;3 | An adverse event that is medically significant but not life-threatening; or for which inpatient care or prolongation of hospitalization are indicated; or that is an important medical event that does not result in hospitalization, but may jeopardize the patient or may require intervention either to prevent hospitalization, to prevent the AE from becoming life-threatening or causing death; or that is disabling; or that results in persistent or significant disability, incapacity, or limitation of self care activities of daily living (ADLs, e.g., getting in and out of bed, dressing, eating, getting around inside, bathing, or using the toilet). | Severe Adverse Event | ||
4 | C84266 | LIFE THREATENING;Grade 4;4 | An adverse event that has life-threatening consequences; for which urgent intervention is indicated; that puts the patient at risk of death at the time of the event if immediate intervention is not undertaken; or that causes blindness or deafness. | Life Threatening Adverse Event | ||
5 | C48275 | FATAL;Grade 5;5 | The termination of life as a result of an adverse event. (NCI) | Death Related to Adverse Event | ||
Back to top | ||||||
CL.C66785.TCNTRL | Control Type (TCNTRL) | text Extensible: Yes | C66785 | Control Type | Comparator against which the study treatment is evaluated (e.g., concurrent (placebo, no treatment, dose-response, active), external (historical, published literature). | CDISC SDTM Control Type Terminology |
ACTIVE | C49649 | A type of control, which has a demonstrated effect, administered as a comparator, to subjects in a clinical trial. [From ICH E10]. | Active Control | |||
NONE | C41132 | No person or thing, nobody, not any. (NCI) | None | |||
PLACEBO | C49648 | Use of an inactive compound identical in appearance to drug or treatment being tested in experimental research, which may or may not be known to the physician and/or subject, administered to distinguish between drug action and suggestive effect of the drug or treatment under study. The effects of the active drug or treatment are compared to the effects of the placebo. (NCI) | Placebo Control | |||
Back to top | ||||||
CL.C66786.COUNTRY | Country (COUNTRY) | text Extensible: No | C66786 | Country | A collective generic term that refers here to a wide variety of dependencies, areas of special sovereignty, uninhabited islands, and other entities in addition to the traditional countries or independent states. (NCI) | CDISC SDTM Country Terminology |
ABW | C17884 | ARUBA | Island in the Caribbean Sea, north of Venezuela. (NCI) | Aruba | ||
AFG | C16267 | AFGHANISTAN | A country in Southern Asia, north and west of Pakistan, east of Iran. (NCI) | Afghanistan | ||
AGO | C16292 | ANGOLA | A country in Southern Africa, bordering the South Atlantic Ocean, between Namibia and Democratic Republic of the Congo. (NCI) | Angola | ||
AIA | C20133 | ANGUILLA | An island in the Caribbean Sea, east of Puerto Rico. (NCI) | Anguilla | ||
ALA | C44481 | ALAND ISLANDS | An archipelago in the Baltic Sea at the entrance to the Gulf of Bothnia between Sweden and Finland. (NCI) | Aland Islands | ||
ALB | C16271 | ALBANIA | A country in Southeastern Europe, bordering the Adriatic Sea and Ionian Sea, between Greece and Serbia and Montenegro. (NCI) | Albania | ||
AND | C16289 | ANDORRA | A country in Southwestern Europe, between France and Spain. (NCI) | Andorra | ||
ANT | C16904 | NETHERLANDS ANTILLES | A country in the Caribbean, comprising two island groups in the Caribbean Sea - one includes Curacao and Bonaire north of Venezuela; the other is east of the Virgin Islands. (NCI) | Netherlands Antilles | ||
ARE | C17232 | UNITED ARAB EMIRATES | A country in the Middle East, bordering the Gulf of Oman and the Persian Gulf, between Oman and Saudi Arabia. (NCI) | United Arab Emirates | ||
ARG | C16305 | ARGENTINA | A country in Southern South America, bordering the South Atlantic Ocean, between Chile and Uruguay. (NCI) | Argentina | ||
ARM | C16306 | ARMENIA | A country in Southwestern Asia, east of Turkey. (NCI) | Armenia | ||
ASM | C17739 | AMERICAN SAMOA | A group of islands in the South Pacific Ocean, about half way between Hawaii and New Zealand. (NCI) | American Samoa | ||
ATA | C18007 | ANTARCTICA | The continent lying mostly south of the Antarctic Circle. (NCI) | Antarctica | ||
ATF | C20105 | FRENCH SOUTHERN TERRITORIES | Islands in the southern Indian Ocean, south of Africa, about equidistant between Africa, Antarctica, and Australia. (NCI) | French Southern Territories | ||
ATG | C16303 | ANTIGUA AND BARBUDA | Islands between the Caribbean Sea and the North Atlantic Ocean, east-southeast of Puerto Rico. (NCI) | Antigua and Barbuda | ||
AUS | C16311 | AUSTRALIA | The continent between the Indian Ocean and the South Pacific Ocean. (NCI) | Australia | ||
AUT | C16312 | AUSTRIA | A country in Central Europe, north of Italy and Slovenia. (NCI) | Austria | ||
AZE | C16316 | AZERBAIJAN | A country in Southwestern Asia, bordering the Caspian Sea, between Iran and Russia. (NCI) | Azerbaijan | ||
BDI | C16371 | BURUNDI | A country in Central Africa, east of Democratic Republic of the Congo. (NCI) | Burundi | ||
BEL | C16329 | BELGIUM | A country in Western Europe, bordering the North Sea, between France and the Netherlands. (NCI) | Belgium | ||
BEN | C16333 | BENIN REPUBLIC | A country in Western Africa, bordering the North Atlantic Ocean, between Nigeria and Togo. (NCI) | Benin | ||
BFA | C16369 | BURKINA FASO | A country in Western Africa, north of Ghana. (NCI) | Burkina Faso | ||
BGD | C16323 | BANGLADESH | A country in Southern Asia, bordering the Bay of Bengal, between Burma and India. (NCI) | Bangladesh | ||
BGR | C16368 | BULGARIA | A country in Southeastern Europe, bordering the Black Sea, between Romania and Turkey. (NCI) | Bulgaria | ||
BHR | C16322 | BAHRAIN | An archipelago in the Persian Gulf, east of Saudi Arabia. (NCI) | Bahrain | ||
BHS | C16321 | BAHAMAS | A chain of islands in the North Atlantic Ocean, southeast of Florida. (NCI) | Bahamas | ||
BIH | C16361 | BOSNIA-HERZEGOVINA | A country in Southeastern Europe, bordering the Adriatic Sea and Croatia. (NCI) | Bosnia and Herzegovina | ||
BLM | C83609 | SAINT BARTHELEMY | An island in the Caribbean sea, between Saint Martin and Saint Kitts and Nevis. (NCI) | Saint Barthelemy | ||
BLR | C16372 | BELARUS | A country in Eastern Europe, east of Poland. (NCI) | Belarus | ||
BLZ | C16331 | BELIZE | A country in Central America, bordering the Caribbean Sea, between Guatemala and Mexico. (NCI) | Belize | ||
BMU | C16334 | BERMUDA | A group of islands in the North Atlantic Ocean, east of South Carolina. (NCI) | Bermuda | ||
BOL | C16359 | BOLIVIA | A country in Central South America, southwest of Brazil. (NCI) | Bolivia | ||
BRA | C16364 | BRAZIL | A country in Eastern South America, bordering the Atlantic Ocean. (NCI) | Brazil | ||
BRB | C16324 | BARBADOS | An island between the Caribbean Sea and the North Atlantic Ocean, northeast of Venezuela. (NCI) | Barbados | ||
BRN | C16367 | BRUNEI | A country in Southeastern Asia, bordering the South China Sea and Malaysia. (NCI) | Brunei Darussalam | ||
BTN | C16336 | BHUTAN | A country in Southern Asia, between China and India. (NCI) | Bhutan | ||
BVT | C20104 | BOUVET ISLAND | An island in the South Atlantic Ocean, south-southwest of the Cape of Good Hope (South Africa). (NCI) | Bouvet Island | ||
BWA | C16363 | BOTSWANA | A country in Southern Africa, north of South Africa. (NCI) | Botswana | ||
CAF | C16409 | CENTRAL AFRICAN REPUBLIC | A country in Central Africa, north of Democratic Republic of the Congo. (NCI) | Central African Republic | ||
CAN | C16380 | CANADA | A country in Northern North America, bordering the North Atlantic Ocean on the east, North Pacific Ocean on the west, and the Arctic Ocean on the north, north of the conterminous US. (NCI) | Canada | ||
CCK | C16445 | COCOS (KEELING) ISLANDS | A group of islands in the Indian Ocean, south of Indonesia, about halfway from Australia to Sri Lanka. (NCI) | Cocos (Keeling) Islands | ||
CHE | C17181 | SWITZERLAND | A country in Central Europe, east of France, north of Italy. (NCI) | Switzerland | ||
CHL | C16427 | CHILE | A country in Southern South America, bordering the South Atlantic Ocean and South Pacific Ocean, between Argentina and Peru. (NCI) | Chile | ||
CHN | C16428 | CHINA | A country in Eastern Asia, bordering the East China Sea, Korea Bay, Yellow Sea, and South China Sea, between North Korea and Vietnam. (NCI) | China | ||
CIV | C16762 | COTE D'IVOIRE | A country in Western Africa, bordering the North Atlantic Ocean, between Ghana and Liberia. (NCI) | Cote d'Ivoire | ||
CMR | C16379 | CAMEROON | A country in Western Africa, bordering the Bight of Biafra, between Equatorial Guinea and Nigeria. (NCI) | Cameroon | ||
COD | C17266 | DEMOCRATIC REPUBLIC OF THE CONGO | A country in Central Africa, northeast of Angola. (NCI) | Congo, the Democratic Republic of the | ||
COG | C16467 | CONGO | A country in Western Africa, bordering the South Atlantic Ocean, between Angola and Gabon. (NCI) | Congo | ||
COK | C16469 | COOK ISLANDS | A group of islands in the South Pacific Ocean, about one-half of the way from Hawaii to New Zealand. (NCI) | Cook Islands | ||
COL | C16449 | COLOMBIA | A country in Northern South America, bordering the Caribbean Sea, between Panama and Venezuela, and bordering the North Pacific Ocean, between Ecuador and Panama. (NCI) | Colombia | ||
COM | C16458 | COMOROS | A group of islands in the Mozambique Channel, about two-thirds of the way between northern Madagascar and northern Mozambique. (NCI) | Comoros | ||
CPV | C16382 | CAPE VERDE | A group of islands in the North Atlantic Ocean, west of Senegal. (NCI) | Cape Verde | ||
CRI | C16470 | COSTA RICA | A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Nicaragua and Panama. (NCI) | Costa Rica | ||
CUB | C16477 | CUBA | An island between the Caribbean Sea and the North Atlantic Ocean, 150 km south of Key West, Florida. (NCI) | Cuba | ||
CXR | C44482 | CHRISTMAS ISLAND | An Australian-administered island in the eastern Indian Ocean south of Java, Indonesia. (NCI) | Christmas Island | ||
CYM | C16391 | CAYMAN ISLANDS | An island group in the Caribbean Sea, nearly one-half of the way from Cuba to Honduras. (NCI) | Cayman Islands | ||
CYP | C16480 | CYPRUS | An island in the Mediterranean Sea, south of Turkey. (NCI) | Cyprus | ||
CZE | C17668 | CZECH REPUBLIC | A country in Central Europe, southeast of Germany. (NCI) | Czech Republic | ||
DEU | C16636 | GERMANY | A country in Central Europe, bordering the Baltic Sea and the North Sea, between the Netherlands and Poland, south of Denmark. (NCI) | Germany | ||
DJI | C16506 | DJIBOUTI | A country in Eastern Africa, bordering the Gulf of Aden and the Red Sea, between Eritrea and Somalia. (NCI) | Djibouti | ||
DMA | C16519 | DOMINICA | An island between the Caribbean Sea and the North Atlantic Ocean, about one-half of the way from Puerto Rico to Trinidad and Tobago. (NCI) | Dominica | ||
DNK | C16496 | DENMARK | A country in Northern Europe, bordering the Baltic Sea and the North Sea, on a peninsula north of Germany (Jutland); also includes two major islands (Sjaelland and Fyn). (NCI) | Denmark | ||
DOM | C16520 | DOMINICAN REPUBLIC | A country comprising the eastern two-thirds of the island of Hispaniola, between the Caribbean Sea and the North Atlantic Ocean, east of Haiti. (NCI) | Dominican Republic | ||
DZA | C16274 | ALGERIA | A country in Northern Africa, bordering the Mediterranean Sea, between Morocco and Tunisia. (NCI) | Algeria | ||
ECU | C16528 | ECUADOR | A country in Western South America, bordering the Pacific Ocean at the Equator, between Colombia and Peru. (NCI) | Ecuador | ||
EGY | C16530 | EGYPT | A country in Northern Africa, bordering the Mediterranean Sea, between Libya and the Gaza Strip. (NCI) | Egypt | ||
ERI | C16558 | ERITREA | A country in Eastern Africa, bordering the Red Sea, between Djibouti and Sudan. (NCI) | Eritrea | ||
ESH | C20113 | WESTERN SAHARA | A country in Northern Africa, bordering the North Atlantic Ocean, between Mauritania and Morocco. (NCI) | Western Sahara | ||
ESP | C17152 | SPAIN | A country in Southwestern Europe, bordering the Bay of Biscay, Mediterranean Sea, North Atlantic Ocean, and Pyrenees Mountains, southwest of France. (NCI) | Spain | ||
EST | C16562 | ESTONIA | A country in Eastern Europe, bordering the Baltic Sea and Gulf of Finland, between Latvia and Russia. (NCI) | Estonia | ||
ETH | C16563 | ETHIOPIA | A country in Eastern Africa, west of Somalia. (NCI) | Ethiopia | ||
FIN | C16584 | FINLAND | A country in Northern Europe, bordering the Baltic Sea, Gulf of Bothnia, and Gulf of Finland, between Sweden and Russia. (NCI) | Finland | ||
FJI | C16582 | FIJI | An island group in the South Pacific Ocean, about two-thirds of the way from Hawaii to New Zealand. (NCI) | Fiji | ||
FLK | C17954 | FALKLAND ISLANDS | Islands in the South Atlantic Ocean, east of southern Argentina. (NCI) | Falkland Islands (Malvinas) | ||
FRA | C16592 | FRANCE | A country in Western Europe, bordering the Bay of Biscay and English Channel, between Belgium and Spain, southeast of the UK; bordering the Mediterranean Sea, between Italy and Spain. (NCI) | France | ||
FRO | C16573 | FAROE ISLANDS | An island group between the Norwegian Sea and the North Atlantic Ocean, about one-half of the way from Iceland to Norway. (NCI) | Faroe Islands | ||
FSM | C17881 | MICRONESIA, FEDERATED STATES OF | An island group in the North Pacific Ocean, about three-quarters of the way from Hawaii to Indonesia. (NCI) | Micronesia, Federated States of | ||
GAB | C16596 | GABON | A country in Western Africa, bordering the Atlantic Ocean at the Equator, between Republic of the Congo and Equatorial Guinea. (NCI) | Gabon | ||
GBR | C17233 | UNITED KINGDOM | A country in Western Europe, comprising islands, including the northern one-sixth of the island of Ireland, between the North Atlantic Ocean and the North Sea, northwest of France. (NCI) | United Kingdom | ||
GEO | C16634 | GEORGIA | A country in Southwestern Asia, bordering the Black Sea, between Turkey and Russia. (NCI) | Georgia | ||
GGY | C64375 | GUERNSEY | The island of Guernsey and the other Channel Islands represent the last remnants of the medieval Dukedom of Normandy, which held sway in both France and England. Guernsey is a British crown dependency, but is not part of the UK. (NCI) | Guernsey | ||
GHA | C26330 | GHANA | A country in Western Africa, bordering the Gulf of Guinea, between Cote d'Ivoire and Togo. (NCI) | Ghana | ||
GIB | C16638 | GIBRALTAR | A dependency in Southwestern Europe, bordering the Strait of Gibraltar, on the southern coast of Spain. (NCI) | Gibraltar | ||
GIN | C16655 | GUINEA | A country in Western Africa, bordering the North Atlantic Ocean, between Guinea-Bissau and Sierra Leone. (NCI) | Guinea | ||
GLP | C16651 | GUADELOUPE | Islands in the eastern Caribbean Sea, southeast of Puerto Rico. (NCI) | Guadeloupe | ||
GMB | C16598 | GAMBIA | A country in Western Africa, bordering the North Atlantic Ocean and Senegal. (NCI) | Gambia | ||
GNB | C16656 | GUINEA-BISSAU | A country in Western Africa, bordering the North Atlantic Ocean, between Guinea and Senegal. (NCI) | Guinea-Bissau | ||
GNQ | C16557 | EQUATORIAL GUINEA | A country in Western Africa, bordering the Bight of Biafra, between Cameroon and Gabon; composed of a mainland portion and five inhabited islands. (NCI) | Equatorial Guinea | ||
GRC | C16645 | GREECE | A country in Southern Europe, bordering the Aegean Sea, Ionian Sea, and the Mediterranean Sea, between Albania and Turkey. (NCI) | Greece | ||
GRD | C16647 | GRENADA | An island between the Caribbean Sea and Atlantic Ocean, north of Trinidad and Tobago. (NCI) | Grenada | ||
GRL | C16646 | GREENLAND | An island between the Arctic Ocean and the North Atlantic Ocean, northeast of Canada. (NCI) | Greenland | ||
GTM | C16654 | GUATEMALA | A country in Central America, bordering the Caribbean Sea, between Honduras and Belize and bordering the North Pacific Ocean, between El Salvador and Mexico. (NCI) | Guatemala | ||
GUF | C16593 | FRENCH GUIANA | A country in Northern South America, bordering the North Atlantic Ocean, between Brazil and Suriname. (NCI) | French Guiana | ||
GUM | C16652 | GUAM | Island in the North Pacific Ocean, about three-quarters of the way from Hawaii to the Philippines. (NCI) | Guam | ||
GUY | C16657 | GUYANA | A country in Northern South America, bordering the North Atlantic Ocean, between Suriname and Venezuela. (NCI) | Guyana | ||
HKG | C16695 | HONG KONG | A special administrative region of China, bordering the South China Sea and China. (NCI) | Hong Kong | ||
HMD | C20106 | HEARD ISLAND AND MCDONALD ISLANDS | Islands in the Indian Ocean, about two-thirds of the way from Madagascar to Antarctica. (NCI) | Heard Island and McDonald Islands | ||
HND | C16694 | HONDURAS | A country in Central America, bordering the Caribbean Sea, between Guatemala and Nicaragua and bordering the North Pacific Ocean, between El Salvador and Nicaragua. (NCI) | Honduras | ||
HRV | C16474 | CROATIA | A country in Southeastern Europe, bordering the Adriatic Sea, between Bosnia and Herzegovina and Slovenia. (NCI) | Croatia | ||
HTI | C16660 | HAITI | A country comprising the western one-third of the island of Hispaniola, between the Caribbean Sea and the North Atlantic Ocean, west of the Dominican Republic. (NCI) | Haiti | ||
HUN | C16699 | HUNGARY | A country in Central Europe, northwest of Romania. (NCI) | Hungary | ||
IDN | C16728 | INDONESIA | A country in Southeastern Asia, comprising the archipelago between the Indian Ocean and the Pacific Ocean. (NCI) | Indonesia | ||
IND | C16727 | INDIA | A country in Southern Asia, bordering the Arabian Sea and the Bay of Bengal, between Burma and Pakistan. (NCI) | India | ||
IMN | C44480 | ISLE OF MAN | An island in the Irish Sea, between Great Britain and Ireland. (NCI) | Isle of Man | ||
IOT | C16365 | BRITISH INDIAN OCEAN TERRITORY | An archipelago in the Indian Ocean, about one-half the way from Africa to Indonesia. (NCI) | British Indian Ocean Territory | ||
IRL | C16757 | IRELAND | A country in Western Europe, occupying five-sixths of the island of Ireland in the North Atlantic Ocean, west of Great Britain. (NCI) | Ireland | ||
IRN | C16755 | IRAN | A country in the Middle East, bordering the Gulf of Oman, the Persian Gulf, and the Caspian Sea, between Iraq and Pakistan. (NCI) | Iran, Islamic Republic of | ||
IRQ | C16756 | IRAQ | A country in the Middle East, bordering the Persian Gulf, between Iran and Kuwait. (NCI) | Iraq | ||
ISL | C16704 | ICELAND | A country in Northern Europe, island between the Greenland Sea and the North Atlantic Ocean, northwest of the UK. (NCI) | Iceland | ||
ISR | C16760 | ISRAEL | A country in the Middle East, bordering the Mediterranean Sea, between Egypt and Lebanon. (NCI) | Israel | ||
ITA | C16761 | ITALY | A country in Southern Europe, occupying a peninsula extending into the central Mediterranean Sea, northeast of Tunisia. (NCI) | Italy | ||
JAM | C16763 | JAMAICA | An island in the Caribbean Sea, south of Cuba. (NCI) | Jamaica | ||
JOR | C16765 | JORDAN | A country in the Middle East, northwest of Saudi Arabia. (NCI) | Jordan | ||
JPN | C16764 | JAPAN | A country in Eastern Asia, occupying an island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. (NCI) | Japan | ||
JEY | C64374 | JERSEY | Jersey and the other Channel Islands represent the last remnants of the medieval Dukedom of Normandy that held sway in both France and England. Jersey is a British crown dependency, but is not part of the UK. (NCI) | Jersey | ||
KAZ | C20107 | KAZAKHSTAN | A country in Central Asia, northwest of China. (NCI) | Kazakhstan | ||
KEN | C16769 | KENYA | A country in Eastern Africa, bordering the Indian Ocean, between Somalia and Tanzania. (NCI) | Kenya | ||
KGZ | C16771 | KYRGYZSTAN | A country in Central Asia, west of China. (NCI) | Kyrgyzstan | ||
KHM | C16378 | CAMBODIA | A country in Southeastern Asia, bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos. (NCI) | Cambodia | ||
KIR | C16639 | KIRIBATI | A group of 33 coral atolls in the Pacific Ocean, straddling the equator; the capital Tarawa is about one-half of the way from Hawaii to Australia. (NCI) | Kiribati | ||
KNA | C17885 | SAINT KITTS AND NEVIS | Islands in the Caribbean Sea, about one-third of the way from Puerto Rico to Trinidad and Tobago. (NCI) | Saint Kitts and Nevis | ||
KOR | C16774 | SOUTH KOREA | A country in Eastern Asia, occupying the southern half of the Korean Peninsula, bordering the Sea of Japan and the Yellow Sea. (NCI) | Korea, Republic of | ||
KWT | C16775 | KUWAIT | A country in the Middle East, bordering the Persian Gulf, between Iraq and Saudi Arabia. (NCI) | Kuwait | ||
LAO | C16780 | LAO PEOPLE'S DEMOCRATIC REPUBLIC | A country in Southeastern Asia, northeast of Thailand, west of Vietnam. (NCI) | Lao People's Democratic Republic | ||
LBN | C16784 | LEBANON | A country in the Middle East, bordering the Mediterranean Sea, between Israel and Syria. (NCI) | Lebanon | ||
LBR | C16791 | LIBERIA | A country in Western Africa, bordering the North Atlantic Ocean, between Cote d'Ivoire and Sierra Leone. (NCI) | Liberia | ||
LBY | C16793 | LIBYAN ARAB JAMAHIRIYA | A country in Northern Africa, bordering the Mediterranean Sea, between Egypt and Tunisia. (NCI) | Libyan Arab Jamahiriya | ||
LCA | C17113 | SAINT LUCIA | A country in the Caribbean, occupying an island between the Caribbean Sea and North Atlantic Ocean, north of Trinidad and Tobago. (NCI) | Saint Lucia | ||
LIE | C16794 | LIECHTENSTEIN | A country in Central Europe, between Austria and Switzerland. (NCI) | Liechtenstein | ||
LKA | C17163 | SRI LANKA | A country in Southern Asia, occupying an island in the Indian Ocean, south of India. (NCI) | Sri Lanka | ||
LSO | C16787 | LESOTHO | A country in Southern Africa, an enclave of South Africa. (NCI) | Lesotho | ||
LTU | C16799 | LITHUANIA | A country in Eastern Europe, bordering the Baltic Sea, between Latvia and Russia. (NCI) | Lithuania | ||
LUX | C16803 | LUXEMBOURG | A country in Western Europe, between France, Belgium, and Germany. (NCI) | Luxembourg | ||
LVA | C16783 | LATVIA | A country in Eastern Europe, bordering the Baltic Sea, between Estonia and Lithuania. (NCI) | Latvia | ||
MAC | C16807 | MACAO | A country in Eastern Asia, bordering the South China Sea and China. (NCI) | Macao | ||
MAF | C83610 | SAINT MARTIN, FRENCH | An island in the Caribbean sea, between Anguilla and Saint Barthelemy. (NCI) | Saint Martin, French | ||
MAR | C16878 | MOROCCO | A country in Northern Africa, bordering the North Atlantic Ocean and the Mediterranean Sea, between Algeria and Western Sahara. (NCI) | Morocco | ||
MCO | C16874 | MONACO | A country in Western Europe, bordering the Mediterranean Sea on the southern coast of France, near the border with Italy. (NCI) | Monaco | ||
MDA | C16871 | MOLDOVA, REPUBLIC OF | A country in Eastern Europe, northeast of Romania. (NCI) | Moldova, Republic of | ||
MDG | C16808 | MADAGASCAR | A country in Southern Africa, occupying an island in the Indian Ocean, east of Mozambique. (NCI) | Madagascar | ||
MDV | C16815 | MALDIVES | A country in Southern Asia, occupying a group of atolls in the Indian Ocean, south-southwest of India. (NCI) | Maldives | ||
MEX | C16850 | MEXICO | A country in Central America, bordering the Caribbean Sea and the Gulf of Mexico, between Belize and the US and bordering the North Pacific Ocean, between Guatemala and the US. (NCI) | Mexico | ||
MHL | C16822 | MARSHALL ISLANDS | A group of atolls and reefs in the North Pacific Ocean, about one-half of the way from Hawaii to Australia. (NCI) | Marshall Islands | ||
MKD | C17654 | REPUBLIC OF MACEDONIA | A country in Southeastern Europe, north of Greece. (NCI) | Macedonia, the Former Yugoslav Republic of | ||
MLI | C16816 | MALI | A country in Western Africa, southwest of Algeria. (NCI) | Mali | ||
MLT | C16817 | MALTA | A country in Southern Europe, occupying islands in the Mediterranean Sea, south of Sicily (Italy). (NCI) | Malta | ||
MMR | C16370 | MYANMAR | A country in Southeastern Asia, bordering the Andaman Sea and the Bay of Bengal, between Bangladesh and Thailand. (NCI) | Myanmar | ||
MNE | C64378 | MONTENEGRO | A republic in Southeastern Europe, bordering the Adriatic Sea, between Albania and Bosnia and Herzegovina. Formerly part of Serbia and Montenegro (Federation Republic of Yugoslavia). (NCI) | Montenegro | ||
MNG | C16875 | MONGOLIA | A country in Northern Asia, between China and Russia. (NCI) | Mongolia | ||
MNP | C17882 | NORTHERN MARIANA ISLANDS | A country in the Pacific, comprising islands in the North Pacific Ocean, about three-quarters of the way from Hawaii to the Philippines. (NCI) | Northern Mariana Islands | ||
MOZ | C16882 | MOZAMBIQUE | A country in Southern Africa, bordering the Mozambique Channel, between South Africa and Tanzania. (NCI) | Mozambique | ||
MRT | C16826 | MAURITANIA | A country in Northern Africa, bordering the North Atlantic Ocean, between Senegal and Western Sahara. (NCI) | Mauritania | ||
MSR | C16876 | MONTSERRAT | A country in the Caribbean, occupying an island in the Caribbean Sea, southeast of Puerto Rico. (NCI) | Montserrat | ||
MTQ | C16823 | MARTINIQUE | An island in the Caribbean Sea, north of Trinidad and Tobago. (NCI) | Martinique | ||
MUS | C16827 | MAURITIUS | A country in Southern Africa, occupying an island in the Indian Ocean, east of Madagascar. (NCI) | Mauritius | ||
MWI | C16813 | MALAWI | A country in Southern Africa, east of Zambia. (NCI) | Malawi | ||
MYS | C16814 | MALAYSIA | A country in Southeastern Asia, occupying a peninsula and the northern one-third of the island of Borneo, bordering Indonesia and the South China Sea, south of Vietnam. (NCI) | Malaysia | ||
MYT | C16828 | MAYOTTE | A country in Southern Africa, occupying an island in the Mozambique Channel, about one-half of the way from northern Madagascar to northern Mozambique. (NCI) | Mayotte | ||
NAM | C16891 | NAMIBIA | A country in Southern Africa, bordering the South Atlantic Ocean, between Angola and South Africa. (NCI) | Namibia | ||
NCL | C16913 | NEW CALEDONIA | A country in the Pacific, comprised of islands in the South Pacific Ocean, east of Australia. (NCI) | New Caledonia | ||
NER | C16916 | NIGER | A country in Western Africa, southeast of Algeria. (NCI) | Niger | ||
NFK | C16919 | NORFOLK ISLAND | A country in the Pacific, occupying an island in the South Pacific Ocean, east of Australia. (NCI) | Norfolk Island | ||
NGA | C16917 | NIGERIA | A country in Western Africa, bordering the Gulf of Guinea, between Benin and Cameroon. (NCI) | Nigeria | ||
NIC | C16915 | NICARAGUA | A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Costa Rica and Honduras. (NCI) | Nicaragua | ||
NIU | C16918 | NIUE | A country in the Pacific, occupying an island in the South Pacific Ocean, east of Tonga. (NCI) | Niue | ||
NLD | C16903 | NETHERLANDS | A country in Western Europe, bordering the North Sea, between Belgium and Germany. (NCI) | Netherlands | ||
NOR | C16920 | NORWAY | A country in Northern Europe, bordering the North Sea and the North Atlantic Ocean, west of Sweden. (NCI) | Norway | ||
NPL | C16901 | NEPAL | A country in Southern Asia, between China and India. (NCI) | Nepal | ||
NRU | C16896 | NAURU | A country in Oceania, occupying an island in the South Pacific Ocean, south of the Marshall Islands. (NCI) | Nauru | ||
NZL | C16914 | NEW ZEALAND | A country in the Pacific, comprised of islands in the South Pacific Ocean, southeast of Australia. (NCI) | New Zealand | ||
OMN | C16933 | OMAN | A country in the Middle East, bordering the Arabian Sea, Gulf of Oman, and Persian Gulf, between Yemen and the United Arab Emirates. (NCI) | Oman | ||
PAK | C16949 | PAKISTAN | A country in Southern Asia, bordering the Arabian Sea, between India on the east and Iran and Afghanistan on the west and China in the north. (NCI) | Pakistan | ||
PAN | C16951 | PANAMA | A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Colombia and Costa Rica. (NCI) | Panama | ||
PCN | C16993 | PITCAIRN | A country in the Pacific, comprised of islands in the South Pacific Ocean, about midway between Peru and New Zealand. (NCI) | Pitcairn | ||
PER | C16972 | PERU | A country in Western South America, bordering the South Pacific Ocean, between Chile and Ecuador. (NCI) | Peru | ||
PHL | C16978 | PHILIPPINES | A country in Southeastern Asia, comprised of an archipelago between the Philippine Sea and the South China Sea, east of Vietnam. (NCI) | Philippines | ||
PLW | C17733 | PALAU | A country in the Pacific, comprising a group of islands in the North Pacific Ocean, southeast of the Philippines. (NCI) | Palau | ||
PNG | C16952 | PAPUA NEW GUINEA | A country in Southeastern Asia, comprising a group of islands and including the eastern half of the island of New Guinea, between the Coral Sea and the South Pacific Ocean, east of Indonesia. (NCI) | Papua New Guinea | ||
POL | C17002 | POLAND | A country in Central Europe, east of Germany. (NCI) | Poland | ||
PRI | C17043 | PUERTO RICO | An island between the Caribbean Sea and the North Atlantic Ocean, east of the Dominican Republic. (NCI) | Puerto Rico | ||
PRK | C16773 | NORTH KOREA | A country in Eastern Asia, occupying the northern half of the Korean Peninsula, bordering the Korea Bay and the Sea of Japan, between China and South Korea. (NCI) | Korea, Democratic People's Republic of | ||
PRT | C17006 | PORTUGAL | A country in Southwestern Europe, bordering the North Atlantic Ocean, west of Spain. (NCI) | Portugal | ||
PRY | C16953 | PARAGUAY | A country in Central South America, northeast of Argentina. (NCI) | Paraguay | ||
PSE | C20110 | PALESTINIAN TERRITORY, OCCUPIED | A collective name for the West Bank and the Gaza Strip, two territories in Palestine. (NCI) | Palestinian Territory, Occupied | ||
PYF | C16594 | FRENCH POLYNESIA | An archipelago in the South Pacific Ocean, about one-half of the way from South America to Australia. (NCI) | French Polynesia | ||
QAT | C17045 | QATAR | A country in the Middle East, occupying a peninsula bordering the Persian Gulf and Saudi Arabia. (NCI) | Qatar | ||
REU | C17095 | REUNION | A country in Southern Africa, occupying an island in the Indian Ocean, east of Madagascar. (NCI) | Reunion | ||
ROU | C17108 | ROMANIA | A country in Southeastern Europe, bordering the Black Sea, between Bulgaria and Ukraine. (NCI) | Romania | ||
RUS | C17111 | RUSSIAN FEDERATION | A country in Northern Asia (that part west of the Urals is sometimes included with Europe), bordering the Arctic Ocean, between Europe and the North Pacific Ocean. (NCI) | Russian Federation | ||
RWA | C17112 | RWANDA | A country in Central Africa, east of Democratic Republic of the Congo. (NCI) | Rwanda | ||
SAU | C17117 | SAUDI ARABIA | A country in the Middle East, bordering the Persian Gulf and the Red Sea, north of Yemen. (NCI) | Saudi Arabia | ||
SRB | C64377 | SERBIA | A republic in Southeastern Europe, bordering the Adriatic Sea, between Albania and Bosnia and Herzegovina. Formerly part of Serbia and Montenegro (Federation Republic of Yugoslavia). (NCI) | Serbia | ||
SDN | C17170 | SUDAN | A country in Northern Africa, bordering the Red Sea, between Egypt and Eritrea. (NCI) | Sudan | ||
SEN | C17121 | SENEGAL | A country in Western Africa, bordering the North Atlantic Ocean, between Guinea-Bissau and Mauritania. (NCI) | Senegal | ||
SGP | C17134 | SINGAPORE | A country in Southeastern Asia, comprised of islands between Malaysia and Indonesia. (NCI) | Singapore | ||
SGS | C20111 | SOUTH GEORGIA AND THE SOUTH SANDWICH ISLANDS | A group of islands in the South Atlantic Ocean, east of the tip of South America. (NCI) | South Georgia and the South Sandwich Islands | ||
SHN | C17164 | SAINT HELENA | Islands in the South Atlantic Ocean, about midway between South America and Africa. (NCI) | Saint Helena | ||
SJM | C17178 | SVALBARD AND JAN MAYEN | Islands between the Arctic Ocean, Barents Sea, Greenland Sea, and Norwegian Sea, northeast of Iceland and north of Norway. (NCI) | Svalbard and Jan Mayen | ||
SLB | C17148 | SOLOMON ISLANDS | A group of islands in the South Pacific Ocean, east of Papua New Guinea. (NCI) | Solomon Islands | ||
SLE | C17130 | SIERRA LEONE | A country in Western Africa, bordering the North Atlantic Ocean, between Guinea and Liberia. (NCI) | Sierra Leone | ||
SLV | C16532 | EL SALVADOR | A country in Central America, bordering the North Pacific Ocean, between Guatemala and Honduras. (NCI) | El Salvador | ||
SMR | C17115 | SAN MARINO | A country in Southern Europe, an enclave in central Italy. (NCI) | San Marino | ||
SOM | C17149 | SOMALIA | A country in Eastern Africa, bordering the Gulf of Aden and the Indian Ocean, east of Ethiopia. (NCI) | Somalia | ||
SPM | C17165 | SAINT PIERRE AND MIQUELON | A country in Northern North America, comprised of islands in the North Atlantic Ocean, south of Newfoundland (Canada). (NCI) | Saint Pierre and Miquelon | ||
STP | C17116 | SAO TOME AND PRINCIPE | A country in Western Africa, comprised of islands in the Gulf of Guinea, straddling the Equator, west of Gabon. (NCI) | Sao Tome and Principe | ||
SUR | C17175 | SURINAME | A country in Northern South America, bordering the North Atlantic Ocean, between French Guiana and Guyana. (NCI) | Suriname | ||
SVK | C17669 | SLOVAKIA | A country in Central Europe, south of Poland. (NCI) | Slovakia | ||
SVN | C17138 | SLOVENIA | A country in Central Europe, bordering the Adriatic Sea, between Austria and Croatia. (NCI) | Slovenia | ||
SWE | C17180 | SWEDEN | A country in Northern Europe, bordering the Baltic Sea, Gulf of Bothnia, Kattegat, and Skagerrak, between Finland and Norway. (NCI) | Sweden | ||
SWZ | C17179 | SWAZILAND | A country in Southern Africa, between Mozambique and South Africa. (NCI) | Swaziland | ||
SYC | C17129 | SEYCHELLES | A country in Eastern Africa, comprised of a group of islands in the Indian Ocean, northeast of Madagascar. (NCI) | Seychelles | ||
SYR | C17182 | SYRIAN ARAB REPUBLIC | A country in the Middle East, bordering the Mediterranean Sea, between Lebanon and Turkey. (NCI) | Syrian Arab Republic | ||
TCA | C17224 | TURKS AND CAICOS ISLANDS | Two island groups in the North Atlantic Ocean, southeast of The Bahamas. (NCI) | Turks and Caicos Islands | ||
TCD | C16412 | CHAD | A country in Central Africa, south of Libya. (NCI) | Chad | ||
TGO | C17202 | TOGO | A country in Western Africa, bordering the Bight of Benin, between Benin and Ghana. (NCI) | Togo | ||
THA | C17192 | THAILAND | A country in Southeastern Asia, bordering the Andaman Sea and the Gulf of Thailand, southeast of Burma. (NCI) | Thailand | ||
TJK | C17183 | TAJIKISTAN | A country in Central Asia, west of China. (NCI) | Tajikistan | ||
TKL | C17704 | TOKELAU | A group of three atolls in the South Pacific Ocean, about one-half of the way from Hawaii to New Zealand. (NCI) | Tokelau | ||
TKM | C17223 | TURKMENISTAN | A country in Central Asia, bordering the Caspian Sea, between Iran and Kazakhstan. (NCI) | Turkmenistan | ||
TLS | C17200 | TIMOR-LESTE | A country in Southeastern Asia, northwest of Australia in the Lesser Sunda Islands at the eastern end of the Indonesian archipelago. East Timor includes the eastern half of the island of Timor, the Oecussi (Ambeno) region on the northwest portion of the island of Timor, and the islands of Pulau Atauro and Pulau Jaco. (NCI) | Timor-Leste | ||
TON | C17205 | TONGA | An archipelago in the South Pacific Ocean, about two-thirds of the way from Hawaii to New Zealand. (NCI) | Tonga | ||
TTO | C17217 | TRINIDAD AND TOBAGO | Islands between the Caribbean Sea and the North Atlantic Ocean, northeast of Venezuela. (NCI) | Trinidad and Tobago | ||
TUN | C17221 | TUNISIA | A country in Northern Africa, bordering the Mediterranean Sea, between Algeria and Libya. (NCI) | Tunisia | ||
TUR | C17222 | TURKEY | A country in southeastern Europe and southwestern Asia (that portion of Turkey west of the Bosporus is geographically part of Europe), bordering the Black Sea, between Bulgaria and Georgia, and bordering the Aegean Sea and the Mediterranean Sea, between Greece and Syria. (NCI) | Turkey | ||
TUV | C17225 | TUVALU | An island group consisting of nine coral atolls in the South Pacific Ocean, about one-half of the way from Hawaii to Australia. (NCI) | Tuvalu | ||
TWN | C17184 | TAIWAN | A group of islands bordering the East China Sea, Philippine Sea, South China Sea, and Taiwan Strait, north of the Philippines, off the southeastern coast of China. (NCI) | Taiwan, Province of China | ||
TZA | C17185 | TANZANIA, UNITED REPUBLIC OF | A country in Eastern Africa, bordering the Indian Ocean, between Kenya and Mozambique. (NCI) | Tanzania, United Republic of | ||
UGA | C17228 | UGANDA | A country in Eastern Africa, west of Kenya. (NCI) | Uganda | ||
UKR | C17229 | UKRAINE | A country in Eastern Europe, bordering the Black Sea, between Poland and Russia. (NCI) | Ukraine | ||
UMI | C20112 | UNITED STATES MINOR OUTLYING ISLANDS | The U.S. Minor Outlying Islands consist of Baker Island, Howland Island, Jarvis Island, Johnston Atoll, Kingman Reef, Midway Island, Navassa Island, Palmyra Atoll, and Wake Island (Wake Atoll). (NCI) | United States Minor Outlying Islands | ||
URY | C17244 | URUGUAY | A country in Southern South America, bordering the South Atlantic Ocean, between Argentina and Brazil. (NCI) | Uruguay | ||
USA | C17234 | UNITED STATES | A country in North America, bordering both the North Atlantic Ocean and the North Pacific Ocean, between Canada and Mexico. (NCI) | United States | ||
UZB | C17246 | UZBEKISTAN | A country in Central Asia, north of Afghanistan. (NCI) | Uzbekistan | ||
VAT | C17249 | VATICAN CITY STATE | An enclave of Rome (Italy). (NCI) | Holy See (Vatican City State) | ||
VCT | C17114 | SAINT VINCENT AND THE GRENADINES | A country in the Caribbean, comprised of islands in the Caribbean Sea, north of Trinidad and Tobago. (NCI) | Saint Vincent and the Grenadines | ||
VEN | C17250 | VENEZUELA | A country in Northern South America, bordering the Caribbean Sea and the North Atlantic Ocean, between Colombia and Guyana. (NCI) | Venezuela | ||
VGB | C17653 | VIRGIN ISLANDS, BRITISH | Islands between the Caribbean Sea and the North Atlantic Ocean, east of Puerto Rico. (NCI) | Virgin Islands, British | ||
VIR | C17255 | VIRGIN ISLANDS, U.S. | Islands between the Caribbean Sea and the North Atlantic Ocean, east of Puerto Rico. (NCI) | Virgin Islands, U.S. | ||
VNM | C17252 | VIETNAM | A country in Southeastern Asia, bordering the Gulf of Thailand, Gulf of Tonkin, and South China Sea, alongside China, Laos, and Cambodia. (NCI) | Viet Nam | ||
VUT | C17247 | VANUATU | A group of islands in the South Pacific Ocean, about three-quarters of the way from Hawaii to Australia. (NCI) | Vanuatu | ||
WLF | C17259 | WALLIS AND FUTUNA | Islands in the South Pacific Ocean, about two-thirds of the way from Hawaii to New Zealand. (NCI) | Wallis and Futuna | ||
WSM | C17740 | SAMOA | A group of islands in the South Pacific Ocean, about one-half of the way from Hawaii to New Zealand. (NCI) | Samoa | ||
YEM | C17264 | YEMEN | A country in the Middle East, bordering the Arabian Sea, Gulf of Aden, and Red Sea, between Oman and Saudi Arabia. (NCI) | Yemen | ||
ZAF | C17151 | SOUTH AFRICA | A country in Southern Africa, at the southern tip of the continent of Africa. (NCI) | South Africa | ||
ZMB | C17267 | ZAMBIA | A country in Southern Africa, east of Angola. (NCI) | Zambia | ||
ZWE | C17268 | ZIMBABWE | A country in Southern Africa, between South Africa and Zambia. (NCI) | Zimbabwe | ||
Back to top | ||||||
CL.C66787.TDIGRP | Diagnosis Group (TDIGRP) | text Extensible: Yes | C66787 | Diagnosis Group | A grouping of individuals on the basis of a shared procedure or disease, or lack thereof (e.g. healthy volunteers, type 2 diabetic subjects, subjects with renal cell cancer). Standardized naming systems are available that define the groups within which a subject should be placed. (NCI) | CDISC SDTM Diagnosis Group Terminology |
HEALTHY SUBJECTS | C49651 | An individual who is or becomes a participant in a research study and has no significant health-related issues. (NCI) | Healthy Subject | |||
Back to top | ||||||
CL.C66788.DICTNAM | Dictionary Name (DICTNAM) | text Extensible: Yes | C66788 | Dictionary Name | A name given to a reference source that lists words and gives their meaning. (NCI) | CDISC SDTM Dictionary Name Terminology |
COSTART | C49471 | Coding Symbols for a Thesaurus of Adverse Reaction Terms | A terminology developed and used by the Food and Drug Administration (FDA) for the coding, filing and retrieving of post marketing adverse reaction reports. (NCI) | Thesaurus of Adverse Reaction Term Coding Symbols | ||
ICD | C49474 | International Classification of Diseases | A system of categories to which morbid entries are assigned according to established criteria. Included is the entire range of conditions in a manageable number of categories, grouped to facilitate mortality reporting. It is produced by the World Health Organization (from ICD-10, p1). The Clinical Modifications, produced by the United States Dept. of Health and Human Services, are larger extensions used for morbidity and general epidemiological purposes, primarily in the U.S. (MSH2005_2004_10_12) | International Classification of Diseases | ||
LOINC | C49476 | Logical Observation Identifiers Names and Codes | Published by The Regenstrief Institute, the Logical Observation Identifiers Names and Codes covers clinical and clinical laboratory terminology. (NCI) | Logical Observation Identifiers Names and Codes | ||
MedDRA | C43820 | Medical Dictionary for Regulatory Activities | MedDRA is an international medical terminology designed to support the classification, retrieval, presentation, and communication of medical information throughout the medical product regulatory cycle. MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The MedDRA Maintenance and Support Services Organization (MSSO) holds a contract with the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) to maintain and support the implementation of the terminology. (NCI) | MedDRA | ||
SNOMED | C53489 | Systematized Nomenclature of Medicine | A multiaxial, hierarchical classification system for diseases in man developed by the College of American Pathologists. (NCI) | Systematized Nomenclature of Medicine | ||
WHOART | C49468 | World Health Organization Adverse Reaction Terms | A terminology implemented by the World Health Organization to describe adverse reactions to a prescribed medication or treatment regimen. (NCI) | World Health Organization Adverse Reaction Terminology | ||
WHODD | C49475 | World Health Organization Drug Dictionary | A reference source of drugs and drug associated information maintained by the World Health Organization. (NCI) | World Health Organization Drug Dictionary | ||
Back to top | ||||||
CL.C66789.ND | Not Done (ND) | text Extensible: No | C66789 | Not Done | Indicates a task, process or examination that has either not been initiated or completed. (NCI) | CDISC SDTM Not Done Terminology |
NOT DONE | C49484 | Indicates a task, process or examination that has either not been initiated or completed. (NCI) | Not Done | |||
Back to top | ||||||
CL.C66790.ETHNIC | Ethnic Group (ETHNIC) | text Extensible: Yes | C66790 | Ethnic Group | A social group characterized by a distinctive social and cultural tradition maintained from generation to generation, a common history and origin and a sense of identification with the group; members of the group have distinctive features in their way of life, shared experiences and often a common genetic heritage; these features may be reflected in their experience of health and disease. (NCI) | CDISC SDTM Ethnic Group Terminology |
HISPANIC OR LATINO | C17459 | A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race. (NCI) | Hispanic or Latino | |||
NOT HISPANIC OR LATINO | C41222 | A person not of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race. An arbitrary ethnic classification. (NCI) | Not Hispanic or Latino | |||
NOT REPORTED | C43234 | Not reported | Not provided or available. | Not Stated | ||
UNKNOWN | C17998 | U;Unknown | Not known, not observed, not recorded, or refused. (NCI) | Unknown | ||
Back to top | ||||||
CL.C66726.FRM | Pharmaceutical Dosage Form (FRM) | text Extensible: Yes | C66726 | Pharmaceutical Dosage Form;Dose Form | The form of the completed pharmaceutical product, e.g. tablet, capsule, injection, elixir, suppository. Dosage form can have a significant effect on the onset, duration and intensity of the pharmacological action of a drug. A pharmaceutical dosage form controls the rate at which the drug is released into the biological fluids. This release rate affects its intrinsic absorption pattern and therefore, the bioavailability of the drug. | CDISC SDTM Pharmaceutical Dosage Form Terminology |
AEROSOL | C42887 | aer | A product that is packaged under pressure and contains therapeutically active ingredients that are released upon activation of an appropriate valve system; it is intended for topical application to the skin as well as local application into the nose (nasal aerosols), mouth (lingual aerosols), or lungs (inhalation aerosols). (FDA) | Aerosol Dosage Form | ||
AEROSOL, FOAM | C42888 | A dosage form containing one or more active ingredients, surfactants, aqueous or non-aqueous liquids, and the propellants; if the propellant is in the internal (discontinuous) phase (i.e., of the oil-in-water type), a stable foam is discharged, and if the propellant is in the external (continuous) phase (i.e., of the water-in-oil type), a spray or a quick-breaking foam is discharged. (FDA) | Aerosol Foam Dosage Form | |||
AEROSOL, METERED | C42960 | A pressurized dosage form consisting of metered dose valves which allow for the delivery of a uniform quantity of spray upon each activation. (NCI) | Metered Aerosol Dosage Form | |||
AEROSOL, POWDER | C42971 | A product that is packaged under pressure and contains therapeutically active ingredients, in the form of a powder, that are released upon activation of an appropriate valve system. (NCI) | Powder Aerosol Dosage Form | |||
AEROSOL, SPRAY | C42889 | An aerosol product which utilizes a compressed gas as the propellant to provide the force necessary to expel the product as a wet spray; it is applicable to solutions of medicinal agents in aqueous solvents. (NCI) | Aerosol Spray Dosage Form | |||
BAR, CHEWABLE | C42892 | A solid dosage form usually in the form of a rectangle that is meant to be chewed. (NCI) | Chewable Bar Dosage Form | |||
BEAD | C42890 | A solid dosage form in the shape of a small ball. (NCI) | Bead Dosage Form | |||
BEAD, IMPLANT, EXTENDED RELEASE | C43451 | A small sterile solid mass consisting of a highly purified drug intended for implantation in the body which would allow at least a reduction in dosing frequency as compared to that drug presented as a conventional dosage form. (NCI) | Extended Release Bead Implant Dosage Form | |||
BLOCK | C42891 | Solid dosage form, usually in the shape of a square or rectangle. (NCI) | Block Dosage Form | |||
CAPLET | C97197 | A solid dosage form in which a tablet has been compacted into capsule shape. | Caplet Dosage Form | |||
CAPSULE | C25158 | cap | A solid pharmaceutical dosage form that contains medicinal agent within either a hard or soft soluble container or shell, usually used for the oral administration of medicine. The shells are made of a suitable form of gelatin or other substance. (NCI) | Capsule Dosage Form | ||
CAPSULE, COATED | C42895 | A solid dosage form in which the drug is enclosed within either a hard or soft soluble container or "shell" made from a suitable form of gelatin; additionally, the capsule is covered in a designated coating. (NCI) | Coated Capsule Dosage Form | |||
CAPSULE, COATED PELLETS | C42896 | A solid dosage form in which the drug is enclosed within either a hard or soft soluble container or "shell" made from a suitable form of gelatin; the drug itself is in the form of granules to which varying amounts of coating have been applied. (NCI) | Coated Pellets in Capsule Dosage Form | |||
CAPSULE, COATED, EXTENDED RELEASE | C42917 | A solid dosage form in which the drug is enclosed within either a hard or soft soluble container or "shell" made from a suitable form of gelatin; additionally, the capsule is covered in a designated coating, and which releases a drug (or drugs) in such a manner to allow at least a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form. (NCI) | Extended Release Coated Capsule Dosage Form | |||
CAPSULE, DELAYED RELEASE | C42902 | A solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin, and which releases a drug (or drugs) at a time other than promptly after administration. Enteric-coated articles are delayed release dosage forms. (NCI) | Delayed Release Capsule Dosage Form | |||
CAPSULE, DELAYED RELEASE PELLETS | C42904 | A solid dosage form in which the drug is enclosed within either a hard or soft soluble container or "shell" made from a suitable form of gelatin; the drug itself is in the form of granules to which enteric coating has been applied, thus delaying release of the drug until its passage into the intestines. (NCI) | Delayed Release Pellets in Capsule Dosage Form | |||
CAPSULE, EXTENDED RELEASE | C42916 | A solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin, and which releases a drug (or drugs) in such a manner to allow a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form. (NCI) | Extended Release Capsule Dosage Form | |||
CAPSULE, FILM COATED, EXTENDED RELEASE | C42928 | A solid dosage form in which the drug is enclosed within either a hard or soft soluble container or "shell" made from a suitable form of gelatin; additionally, the capsule is covered in a designated film coating, and which releases a drug (or drugs) in such a manner to allow at least a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form. (NCI) | Extended Release Film Coated Capsule Dosage Form | |||
CAPSULE, GELATIN COATED | C42936 | A solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin; through a banding process, the capsule is coated with additional layers of gelatin so as to form a complete seal. (NCI) | Gelatin Coated Capsule Dosage Form | |||
CAPSULE, LIQUID FILLED | C42954 | A solid dosage form in which the drug is enclosed within a soluble, gelatin shell which is plasticized by the addition of a polyol, such as sorbitol or glycerin, and is therefore of a somewhat thicker consistency than that of a hard shell capsule; typically, the active ingredients are dissolved or suspended in a liquid vehicle. (NCI) | Liquid Filled Capsule Dosage Form | |||
CEMENT | C45414 | A substance that serves to produce solid union between two surfaces. (NCI) | Cement Dosage Form | |||
CIGARETTE | C42678 | A narrow tube filled with material that is capable to burn with release of therapeutically-active substance(s) during the process of smoking. Cigarette is a very efficient drug-delivery inhaler system for fast-acting substances.(FDA) | Cigarette Dosage Form | |||
CLOTH | C60884 | A large piece of relatively flat, absorbent material that contains a drug. It is typically used for applying medication or for cleansing. (FDA) | Cloth Dosage Form | |||
CONCENTRATE | C60891 | A liquid preparation of increased strength and reduced volume which is usually diluted prior to administration. (NCI) | Concentrate Dosage Form | |||
CONE | C42900 | A solid dosage form bounded by a circular base and the surface formed by line segments joining every point of the boundary of the base to a common vertex. A cone (usually containing antibiotics) is normally placed below the gingiva after a dental extraction. (NCI) | Cone Dosage Form | |||
CORE, EXTENDED RELEASE | C42919 | An ocular system placed in the eye from which the drug diffuses through a membrane at a constant rate over a specified period. (NCI) | Extended Release Core Dosage Form | |||
CREAM | C28944 | A semisolid emulsion of either the oil-in-water or the water-in-oil type, ordinarily intended for topical use. (NCI) | Cream Dosage Form | |||
CREAM, AUGMENTED | C60897 | A cream dosage form that enhances drug delivery. Augmentation does not refer to the strength of the drug in the dosage form. NOTE: CDER has decided to refrain from expanding the use of this dosage form due to difficulties in setting specific criteria that must be met to be considered augmented. (FDA) | Augmented Cream Dosage Form | |||
CRYSTAL | C42901 | A naturally produced angular solid of definite form in which the ultimate units from which it is built up are systematically arranged; they are usually evenly spaced on a regular space lattice. | Crystal Dosage Form | |||
CULTURE | C45415 | The propagation of microorganisms or of living tissue cells in special media conducive to their growth. (NCI) | Culture Dosage Form | |||
DIAPHRAGM | C47890 | A device usually dome-shaped, worn during copulation over the cervical mouth for prevention of conception or infection. (NCI) | Diaphragm Dosage Form | |||
DISC | C43525 | A circular plate-like organ or structure. (FDA) | Disc Dosage Form | |||
DOUCHE | C42679 | A liquid preparation, intended for the irrigative cleansing of the vagina, that is prepared from powders, liquid solutions, or liquid concentrates and contains one or more chemical substances dissolved in a suitable solvent or mutually miscible solvents. (NCI) | Douche Dosage Form | |||
DRESSING | C42763 | The application of various materials for protecting a wound.(FDA) | Dressing Dosage Form | |||
DRUG DELIVERY SYSTEM | C17423 | Modern technology, distributed with or as a part of a drug product that allows for the uniform release or targeting of drugs to the body. (FDA) | Drug Delivery System | |||
ELIXIR | C42912 | A clear, pleasantly flavored, sweetened hydroalcoholic liquid containing dissolved medicinal agents; it is intended for oral use. (NCI) | Elixir Dosage Form | |||
EMULSION | C42913 | A dosage form consisting of a two-phase system comprised of at least two immiscible liquids (1), one of which is dispersed as droplets (internal or dispersed phase) within the other liquid (external or continuous phase), generally stabilized with one or more emulsifying agents. Note 1: A liquid is pourable; it flows and conforms to its container at room temperature. It displays Newtonian or pseudoplastic flow behavior. Note 2: Emulsion is used as a dosage form term unless a more specific term is applicable, e.g. cream, lotion, ointment. (NCI) | Emulsion Dosage Form | |||
ENEMA | C42915 | A rectal preparation for therapeutic, diagnostic, or nutritive purposes. (NCI) | Enema Dosage Form | |||
EXTRACT | C42929 | A concentrated preparation of vegetable or animal drugs obtained by removal of the active constituents of the respective drugs with a suitable menstrua, evaporation of all or nearly all of the solvent, and adjustment of the residual masses or powders to the prescribed standards. (NCI) | Extract Dosage Form | |||
FIBER, EXTENDED RELEASE | C60926 | A slender and elongated solid thread-like substance that delivers drug in such a manner to allow a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form. (FDA) | Extended Release Fiber Dosage Form | |||
FILM | C42932 | A thin layer or coating. (NCI) | Film Dosage Form | |||
FILM, EXTENDED RELEASE | C42920 | A drug delivery system in the form of a film that releases the drug over an extended period in such a way as to maintain constant drug levels in the blood or target tissue. (NCI) | Extended Release Film Dosage Form | |||
FILM, SOLUBLE | C42984 | A thin layer or coating which is susceptible to being dissolved when in contact with a liquid. (NCI) | Soluble Film Dosage Form | |||
FOR SOLUTION | C60927 | A product, usually a solid, intended for solution prior to administration. (FDA) | Dosage Form For Solution | |||
FOR SUSPENSION | C60928 | A product, usually a solid, intended for suspension prior to administration. (FDA) | Dosage Form For Suspension | |||
FOR SUSPENSION, EXTENDED RELEASE | C60929 | A product, usually a solid, intended for suspension prior to administration; once the suspension is administered, the drug will be released at a constant rate over a specified period. (FDA) | Extended Release Dosage Form For Suspension | |||
GAS | C42933 | Any elastic aeriform fluid in which the molecules are separated from one another and have free paths. (NCI) | Gas Dosage Form | |||
GEL | C42934 | A semisolid (1) dosage form that contains a gelling agent to provide stiffness to a solution or a colloidal dispersion (2). A gel may contain suspended particles. Note 1: A semisolid is not pourable; it does not flow or conform to its container at room temperature. It does not flow at low shear stress and generally exhibits plastic flow behavior. Note 2: A colloidal dispersion is a system in which particles of colloidal dimension (i.e., typically between 1 nm and 1 micrometer) are distributed uniformly throughout a liquid. (NCI) | Gel Dosage Form | |||
GEL, DENTIFRICE | C42906 | A combination of a dentifrice (formulation intended to clean and/or polish the teeth, and which may contain certain additional agents), and a gel. It is used with a toothbrush for the purpose of cleaning and polishing the teeth. (NCI) | Dentifrice Gel Dosage Form | |||
GEL, METERED | C60930 | A gel preparation, with metered dose valves, which allow for the delivery of a uniform quantity of gel upon each activation. (FDA) | Metered Gel Dosage Form | |||
GENERATOR | C48193 | An apparatus for the formation of vapor or gas from a liquid or solid by heat or chemical action. The term GENERATOR also applies to radioactive columns from which radionuclides are provided. (NCI) | Generator Dosage Form | |||
GLOBULE | C42937 | Also called pellets or pilules, are made of pure sucrose, lactose, or other polysaccharides. They are formed into small globular masses of various sizes, and are medicated by placing them in a vial and adding the liquid drug attenuation in the proportion not less than one percent (v/w). After shaking, the medicated globules are dried at temperatures not to exceed 40 degrees Centigrade. (NCI) | Globule Dosage Form | |||
GRAFT | C45416 | A slip of skin or of other tissue for implantation. (NCI) | Graft Dosage Form | |||
GRANULE | C42938 | A small particle or grain. (NCI) | Granule Dosage Form | |||
GRANULE, DELAYED RELEASE | C42903 | A small medicinal particle or grain to which an enteric or other coating has been applied, thus delaying release of the drug until its passage into the intestines. (NCI) | Delayed Release Granule Dosage Form | |||
GRANULE, EFFERVESCENT | C42909 | A small particle or grain containing a medicinal agent in a dry mixture usually composed of sodium bicarbonate, citric acid, and tartaric acid which, when in contact with water, has the capability to release gas, resulting in effervescence. (NCI) | Effervescent Granule Dosage Form | |||
GRANULE, FOR SOLUTION | C42939 | A small medicinal particle or grain made available in its more stable dry form, to be reconstituted with solvent just before dispensing; the granules are so prepared to contain not only the medicinal agent, but the colorants, flavorants, and any other desired pharmaceutic ingredient. (NCI) | Granule For Solution Dosage Form | |||
GRANULE, FOR SUSPENSION | C42940 | A small medicinal particle or grain made available in its more stable dry form, to be reconstituted with solvent just before dispensing to form a suspension; the granules are so prepared to contain not only the medicinal agent, but the colorants, flavorants, and any other desired pharmaceutic ingredient. (NCI) | Granule For Suspension Dosage Form | |||
GRANULE, FOR SUSPENSION, EXTENDED RELEASE | C42921 | A small medicinal particle or grain made available in its more stable dry form, to be reconstituted with solvent just before dispensing to form a suspension; the extended release system achieves slow release of the drug over an extended period of time and maintains constant drug levels in the blood or target tissue. (NCI) | Extended Release Granule For Suspension Dosage Form | |||
GUM | C42941 | A mucilaginous excretion from various plants. (NCI) | Gum Dosage Form | |||
GUM, CHEWING | C42894 | A sweetened and flavored insoluble plastic material of various shapes which when chewed, releases a drug substance into the oral cavity. (NCI) | Chewing Gum Dosage Form | |||
GUM, RESIN | C42978 | Natural mixture of gum and resin, usually obtained as exudations from plants. (NCI) | Resin Gum Dosage Form | |||
IMPLANT | C42942 | A material containing drug intended to be inserted securely and deeply in a living site for growth, slow release, or formation of an organic union. (NCI) | Implant Dosage Form | |||
INHALANT | C42944 | A special class of inhalations consisting of a drug or combination of drugs, that by virtue of their high vapor pressure, can be carried by an air current into the nasal passage where they exert their effect; the container from which the inhalant generally is administered is known as an inhaler. (NCI) | Inhalant Dosage Form | |||
INJECTABLE, LIPOSOMAL | C60931 | An injection, which either consists of or forms liposomes (a lipid bilayer vesicle usually composed of phospholipids which is used to encapsulate an active drug substance). (FDA) | Liposomal Injection Dosage Form | |||
INJECTION | C42946 | A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP. (NCI) | Injectable Dosage Form | |||
INJECTION, EMULSION | C42914 | An emulsion consisting of a sterile, pyrogen-free preparation intended to be administered parenterally.(FDA) | Emulsion for Injection Dosage Form | |||
INJECTION, LIPID COMPLEX | C42950 | [definition pending](FDA) | Injectable Lipid Complex Dosage Form | |||
INJECTION, POWDER, FOR SOLUTION | C42974 | A sterile preparation intended for reconstitution to form a solution for parenteral use. (NCI) | Powder For Injectable Solution Dosage Form | |||
INJECTION, POWDER, FOR SUSPENSION | C42976 | A sterile preparation intended for reconstitution to form a suspension for parenteral use. (NCI) | Powder For Injectable Suspension Dosage Form | |||
INJECTION, POWDER, FOR SUSPENSION, EXTENDED RELEASE | C42977 | A dried preparation intended for reconstitution to form a suspension for parenteral use which has been formulated in a manner to allow at least a reduction in dosing frequency as compared to that drug presented as a conventional dosage form (e.g., as a solution).(FDA) | Powder For Injectable Extended Release Suspension Dosage Form | |||
INJECTION, POWDER, LYOPHILIZED, FOR LIPOSOMAL SUSPENSION | C42959 | A sterile freeze dried preparation intended for reconstitution for parenteral use which has been formulated in a manner that would allow liposomes (a lipid bilayer vesicle usually composed of phospholipids which is used to encapsulate an active drug substance, either within a lipid bilayer or in an aqueous space) to be formed upon reconstitution. (NCI) | Lyophilized Powder For Injectable Liposomal Suspension Dosage Form | |||
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | C42957 | A dosage form intended for the solution prepared by lyophilization ('freeze drying'), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections. (NCI) | Lyophilized Powder For Injectable Solution Dosage Form | |||
INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION | C42958 | A liquid preparation, intended for parenteral use, that contains solids suspended in a suitable fluid medium and conforms in all respects to the requirements for Sterile Suspensions; the medicinal agents intended for the suspension are prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures. (NCI) | Lyophilized Powder For Injectable Suspension Dosage Form | |||
INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION, EXTENDED RELEASE | C42956 | A sterile freeze dried preparation intended for reconstitution for parenteral use which has been formulated in a manner to allow at least a reduction in dosing frequency as compared to that drug presented as a conventional dosage form (e.g., as a solution). (NCI) | Lyophilized Powder For Extended Release Injectable Suspension Dosage Form | |||
INJECTION, SOLUTION | C42945 | A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection. (NCI) | Injectable Solution Dosage Form | |||
INJECTION, SOLUTION, CONCENTRATE | C42899 | A sterile preparation for parenteral use which, upon the addition of suitable solvents, yields a solution conforming in all respects to the requirements for Injections. (NCI) | Concentrate for Injectable Solution Dosage Form | |||
INJECTION, SUSPENSION | C42995 | A liquid preparation, suitable for injection, which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble. It can also consist of an oil phase dispersed throughout an aqueous phase, or vice-versa. (NCI) | Injectable Suspension Dosage Form | |||
INJECTION, SUSPENSION, EXTENDED RELEASE | C42926 | A sterile preparation intended for parenteral use which has been formulated in a manner to allow at least a reduction in dosing frequency as compared to that drug presented as a conventional dosage form (e.g., as a solution or a prompt drug-releasing, conventional solid dosage form). (NCI) | Injectable Extended Release Suspension Dosage Form | |||
INJECTION, SUSPENSION, LIPOSOMAL | C42951 | A liquid parenteral pharmaceutical dosage form structured as a multilamellar composition of concentric phospholipid spheres that encapsulate the drug (drug delivery systems) separated by layers of water. Drug release is facilitated and controlled by in vivo erosion of the liposomes. To further increase the in vivo circulation time, liposomes in some preparations are covalently derivatized with PEG to produce PEGylated or stealth liposomes. Covalent attachment of drugs to the outer surface of liposomes can potentially serve as a delayed-release product. (NCI) | Injectable Liposomal Suspension Dosage Form | |||
INJECTION, SUSPENSION, SONICATED | C42988 | A liquid preparation, suitable for injection, which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble. In addition, the product is sonicated while a gas is bubbled through the suspension, and this results in the formation of microspheres by the solid particles. (NCI) | Injectable Sonicated Suspension Dosage Form | |||
INSERT | C60933 | A specially formulated and shaped non-encapsulated solid preparation intended to be placed into a non-rectal orifice of the body, where drug is released, generally for localized effects. (FDA) | Insert Dosage Form | |||
INSERT, EXTENDED RELEASE | C42922 | A specially formulated and shaped solid preparation (e.g., ring, tablet, or stick) intended to be placed in the vagina by special inserters, where the medication is released, generally for localized effects; the extended release preparation is designed to allow a reduction in dosing frequency. (NCI) | Extended Release Insert Dosage Form | |||
INTRAUTERINE DEVICE | C47915 | A device inserted and left in the uterus to prevent effective conception. (NCI) | Intrauterine Device Dosage Form | |||
IRRIGANT | C42947 | A sterile solution intended to bathe or flush open wounds or body cavities; they're used topically, never parenterally. (NCI) | Irrigant Dosage Form | |||
JELLY | C42948 | A class of gels--semisolid systems which consist of suspensions made up of either small inorganic particles or large organic molecules interpenetrated by a liquid--in which the structural coherent matrix contains a high portion of liquid, usually water. (NCI) | Jelly Dosage Form | |||
KIT | C47916 | A packaged collection of related material. (NCI) | Kit Dosage Form | |||
LINER, DENTAL | C45413 | A material applied to the inside of the dental cavity, for protection or insulation of the surface.(FDA) | Dental Liner Dosage Form | |||
LINIMENT | C42949 | A solution or mixture of various substances in oil, alcoholic solutions of soap, or emulsions intended for external application. (NCI) | Liniment Dosage Form | |||
LIPSTICK | C42952 | A waxy solid, usually colored cosmetic, in stick form for the lips. (NCI) | Lipstick Dosage Form | |||
LIQUID | C42953 | A dosage form consisting of a pure chemical in its liquid state. This dosage form term should not be applied to solutions. Note: A liquid is pourable; it flows and conforms to its container at room temperature. It displays Newtonian or pseudoplastic flow behavior.(FDA) | Liquid Dosage Form | |||
LIQUID, EXTENDED RELEASE | C60934 | A liquid that delivers a drug in such a manner to allow a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form. (FDA) | Extended Release Liquid Dosage Form | |||
LOTION | C29167 | An emulsion, liquid (1) dosage form. This dosage form is generally for external application to the skin (2). Note 1: A liquid is pourable; it flows and conforms to its container at room temperature. It displays Newtonian or pseudoplastic flow behavior. Note 2: Previously the definition of a lotion was: The term lotion has been used to categorize many topical suspensions, solutions, and emulsions intended for application to the skin. The current definition of a lotion is restricted to an emulsion. (FDA) | Lotion Dosage Form | |||
LOTION, AUGMENTED | C60957 | A lotion dosage form that enhances drug delivery. Augmentation does not refer to the strength of the drug in the dosage form. NOTE: CDER has decided to refrain from expanding the use of this dosage form due to difficulties in setting specific criteria that must be met to be considered augmented. (FDA) | Augmented Lotion Dosage Form | |||
LOTION/SHAMPOO | C60958 | A lotion dosage form which has a soap or detergent that is usually used to clean the hair and scalp; it is often used as a vehicle for dermatologic agents. (FDA) | Lotion Shampoo Dosage Form | |||
LOZENGE | C42955 | A solid preparation containing one or more medicaments, usually in a flavored, sweetened base which is intended to dissolve or disintegrate slowly in the mouth. A lollipop is a lozenge on a stick.(FDA) | Lozenge Dosage Form | |||
MOUTHWASH | C29269 | An aqueous solution which is most often used for its deodorant, refreshing, or antiseptic effect. (NCI) | Mouthwash Dosage Form | |||
NOT APPLICABLE | C48624 | The use of a dosage form term is not relevant or appropriate. (NCI) | Dosage Form Not Applicable | |||
OIL | C42965 | An unctuous, combustible substance which is liquid, or easily liquefiable, on warming, and is soluble in ether but insoluble in water. Such substances, depending on their origin, are classified as animal, mineral, or vegetable oils. (NCI) | Oil Dosage Form | |||
OINTMENT | C42966 | oint | A suspension or emulsion, semisolid (1) dosage form, usually containing < 20% water and volatiles (2) and > 50% hydrocarbons, waxes, or polyols as the vehicle. This dosage form is generally for external application to the skin or mucous membranes. Note 1: A semisolid is not pourable; it does not flow or conform to its container at room temperature. It does not flow at low shear stress and generally exhibits plastic flow behavior. Note 2: Percent water and volatiles are measured by a loss on drying test in which the sample is heated at 105 degrees C until constant weight is achieved. (NCI) | Ointment Dosage Form | ||
OINTMENT, AUGMENTED | C60984 | An ointment dosage form that enhances drug delivery. Augmentation does not refer to the strength of the drug in the dosage form. NOTE: CDER has decided to refrain from expanding the use of this dosage form due to difficulties in setting specific criteria that must be met to be considered augmented. (FDA) | Augmented Ointment Dosage Form | |||
PACKING | C47887 | A material, usually covered by or impregnated with a drug, that is inserted into a body cavity or between the tooth enamel and the gingival margin.(FDA) | Packing Dosage Form | |||
PASTE | C42967 | A semisolid dosage form, containing a large proportion (20 - 50%) of solids finely dispersed in a fatty vehicle. This dosage form is generally for external application to the skin or mucous membranes. Note: A semisolid is not pourable; it does not flow or conform to its container at room temperature. It does not flow at low shear stress and generally exhibits plastic flow behavior. (NCI) | Paste Dosage Form | |||
PASTE, DENTIFRICE | C42907 | A paste formulation intended to clean and/or polish the teeth, and which may contain certain additional agents. (NCI) | Dentifrice Paste Dosage Form | |||
PASTILLE | C60985 | An aromatic preparation, often with a pleasing flavor, usually intended to dissolve in the mouth. (FDA) | Pastille Dosage Form | |||
PATCH | C42968 | A drug delivery system that often contains an adhesive backing that is usually applied to an external site on the body. Its ingredients either passively diffuse from, or are actively transported from, some portion of the patch. Depending upon the patch, the ingredients are either delivered to the outer surface of the body or into the body. A patch is sometimes synonymous with the terms Extended Release Film and System. (NCI) | Patch Dosage Form | |||
PATCH, EXTENDED RELEASE | C42923 | A drug delivery system in the form of a patch that releases the drug in such a manner that a reduction in dosing frequency compared to that drug presented as a conventional dosage form (e.g., a solution or a prompt drug-releasing, conventional solid dosage form). (NCI) | Extended Release Patch Dosage Form | |||
PATCH, EXTENDED RELEASE, ELECTRICALLY CONTROLLED | C42911 | A drug delivery system in the form of a patch which is controlled by an electric current that releases the drug in such a manner that a reduction in dosing frequency compared to that drug presented as a conventional dosage form (e.g., a solution or a prompt drug-releasing, conventional solid dosage form). (NCI) | Electrically Controlled Extended Release Patch Dosage Form | |||
PELLET | C42969 | A small sterile solid mass consisting of a highly purified drug (with or without excipients) made by the formation of granules, or by compression and molding. (NCI) | Pellet Dosage Form | |||
PELLET, IMPLANTABLE | C42943 | A small sterile solid mass consisting of a highly purified drug (with or without excipients) made by the formation of granules, or by compression and molding; they are intended for implantation in the body (usually subcutaneously) for the purpose of providing continuous release of the drug over long periods of time. (NCI) | Implantable Pellet Dosage Form | |||
PELLETS, COATED, EXTENDED RELEASE | C42918 | A solid dosage form in which the drug itself is in the form of granules to which varying amounts of coating have been applied, and which releases a drug (or drugs) in such a manner to allow a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form. (NCI) | Extended Release Coated Pellets Dosage Form | |||
PILL | C25394 | A dose of medicine in the form of a small pellet. (NCI) | Pill Dosage Form | |||
PLASTER | C42970 | Substance intended for external application made of such materials and of such consistency as to adhere to the skin and attach to a dressing; plasters are intended to afford protection and support and/or to furnish an occlusion and macerating action and to bring medication into close contact with the skin. (NCI) | Plaster Dosage Form | |||
POULTICE | C47913 | A soft, moist mass of meal, herbs, seed, etc., usually applied hot in cloth that consists of gruel-like consistency. (NCI) | Poultice Dosage Form | |||
POWDER | C42972 | An intimate mixture of dry, finely divided drugs and/or chemicals that may be intended for internal or external use. (NCI) | Powder Dosage Form | |||
POWDER, DENTIFRICE | C42908 | A powder formulation intended to clean and/or polish the teeth, and which may contain certain additional agents. (NCI) | Dentifrice Powder Dosage Form | |||
POWDER, FOR SOLUTION | C42973 | An intimate mixture of dry, finely divided drugs and/or chemicals, which, upon the addition of suitable vehicles, yields a solution. (NCI) | Powder for Solution Dosage Form | |||
POWDER, FOR SUSPENSION | C42975 | An intimate mixture of dry, finely divided drugs and/or chemicals, which, upon the addition of suitable vehicles, yields a suspension (a liquid preparation containing the solid particles dispersed in the liquid vehicle). (NCI) | Powder for Suspension Dosage Form | |||
POWDER, METERED | C42961 | A powder dosage form that is situated inside a container that has a mechanism to deliver a specified quantity. (NCI) | Metered Powder Dosage Form | |||
RING | C60988 | A small circular object with a vacant circular center that is usually intended to be placed in the body by special inserters, where the medication is released, generally for localized effects. (FDA) | Ring Dosage Form | |||
RINSE | C42979 | A liquid used to cleanse by flushing. (NCI) | Rinse Dosage Form | |||
SALVE | C42980 | A thick ointment or cerate (a fat or wax based preparation with a consistency between an ointment and a plaster). (NCI) | Salve Dosage Form | |||
SHAMPOO | C42981 | A liquid soap or detergent used to clean the hair and scalp and is often used as a vehicle for dermatologic agents. (NCI) | Shampoo Dosage Form | |||
SHAMPOO, SUSPENSION | C42982 | A liquid soap or detergent containing one or more solid, insoluble substances dispersed in a liquid vehicle that is used to clean the hair and scalp and is often used as a vehicle for dermatologic agents. (NCI) | Shampoo Suspension Dosage Form | |||
SOAP | C42983 | Any compound of one or more fatty acids, or their equivalents, with an alkali; soap is detergent and is much employed in liniments, enemas, and in making pills. It is also a mild aperient, antacid and antiseptic. (NCI) | Soap Dosage Form | |||
SOLUTION | C42986 | A clear, homogeneous liquid dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents. Note: A liquid is pourable; it flows and conforms to its container at room temperature. It displays Newtonian or pseudoplastic flow behavior. (NCI) | Solution Dosage Form | |||
SOLUTION, CONCENTRATE | C42898 | A liquid preparation (i.e., a substance that flows readily in its natural state) that contains a drug dissolved in a suitable solvent or mixture of mutually miscible solvents; the drug has been strengthened by the evaporation of its non-active parts. (NCI) | Concentrate for Solution Dosage Form | |||
SOLUTION, FOR SLUSH | C42987 | A solution for the preparation of an iced saline slush, which is administered by irrigation and used to induce regional hypothermia (in conditions such as certain open heart and kidney surgical procedures) by its direct application. (NCI) | Solution For Slush Dosage Form | |||
SOLUTION, GEL FORMING / DROPS | C60994 | A solution, which after usually being administered in a drop-wise fashion, forms a gel. (FDA) | Gel Forming Drops Solution Dosage Form | |||
SOLUTION, GEL FORMING, EXTENDED RELEASE | C42935 | A solution that forms a gel when it comes in contact with ocular fluid, and which allows at least a reduction in dosing frequency. (FDA) | Extended Release Gel Forming Solution Dosage Form | |||
SOLUTION/ DROPS | C60992 | A solution which is usually administered in a drop-wise fashion. (FDA) | Drops Solution Dosage Form | |||
SPONGE | C47912 | A porous, interlacing, absorbent material that contains a drug. It is typically used for applying or introducing medication, or for cleansing. A sponge usually retains its shape.(FDA) | Sponge Dosage Form | |||
SPRAY | C42989 | A liquid minutely divided as by a jet of air or steam. (NCI) | Spray Dosage Form | |||
SPRAY, METERED | C42962 | A non-pressurized dosage form consisting of valves which allow the dispensing of a specified quantity of spray upon each activation. (NCI) | Metered Spray Dosage Form | |||
SPRAY, SUSPENSION | C42990 | A liquid preparation containing solid particles dispersed in a liquid vehicle and in the form of coarse droplets or as finely divided solids to be applied locally, most usually to the nasal-pharyngeal tract, or topically to the skin. (NCI) | Spray Suspension Dosage Form | |||
STICK | C42991 | A dosage form prepared in a relatively long and slender often cylindrical form. (NCI) | Stick Dosage Form | |||
STRIP | C47914 | A long narrow piece of material. | Strip Dosage Form | |||
SUPPOSITORY | C42993 | supp | A solid body of various weights and shapes, adapted for introduction into the rectal, vaginal, or urethral orifice of the human body; they usually melt, soften, or dissolve at body temperature. (NCI) | Suppository Dosage Form | ||
SUPPOSITORY, EXTENDED RELEASE | C42924 | A drug delivery system in the form of a suppository that allows at least a reduction in dosing frequency. (NCI) | Extended Release Suppository Dosage Form | |||
SUSPENSION | C42994 | susp | A liquid dosage form that contains solid particles dispersed in a liquid vehicle. Note: A liquid is pourable; it flows and conforms to its container at room temperature. It displays Newtonian or pseudoplastic flow behavior.(FDA) | Suspension Dosage Form | ||
SUSPENSION, EXTENDED RELEASE | C42925 | A liquid preparation consisting of solid particles dispersed throughout a liquid phase in which the particles are not soluble; the suspension has been formulated in a manner to allow at least a reduction in dosing frequency as compared to that drug presented as a conventional dosage form (e.g., as a solution or a prompt drug-releasing, conventional solid dosage form). (NCI) | Extended Release Suspension Dosage Form | |||
SUSPENSION/DROPS | C60995 | A suspension which is usually administered in a dropwise fashion. (FDA) | Drops Suspension Dosage Form | |||
SUTURE | C47889 | A strand or fiber used to hold wound edges in apposition during healing. (NCI) | Suture Dosage Form | |||
SWAB | C47898 | A small piece of relatively flat absorbent material that contains a drug. A swab may also be attached to one end of a small stick. A swab is typically used for applying medication or for cleansing. (NCI) | Swab Dosage Form | |||
SYRUP | C42996 | An oral solution containing high concentrations of sucrose or other sugars; the term has also been used to include any other liquid dosage form prepared in a sweet and viscid vehicle, including oral suspensions. (NCI) | Syrup Dosage Form | |||
TABLET | C42998 | tab | A solid dosage form containing medicinal substances with or without suitable diluents. (NCI) | Tablet Dosage Form | ||
TABLET, CHEWABLE | C42893 | A solid dosage form containing medicinal substances with or without suitable diluents that is intended to be chewed, producing a pleasant tasting residue in the oral cavity that is easily swallowed and does not leave a bitter or unpleasant after-taste. (NCI) | Chewable Tablet Dosage Form | |||
TABLET, COATED | C42897 | A solid dosage form that contains medicinal substances with or without suitable diluents and is covered with a designated coating. (NCI) | Coated Tablet Dosage Form | |||
TABLET, COATED PARTICLES | C60997 | A solid dosage form containing a conglomerate of medicinal particles that have each been covered with a coating. (FDA) | Tablet Coated Particles Dosage Form | |||
TABLET, DELAYED RELEASE | C42905 | A solid dosage form which releases a drug (or drugs) at a time other than promptly after administration. Enteric-coated articles are delayed release dosage forms. (NCI) | Delayed Release Tablet Dosage Form | |||
TABLET, DELAYED RELEASE PARTICLES | C42997 | A solid dosage form containing a conglomerate of medicinal particles that have been covered with a coating which releases a drug (or drugs) at a time other than promptly after administration. Enteric-coated articles are delayed release dosage forms. (NCI) | Delayed Release Particles Tablet Dosage Form | |||
TABLET, EFFERVESCENT | C42910 | A solid dosage form containing mixtures of acids (e.g., citric acid, tartaric acid) and sodium bicarbonate, which release carbon dioxide when dissolved in water; it is intended to be dissolved or dispersed in water before administration.(FDA) | Effervescent Tablet Dosage Form | |||
TABLET, EXTENDED RELEASE | C42927 | A solid dosage form containing a drug which allows at least a reduction in dosing frequency as compared to that drug presented in conventional dosage form. (NCI) | Extended Release Tablet Dosage Form | |||
TABLET, FILM COATED | C42931 | A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer. (NCI) | Film Coated Tablet Dosage Form | |||
TABLET, FILM COATED, EXTENDED RELEASE | C42930 | A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer; the tablet is formulated in such manner as to make the contained medicament available over an extended period of time following ingestion. (NCI) | Film Coated Extended Release Tablet Dosage Form | |||
TABLET, FOR SOLUTION | C61004 | A tablet that forms a solution when placed in a liquid. (FDA) | Tablet For Solution Dosage Form | |||
TABLET, FOR SUSPENSION | C61005 | A tablet that forms a suspension when placed in a liquid (formerly referred to as a Dispersible Tablet). | Tablet For Suspension Dosage Form | |||
TABLET, MULTILAYER | C42964 | A solid dosage form containing medicinal substances that have been compressed to form a multiple-layered tablet or a tablet-within-a-tablet, the inner tablet being the core and the outer portion being the shell. (NCI) | Multilayered Tablet Dosage Form | |||
TABLET, MULTILAYER, EXTENDED RELEASE | C42963 | A solid dosage form containing medicinal substances that have been compressed to form a multiple-layered tablet or a tablet-within-a-tablet, the inner tablet being the core and the outer portion being the shell, which, additionally, is covered in a designated coating; the tablet is formulated in such manner as to allow at least a reduction in dosing frequency as compared to that drug presented as a conventional dosage form. (NCI) | Multilayered Extended Release Tablet Dosage Form | |||
TABLET, ORALLY DISINTEGRATING | C42999 | A solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue. (NCI) | Orally Disintegrating Tablet Dosage Form | |||
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | C61006 | A solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue, but which releases a drug (or drugs) at a time other than promptly after administration. (FDA) | Tablet Orally Disintegrating Delayed Release Dosage Form | |||
TABLET, SOLUBLE | C42985 | A solid dosage form that contains medicinal substances with or without suitable diluents and possesses the ability to dissolve in fluids. (NCI) | Soluble Tablet Dosage Form | |||
TABLET, SUGAR COATED | C42992 | A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a colored or an uncolored water-soluble sugar. (NCI) | Sugar Coated Tablet Dosage Form | |||
TAMPON | C47892 | A plug made of cotton, sponge, or oakum variously used in surgery to plug the nose, vagina, etc., for the control of hemorrhage or the absorption of secretions. (NCI) | Tampon Dosage Form | |||
TAPE | C47897 | A narrow woven fabric, or a narrow extruded synthetic (such as plastic), usually with an adhesive on one or both sides. (NCI) | Tape Dosage Form | |||
TINCTURE | C43000 | An alcoholic or hydroalcoholic solution prepared from vegetable materials or from chemical substances. (NCI) | Tincture Dosage Form | |||
TROCHE | C43001 | A discoid-shaped solid containing the medicinal agent in a suitably flavored base; troches are placed in the mouth where they slowly dissolve, liberating the active ingredients. (NCI) | Troche Dosage Form | |||
UNASSIGNED | C43002 | A dosage form has yet to be assigned. (NCI) | Unassigned Dosage Form | |||
WAFER | C43003 | A thin slice of material containing a medicinal agent. (NCI) | Wafer Dosage Form | |||
Back to top | ||||||
CL.C66727.NCOMPLT | Completion/Reason for Non-Completion (NCOMPLT) | text Extensible: Yes | C66727 | Completion/Reason for Non-Completion | The status of the subject's completion of the study or a segment of the study, or the reason the subject discontinued the study or segment of the study. | CDISC SDTM Reason for Non-Completion Terminology |
ADVERSE EVENT | C41331 | Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. NOTE: For further information, see the ICH Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. [Modified from ICH E2A] Synonyms: side effect, adverse experience. See also serious adverse event, serious adverse experience. (CDISC glossary) | Adverse Event | |||
COMPLETED | C25250 | To possess every necessary or normal part or component or step; having come or been brought to a conclusion. (NCI) | Complete | |||
DEATH | C28554 | The absence of life or state of being dead. (NCI) | Death | |||
LACK OF EFFICACY | C48226 | The lack of expected or desired effect related to a therapy. (NCI) | Lack of Efficacy | |||
LOST TO FOLLOW-UP | C48227 | The loss or lack of continuation of a subject to follow-up. | Lost To Follow-up | |||
NON-COMPLIANCE WITH STUDY DRUG | C49631 | An indication that a subject has not agreed with or followed the instructions related to the study medication. (NCI) | Non-Compliance With Study Drug | |||
OTHER | C17649 | Other | Different than the one(s) previously specified or mentioned. (NCI) | Other | ||
PHYSICIAN DECISION | C48250 | A position, opinion or judgment reached after consideration by a physician with reference to subject. (NCI) | Physician Decision | |||
PREGNANCY | C25742 | Pregnancy is the state or condition of having a developing embryo or fetus in the body (uterus), after union of an ovum and spermatozoon, during the period from conception to birth. (NCI) | Pregnancy | |||
PROGRESSIVE DISEASE | C35571 | A disease process that is increasing in scope or severity. (NCI) | Progressive Disease | |||
PROTOCOL VIOLATION | C48251 | An event or decision that stands in contrast to the guidelines set out by the protocol. (NCI) | Protocol Violation | |||
RECOVERY | C25746 | A healing process and/or an outcome implying relative health. The term is typically used in the context of direct and indirect effects of sickness or injury. (NCI) | Recovery | |||
SCREEN FAILURE | C49628 | The potential subject who does not meet one or more criteria required for participation in a trial. | Trial Screen Failure | |||
STUDY TERMINATED BY SPONSOR | C49632 | An indication that a clinical study was stopped by its sponsor. (NCI) | Study Terminated By Sponsor | |||
TECHNICAL PROBLEMS | C49633 | A problem with some technical aspect of a clinical study, usually related to an instrument. (NCI) | Technical Problem | |||
WITHDRAWAL BY SUBJECT | C49634 | An indication that a study participant has removed itself from the study. (NCI) | Withdrawal by Subject | |||
Back to top | ||||||
CL.C66728.STENRF | Relation to Reference Period (STENRF) | text Extensible: No | C66728 | Relation to Reference Period | The relative relationship of a timepoint to a reference timepoint. | CDISC SDTM Relation to Reference Period Terminology |
AFTER | C38008 | The time period following a point or another period of time. (NCI) | Post | |||
BEFORE | C25629 | Earlier in time or order. (NCI) | Prior | |||
DURING | C25490 | At some point in a given period of time. (NCI) | During | |||
DURING/AFTER | C49640 | Within a certain period of time or after a certain point or period in time. (NCI) | During Or After | |||
U | C17998 | U;Unknown | Not known, not observed, not recorded, or refused. (NCI) | Unknown | ||
COINCIDENT | C25456 | Occurring or operating at the same time. | Concurrent | |||
ONGOING | C53279 | Continuous | Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption. (NCI) | Continue | ||
Back to top | ||||||
CL.C66729.ROUTE | Route of Administration (ROUTE) | text Extensible: Yes | C66729 | Route of Administration | The course by which a substance was administered in order to reach the site of action in the body. | CDISC SDTM Route of Administration Terminology |
AURICULAR (OTIC) | C38192 | Administration to or by way of the ear. (FDA) | Auricular Route of Administration | |||
BUCCAL | C38193 | Administration directed toward the cheek, generally from within the mouth. (FDA) | Buccal Route of Administration | |||
CONJUNCTIVAL | C38194 | Administration to the conjunctiva, the delicate membrane that lines the eyelids and covers the exposed surface of the eyeball. (FDA) | Conjunctival Route of Administration | |||
CUTANEOUS | C38675 | Administration to the skin. (FDA) | Cutaneous Route of Administration | |||
DENTAL | C38197 | Administration to a tooth or teeth. (FDA) | Dental Route of Administration | |||
ELECTRO-OSMOSIS | C38633 | Administration of through the diffusion of substance through a membrane in an electric field. (FDA) | Electro-osmosis Route of Administration | |||
ENDOCERVICAL | C38205 | Administration within the canal of the cervix uteri. Synonymous with the term intracervical. (FDA) | Endocervical Route of Administration | |||
ENDOSINUSIAL | C38206 | Administration within the nasal sinuses of the head. (FDA) | Endosinusial Route of Administration | |||
ENDOTRACHEAL | C38208 | Administration directly into the trachea. Synonymous with the term intratracheal. (FDA) | Endotracheal Route of Administration | |||
ENTERAL | C38209 | Administration directly into the intestines. (FDA) | Enteral Route of Administration | |||
EPIDURAL | C38210 | Administration upon or over the dura mater. (FDA) | Epidural Route of Administration | |||
EXTRA-AMNIOTIC | C38211 | Administration to the outside of the membrane enveloping the fetus. (FDA) | Extraamniotic Route of Administration | |||
EXTRACORPOREAL | C38212 | Administration outside of the body. (FDA) | Extracorporeal Circulation Route of Administration | |||
HEMODIALYSIS | C38200 | Administration through hemodialysate fluid. (FDA) | Administration Via Hemodialysis | |||
INFILTRATION | C38215 | Administration that results in substances passing into tissue spaces or into cells. (FDA) | Infiltration Route of Administration | |||
INTERSTITIAL | C38219 | Administration to or in the interstices of a tissue. (FDA) | Interstitial Route of Administration | |||
INTRA-ABDOMINAL | C38220 | Administration within the abdomen. (FDA) | Intraabdominal Route of Administration | |||
INTRA-AMNIOTIC | C38221 | Administration within the amnion. (FDA) | Intraamniotic Route of Administration | |||
INTRA-ARTERIAL | C38222 | Administration within an artery or arteries. (FDA) | Intraarterial Route of Administration | |||
INTRA-ARTICULAR | C38223 | Administration within a joint. (FDA) | Intraarticular Route of Administration | |||
INTRABILIARY | C38224 | Administration within the bile, bile ducts or gallbladder. (FDA) | Intrabiliary Route of Administration | |||
INTRABRONCHIAL | C38225 | Administration within a bronchus. (FDA) | Intrabronchial Route of Administration | |||
INTRABURSAL | C38226 | Administration within a bursa. (FDA) | Intrabursal Route of Administration | |||
INTRACARDIAC | C38227 | Administration within the heart. (FDA) | Intracardiac Route of Administration | |||
INTRACARTILAGINOUS | C38228 | Administration within a cartilage; endochondral. (FDA) | Intracartilaginous Route of Administration | |||
INTRACAUDAL | C38229 | Administration within the cauda equina. (FDA) | Intracaudal Route of Administration | |||
INTRACAVERNOUS | C38230 | Administration within a pathologic cavity, such as occurs in the lung in tuberculosis. (FDA) | Intracavernous Route of Administration | |||
INTRACAVITARY | C38231 | Administration within a non-pathologic cavity, such as that of the cervix, uterus, or penis, or such as that is formed as the result of a wound. (FDA) | Intracavitary Route of Administration | |||
INTRACEREBRAL | C38232 | Administration within the cerebrum. (FDA) | Intracerebral Route of Administration | |||
INTRACISTERNAL | C38233 | Administration within the cisterna magna cerebellomedularis. (FDA) | Intracisternal Route of Administration | |||
INTRACORNEAL | C38234 | Administration within the cornea (the transparent structure forming the anterior part of the fibrous tunic of the eye). (FDA) | Intracorneal Route of Administration | |||
INTRACORONAL, DENTAL | C38217 | Administration of a drug within a portion of a tooth which is covered by enamel and which is separated from the roots by a slightly constricted region known as the neck. (FDA) | Intracoronal Dental Route of Administration | |||
INTRACORONARY | C38218 | Administration within the coronary arteries. (FDA) | Intracoronary Route of Administration | |||
INTRACORPORUS CAVERNOSUM | C38235 | Administration within the dilatable spaces of the corporus cavernosa of the penis. (FDA) | Intracorporus Cavernosum Route of Administration | |||
INTRADERMAL | C38238 | Administration within the dermis. (FDA) | Intradermal Route of Administration | |||
INTRADISCAL | C38239 | Administration within a disc. (FDA) | Intradiscal Route of Administration | |||
INTRADUCTAL | C38240 | Administration within the duct of a gland. (FDA) | Intraductal Route of Administration | |||
INTRADUODENAL | C38241 | Administration within the duodenum. (FDA) | Intraduodenal Route of Administration | |||
INTRADURAL | C38242 | Administration within or beneath the dura. (FDA) | Intradural Route of Administration | |||
INTRAEPIDERMAL | C38243 | Administration within the epidermis. (FDA) | Intraepidermal Route of Administration | |||
INTRAESOPHAGEAL | C38245 | Administration within the esophagus. (FDA) | Intraesophageal Route of Administration | |||
INTRAGASTRIC | C38246 | Administration within the stomach. (FDA) | Intragastric Route of Administration | |||
INTRAGINGIVAL | C38247 | Administration within the gingivae. (FDA) | Intragingival Route of Administration | |||
INTRAILEAL | C38249 | Administration within the distal portion of the small intestine, from the jejunum to the cecum. (FDA) | Intraileal Route of Administration | |||
INTRALESIONAL | C38250 | Administration within or introduced directly into a localized lesion. (FDA) | Intralesional Route of Administration | |||
INTRALUMINAL | C38251 | Administration within the lumen of a tube. (FDA) | Intraluminal Route of Administration | |||
INTRALYMPHATIC | C38252 | Administration within the lymph. (FDA) | Intralymphatic Route of Administration | |||
INTRAMEDULLARY | C38253 | Administration within the marrow cavity of a bone. (FDA) | Intramedullary Route of Administration | |||
INTRAMENINGEAL | C38254 | Administration within the meninges (the three membranes that envelope the brain and spinal cord). (FDA) | Intrameningeal Route of Administration | |||
INTRAMUSCULAR | C28161 | Administration within a muscle. (FDA) | Intramuscular Route of Administration | |||
INTRAOCULAR | C38255 | Administration within the eye. (FDA) | Intraocular Route of Administration | |||
INTRAOVARIAN | C38256 | Administration within the ovary. (FDA) | Intraovarian Route of Administration | |||
INTRAPERICARDIAL | C38257 | Administration within the pericardium. (FDA) | Intrapericardial Route of Administration | |||
INTRAPERITONEAL | C38258 | Administration within the peritoneal cavity. (FDA) | Intraperitoneal Route of Administration | |||
INTRAPLEURAL | C38259 | Administration within the pleura. (FDA) | Intrapleural Route of Administration | |||
INTRAPROSTATIC | C38260 | Administration within the prostate gland. (FDA) | Intraprostatic Route of Administration | |||
INTRAPULMONARY | C38261 | Administration within the lungs or its bronchi. (FDA) | Intrapulmonary Route of Administration | |||
INTRASINAL | C38262 | Administration within the nasal or periorbital sinuses. (FDA) | Intrasinal Route of Administration | |||
INTRASPINAL | C38263 | Administration within the vertebral column. (FDA) | Intraspinal Route of Administration | |||
INTRASYNOVIAL | C38264 | Administration within the synovial cavity of a joint. (FDA) | Intrasynovial Route of Administration | |||
INTRATENDINOUS | C38265 | Administration within a tendon. (FDA) | Intratendinous Route of Administration | |||
INTRATESTICULAR | C38266 | Administration within the testicle. (FDA) | Intratesticular Route of Administration | |||
INTRATHECAL | C38267 | Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles. (FDA) | Intrathecal Route of Administration | |||
INTRATHORACIC | C38207 | Administration within the thorax (internal to the ribs); synonymous with the term endothoracic. (FDA) | Endothoracic Route of Administration | |||
INTRATUBULAR | C38268 | Administration within the tubules of an organ. (FDA) | Intratubular Route of Administration | |||
INTRATUMOR | C38269 | Intratumor Route of Administration | Administration within a tumor. (FDA) | Intratumoral Route of Administration | ||
INTRATYMPANIC | C38270 | Administration within the auris media. (FDA) | Intratympanic Route of Administration | |||
INTRAUTERINE | C38272 | Administration within the uterus. (FDA) | Intrauterine Route of Administration | |||
INTRAVASCULAR | C38273 | Administration within a vessel or vessels. (FDA) | Intravascular Route of Administration | |||
INTRAVENOUS | C38276 | Administration within or into a vein or veins. (FDA) | Intravenous Route of Administration | |||
INTRAVENOUS BOLUS | C38274 | Administration within or into a vein or veins all at once. (FDA) | Intravenous Bolus | |||
INTRAVENOUS DRIP | C38279 | Administration within or into a vein or veins over a sustained period of time. (FDA) | Intravenous Drip | |||
INTRAVENTRICULAR | C38277 | Administration within a ventricle. (FDA) | Intraventricular Route of Administration | |||
INTRAVESICAL | C38278 | Administration within the bladder. (FDA) | Intravesical Route of Administration | |||
INTRAVITREAL | C38280 | Administration within the vitreous body of the eye. (FDA) | Intravitreal Route of Administration | |||
IONTOPHORESIS | C38203 | Administration by means of an electric current where ions of soluble salts migrate into the tissues of the body. (FDA) | Iontophoresis Route of Administration | |||
IRRIGATION | C38281 | Administration to bathe or flush open wounds or body cavities. (FDA) | Irrigation-Route of Administration | |||
LARYNGEAL | C38282 | Administration directly upon the larynx. (FDA) | Laryngeal Route of Administration | |||
NASAL | C38284 | Administration to the nose; administered by way of the nose. (FDA) | Nasal Route of Administration | |||
NASOGASTRIC | C38285 | Administration through the nose and into the stomach, usually by means of a tube. (FDA) | Nasogastric Route of Administration | |||
NOT APPLICABLE | C48623 | Routes of administration are not applicable. (FDA) | Route of Administration Not Applicable | |||
OCCLUSIVE DRESSING TECHNIQUE | C38286 | Administration by the topical route which is then covered by a dressing which occludes the area. (FDA) | Occlusive Dressing Technique | |||
OPHTHALMIC | C38287 | Administration to the external eye. (FDA) | Ophthalmic Route of Administration | |||
ORAL | C38288 | PO | Administration to or by way of the mouth. (FDA) | Oral Route of Administration | ||
OROPHARYNGEAL | C38289 | Administration directly to the mouth and pharynx. (FDA) | Oropharyngeal Route of Administration | |||
OTHER | C38290 | Administration is different from others on this list. (FDA) | Other Route of Administration | |||
PARENTERAL | C38291 | Administration by injection, infusion, or implantation. (FDA) | Parenteral Route of Administration | |||
PERCUTANEOUS | C38676 | Administration through the skin. (FDA) | Percutaneous Route of Administration | |||
PERIARTICULAR | C38292 | Administration around a joint. (FDA) | Periarticular Route of Administration | |||
PERIDURAL | C38677 | Administration to the outside of the dura mater of the spinal cord. (FDA) | Peridural Route of Administration | |||
PERINEURAL | C38293 | Administration surrounding a nerve or nerves. (FDA) | Perineural Route of Administration | |||
PERIODONTAL | C38294 | Administration around a tooth. (FDA) | Periodontal Route of Administration | |||
RECTAL | C38295 | Administration to the rectum. (FDA) | Rectal Route of Administration | |||
RESPIRATORY (INHALATION) | C38216 | Administration within the respiratory tract by inhaling orally or nasally for local or systemic effect. (FDA) | Inhalation Route of Administration | |||
RETROBULBAR | C38296 | Administration behind the pons or behind the eyeball. (FDA) | Retrobulbar Route of Administration | |||
SOFT TISSUE | C38198 | Administration into any soft tissue. (FDA) | Soft Tissue Route Of Administration | |||
SUBARACHNOID | C38297 | Administration beneath the arachnoid. (FDA) | Subarachnoid Route of Administration | |||
SUBCONJUNCTIVAL | C38298 | Administration beneath the conjunctiva. (FDA) | Subconjunctival Route of Administration | |||
SUBCUTANEOUS | C38299 | SC | Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL. (FDA) | Subcutaneous Route of Administration | ||
SUBLINGUAL | C38300 | Administration beneath the tongue. (FDA) | Sublingual Route of Administration | |||
SUBMUCOSAL | C38301 | Administration beneath the mucous membrane. (FDA) | Submucosal Route of Administration | |||
TOPICAL | C38304 | TOP | Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL. (FDA) | Topical Route of Administration | ||
TRANSDERMAL | C38305 | Administration through the dermal layer of the skin to the systemic circulation by diffusion. (FDA) | Transdermal Route of Administration | |||
TRANSMUCOSAL | C38283 | Administration across the mucosa. (FDA) | Mucosal Route of Administration | |||
TRANSPLACENTAL | C38307 | Administration through or across the placenta. (FDA) | Transplacental Route of Administration | |||
TRANSTRACHEAL | C38308 | Administration through the wall of the trachea. (FDA) | Transtracheal Route of Administration | |||
TRANSTYMPANIC | C38309 | Administration across or through the tympanic cavity. (FDA) | Transtympanic Route of Administration | |||
UNASSIGNED | C38310 | Route of administration has not yet been assigned. (FDA) | Unassigned Route of Administration | |||
UNKNOWN | C38311 | Route of administration is unknown. (FDA) | Unknown Route of Administration | |||
URETERAL | C38312 | Administration into the ureter. (FDA) | Ureteral Route of Administration | |||
URETHRAL | C38271 | Administration into the urethra. (FDA) | Intraurethral Route of Administration | |||
VAGINAL | C38313 | Administration into the vagina. (FDA) | Vaginal Route of Administration | |||
DIETARY | C78373 | Administration by way of food stuff. (NCI) | Dietary Route of Administration | |||
ORAL GAVAGE | C78374 | Administration through the mouth and into the stomach, usually by means of a tube. (NCI) | Oral Gavage Route of Administration | |||
Back to top | ||||||
CL.C66769.AESEV | Severity/Intensity Scale for Adverse Events (AESEV) | text Extensible: No | C66769 | Severity/Intensity Scale for Adverse Events | A scale that defines the degree or state of disease existing in a patient as a result of the occurrence of an adverse event. (NCI) | CDISC SDTM Severity Intensity Scale for Adverse Event Terminology |
MILD | C41338 | Grade 1;1 | A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. | Mild Adverse Event | ||
MODERATE | C41339 | Grade 2;2 | A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. | Moderate Adverse Event | ||
SEVERE | C41340 | Grade 3;3 | A type of adverse event that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. | Severe Adverse Event | ||
Back to top | ||||||
CL.C66731.SEX | Sex (SEX) | text Extensible: No | C66731 | Sex | The assemblage of physical properties or qualities by which male is distinguished from female; the physical difference between male and female; the distinguishing peculiarity of male or female. (NCI) | CDISC SDTM Sex of Individual Terminology |
F | C16576 | Female | A person who belongs to the sex that normally produces ova. The term is used to indicate biological sex distinctions, or cultural gender role distinctions, or both. (NCI) | Female | ||
M | C20197 | Male | A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both. (NCI) | Male | ||
U | C17998 | U;Unknown | Not known, not observed, not recorded, or refused. (NCI) | Unknown | ||
UN | C45908 | Undifferentiated | A person (one of unisexual specimens) who is born with genitalia and/or secondary sexual characteristics of indeterminate sex, or which combine features of both sexes. (NCI) | Intersex | ||
Back to top | ||||||
CL.C66732.SEXPOP | Sex of Participants (SEXPOP) | text Extensible: No | C66732 | Sex of Participants | The specific sex, either male, female, or mixed of the subject group being studied. (NCI) | CDISC SDTM Sex of Study Group Terminology |
BOTH | C49636 | One and the other; relating to or being two in conjunction. (NCI) | Both | |||
F | C16576 | Female | A person who belongs to the sex that normally produces ova. The term is used to indicate biological sex distinctions, or cultural gender role distinctions, or both. (NCI) | Female | ||
M | C20197 | Male | A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both. (NCI) | Male | ||
Back to top | ||||||
CL.C66733.SIZE | Size (SIZE) | text Extensible: Yes | C66733 | Size | The physical magnitude of something. (NCI) | CDISC SDTM Size Terminology |
LARGE | C49508 | Of considerable or relatively great size, extent, or capacity. (NCI) | Large | |||
MEDIUM | C49507 | Mid-way between small and large in number, quantity, magnitude or extent. (NCI) | Medium | |||
SMALL | C25376 | Limited in number, quantity, magnitude or extent. (NCI) | Small | |||
Back to top | ||||||
CL.C66734.DOMAIN | Domain Abbreviation (DOMAIN) | text Extensible: Yes | C66734 | Domain Abbreviation | A unique, 2-character domain code used in the regulatory submission process. The domain abbreviation is used consistently throughout the submission, i.e. in the dataset name, as the value of the domain variable within the dataset, and as a prefix for most variable names in the dataset. (CDISC Glossary) | CDISC SDTM Submission Domain Abbreviation Terminology |
AD | C49563 | Analysis Dataset | Datasets used for statistical analysis and reporting by the sponsor. These are submitted in addition to the data tabulation datasets. | Analysis Dataset Domain | ||
AE | C49562 | Adverse Events | Adverse events may be captured either as free text or a pre-specified list of terms. | Adverse Event Domain | ||
AU | C49565 | Autopsy | Additional data about deaths, specific to findings from autopsies. | Autopsy Domain | ||
BM | C49566 | Bone Measurements | Findings resulting from evaluations of bone mineral density. | Bone Measurements Domain | ||
BR | C49567 | Biopsy | Findings resulting from biopsies. | Biopsy Domain | ||
CE | C85441 | Clinical Events | A dataset used to capture clinical events of interest that would not be classified as adverse events. | Clinical Events Domain | ||
CM | C49568 | Concomitant Meds | Case report form (CRF) data that captures the Concomitant and Prior Medications/Therapies used by the subject. Examples are the Concomitant Medications/Therapies given on an as needed basis and the usual Background Medications/Therapies given for a condition. | Concomitant Medication Domain | ||
CO | C49569 | Comments | The Comments dataset accommodates two sources of comments: 1) those collected alongside other data on topical case report form (CRF) pages such as Adverse Events and 2) those collected on a separate page specifically dedicated to comments. | Comment Domain | ||
DA | C49578 | Drug Accountability | Data regarding the accountability of study drug, such as information on the receipt, dispensing, return, and packaging. | Drug Accountability Domain | ||
DC | C49570 | Disease Characteristics | Data related to the characteristics of a specific disease state under study for a subject. | Disease Characteristics Domain | ||
DM | C49572 | Demographics | The Demographics domain includes a set of essential standard variables that describe each subject in a clinical study. It is the parent domain for all other observations for human clinical subjects | Demographics Domain | ||
DS | C49576 | Disposition | A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to disposition. (NCI) | Disposition Domain | ||
DV | C49585 | Protocol Deviations | The intent of the domain is to capture protocol violations and deviations during the course of the study and will store only those criteria violation by or deviated from by the subject and not a response to each violation or deviation. | Protocol Deviations Domain | ||
EE | C49625 | Electroencephalogram | Findings resulting from electroencephalogram (EEG) tests. | Electroencephalogram Domain | ||
EG | C49626 | Electrocardiogram | Findings related to the collection of ECG data, including position of the subject, method of evaluation, all cycle measurements and all findings from the ECG including an overall interpretation if collected or derived. | Electrocardiogram Domain | ||
EX | C49587 | Exposure | The Exposure domain model records the details of a subject's exposure to protocol-specified study treatment. Study treatment may be any intervention that is prospectively defined as a test material within a study, and is typically but not always supplied to the subject. | Exposure Domain | ||
FA | C85442 | Findings About Events or Interventions | A dataset used to capture the findings about an event or intervention that cannot be represented within an event or intervention record or as a supplemental qualifier. | Findings About Events or Interventions Domain | ||
FH | C49588 | Family History | A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to family history. (NCI) | Family History Domain | ||
HU | C49589 | Healthcare Resource Utilization | Healthcare resource utilization data such as subject visits to physicians, hospitalizations, and nursing home stays. | Healthcare Resource Utilization Domain | ||
IE | C61536 | Inclusion/Exclusion | The intent of the domain model is to only collect those criteria that cause the subject to be in violation of the inclusion/exclusion criteria not a response to each criterion. | Inclusion Exclusion Domain | ||
LB | C49592 | Laboratory Data | Laboratory test findings including, but is not limited to hematology, clinical chemistry and urinalysis data. This domain does not include microbiology or pharmacokinetic data, which are stored in separate domains. | Laboratory Data Domain | ||
MB | C49602 | Microbiology | Microbiology specimen findings, including gram stain results, and organisms found. | Microbiology Specimen Domain | ||
MH | C49603 | Medical History | The medical history dataset includes the subject's prior history at the start of the trial. Examples of subject medical history information could include general medical history, gynecological history, and primary diagnosis. | Medical History Domain | ||
ML | C49604 | Meal Data | Information regarding the subject's meal consumption, such as fluid intake, amounts, form (solid or liquid state), frequency, etc., typically used for pharmacokinetic analysis. | Meal Data Domain | ||
MS | C61531 | Microbiology Susceptibility | This includes microbiology susceptibility test results, plus results of any other organism-related tests. | Microbiology Susceptibility Domain | ||
OM | C49605 | Organ Measurements | Findings from organ measurement evaluations. | Organ Measurement Domain | ||
PC | C49606 | Pharmacokinetic Concentration | Concentrations of drugs/metabolites in fluids or tissues as a function of time. | Pharmacokinetic Concentration Domain | ||
PE | C49608 | Physical Exam | Findings collected during a physical examination of the subject. It has findings that are discovered that are related to body systems. Does not include vital signs measurements, which are stored in the vital signs domain. | Physical Exam Domain | ||
PG | C61529 | Pharmacogenomics | Pharmacogenomics findings that initially focus on genotype and gene expression data. | Pharmacogenomics Domain | ||
PP | C49607 | Pharmacokinetic Parameters | Pharmacokinetic parameters derived from pharmacokinetic concentration-time (PC) data. | Pharmacokinetic Parameters Domain | ||
QS | C49609 | Questionnaires | Questionnaire data may include, but are not limited to the following: subject reported outcomes, validated or non-validated questionnaires, and validated or non-validated diaries (i.e. data with a common topicality). | Questionnaire Domain | ||
SC | C49610 | Subject Characteristics | The subject characteristics domain is for data not collected in other domains that is subject-related. | Subject Characteristics Domain | ||
SE | C49616 | Subject Element | The subject element table describes the actual order of elements followed by the subject, together with the start date/time and end date/time for each element. | Subject Element Domain | ||
SG | C49611 | Surgery | Surgical information. | Surgery Domain | ||
SK | C49612 | Skin Test | Findings from diagnostic skin tests. | Skin Test Domain | ||
SL | C49613 | Sleep Polysomnography Data | Findings from diagnostic sleep tests (polysomnography). | Sleep Polysomnography Domain | ||
ST | C49614 | Stress (Exercise) Test Data | Findings from exercise stress tests. | Stress Exercise Test Data Domain | ||
SU | C49615 | Substance Use | The intent of the domain is to capture substance use information that may be used to assess the efficacy and/or safety of therapies that look to mitigate the effects of chronic substance use. | Substance Use Domain | ||
SV | C49617 | Subject Visits | The subject visits table describes the actual start and end data/time for each visit of each individual subject. | Subject Visits Domain | ||
TA | C49618 | Trial Arms | The trial arms table describes each planned arm in the trial. An arm is described as an ordered sequence of elements. | Trial Arms Domain | ||
TE | C49619 | Trial Elements | The trial elements table describes the element code that is unique for each element, the element description, and the rules for starting and ending an element. | Trial Elements Domain | ||
TI | C49620 | Trial Inclusion/Exclusion Criteria | The trial summary information domain is not subject oriented. It contains one record for each of the inclusion and exclusion criteria for the trial. | Trial Inclusion and Exclusion Criteria Domain | ||
TS | C53483 | Trial Summary | The trial summary information domain is not subject oriented. It contains one record for each trial summary characteristic. | Trial Summary Domain | ||
TV | C49621 | Trial Visits | The trial visits table describes the planned order and number of visits in the study within each arm. | Trial Visits Domain | ||
VS | C49622 | Vital Signs | Measurements including but not limited to blood pressure, temperature, respiration, body surface area, BMI, height and weight. | Vital Signs Domain | ||
BG | C95083 | Body Weight Gain | Body weight gain is the actual difference between two body weight measurements for any given interval for a subject. This is most commonly shown as the difference between two consecutive body weight measurements. | Body Weight Gain Domain | ||
BH | C95084 | Behavioral | This domain captures behavioral testing measurements on individual subjects. | Behavioral Domain | ||
BW | C95085 | Body Weight | This domain captures body weights collected for subjects during the study and at the end of the study (terminal body weights). | Body Weight Domain | ||
CL | C95086 | Clinical Observation | This domain captures clinical sign information including ophthalmology, physical examination, and dermal examination collected in life while executing the study. | Clinical Observation Domain | ||
DD | C95087 | Death Diagnosis | This domain captures the diagnosis of the cause of death for a subject. | Death Diagnosis Domain | ||
DP | C95088 | Developmental Milestone | This domain captures the outcome of developmental milestone testing during a scheduled period of observation. | Developmental Milestone Domain | ||
FE | C95089 | Fertility | This domain captures test results relative to male and female fertility. | Fertility Domain | ||
FW | C95090 | Food And Water | This domain captures food/water consumption of animals in the study. The data in this domain is derived data. | Food and Water Consumption Domain | ||
FX | C95091 | Fetal and Neonatal Developmental Morphology | This domain captures observations for fetal and pup morphological examinations. | Fetal and Neonatal Developmental Morphology Domain | ||
IC | C95092 | Implantation Classification | The Implantation Classification domain provides a record for each implantation identified for the scheduled cesarean section component of a study. | Implantation Classification Domain | ||
LR | C95093 | Cesarean Section and Delivery Litter Results | This domain captures litter based results in female animals for cesarean section and/or delivery components of a study, including litter survival during preweaning. | Cesarean Section and Delivery Litter Results Domain | ||
MA | C95094 | Macroscopic Findings | The gross pathology findings recorded at necropsy. | Macroscopic Findings Domain | ||
MI | C95095 | Microscopic Findings | The histopathology findings and microscopic evaluations recorded. | Microscopic Findings Domain | ||
PM | C95097 | Palpable Masses | This domain captures information of any palpable masses examined during the experimental phase. | Palpable Masses Domain | ||
SJ | C95099 | Subject Stages | The Subject Stages domain captures subject level non-treatment related blocks of time known as stages, such as Gestation, Lactation and Premating. | Subject Stages Domain | ||
TF | C95100 | Tumor Findings | This domain captures the tumor findings of the nonclinical subject. | Tumor Findings Domain | ||
TP | C95101 | Trial Paths | The trial paths domain is not subject oriented. This domain provides the complete planned non-treatment related sequences of stages for each path in a study. | Trial Paths Domain | ||
TT | C95102 | Trial Stages | The trial stages domain is not subject oriented. It captures non-treatment related planned blocks of time known as stages, such as Gestation, Lactation and Premating. | Trial Stages Domain | ||
TX | C95103 | Trial Sets | The trial stages domain is not subject oriented. It contains one record for each trial set characteristic including experimental factors, treatment factors, inherent characteristics, or distinct sponsor designations. | Trial Sets Domain | ||
Back to top | ||||||
CL.C66735.TBLIND | Trial Blinding Schema (TBLIND) | text Extensible: Yes | C66735 | Trial Blinding Schema | The name of a code list that contains terms to define the type of blinding for the trial. (NCI) | CDISC SDTM Trial Blinding Schema Terminology |
DOUBLE BLIND | C15228 | A study in which neither the subject nor the investigator nor the research team interacting with the subject or data during the trial knows what treatment a subject is receiving. (CDISC glossary) | Double Blind Study | |||
OPEN LABEL | C49659 | A trial in which subjects and investigators know which product each subject is receiving; opposite of a blinded or double-blind study. (CDISC glossary) | Open Label Study | |||
SINGLE BLIND | C28233 | A study in which one party, either the investigator or the subject, does not know which medication or placebo is administered to the subject; also called singlemasked study. (CDISC glossary) | Single Blind Study | |||
Back to top | ||||||
CL.C66736.TINDTP | Trial Indication Type (TINDTP) | text Extensible: Yes | C66736 | Trial Indication Type | The name of a code list that contains terms to define the type of trial, e.g. cure or prevention. (NCI) | CDISC SDTM Trial Indication Type Terminology |
CURE | C49654 | A type of study protocol designed to evaluate intervention(s) aimed to cure a disease or condition. (NCI) | Cure Study | |||
DIAGNOSIS | C49653 | A type of study protocol designed to evaluate intervention(s) aimed at identifying a disease or condition. (NCI) | Diagnosis Study | |||
MITIGATION | C49655 | A type of study designed to identify actions necessary to eliminate or reduce the risk to human life or well-being as a result of a particular medication or treatment regimen. (NCI) | Adverse Effect Mitigation Study | |||
PREVENTION | C49657 | A type of study designed to identify actions necessary to permanently eliminate or reduce the long-term risk to human life as a result of a particular medication or treatment regimen. | Prevention Study | |||
TREATMENT | C49656 | A type of study protocol designed to evaluate intervention(s) for treatment of disease, syndrome or condition. | Treatment Study | |||
Back to top | ||||||
CL.C66737.TPHASE | Trial Phase (TPHASE) | text Extensible: Yes | C66737 | Trial Phase | Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed. (NCI) | CDISC SDTM Trial Phase Terminology |
Phase I Trial | C15600 | Trial Phase 1;1 | The initial introduction of an investigational new drug into humans. Phase 1 studies are typically closely monitored and may be conducted in patients or normal volunteer subjects. NOTE: These studies are designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. During Phase 1, sufficient information about the drug's pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid, Phase 2 studies. The total number of subjects and patients included in Phase I studies varies with the drug, but is generally in the range of 20 to 80. Phase 1 studies also include studies of drug metabolism, structure-activity relationships, and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes. [After FDA CDER Handbook, ICH E8] (CDISC glossary) | Phase I Trial | ||
Phase I/II Trial | C15693 | Trial Phase 1-2;1-2 | A class of clinical study that combines elements characteristic of traditional Phase I and Phase II trials. See also Phase I, Phase II. | Phase I/II Trial | ||
Phase II Trial | C15601 | Trial Phase 2;2 | Phase 2. Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug. NOTE: Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects. [After FDA CDER Handbook, ICH E8] (CDISC glossary) | Phase II Trial | ||
Phase II/III Trial | C15694 | Trial Phase 2-3;2-3 | A class of clinical study that combines elements characteristic of traditional Phase II and Phase III trials. | Phase II/III Trial | ||
Phase IIa Trial | C49686 | Trial Phase 2A;2A | A clinical research protocol generally referred to as a pilot or feasibility trial that aims to prove the concept of the new intervention in question. (NCI) | Phase IIa Trial | ||
Phase IIb Trial | C49688 | Trial Phase 2B;2B | A clinical research protocol generally referred to as a well-controlled and pivotal trial that aims to prove the mechanism of action of the new intervention in question. A pivotal study will generally be well-controlled, randomized, of adequate size, and whenever possible, double-blind. (NCI) | Phase IIb Trial | ||
Phase III Trial | C15602 | Trial Phase 3;3 | Phase 3. Studies are expanded controlled and uncontrolled trials. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather the additional information about effectiveness and safety that is needed to confirm efficacy and evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. NOTE: Phase 3 studies usually include from several hundred to several thousand subjects. [After FDA CDER Handbook, ICH E8] (CDISC glossary) | Phase III Trial | ||
Phase IIIa Trial | C49687 | Trial Phase 3A;3A | A classification typically assigned retrospectively to a Phase III trial upon determination by regulatory authorities of a need for a Phase III B trial. | Phase IIIa Trial | ||
Phase IIIb Trial | C49689 | Trial Phase 3B;3B | A subcategory of Phase III trials done near the time of approval to elicit additional findings. NOTE: Dossier review may continue while associated Phase IIIB trials are conducted. These trials may be required as a condition of regulatory authority approval. | Phase IIIb Trial | ||
Phase IV Trial | C15603 | Trial Phase 4;4 | Phase 4. Postmarketing (Phase 4) studies to delineate additional information about the drug's risks, benefits, and optimal use that may be requested by regulatory authorities in conjunction with marketing approval. NOTE: These studies could include, but would not be limited to, studying different doses or schedules of administration than were used in Phase 2 studies, use of the drug in other patient populations or other stages of the disease, or use of the drug over a longer period of time. [After FDA CDER Handbook, ICH E8] (CDISC glossary) | Phase IV Trial | ||
Phase V Trial | C47865 | Trial Phase 5;5 | Postmarketing surveillance is sometimes referred to as Phase V. | Phase V Trial | ||
NA | C48660 | NA | Determination of a value is not relevant in the current context. (NCI) | Not Applicable | ||
Back to top | ||||||
CL.C66738.TSPARMCD | Trial Summary Parameter Test Code (TSPARMCD) | text Extensible: Yes | C66738 | Trial Summary Parameter Test Code | Individual characteristics of a clinical trial, e.g. description of trial design, trial blinding schema, and primary objective of trial. (NCI) | CDISC SDTM Trial Summary Parameter Terminology by Code |
ADDON | C49703 | Added on to Existing Treatments | The addition of a therapeutic product to the existing regimen in a clinical trial, where both entities remain as discrete products. | Test Product Added to Existing Treatment | ||
AGEMAX | C49694 | Planned Maximum Age of Subjects | The anticipated maximum age of the subjects to be entered in a clinical trial. (NCI) | Planned Maximum Age of Subjects | ||
AGEMIN | C49693 | Planned Minimum Age of Subjects | The anticipated minimum age of the subjects to be entered in a clinical trial. (NCI) | Planned Minimum Age of Subjects | ||
AGESPAN | C20587 | Age Span | Subgroups of populations based on age. (NCI) | Age Group | ||
DOSE | C25488 | Dose per Administration | The amount of drug administered to a patient or test subject at one time or the total quantity administered. [AMA Manual of Style] (CDISC Glossary) | Dose | ||
LENGTH | C49697 | Trial Length | Planned length of observation for a single subject. | Trial Length | ||
PLANSUB | C49692 | Planned Number of Subjects;Planned Enrollment;Target Enrollment;Anticipated Enrollment | The planned number of subjects to be entered in a clinical trial. (NCI) | Planned Subject Number | ||
RANDOM | C25196 | Trial is Randomized | The process of assigning trial subjects to treatment or control groups using an element of chance to determine the assignments in order to reduce bias. NOTE: Unequal randomization is used to allocate subjects into groups at a differential rate; for example, three subjects may be assigned to a treatment group for every one assigned to the control group. [ICH E6 1.48] See also balanced study. (CDISC glossary) | Randomization | ||
ROUTE | C38114 | Route of Administration | The course by which a substance was administered in order to reach the site of action in the body. | Route of Administration | ||
SEXPOP | C49696 | Sex of Participants | The specific sex, either male, female, or mixed of the subject group being studied. (NCI) | Sex of Study Group | ||
STOPRULE | C49698 | Study Stop Rules | The rule, regulation and/or condition that determines the point in time when a clinical trial will be terminated. (NCI) | Study Stop Rules | ||
TBLIND | C49658 | Trial Blinding Schema | The name of a code list that contains terms to define the type of blinding for the trial. (NCI) | Trial Blinding Schema | ||
TCNTRL | C49647 | Control Type | Comparator against which the study treatment is evaluated (e.g., concurrent (placebo, no treatment, dose-response, active), external (historical, published literature). | Control Type | ||
TDIGRP | C49650 | Diagnosis Group | A grouping of individuals on the basis of a shared procedure or disease, or lack thereof (e.g. healthy volunteers, type 2 diabetic subjects, subjects with renal cell cancer). Standardized naming systems are available that define the groups within which a subject should be placed. (NCI) | Diagnosis Group | ||
TINDTP | C49652 | Trial Indication Type | The name of a code list that contains terms to define the type of trial, e.g. cure or prevention. (NCI) | Trial Indication Type | ||
TITLE | C49802 | Trial Title | The name of a clinical trial. (NCI) | Trial Title | ||
TPHASE | C48281 | Trial Phase Classification | Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed. (NCI) | Trial Phase | ||
TTYPE | C49660 | Trial Type | The type of clinical trial performed e.g. efficacy, safety. (NCI) | Trial Type | ||
CURTRT | C85582 | Current Therapy or Treatment | The literal identifier of the therapy or medication that is currently being given per protocol. | Current Therapy | ||
OBJPRIM | C85826 | Trial Primary Objective | The principal purpose of the trial. | Trial Primary Objective | ||
OBJSEC | C85827 | Trial Secondary Objective | The auxiliary purpose of the trial. | Trial Secondary Objective | ||
SPONSOR | C70793 | Clinical Study Sponsor;Study Sponsor;Sponsor | An entity that is responsible for the initiation, management, and/or financing of a clinical study. | Clinical Study Sponsor | ||
COMPTRT | C68612 | Comparative Treatment Name | A therapeutically active agent that is intended to provide reference measurements for the experimental protocol of a clinical trial. | Active Comparator Drug | ||
DOSU | C73558 | Dose Units | The unit of measure for the dosage form. | Dosage Form Unit | ||
DOSFRQ | C89081 | Dosing Frequency | The number of doses administered per a specific interval. | Dose Frequency | ||
INDIC | C41184 | Trial Indication | The basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication). | Indication | ||
TRT | C41161 | Investigational Therapy or Treatment | The investigational product under study. | Protocol Agent | ||
ACTSUB | C98703 | Actual Number of Subjects | Actual number of subjects enrolled; may include subjects who were not randomized. | Actual Subject Number | ||
ADAPT | C98704 | Adaptive Design | Indicate if the study includes a prospectively planned opportunity for modification of one or more specified aspects of the study design and hypotheses based on analysis of data (usually interim data) from subjects in the study. | Adaptive Design | ||
CRMDUR | C98715 | Confirmed Response Minimum Duration | The protocol specified minimum amount of time needed to meet the definition of a confirmed response to treatment. | Confirmed Response Minimum Duration | ||
DCUTDESC | C98718 | Data Cutoff Description | Text that describes the cutoff date. | Data Cutoff Date Description | ||
DCUTDTC | C98717 | Data Cutoff Date | A date which indicates any data collected by this date will be used for analysis. | Data Cutoff Date | ||
FCNTRY | C98770 | Planned Country of Investigational Site(s) | The country name of planned study facility which has received IRB approval. | Planned Country of Investigational Site | ||
HLTSUBJI | C98737 | Healthy Subject Indicator | Indicate if persons who have not had the condition(s) being studied or otherwise related conditions or symptoms, as specified in the eligibility requirements, may participate in the study. | Healthy Subject Indicator | ||
INTMODEL | C98746 | Intervention Model | The trial design developed to compare treatment groups. | Intervention Model | ||
INTTYPE | C98747 | Intervention Type | The kind of product or procedure studied in a trial. | Intervention Type | ||
NARMS | C98771 | Planned Number of Arms | The planned number of intervention groups. | Planned Number of Arms | ||
OUTMSEXP | C98724 | Exploratory Outcome Measure | Exploratory measures that will be used to evaluate the intervention(s) or, for observational studies, that are exploratory of the study. | Exploratory Outcome Measure | ||
OUTMSPRI | C98772 | Primary Outcome Measure | The primary measurement(s) or observation(s) used to measure the effect of experimental variables in a study, or for observational studies, to describe patterns of diseases or traits or associations with exposures, risk factors or treatment. These are the outcome measures used to assess the primary objective(s). | Primary Outcome Measure | ||
OUTMSSEC | C98781 | Secondary Outcome Measure | Other key measures that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study. These are the outcome measures used to assess the secondary objective(s). | Secondary Outcome Measure | ||
PCLAS | C98768 | Pharmacological Class of Investigational Therapy | The pharmacological class of the investigational product. | Pharmacological Class of Investigational Therapy | ||
RANDQT | C98775 | Randomization Quotient | The randomization quotient is the number of planned subjects to be exposed to investigational therapy, independent of dose or other factors, divided by the total number of planned subjects. | Randomization Quotient | ||
REGID | C98714 | Registry Identifier | Identification numbers assigned to the protocol by ct.gov, EudraCT, or other registries. | Clinical Trial Registry Identifier | ||
SDMDUR | C98783 | Stable Disease Minimum Duration | The protocol specified minimum amount of time needed to meet the definition of stable disease. | Stable Disease Minimum Duration | ||
SENDTC | C90462 | Study End Date | Final date on which data was collected for any subject (Date/Time of End of Participation, RFPENDTC) based on the protocol. | Study End Date | ||
SSTDTC | C69208 | Study Start Date | The earliest date of informed consent among any subject (Date/Time of Informed Consent, RFICDTC) that enrolled in the study. For studies conducted without informed consent (ie. emergency use) use the date of treatment. Dates for subjects who were screen failures are not included. | Study Date | ||
STYPE | C15320 | Study Type | Describes the role the study plays in determining the interventions a subject receives. | Study Design | ||
Back to top | ||||||
CL.C67152.TSPARM | Trial Summary Parameter Test Name (TSPARM) | text Extensible: Yes | C67152 | Trial Summary Parameter Test Name | Individual characteristics of a clinical trial, e.g. description of trial design, trial blinding schema, and primary objective of trial. (NCI) | CDISC SDTM Trial Summary Parameter Terminology by Name |
Added on to Existing Treatments | C49703 | Added on to Existing Treatments | The addition of a therapeutic product to the existing regimen in a clinical trial, where both entities remain as discrete products. | Test Product Added to Existing Treatment | ||
Planned Maximum Age of Subjects | C49694 | Planned Maximum Age of Subjects | The anticipated maximum age of the subjects to be entered in a clinical trial. (NCI) | Planned Maximum Age of Subjects | ||
Planned Minimum Age of Subjects | C49693 | Planned Minimum Age of Subjects | The anticipated minimum age of the subjects to be entered in a clinical trial. (NCI) | Planned Minimum Age of Subjects | ||
Age Span | C20587 | Age Span | Subgroups of populations based on age. (NCI) | Age Group | ||
Dose per Administration | C25488 | Dose per Administration | The amount of drug administered to a patient or test subject at one time or the total quantity administered. [AMA Manual of Style] (CDISC Glossary) | Dose | ||
Trial Length | C49697 | Trial Length | Planned length of observation for a single subject. | Trial Length | ||
Planned Number of Subjects | C49692 | Planned Number of Subjects;Planned Enrollment;Target Enrollment;Anticipated Enrollment | The planned number of subjects to be entered in a clinical trial. (NCI) | Planned Subject Number | ||
Trial is Randomized | C25196 | Trial is Randomized | The process of assigning trial subjects to treatment or control groups using an element of chance to determine the assignments in order to reduce bias. NOTE: Unequal randomization is used to allocate subjects into groups at a differential rate; for example, three subjects may be assigned to a treatment group for every one assigned to the control group. [ICH E6 1.48] See also balanced study. (CDISC glossary) | Randomization | ||
Route of Administration | C38114 | Route of Administration | The course by which a substance was administered in order to reach the site of action in the body. | Route of Administration | ||
Sex of Participants | C49696 | Sex of Participants | The specific sex, either male, female, or mixed of the subject group being studied. (NCI) | Sex of Study Group | ||
Study Stop Rules | C49698 | Study Stop Rules | The rule, regulation and/or condition that determines the point in time when a clinical trial will be terminated. (NCI) | Study Stop Rules | ||
Trial Blinding Schema | C49658 | Trial Blinding Schema | The name of a code list that contains terms to define the type of blinding for the trial. (NCI) | Trial Blinding Schema | ||
Control Type | C49647 | Control Type | Comparator against which the study treatment is evaluated (e.g., concurrent (placebo, no treatment, dose-response, active), external (historical, published literature). | Control Type | ||
Diagnosis Group | C49650 | Diagnosis Group | A grouping of individuals on the basis of a shared procedure or disease, or lack thereof (e.g. healthy volunteers, type 2 diabetic subjects, subjects with renal cell cancer). Standardized naming systems are available that define the groups within which a subject should be placed. (NCI) | Diagnosis Group | ||
Trial Indication Type | C49652 | Trial Indication Type | The name of a code list that contains terms to define the type of trial, e.g. cure or prevention. (NCI) | Trial Indication Type | ||
Trial Title | C49802 | Trial Title | The name of a clinical trial. (NCI) | Trial Title | ||
Trial Phase Classification | C48281 | Trial Phase Classification | Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed. (NCI) | Trial Phase | ||
Trial Type | C49660 | Trial Type | The type of clinical trial performed e.g. efficacy, safety. (NCI) | Trial Type | ||
Current Therapy or Treatment | C85582 | Current Therapy or Treatment | The literal identifier of the therapy or medication that is currently being given per protocol. This does not include treatment that has been given in the past. | Current Therapy | ||
Trial Primary Objective | C85826 | Trial Primary Objective | The principal purpose of the trial. | Trial Primary Objective | ||
Trial Secondary Objective | C85827 | Trial Secondary Objective | The auxiliary purpose of the trial. | Trial Secondary Objective | ||
Clinical Study Sponsor | C70793 | Clinical Study Sponsor;Study Sponsor;Sponsor | An entity that is responsible for the initiation, management, and/or financing of a clinical study. | Clinical Study Sponsor | ||
Comparative Treatment Name | C68612 | Comparative Treatment Name | A therapeutically active agent that is intended to provide reference measurements for the experimental protocol of a clinical trial. | Active Comparator Drug | ||
Dose Units | C73558 | Dose Units | The unit of measure for the dosage form. | Dosage Form Unit | ||
Dosing Frequency | C89081 | Dosing Frequency | The number of doses administered per a specific interval. | Dose Frequency | ||
Trial Indication | C41184 | Trial Indication | The basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication). | Indication | ||
Investigational Therapy or Treatment | C41161 | Investigational Therapy or Treatment | The investigational product under study. | Protocol Agent | ||
Actual Number of Subjects | C98703 | Actual Number of Subjects | Actual number of subjects enrolled; may include subjects who were not randomized. | Actual Subject Number | ||
Adaptive Design | C98704 | Adaptive Design | Indicate if the study includes a prospectively planned opportunity for modification of one or more specified aspects of the study design and hypotheses based on analysis of data (usually interim data) from subjects in the study. | Adaptive Design | ||
Confirmed Response Minimum Duration | C98715 | Confirmed Response Minimum Duration | The protocol specified minimum amount of time needed to meet the definition of a confirmed response to treatment. | Confirmed Response Minimum Duration | ||
Data Cutoff Description | C98718 | Data Cutoff Description | Text that describes the cutoff date. | Data Cutoff Date Description | ||
Data Cutoff Date | C98717 | Data Cutoff Date | A date which indicates any data collected by this date will be used for analysis. | Data Cutoff Date | ||
Planned Country of Investigational Site(s) | C98770 | Planned Country of Investigational Site(s) | The country name of planned study facility which has received IRB approval. | Planned Country of Investigational Site | ||
Healthy Subject Indicator | C98737 | Healthy Subject Indicator | Indicate if persons who have not had the condition(s) being studied or otherwise related conditions or symptoms, as specified in the eligibility requirements, may participate in the study. | Healthy Subject Indicator | ||
Intervention Model | C98746 | Intervention Model | The trial design developed to compare treatment groups. | Intervention Model | ||
Intervention Type | C98747 | Intervention Type | The kind of product or procedure studied in a trial. | Intervention Type | ||
Planned Number of Arms | C98771 | Planned Number of Arms | The planned number of intervention groups. | Planned Number of Arms | ||
Exploratory Outcome Measure | C98724 | Exploratory Outcome Measure | Exploratory measures that will be used to evaluate the intervention(s) or, for observational studies, that are exploratory of the study. | Exploratory Outcome Measure | ||
Primary Outcome Measure | C98772 | Primary Outcome Measure | The primary measurement(s) or observation(s) used to measure the effect of experimental variables in a study, or for observational studies, to describe patterns of diseases or traits or associations with exposures, risk factors or treatment. These are the outcome measures used to assess the primary objective(s). | Primary Outcome Measure | ||
Secondary Outcome Measure | C98781 | Secondary Outcome Measure | Other key measures that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study. These are the outcome measures used to assess the secondary objective(s). | Secondary Outcome Measure | ||
Pharmacological Class of Investigational Therapy | C98768 | Pharmacological Class of Investigational Therapy | The pharmacological class of the investigational product. | Pharmacological Class of Investigational Therapy | ||
Randomization Quotient | C98775 | Randomization Quotient | The randomization quotient is the number of planned subjects to be exposed to investigational therapy, independent of dose or other factors, divided by the total number of planned subjects. | Randomization Quotient | ||
Registry Identifier | C98714 | Registry Identifier | Identification numbers assigned to the protocol by ct.gov, EudraCT, or other registries. | Clinical Trial Registry Identifier | ||
Stable Disease Minimum Duration | C98783 | Stable Disease Minimum Duration | The protocol specified minimum amount of time needed to meet the definition of stable disease. | Stable Disease Minimum Duration | ||
Study End Date | C90462 | Study End Date | Final date on which data was collected for any subject (Date/Time of End of Participation, RFPENDTC) based on the protocol. | Study End Date | ||
Study Start Date | C69208 | Study Start Date | The earliest date of informed consent among any subject (Date/Time of Informed Consent, RFICDTC) that enrolled in the study. For studies conducted without informed consent (ie. emergency use) use the date of treatment. Dates for subjects who were screen failures are not included. | Study Date | ||
Study Type | C15320 | Study Type | Describes the role the study plays in determining the interventions a subject receives. | Study Design | ||
Back to top | ||||||
CL.C66739.TTYPE | Trial Type (TTYPE) | text Extensible: Yes | C66739 | Trial Type | The type of clinical trial performed e.g. efficacy, safety. (NCI) | CDISC SDTM Trial Type Terminology |
BIO-AVAILABILITY | C49664 | A study of the degree to which or rate at which a drug or other substance is absorbed or becomes available at the site of physiological activity after administration. (NCI) | Bioavailability Study | |||
BIO-EQUIVALENCE | C49665 | A study most often used to compare the efficacy of different formulations to treat a given disease. It is the testing of an old versus a new formulation in healthy volunteers or subjects with the disease under study and usually in one dose. (NCI) | Therapeutic Equivalency Study | |||
EFFICACY | C49666 | A study of the relative therapeutic efficacy of treatment of a disease. Usually this is a Phase II or III study. (NCI) | Efficacy Study | |||
PHARMACODYNAMIC | C49662 | A study of the biochemical and physiological effect of a drug and the mechanism of drug action and the relationship between drug concentration and effect. (NCI) | Pharmacodynamic Study | |||
PHARMACOECONOMIC | C39493 | A study that assesses the value associated with a given drug in therapeutic and economic terms. This type of study is multidisciplinary in nature and takes into consideration the social and economic costs (resource utilization costs including direct, indirect, and intangible costs) of drug therapy in addition to its direct therapeutic benefits. Analyses relate the difference in therapeutic benefits to the difference in costs between treatment alternatives. (NCI) | Pharmacoeconomic Study | |||
PHARMACOGENOMIC | C49661 | A study of identification and analysis of genomic variations that affect the efficacy of a drug. Pharmacogenomic studies can potentially be predictive of an individual's drug-response or adverse reactions or susceptibility to iatrogenic disorders, and may also reveal new targets that can help in the design of new drugs. (NCI) | Pharmacogenomic Study | |||
PHARMACOKINETIC | C49663 | A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. (NCI) | Pharmacokinetic Study | |||
SAFETY | C49667 | A study that assesses the medical risks to a subject. Safety is usually assessed by examining a wide range of clinical parameters, including adverse events, vital signs, physical exam, laboratory tests. | Safety Study | |||
FOOD EFFECT | C98729 | Studies that are conducted to assess the effect of food on the rate and extent of absorption of a drug, either compared to a fasted state or to a reference drug. | Food Effect Study | |||
TOLERABILITY | C98791 | A type of safety study thatassesses the degree to which overt adverse effects can be toleratedby the subject. | Tolerability Study | |||
Back to top | ||||||
CL.C66770.VSRESU | Units for Vital Signs Results (VSRESU) | text Extensible: Yes | C66770 | Units for Vital Signs Results | The unit used to record and describe the result of a test investigating a vital sign. (NCI) | CDISC SDTM Unit for Vital Sign Result Terminology |
% | C25613 | Percentage | A fraction or ratio with 100 understood as the denominator. (NCI) | Percentage | ||
BEATS/MIN | C49673 | Beats per Minute | The number of heartbeats measured per minute time. (NCI) | Beats per Minute | ||
BREATHS/MIN | C49674 | Breaths per Minute | The number of breaths (inhalation and exhalation) taken per minute time. (NCI) | Breaths per Minute | ||
C | C42559 | Degree Celsius | A unit of temperature of the temperature scale designed so that the freezing point of water is 0 degrees and the boiling point is 100 degrees at standard atmospheric pressure. The current official definition of the Celsius sets 0.01 C to be at the triple point of water and a degree to be 1/273.16 of the difference in temperature between the triple point of water and absolute zero. One degree Celsius represents the same temperature difference as one Kelvin. (NCI) | Degree Celsius | ||
cm | C49668 | Centimeter | A basic unit of length in the former CGS version of metric system, equal to one hundredth of a meter or approximately 0.393 700 787 inch. (NCI) | Centimeter | ||
F | C44277 | Degree Fahrenheit | The Fahrenheit temperature scale is named after the German physicist Gabriel Fahrenheit (1686-1736), who proposed it in 1724. In this scale, the freezing point of water is 32 degrees Fahrenheit and the boiling point is 212 degrees, placing the boiling and melting points of water 180 degrees apart. In this scale a degree Fahrenheit is 5/9ths of a Kelvin (or of a degree Celsius), and minus 40 degrees Fahrenheit is equal to minus 40 degrees Celsius. (NCI) | Degree Fahrenheit | ||
g | C48155 | Gram | A metric unit of mass equal to one one thousandth of a kilogram. (NCI) | Gram | ||
IN | C48500 | Inch | A traditional unit of length equal to 2.54 centimeters. (NCI) | Inch | ||
kg | C28252 | Kilogram | The basic SI unit of mass. It is defined as the mass of an international prototype in the form of a platinum-iridium cylinder kept at Sevres in France. It is the only basic unit still defined in terms of a material object, and also the only one with a prefix [kilo] already in place. A kilogram is equal to 1,000 grams and 2.204 622 6 pounds. (NCI) | Kilogram | ||
kg/m2 | C49671 | Kilogram Per Square Meter | The SI derived unit of spread rate of a substance by mass, used also as a measure of area density. (NCI) | Kilogram Per Square Meter | ||
LB | C48531 | Pound | A traditional unit of mass. By international agreement, one avoirdupois pound is equal to exactly 0.453 592 37 kilogram, 16 ounces, or 1.215 28 troy pounds. (NCI) | Pound | ||
m2 | C42569 | Square Meter | The SI unit of area measurement equal to a square whose sides are one meter long. Square meter is equal to 10,000 square centimeters; 0.01 ares; 1.196 square yards; 10.76 square feet; 1550 square inches. (NCI) | Square Meter | ||
mmHg | C49670 | Millimeter of Mercury | A unit of pressure equal to 0.001316 atmosphere and equal to the pressure indicated by one millimeter rise of mercury in a barometer at the Earth's surface. (NCI) | Millimeter of Mercury | ||
ohm | C42554 | Ohm | A unit of electrical resistance equal to the resistance between two points on a conductor when a potential difference of one volt between them produces a current of one Ampere. Ohm is also used to measure impedance and reactance for complex resistance. A measurement in ohms is the reciprocal of a measurement in Siemens. (NCI) | Ohm | ||
Back to top | ||||||
CL.C66741.VSTESTCD | Vital Signs Test Code (VSTESTCD) | text Extensible: Yes | C66741 | Vital Signs Test Code | The name given to the test that analyzes a particular set of vital signs including temperature, respiratory rate, heart beat (pulse), and blood pressure. (NCI) | CDISC SDTM Vital Sign Terminology by Code |
BMI | C16358 | Body Mass Index | A general indicator of the body fat an individual is carrying based upon the ratio of weight to height. (NCI) | Body Mass Index | ||
BODYFAT | C12472 | Adipose Tissue | A specialized form of connective tissue consisting primarily of adipocytes (fat cells), surrounded by a meshwork of collagen fibers. | Adipose Tissue | ||
BSA | C25157 | Body Surface Area | A measure of the 2-dimensional extent of the body surface (i.e., the skin). Body surface area (BSA) can be calculated by mathematical formula or from a chart that relates height to weight. BSA is often an important factor in dosing. (NCI) | Body Surface Area | ||
DIABP | C25299 | Diastolic Blood Pressure | The blood pressure after the contraction of the heart while the chambers of the heart refill with blood. (NCI) | Diastolic Blood Pressure | ||
FRMSIZE | C49680 | Body Frame Size | The categorization of a person's body frame into small, medium and large based on the measurement of wrist circumference or the breadth of the elbow. (NCI) | Body Frame Size | ||
HEIGHT | C25347 | Height | The vertical measurement or distance from the base to the top of an object; the vertical dimension of extension. (NCI) | Height | ||
HR | C49677 | Heart Rate | The number of heartbeats per unit of time, usually expressed as beats per minute. (NCI) | Heart Rate | ||
MAP | C49679 | Mean Arterial Pressure | The mean pressure of the blood within the arterial circulation. The arterial pressure may be directly measured by insertion of an intra-arterial catheter connected to a transducer. The mean arterial pressure (MAP) can be calculated by subsequent analysis of the waveform. MAP can be approximated without an invasive procedure using the following formula: diastolic pressure plus 1/3 of the pulse pressure, where pulse pressure is systolic pressure - diastolic pressure. (NCI) | Mean Arterial Pressure | ||
PULSE | C49676 | Pulse Rate | The rate of the pulse as observed in an artery, expressed as beats per minute. It can be measured at several anatomical sites, including the wrist, neck, temple, groin, behind the knees, or on top of the foot. (NCI) | Pulse Rate | ||
RESP | C49678 | Respiratory Rate | The rate of breathing (inhalation and exhalation) measured within in a unit time, usually expressed as breaths per minute. (NCI) | Respiratory Rate | ||
SYSBP | C25298 | Systolic Blood Pressure | The blood pressure during the contraction of the left ventricle of the heart. | Systolic Blood Pressure | ||
TEMP | C25206 | Temperature | The property of a body or region of space that determines whether or not there will be a net flow of heat into it or out of it from a neighboring body or region and in which direction (if any) the heat will flow, perceptible by living organism as a somatic sensation of cold or heat. It is a measure of the average translational kinetic energy associated with the disordered microscopic motion of atoms and molecules. Temperature is measured in one of the three standard temperature scales: Celsius, Kelvin, and Fahrenheit. (NCI) | Temperature | ||
WEIGHT | C25208 | Weight | The vertical force exerted by a mass as a result of gravity. (NCI) | Weight | ||
SAD | C87054 | Sagittal Abdominal Diameter | A standard measure of visceral obesity, or abdominal fat, which is measured from the patient's back to upper abdomen between the bottom of the rib cage and the top of the pelvic area. This measurement may be taken with the patient standing or in the supine position. (NCI) | Sagittal Abdominal Diameter | ||
KNEEHEEL | C84372 | Knee to Heel Length;Lower Leg Length | A measurement of the length of the lower leg from the top of the knee to the bottom of the heel. This measurement may be taken with a knemometer or calipers. (NCI) | Knee to Heel Length Measurement | ||
HDCIRC | C81255 | Head Circumference | A circumferential measurement of the head at the widest point, which is traditionally above the eyebrows. | Head Circumference | ||
SSSKNF | C98785 | Subscapular Skinfold Thickness | A measurement of the thickness of a pinch of skin situated below or on the underside of the scapula. (NCI) | Subscapular Skinfold Thickness | ||
TRSKNF | C98793 | Triceps Skinfold Thickness | A measurement of the thickness of a pinch of skin on the triceps. (NCI) | Triceps Skinfold Thickness | ||
FARMCIR | C100946 | Forearm Circumference | The distance around an individual's forearm. | Forearm Circumference | ||
HIPCIR | C100947 | Hip Circumference | The distance around an individual's pelvic area or hips. | Hip Circumference | ||
LBM | C71258 | Lean Body Mass | The weight of all organs and tissue in an individual less the weight of the individual's body fat. | Lean Body Mass | ||
PULSEPR | C100945 | Pulse Pressure | The change in systolic to diastolic pressure which produces a pulse. | Pulse Pressure | ||
WSTCIR | C100948 | Waist Circumference | The distance around an individual's midsection or waist. | Waist Circumference | ||
Back to top | ||||||
CL.C67153.VSTEST | Vital Signs Test Name (VSTEST) | text Extensible: Yes | C67153 | Vital Signs Test Name | The name given to the test that analyzes a particular set of vital signs including temperature, respiratory rate, heart beat (pulse), and blood pressure. (NCI) | CDISC SDTM Vital Sign Terminology by Name |
Body Mass Index | C16358 | Body Mass Index | A general indicator of the body fat an individual is carrying based upon the ratio of weight to height. (NCI) | Body Mass Index | ||
Adipose Tissue | C12472 | Adipose Tissue | A specialized form of connective tissue consisting primarily of adipocytes (fat cells), surrounded by a meshwork of collagen fibers. | Adipose Tissue | ||
Body Surface Area | C25157 | Body Surface Area | A measure of the 2-dimensional extent of the body surface (i.e., the skin). Body surface area (BSA) can be calculated by mathematical formula or from a chart that relates height to weight. BSA is often an important factor in dosing. (NCI) | Body Surface Area | ||
Diastolic Blood Pressure | C25299 | Diastolic Blood Pressure | The blood pressure after the contraction of the heart while the chambers of the heart refill with blood. (NCI) | Diastolic Blood Pressure | ||
Body Frame Size | C49680 | Body Frame Size | The categorization of a person's body frame into small, medium and large based on the measurement of wrist circumference or the breadth of the elbow. (NCI) | Body Frame Size | ||
Height | C25347 | Height | The vertical measurement or distance from the base to the top of an object; the vertical dimension of extension. (NCI) | Height | ||
Heart Rate | C49677 | Heart Rate | The number of heartbeats per unit of time, usually expressed as beats per minute. (NCI) | Heart Rate | ||
Mean Arterial Pressure | C49679 | Mean Arterial Pressure | The mean pressure of the blood within the arterial circulation. The arterial pressure may be directly measured by insertion of an intra-arterial catheter connected to a transducer. The mean arterial pressure (MAP) can be calculated by subsequent analysis of the waveform. MAP can be approximated without an invasive procedure using the following formula: diastolic pressure plus 1/3 of the pulse pressure, where pulse pressure is systolic pressure - diastolic pressure. (NCI) | Mean Arterial Pressure | ||
Pulse Rate | C49676 | Pulse Rate | The rate of the pulse as observed in an artery, expressed as beats per minute. It can be measured at several anatomical sites, including the wrist, neck, temple, groin, behind the knees, or on top of the foot. (NCI) | Pulse Rate | ||
Respiratory Rate | C49678 | Respiratory Rate | The rate of breathing (inhalation and exhalation) measured within in a unit time, usually expressed as breaths per minute. (NCI) | Respiratory Rate | ||
Systolic Blood Pressure | C25298 | Systolic Blood Pressure | The blood pressure during the contraction of the left ventricle of the heart. | Systolic Blood Pressure | ||
Temperature | C25206 | Temperature | The property of a body or region of space that determines whether or not there will be a net flow of heat into it or out of it from a neighboring body or region and in which direction (if any) the heat will flow, perceptible by living organism as a somatic sensation of cold or heat. It is a measure of the average translational kinetic energy associated with the disordered microscopic motion of atoms and molecules. Temperature is measured in one of the three standard temperature scales: Celsius, Kelvin, and Fahrenheit. (NCI) | Temperature | ||
Weight | C25208 | Weight | The vertical force exerted by a mass as a result of gravity. (NCI) | Weight | ||
Sagittal Abdominal Diameter | C87054 | Sagittal Abdominal Diameter | A standard measure of visceral obesity, or abdominal fat, which is measured from the patient's back to upper abdomen between the bottom of the rib cage and the top of the pelvic area. This measurement may be taken with the patient standing or in the supine position. (NCI) | Sagittal Abdominal Diameter | ||
Knee to Heel Length | C84372 | Knee to Heel Length;Lower Leg Length | A measurement of the length of the lower leg from the top of the knee to the bottom of the heel. This measurement may be taken with a knemometer or calipers. (NCI) | Knee to Heel Length Measurement | ||
Head Circumference | C81255 | Head Circumference | A circumferential measurement of the head at the widest point, which is traditionally above the eyebrows. | Head Circumference | ||
Subscapular Skinfold Thickness | C98785 | Subscapular Skinfold Thickness | A measurement of the thickness of a pinch of skin situated below or on the underside of the scapula. (NCI) | Subscapular Skinfold Thickness | ||
Triceps Skinfold Thickness | C98793 | Triceps Skinfold Thickness | A measurement of the thickness of a pinch of skin on the triceps. (NCI) | Triceps Skinfold Thickness | ||
Forearm Circumference | C100946 | Forearm Circumference | The distance around an individual's forearm. | Forearm Circumference | ||
Hip Circumference | C100947 | Hip Circumference | The distance around an individual's pelvic area or hips. | Hip Circumference | ||
Lean Body Mass | C71258 | Lean Body Mass | The weight of all organs and tissue in an individual less the weight of the individual's body fat. | Lean Body Mass | ||
Pulse Pressure | C100945 | Pulse Pressure | The change in systolic to diastolic pressure which produces a pulse. | Pulse Pressure | ||
Waist Circumference | C100948 | Waist Circumference | The distance around an individual's midsection or waist. | Waist Circumference | ||
Back to top | ||||||
CL.C66742.NY | No Yes Response (NY) | text Extensible: No | C66742 | No Yes Response | A term that is used to indicate a question with permissible values of yes/no/unknown/not applicable. | CDISC SDTM Yes No Unknown or Not Applicable Response Terminology |
N | C49487 | No | The non-affirmative response to a question. (NCI) | No | ||
NA | C48660 | NA | Determination of a value is not relevant in the current context. (NCI) | Not Applicable | ||
U | C17998 | U;Unknown | Not known, not observed, not recorded, or refused. (NCI) | Unknown | ||
Y | C49488 | Yes | The affirmative response to a question. (NCI) | Yes | ||
Back to top | ||||||
CL.C65047.LBTESTCD | Laboratory Test Code (LBTESTCD) | text Extensible: Yes | C65047 | Laboratory Test Code | Terminology used for Laboratory Tests of the CDISC Standard Data Tabulation Model. | CDISC SDTM Laboratory Test Terminology by Code |
ANISO | C74797 | Anisocytes | A measurement of the inequality in the size of the red blood cells in a whole blood specimen. | Anisocyte Measurement | ||
POIKILO | C79602 | Poikilocytes | A measurement of the odd-shaped erythrocytes in a whole blood specimen. | Poikilocyte Measurement | ||
BILI | C38037 | Bilirubin;Total Bilirubin | A measurement of the total bilirubin in a biological specimen. | Total Bilirubin Measurement | ||
APTT | C38462 | Activated Partial Thromboplastin Time | A measurement of the length of time that it takes for clotting to occur when reagents are added to a plasma specimen. The test is partial due to the absence of tissue factor (Factor III) from the reaction mixture. | Partial Thromboplastin Time | ||
GLUC | C41376 | Glucose | A measurement of the glucose in a biological specimen. | Plasma Glucose Measurement | ||
PH | C45997 | pH | A measure of the acidity or alkalinity of a fluid on a scale of 0 to 14. | pH | ||
RBC | C51946 | Erythrocytes;Red Blood Cells | A measurement of the total erythrocytes in a biological specimen. | Erythrocyte Count | ||
RETI | C51947 | Reticulocytes | A measurement of the reticulocytes in a biological specimen. | Reticulocyte Count | ||
WBC | C51948 | Leukocytes;White Blood Cells | A measurement of the leukocytes in a biological specimen. | Leukocyte Count | ||
LYM | C51949 | Lymphocytes | A measurement of the lymphocytes in a biological specimen. | Lymphocyte Count | ||
PLAT | C51951 | Platelets | A measurement of the platelets in a biological specimen. | Platelet Count | ||
BUN | C61019 | Blood Urea Nitrogen | A measurement of the urea nitrogen in a blood specimen. | Blood Urea Nitrogen Measurement | ||
CHOL | C61032 | Cholesterol;Total Cholesterol | A measurement of the cholesterol in a biological specimen. | Serum Total Cholesterol Measurement | ||
HDL | C61041 | HDL Cholesterol | A measurement of the high density lipoprotein cholesterol in a biological specimen. | Serum HDL Cholesterol Measurement | ||
LDL | C61042 | LDL Cholesterol | A measurement of the low density lipoprotein cholesterol in a biological specimen. | Serum LDL Cholesterol Measurement | ||
PT | C62656 | Prothrombin Time | A blood clotting measurement that evaluates the extrinsic pathway of coagulation. | Prothrombin Time | ||
NEUT | C63321 | Neutrophils | A measurement of the neutrophils in a biological specimen. | Absolute Neutrophil Count | ||
ALB | C64431 | Albumin;Microalbumin | A measurement of the albumin protein in a biological specimen. | Albumin Measurement | ||
ALP | C64432 | Alkaline Phosphatase | A measurement of the alkaline phosphatase in a biological specimen. | Alkaline Phosphatase Measurement | ||
ALT | C64433 | Alanine Aminotransferase;SGPT | A measurement of the alanine aminotransferase in a biological specimen. | Alanine Aminotransferase Measurement | ||
AMYLASE | C64434 | Amylase | A measurement of the total enzyme amylase in a biological specimen. | Amylase Measurement | ||
AST | C64467 | Aspartate Aminotransferase;SGOT | A measurement of the aspartate aminotransferase in a biological specimen. | Aspartate Aminotransferase Measurement | ||
BACT | C64469 | Bacteria | A measurement of the bacteria in a biological specimen. | Bacterial Count | ||
BASO | C64470 | Basophils | A measurement of the basophils in a biological specimen. | Total Basophil Count | ||
BASOLE | C64471 | Basophils/Leukocytes | A relative measurement (ratio or percentage) of the basophils to leukocytes in a biological specimen. | Basophil To Leukocyte Ratio | ||
BILDIR | C64481 | Direct Bilirubin | A measurement of the conjugated or water-soluble bilirubin in a biological specimen. | Direct Bilirubin Measurement | ||
BILIND | C64483 | Indirect Bilirubin | A measurement of the unconjugated or non-water-soluble bilirubin in a biological specimen. | Indirect Bilirubin Measurement | ||
BLASTLE | C64487 | Blasts/Leukocytes | A relative measurement (ratio or percentage) of the blasts to leukocytes in a biological specimen. | Blast To Leukocyte Ratio | ||
CA | C64488 | Calcium | A measurement of the calcium in a biological specimen. | Calcium Measurement | ||
CK | C64489 | Creatine Kinase | A measurement of the total creatine kinase in a biological specimen. | Creatine Kinase Measurement | ||
CKBB | C64490 | Creatine Kinase BB | A measurement of the homozygous B-type creatine kinase in a biological specimen. | Creatine Kinase BB Measurement | ||
CKMB | C64491 | Creatine Kinase MB | A measurement of the heterozygous MB-type creatine kinase in a biological specimen. | Creatine Kinase MB Measurement | ||
CKMM | C64494 | Creatine Kinase MM | A measurement of the homozygous M-type creatine kinase in a biological specimen. | Creatine Kinase MM Measurement | ||
CL | C64495 | Chloride | A measurement of the chloride in a biological specimen. | Chloride Measurement | ||
CO2 | C64545 | Carbon Dioxide | A measurement of the carbon dioxide gas in a biological specimen. | Carbon Dioxide Measurement | ||
COLOR | C64546 | Color | A measurement of the color of a biological specimen. | Color Assessment | ||
CREAT | C64547 | Creatinine | A measurement of the creatinine in a biological specimen. | Creatinine Measurement | ||
CRP | C64548 | C Reactive Protein | A measurement of the C reactive protein in a biological specimen. | C-Reactive Protein Measurement | ||
ELLIPCY | C64549 | Elliptocytes;Ovalocytes | A measurement of the elliptically shaped erythrocytes in a biological specimen. | Elliptocyte Count | ||
EOS | C64550 | Eosinophils | A measurement of the eosinophils in a biological specimen. | Eosinophil Count | ||
EOSLE | C64604 | Eosinophils/Leukocytes | A relative measurement (ratio or percentage) of the eosinophils to leukocytes in a biological specimen. | Eosinophil To Leukocyte Ratio | ||
EPIC | C64605 | Epithelial Cells | A measurement of the epithelial cells in a biological specimen. | Epithelial Cell Count | ||
FIBRINO | C64606 | Fibrinogen | A measurement of the fibrinogen in a biological specimen. | Fibrinogen Measurement | ||
HCT | C64796 | Hematocrit | The percentage of a whole blood specimen that is composed of red blood cells (erythrocytes). | Hematocrit | ||
MCH | C64797 | Ery. Mean Corpuscular Hemoglobin | A quantitative measurement of the mean amount of hemoglobin per erythrocyte in a biological specimen. | Erythrocyte Mean Corpuscular Hemoglobin | ||
MCHC | C64798 | Ery. Mean Corpuscular HGB Concentration | A quantitative measurement of the mean amount of hemoglobin per erythrocytes in a specified volume of a biological specimen. | Erythrocyte Mean Corpuscular Hemoglobin Concentration | ||
MCV | C64799 | Ery. Mean Corpuscular Volume | A quantitative measurement of the mean volume of erythrocytes in a biological specimen. | Erythrocyte Mean Corpuscular Volume | ||
RDW | C64800 | Erythrocytes Distribution Width | A value derived from mean corpuscular volume and the standard deviation of the red blood cell volume in a whole blood specimen. | Erythrocyte Distribution Width Measurement | ||
TEARDCY | C64801 | Dacryocytes;Tear Shaped Erythrocytes;Teardrop Cells | A measurement of dacryocytes in a biological specimen. | Dacryocyte Analysis | ||
HPOCROM | C64802 | Hypochromia | An observation which indicates that the hemoglobin concentration in a red blood cell specimen has fallen below a specified level. | Hypochromia | ||
POLYCHR | C64803 | Polychromasia | A measurement of the blue-staining characteristic of newly generated erythrocytes. | Polychromasia | ||
INR | C64805 | Prothrombin Intl. Normalized Ratio | A ratio that represents the prothrombin time for a plasma specimen, divided by the result for a control plasma specimen, further standardized for the International Sensitivity Index of the tissue factor (thromboplastin) used in the test. | International Normalized Ratio of Prothrombin Time | ||
VLDL | C64806 | VLDL Cholesterol | A measurement of the very low density lipoprotein cholesterol in a biological specimen. | Serum VLDL Cholesterol Measurement | ||
LIPASE | C64807 | Triacylglycerol Lipase | A measurement of the pancreatic lipase in a biological specimen. | Triacylglycerol Lipase Measurement | ||
SODIUM | C64809 | Sodium | A measurement of the sodium in a biological specimen. | Sodium Measurement | ||
NITRITE | C64810 | Nitrite | A measurement of the nitrite in a urine specimen. | Nitrite Measurement | ||
TRIG | C64812 | Triglycerides | A measurement of the triglycerides in a biological specimen. | Triglyceride Measurement | ||
TSH | C64813 | Thyrotropin | A measurement of the thyrotropin in a biological specimen. | Thyrotropin Measurement | ||
URATE | C64814 | Urate;Uric Acid | A measurement of the urate in a biological specimen. | Urate Measurement | ||
UREA | C64815 | Urea | A measurement of the urea in a biological specimen. | Urea Measurement | ||
UROBIL | C64816 | Urobilinogen | A measurement of the urobilinogen in a biological specimen. | Urobilinogen Measurement | ||
VITB12 | C64817 | Vitamin B12 | A measurement of the Vitamin B12 in a serum specimen. | Vitamin B12 Measurement | ||
LYMAT | C64818 | Lymphocytes Atypical | A measurement of the atypical lymphocytes in a biological specimen. | Atypical Lymphocyte Count | ||
LYMATLE | C64819 | Lymphocytes Atypical/Leukocytes | A relative measurement (ratio or percentage) of the atypical lymphocytes to leukocytes in a biological specimen. | Atypical Lymphocyte To Leukocyte Ratio | ||
LYMLE | C64820 | Lymphocytes/Leukocytes | A relative measurement (ratio or percentage) of the lymphocytes to leukocytes in a biological specimen. | Lymphocyte To Leukocyte Ratio | ||
MACROCY | C64821 | Macrocytes | A measurement of the macrocytes in a biological specimen. | Macrocyte Count | ||
MICROCY | C64822 | Microcytes | A measurement of the microcytes in a biological specimen. | Microcyte Count | ||
MONO | C64823 | Monocytes | A measurement of the monocytes in a biological specimen. | Monocyte Count | ||
MONOLE | C64824 | Monocytes/Leukocytes | A relative measurement (ratio or percentage) of the monocytes to leukocytes in a biological specimen. | Monocyte To Leukocyte Ratio | ||
MYBLALE | C64825 | Myeloblasts/Leukocytes | A relative measure (ratio or percentage) of the myeloblasts to leukocytes in a biological specimen. | Myeloblast To Leukocyte Ratio | ||
MYCYLE | C64826 | Myelocytes/Leukocytes | A relative measurement (ratio or percentage) of the myelocytes to leukocytes in a biological specimen. | Myelocyte To Leukocyte Ratio | ||
NEUTLE | C64827 | Neutrophils/Leukocytes | A relative measurement (ratio or percentage) of the neutrophils to leukocytes in a biological specimen. | Neutrophil To Leukocyte Ratio | ||
RETIRBC | C64828 | Reticulocytes/Erythrocytes | A relative measurement (ratio or percentage) of reticulocytes to erythrocytes in a biological specimen. | Reticulocyte To Erythrocyte Ratio | ||
PRLYMLE | C64829 | Prolymphocytes/Leukocytes | A relative measurement (ratio or percentage) of prolymphocytes to leukocytes in a biological specimen. | Prolymphocyte To Leukocyte Ratio | ||
NEUTB | C64830 | Neutrophils Band Form | A measurement of the banded neutrophils in a biological specimen. | Neutrophil Band Form Count | ||
NEUTBLE | C64831 | Neutrophils Band Form/Leukocytes | A relative measurement (ratio or percentage) of the banded neutrophils to leukocytes in a biological specimen. | Neutrophil Band Form To Leukocyte Ratio | ||
SPGRAV | C64832 | Specific Gravity | A ratio of the density of a fluid to the density of water. | Specific Gravity | ||
MG | C64840 | Magnesium | A measurement of the magnesium in a biological specimen. | Magnesium Measurement | ||
GGT | C64847 | Gamma Glutamyl Transferase | A measurement of the gamma glutamyl transferase in a biological specimen. | Gamma Glutamyl Transpeptidase Measurement | ||
HGB | C64848 | Hemoglobin | A measurement of the hemoglobin in a biological specimen. | Hemoglobin Measurement | ||
HBA1C | C64849 | Hemoglobin A1C | A measurement of the glycosylated hemoglobin in a biological specimen. | Glycosylated Hemoglobin Measurement | ||
HBSAG | C64850 | HBsAg;Hepatitis B Virus Surface Antigen | A measurement of the surface antigen reaction of a biological specimen to the Hepatitis B virus. | Hepatitis B Virus Surface Antigen Measurement | ||
HCG | C64851 | Choriogonadotropin Beta;Pregnancy Test | A measurement of the Choriogonadotropin Beta in a biological specimen. | Choriogonadotropin Beta Measurement | ||
K | C64853 | Potassium | A measurement of the potassium in a biological specimen. | Potassium Measurement | ||
KETONES | C64854 | Ketones | A measurement of the ketones in a biological specimen. | Ketone Measurement | ||
LDH | C64855 | Lactate Dehydrogenase | A measurement of the lactate dehydrogenase in a biological specimen. | Lactate Dehydrogenase Measurement | ||
LEUKASE | C64856 | Leukocyte Esterase | A measurement of the enzyme which indicates the presence of white blood cells in a biological specimen. | Leukocyte Esterase Measurement | ||
PHOS | C64857 | Phosphate;Phosphorus;Inorganic Phosphate | A measurement of the phosphate in a biological specimen. | Phosphate Measurement | ||
PROT | C64858 | Protein | A measurement of a group of complex organic macromolecules composed of one or more alpha-L-amino acid chains in a biological specimen. | Total Protein Measurement | ||
PSA | C17634 | Prostate Specific Antigen | A measurement of the prostate specific antigen in a biological specimen. | Prostate Specific Antigen Measurement | ||
CREATCLR | C25747 | Creatinine Clearance | A measurement of the volume of serum or plasma that would be cleared of creatinine by excretion of urine for a specified unit of time (e.g. one minute). | Creatinine Clearance | ||
HAIRYCE | C74604 | Hairy Cells | A measurement of the hairy cells (b-cell lymphocytes with hairy projections from the cytoplasm) in a biological specimen. | Hairy Cell Count | ||
BLAST | C74605 | Blasts | A measurement of the blast cells in a biological specimen. | Blast Count | ||
CD19 | C74606 | CD19 | A count of the CD19 B cells per unit of a biological specimen. | CD19 Expressing B Cell Count | ||
CD3 | C74607 | CD3 | A count of the CD3 T cells per unit of a biological specimen. | CD3 Expressing T Cell Count | ||
CD4 | C74608 | CD4 | A count of the CD4 T cells per unit of a biological specimen. | CD4 Expressing T Cell Count | ||
CD8 | C74609 | CD8 | A count of the CD8 T cells per unit of a biological specimen. | CD8 Expressing T Cell Count | ||
DOHLE | C74610 | Dohle Bodies | A measurement of the Dohle bodies (blue-gray, basophilic, leukocyte inclusions located in the peripheral cytoplasm of neutrophils) in a biological specimen. | Dohle Body Measurement | ||
ESR | C74611 | Erythrocyte Sedimentation Rate;Biernacki Reaction | The distance (e.g. millimeters) that red blood cells settle in unclotted blood over a specified unit of time (e.g. one hour). | Erythrocyte Sedimentation Rate Measurement | ||
HYPSEGCE | C74612 | Hypersegmented Cells | A measurement of the hypersegmented (more than five lobes) neutrophils in a biological specimen. | Hypersegmented Neutrophil Measurement | ||
LYMMCE | C74613 | Lymphoma Cells | A measurement of the malignant lymphocytes in a biological specimen. | Lymphoma Cell Count | ||
MAYHEG | C74614 | May-Hegglin Anomaly | A measurement of the May-Hegglin anomaly in a blood sample. This anomaly is characterized by large, misshapen platelets and the presence of Dohle bodies in leukocytes. | May-Hegglin Anomaly Measurement | ||
METAMY | C74615 | Metamyelocytes | A measurement of the metamyelocytes (small, myelocytic neutrophils with an indented nucleus) in a biological specimen. | Metamyelocyte Count | ||
PAPPEN | C74616 | Pappenheimer Bodies | A measurement of the cells containing Pappenheimer Bodies (violet or blue staining ferritin granules usually found along the periphery of the red blood cells) in a biological specimen. | Pappenheimer Body Count | ||
PELGERH | C74617 | Pelger Huet Anomaly | A measurement of the Pelger Huet Anomaly (nuclei of neutrophils and eosinophils appear rod-like, spherical or dumbbell shaped) in a biological specimen. | Pelger Huet Anomaly Measurement | ||
LYMPL | C74618 | Plasmacytoid Lymphocytes;Plymphocytes | A measurement of the plasmacytoid lymphocytes (lymphocytes with peripherally clumped chromatin and often deep blue cytoplasm, and that appear similar to plasma cells) in a biological specimen. | Plasmacytoid Lymphocyte Count | ||
PLSPCE | C74619 | Precursor Plasma Cells;Plasmablast | A measurement of the precursor (blast stage) plasma cells (antibody secreting cells derived from B cells via antigen stimulation) in a biological specimen. | Precursor Plasma Cell Count | ||
PROLYM | C74620 | Prolymphocytes | A measurement of the prolymphocytes in a biological specimen. | Prolymphocyte Count | ||
PROMONO | C74621 | Promonocytes | A measurement of the promonocytes in a biological specimen. | Promonocyte Count | ||
PROMY | C74622 | Promyelocytes | A measurement of the promyelocytes (immature myelocytes) in a biological specimen. | Promyelocyte Count | ||
ROULEAUX | C74624 | Rouleaux Formation | A measurement of the number of stacking red blood cells within a biological specimen. | Rouleaux Formation Count | ||
SEZCE | C74625 | Sezary Cells | A measurement of the Sezary cells (atypical lymphocytes with cerebriform nuclei) in a biological specimen. | Sezary Cell Count | ||
SCKLCE | C74626 | Sickle Cells | A measurement of the sickle cells (sickle shaped red blood cells) in a biological specimen. | Sickle Cell Count | ||
SMDGCE | C74627 | Smudge Cells;Basket Cells | A measurement of the smudge cells (the nuclear remnant of a ruptured white blood cell) in a biological specimen. | Smudge Cell Count | ||
NEUTVAC | C74628 | Vacuolated Neutrophils | A measurement of the neutrophils containing small vacuoles in a biological specimen. | Vacuolated Neutrophil Count | ||
BLASTLM | C74630 | Leukemic Blasts;Leukemic Lymphoblasts;Immunoblastic Lymphocytes | A measurement of the leukemic blasts (lymphoblasts that remain in an immature state even when outside the bone marrow) in a biological specimen. | Leukemic Blast Count | ||
MONOBL | C74631 | Monoblasts | A measurement of the monoblast cells in a biological specimen. | Monoblast Count | ||
MYBLA | C74632 | Myeloblasts | A measurement of the myeloblast cells in a biological specimen. | Myeloblast Count | ||
ACANTRBC | C74633 | Acanthocytes/Erythrocytes | A relative measurement (ratio or percentage) of acanthocytes to all erythrocytes in a biological specimen. | Acanthocyte to Erythrocyte Ratio Measurement | ||
BTECERBC | C74634 | Bite Cells/Erythrocytes | A relative measurement (ratio or percentage) of bite cells (erythrocytes with the appearance of a bite having been removed, due to oxidative hemolysis) to all erythrocytes in a biological specimen . | Bite Cell to Erythrocyte Ratio Measurement | ||
CD19LY | C74635 | CD19/Lymphocytes | A relative measurement (ratio or percentage) of CD19 B cells to all lymphocytes in a biological specimen. | CD19 B Cell to Lymphocyte Ratio Measurement | ||
CD3LY | C74636 | CD3/Lymphocytes | A relative measurement (ratio or percentage) of CD3 T cells to all lymphocytes in a biological specimen. | CD3 T Cell to Lymphocyte Ratio Measurement | ||
CD4CD8 | C74637 | CD4/CD8 | A relative measurement (ratio or percentage) of CD4 T cells to the CD8 T cells in a biological specimen. | CD4 T Cell to CD8 T Cell Ratio Measurement | ||
CD4LY | C74638 | CD4/Lymphocytes | A relative measurement (ratio or percentage) of CD4 T cells to all lymphocytes in a biological specimen. | CD4 T Cell to Lymphocyte Ratio Measurement | ||
CD8LY | C74639 | CD8/Lymphocytes | A relative measurement (ratio or percentage) of CD8 T cells to all lymphocytes in a biological specimen. | CD8 T Cell to Lymphocyte Ratio Measurement | ||
HRYCELY | C74640 | Hairy Cells/Lymphocytes | A relative measurement (ratio or percentage) of the hairy cells (b-cell lymphocytes with hairy projections from the cytoplasm) to all lymphocytes in a biological specimen . | Hairy Cell to Lymphocyte Ratio Measurement | ||
BLSTLMLY | C74641 | Leukemic Blasts/Lymphocytes | A relative measurement (ratio or percentage) of the leukemic blasts (immature lymphoblasts) to mature lymphocytes in a biological specimen. | Leukemic Blast to Lymphocyte Ratio Measurement | ||
MLIGCEBC | C74643 | Malignant Cells, NOS/Blood Cells | A relative measurement (ratio or percentage) of the malignant cells of all types to all blood cells in a biological specimen. | Malignant Cell to Blood Cell Ratio Measurement | ||
METAMYLE | C74645 | Metamyelocytes/Leukocytes | A relative measurement (ratio or percentage) of the metamyelocytes (small, myelocytic neutrophils with an indented nucleus) to all leukocytes in a biological specimen. | Metamyelocyte to Leukocyte Ratio Measurement | ||
MONOBLLE | C74646 | Monoblasts/Leukocytes | A relative measurement (ratio or percentage) of the monoblasts to leukocytes in a biological specimen. | Monoblast to Leukocyte Ratio Measurement | ||
RBCNURBC | C74647 | Nucleated Erythrocytes/Erythrocytes;Nucleated Red Blood Cells/Erythrocytes | A relative measurement (ratio or percentage) of the nucleated erythrocytes (large, immature nucleated erythrocytes) to all erythrocytes in a biological specimen. | Nucleated Red Blood Cell to Erythrocyte Ratio Measurement | ||
LYMPLLY | C74648 | Plasmacytoid Lymphocytes/Lymphocytes | A relative measurement (ratio or percentage) of the plasmacytoid lymphocytes (lymphocytes with peripherally clumped chromatin and often deep blue cytoplasm, and that appear similar to plasma cells) to all lymphocytes in a biological specimen. | Plasmacytoid Lymphocyte to Lymphocyte Ratio Measurement | ||
POIKRBC | C74649 | Poikilocytes/Erythrocytes | A relative measurement (ratio or percentage) of the poikilocytes, or irregularly shaped erythrocytes, to all erythrocytes in a biological specimen. | Poikilocyte to Erythrocyte Ratio Measurement | ||
PLSPCELY | C74650 | Precursor Plasma Cells/Lymphocytes | A relative measurement (ratio or percentage) of the precursor (blast stage) plasma cells (antibody secreting cells derived from B cells via antigen stimulation) to all lymphocytes in a biological specimen. | Precursor Plasma Cell to Lymphocyte Ratio Measurement | ||
PROLYMLY | C74651 | Prolymphocytes/Lymphocytes | A relative measurement (ratio or percentage) of the prolymphocytes to all lymphocytes in a biological specimen. | Prolymphocyte to Lymphocyte Ratio Measurement | ||
PROMONLE | C74652 | Promonocytes/Leukocytes | A relative measurement (ratio or percentage) of the promonocytes to all leukocytes in a biological specimen. | Promonocyte to Lymphocyte Ratio Measurement | ||
PROMYLE | C74653 | Promyelocytes/Leukocytes | A relative measurement (ratio or percentage) of the promyelocytes (immature myelocytes) to all leukocytes in a biological specimen. | Promyelocyte to Lymphocyte Ratio Measurement | ||
LYMRCTLY | C74654 | Reactive Lymphocytes/Lymphocytes | A relative measurement (ratio or percentage) of the reactive lymphocytes (lymphocytes which have become large due to an antigen reaction) to all lymphocytes in a biological specimen. | Reactive Lymphocyte to Lymphocyte Ratio Measurement | ||
SEZCELY | C74655 | Sezary Cells/Lymphocytes | A relative measurement (ratio or percentage of the Sezary cells (atypical lymphocytes with cerebriform nuclei) to all lymphocytes in a biological specimen. | Sezary Cell to Lymphocyte Ratio Measurement | ||
SCKCERBC | C74656 | Sickle Cells/Erythrocytes | A relative measurement (ratio or percentage) of the sickle cells (sickle shaped red blood cells) to all erythrocytes in a biological specimen. | Sickle Cell to Erythrocyte Ratio Measurement | ||
AUERRODS | C74657 | Auer Rods | A measurement of the Auer rods (elongated needle structures that are found in the cytoplasm of leukemic blasts and are formed by clumps of azurophilic granular material) in a biological specimen. | Auer Rod Measurement | ||
HELMETCE | C74658 | Helmet Cells | A measurement of the Helmet cells (specialized Keratocytes with two projections on either end that are tapered and hornlike) in a biological specimen. | Helmet Cell Count | ||
LGUNSCE | C74659 | Large Unstained Cells | A measurement of the large, peroxidase-negative cells which cannot be further characterized (i.e. as large lymphocytes, virocytes, or stem cells) present in a biological specimen. | Large Unstained Cell Count | ||
MLIGCE | C74660 | Malignant Cells, NOS | A measurement of the malignant cells of all types in a biological specimen. | Malignant Cell Count | ||
PLSMCE | C74661 | Mature Plasma Cells;Plasmacytes | A measurement of the mature plasma cells (plasmacytes) in a biological specimen. | Mature Plasma Cell Count | ||
MYCY | C74662 | Myelocytes | A measurement of the myelocytes in a biological specimen. | Myelocyte Count | ||
SPERM | C74663 | Spermatozoa | A measurement of the spermatozoa cells present in a biological specimen. | Spermatozoa Cell Count | ||
YEAST | C74664 | Yeast Cells | A measurement of the yeast cells present in a biological specimen. | Yeast Cell Measurement | ||
CYAMORPH | C74665 | Amorphous Crystals | A measurement of the amorphous (Note: phosphate or urate, depending on pH) crystals present in a biological specimen. | Amorphous Crystal Measurement | ||
AMORPHSD | C74666 | Amorphous Sediment;Amorphous Debris | A measurement of the amorphous sediment present in a biological specimen. | Amorphous Sediment Measurement | ||
BICARB | C74667 | Bicarbonate;HCO3 | A measurement of the bicarbonate in a biological specimen. | Bicarbonate Measurement | ||
CYBILI | C74668 | Bilirubin Crystals | A measurement of the bilirubin crystals present in a biological specimen. | Bilirubin Crystal Measurement | ||
CYCACAR | C74669 | Calcium Carbonate Crystals | A measurement of the calcium carbonate crystals present in a biological specimen. | Calcium Carbonate Crystal Measurement | ||
CYCAOXA | C74670 | Calcium Oxalate Crystals | A measurement of the calcium oxalate crystals present in a biological specimen. | Calcium Oxalate Crystal Measurement | ||
CYCAPHOS | C74671 | Calcium Phosphate Crystals | A measurement of the calcium phosphate crystals present in a biological specimen. | Calcium Phosphate Crystal Measurement | ||
CYCHOL | C74672 | Cholesterol Crystals | A measurement of the cholesterol crystals present in a biological specimen. | Cholesterol Crystal Measurement | ||
CRYSTALS | C74673 | Crystals | A statement that indicates crystals were looked for and not found in a biological specimen. | Crystal Present Or Absent | ||
CYCYSTIN | C74674 | Cystine Crystals | A measurement of the cystine crystals present in a biological specimen. | Cystine Crystal Measurement | ||
VITB9 | C74676 | Folic Acid;Vitamin B9 | A measurement of the folic acid in a biological specimen. | Folic Acid Measurement | ||
CARNITF | C74677 | Carnitine, Free | A measurement of the free carnitine in a biological specimen. | Free Carnitine Measurement | ||
FRUCT | C74678 | Fructosamine;Glycated Serum Protein | A measurement of the fructosamine in a biological specimen. | Fructosamine Measurement | ||
IRON | C74679 | Iron;FE | A measurement of the iron in a biological specimen. | Iron Measurement | ||
CYLEUC | C74680 | Leucine Crystals | A measurement of the leucine crystals present in a biological specimen. | Leucine Crystal Measurement | ||
CYMSU | C74681 | Monosodium Urate Crystals | A measurement of the monosodium urate crystals present in a biological specimen. | Monosodium Urate Crystal Measurement | ||
CARNIT | C74682 | Carnitine | A measurement of the total carnitine in a biological specimen. | Total Carnitine Measurement | ||
CYTYRO | C74683 | Tyrosine Crystals | A measurement of the triple phosphate crystals present in a biological specimen. | Tyrosine Crystal Measurement | ||
CYURIAC | C74684 | Uric Acid Crystals | A measurement of the uric acid crystals present in a biological specimen. | Uric Acid Crystal Measurement | ||
ANIONG | C74685 | Anion Gap | A computed estimate of the unmeasured anions (those other than the chloride and bicarbonate anions) in a biological specimen. | Anion Gap Measurement | ||
OCCBLD | C74686 | Occult Blood | A measurement of the blood in body products such as a stool sample, not detectable on gross examination. | Occult Blood Measurement | ||
AMPHET | C74687 | Amphetamine | A measurement of any amphetamine class drug present in a biological specimen. | Amphetamine Drug Class Measurement | ||
BARB | C74688 | Barbiturates | A measurement of any barbiturate class drug present in a biological specimen. | Barbiturate Drug Class Measurement | ||
CANNAB | C74689 | Cannabinoids | A measurement of any cannabinoid class drug present in a biological specimen. | Cannabinoid Drug Class Measurement | ||
COCAINE | C74690 | Cocaine | A measurement of the cocaine present in a biological specimen. | Cocaine Measurement | ||
EPIROCE | C74698 | Round Epithelial Cells | A measurement of the round epithelial cells present in a biological specimen. | Round Epithelial Cell Count | ||
ACANT | C74699 | Acanthocytes | A measurement of the acanthocytes in a biological specimen. | Acanthocyte Count | ||
BITECE | C74700 | Bite Cells | A measurement of the bite cells (erythrocytes with the appearance of a bite having been removed, due to oxidative hemolysis) in a biological specimen . | Bite Cell Count | ||
BURRCE | C74701 | Burr Cells;Keratocytes | A measurement of the Burr cells (erythrocytes characterized by the presence of small, blunt projections evenly distributed across the cell surface) in a biological specimen. | Burr Cell Count | ||
CABOT | C74702 | Cabot Rings | A measurement of the Cabot rings (red-purple staining, threadlike, ring or figure 8 shaped filaments in an erythrocyte) in a biological specimen. | Cabot Ring Count | ||
CRENCE | C74703 | Crenated Cells;Echinocytes | A measurement of the Burr cells (erythrocytes characterized by the presence of multiple small, sharp projections evenly distributed across the cell surface) in a biological specimen. | Crenated Cell Measurement | ||
HOWJOL | C74704 | Howell-Jolly Bodies | A measurement of the Howell-Jolly bodies (spherical, blue-black condensed DNA inclusions within the body of a red blood cell that appear under Wright-stain) in a biological specimen. | Howell-Jolly Body Measurement | ||
RBCNUC | C74705 | Nucleated Erythrocytes;Nucleated Red Blood Cells | A measurement of the nucleated erythrocytes (large, immature nucleated erythrocytes) in a biological specimen. | Nucleated Red Blood Cell Count | ||
SCHISTO | C74706 | Schistocytes | A measurement of the schistocytes (fragmented red blood cells) in a biological specimen. | Schistocyte Count | ||
SPHERO | C74707 | Spherocytes | A measurement of the spherocytes (small, sphere-shaped red blood cells) in a biological specimen. | Spherocyte Count | ||
STOMCY | C74708 | Stomatocytes | A measurement of the stomatocytes (red blood cells with an oval or rectangular area of central pallor, producing the appearance of a cell mouth) in a biological specimen. | Stomatocyte Count | ||
HEINZ | C74709 | Heinz Bodies;Heinz-Erhlich Bodies | A measurement of the Heinz bodies (small round inclusions within the body of a red blood cell) in a biological specimen. | Heinz-Ehrlich Body Measurement | ||
HAAB | C92534 | Hepatitis A Virus Antibody | A measurement of the antibody reaction of a biological specimen to the Hepatitis A virus. | Hepatitis A Antibody Measurement | ||
HBSAB | C74711 | Anti-HBs;HBsAb;Hepatitis B Virus Surface Antibody | A measurement of the surface antibody reaction of a biological specimen to the Hepatitis B virus. | Hepatitis B Surface Antibody Measurement | ||
HCAB | C92535 | Hepatitis C Virus Antibody | A measurement of the antibody reaction of a biological specimen to the Hepatitis C virus. | Hepatitis C Antibody Measurement | ||
HIV1AB | C74713 | HIV-1 Antibody | A measurement of the antibody reaction of a biological specimen to the HIV-1 virus. | HIV-1 Antibody Measurement | ||
HIV12AB | C74714 | HIV-1/2 Antibody | A measurement of the antibody reaction of a biological specimen to the either the HIV-1 or HIV-2 virus. | HIV-1 HIV-2 Antibody Measurement | ||
HIV2AB | C74715 | HIV-2 Antibody | A measurement of the antibody reaction of a biological specimen to the HIV-2 virus. | HIV-2 Antibody Measurement | ||
RPR | C74716 | Rapid Plasma Reagin | A measurement of the antibodies produced by cellular damage caused by Treponema pallidum (syphilis) in a biological specimen. | Rapid Plasma Reagin Measurement | ||
RF | C74717 | Rheumatoid Factor | A measurement of the rheumatoid factor antibody in a biological specimen. | Rheumatoid Factor Measurement | ||
IBCT | C74718 | Total Iron Binding Capacity | A measurement of the amount of iron needed to fully saturate the transferrin in a biological specimen. | Total Iron Binding Capacity | ||
IBCU | C74719 | Unsaturated Iron Binding Capacity | A measurement of the binding capacity of unsaturated iron in a biological specimen. | Unsaturated Iron Binding Capacity Measurement | ||
MUCTHR | C74721 | Mucous Threads | A measurement of the mucous threads present in a biological specimen. | Mucous Thread Measurement | ||
TURB | C74723 | Turbidity | A measurement of the opacity of a biological specimen. | Turbidity Measurement | ||
HAVVLD | C92541 | HAV Viral Load | A measurement of the hepatitis A viral load in a biological specimen. | Hepatitis A Viral Load Measurement | ||
HBVVLD | C92542 | HBV Viral Load | A measurement of the hepatitis B viral load in a biological specimen. | Hepatitis B Viral Load Measurement | ||
HCVVLD | C92543 | HCV Viral Load | A measurement of the hepatitis C viral load in a biological specimen. | Hepatitis C Viral Load Measurement | ||
HIVVLD | C92544 | HIV Viral Load | A measurement of the HIV viral load in a biological specimen. | HIV Viral Load Measurement | ||
PLATGNT | C74728 | Giant Platelets | A measurement of the giant (larger than 7um in diameter) platelets in a biological specimen. | Giant Platelet Count | ||
PLATLRG | C74729 | Large Platelets | A measurement of the large (between 4 um and 7um in diameter) platelets in a biological specimen. | Large Platelet Count | ||
MPV | C74730 | Mean Platelet Volume | A measurement of the average size of the platelets present in a blood sample. | Mean Platelet Volume Measurement | ||
ALDOLASE | C74731 | Aldolase | A measurement of the aldolase enzyme in a biological specimen. | Aldolase Measurement | ||
AFP | C74732 | Alpha Fetoprotein | A measurement of the alpha fetoprotein in a biological specimen. | Alpha-fetoprotein Measurement | ||
APOA1 | C74733 | Apolipoprotein A1 | A measurement of the apolipoprotein A1 in the high density lipoproteins of a biological specimen. | Apolipoprotein A1 Measurement | ||
APOB | C74734 | Apolipoprotein B | A measurement of the apolipoprotein B in the low density lipoproteins of a biological specimen. | Apolipoprotein B Measurement | ||
BNP | C74735 | Brain Natriuretic Peptide;B-Type Natriuretic Peptide | A measurement of the brain (B-type) natriuretic peptide in a biological specimen. | Brain Natriuretic Peptide Measurement | ||
CPEPTIDE | C74736 | C-peptide | A measurement of the C (connecting) peptide of insulin in a biological specimen. | C-peptide Measurement | ||
FERRITIN | C74737 | Ferritin | A measurement of the ferritin in a biological specimen. | Ferritin Measurement | ||
GLOBUL | C74738 | Globulin | A measurement of the globulin protein in a biological specimen. | Globulin Protein Measurement | ||
GLUTAM | C74739 | Glutamate;Glutamic Acid | A measurement of the glutamate in a biological specimen. | Glutamate Measurement | ||
HAPTOG | C74740 | Haptoglobin | A measurement of the haptoglobin protein in a biological specimen. | Haptoglobin Protein Measurement | ||
HOMOCY | C74741 | Homocysteine | A measurement of the homocysteine amino acid in a biological specimen. | Homocysteine Acid Measurement | ||
NTELOP | C74743 | N-telopeptide | A measurement of the N-telopeptide in a biological specimen. | N-telopeptide Measurement | ||
OSTEOC | C74744 | Osteocalcin | A measurement of the osteocalcin in a biological specimen. | Osteocalcin Measurement | ||
SHBG | C74745 | Sex Hormone Binding Globulin;Sex Hormone Binding Protein | A measurement of the sex hormone binding (globulin) protein in a biological specimen. | Sex Hormone Binding Protein Measurement | ||
TBG | C74746 | Thyroxine Binding Globulin | A measurement of the thyroxine binding globulin protein in a biological specimen. | Thyroxine Binding Globulin Protein Measurement | ||
T3 | C74747 | Triiodothyronine;Total T3 | A measurement of the total (free and bound) triiodothyronine in a biological specimen. | Triiodothyronine Measurement | ||
T3UP | C74748 | Triiodothyronine Uptake | A measurement of the binding of triiodothyonine to thyroxine binding globulin protein in a biological specimen. | Triiodothyronine Uptake Measurement | ||
TROPONI | C74749 | Troponin I | A measurement of the actin binding troponin in a biological specimen. | Troponin I Measurement | ||
TROPONT | C74750 | Troponin T | A measurement of the tropomyosin binding troponin in a biological specimen. | Troponin T Measurement | ||
TNF | C74751 | Tumor Necrosis Factor;Tumor Necrosis Factor alpha | A measurement of the total tumor necrosis factor (cachexin) cytokine in a biological specimen. | Tumor Necrosis Factor Measurement | ||
BUNCREAT | C74753 | BUN/Creatinine | A relative measurement (ratio or percentage) (ratio) of the blood urea nitrogen (BUN) to the creatinine in a biological specimen. | Blood Urea Nitrogen To Creatinine Ratio Measurement | ||
CYHIPPAC | C74754 | Hippuric Acid Crystals | A measurement of the hippuric acid crystals present in a biological specimen. | Hippuric Acid Crystal Measurement | ||
CYSULFA | C74755 | Sulfa Crystals | A measurement of the sulfa crystals present in a biological specimen. | Sulfa Crystal Measurement | ||
CYTRPHOS | C74756 | Triple Phosphate Crystals | A measurement of the triple phosphate crystals present in a biological specimen. | Triple Phosphate Crystal Measurement | ||
CYUNCLA | C74757 | Unclassified Crystals | A measurement of the unclassifiable crystals present in a biological specimen. | Unclassified Crystal Measurement | ||
CYAMMBIU | C74758 | Ammonium Biurate Crystals;Ammonium Urate | A measurement of the ammonium biurate crystals present in a biological specimen. | Urine Ammonium Biurate Crystal Measurement | ||
CYAMMOX | C74759 | Ammonium Oxalate Crystals | A measurement of the ammonium oxalate crystals present in a urine specimen. | Urine Ammonium Oxalate Crystal Measurement | ||
ALBCREAT | C74761 | Albumin/Creatinine;Microalbumin/Creatinine Ratio | A relative measurement (ratio or percentage) of the albumin to the creatinine in a biological specimen. | Albumin To Creatinine Protein Ratio Measurement | ||
CSBACT | C74762 | Bacterial Casts | A measurement of the bacterial casts present in a biological specimen. | Bacterial Cast Measurement | ||
CASTS | C74763 | Casts | A statement that indicates casts were looked for and not found in a biological specimen. | Cast Present Or Absent | ||
CSCELL | C74764 | Cellular Casts | A measurement of the cellular (white blood cell, red blood cell, epithelial and bacterial) casts present in a biological specimen. | Cellular Cast Measurement | ||
CSGRANC | C74765 | Granular Coarse Casts | A measurement of the coarse granular casts present in a biological specimen. | Coarse Granular Cast Measurement | ||
CSFAT | C74766 | Fatty Casts | A measurement of the fatty casts present in a biological specimen. | Fatty Cast Measurement | ||
CSGRAN | C74768 | Granular Casts | A measurement of the granular (coarse and fine) casts present in a biological specimen. | Granular Cast Measurement | ||
CSGRANF | C74769 | Granular Fine Casts | A measurement of the fine granular casts present in a biological specimen. | Granular Fine Cast Measurement | ||
CSHYAL | C74770 | Hyaline Casts | A measurement of the hyaline casts present in a biological specimen. | Hyaline Cast Measurement | ||
CSMIX | C74771 | Mixed Casts | A measurement of the mixed (the cast contains a mixture of cell types) casts present in a biological specimen. | Mixed Cast Count | ||
CSRBC | C74772 | RBC Casts | A measurement of the red blood cell casts present in a biological specimen. | Red Blood Cell Cast Measurement | ||
EPISQCE | C74773 | Squamous Epithelial Cells | A measurement of the squamous epithelial cells present in a biological specimen. | Squamous Epithelial Cell Count | ||
EPISQTCE | C74774 | Squamous Transitional Epithelial Cells;Epithelial Cells | A measurement of the squamous transitional epithelial cells present in a biological specimen. | Squamous Transitional Epithelial Cell Count | ||
EPITUCE | C74775 | Tubular Epithelial Cells;Renal Tubular Epithelial Cells | A measurement of the tubular epithelial cells present in a biological specimen. | Tubular Epithelial Cell Count | ||
CSUNCLA | C74776 | Unclassified Casts | A measurement of the unclassifiable casts present in a biological specimen. | Unclassified Cast Measurement | ||
CSWAX | C74777 | Waxy Casts | A measurement of the waxy casts present in a biological specimen. | Waxy Cell Cast Measurement | ||
CSWBC | C74778 | WBC Casts | A measurement of the white blood cell casts present in a biological specimen. | White Blood Cell Cast Measurement | ||
CSEPI | C74779 | Epithelial Casts | A measurement of the epithelial cell casts present in a biological specimen. | Epithelial-Cast Measurement | ||
ACTH | C74780 | Adrenocorticotropic Hormone | A measurement of the adrenocorticotropic hormone in a biological specimen. | Adrenocorticotropic Hormone Measurement | ||
CORTISOL | C74781 | Cortisol;Total Cortisol | A measurement of the cortisol in a biological specimen. | Cortisol Measurement | ||
ESTRDIOL | C74782 | Estradiol;Oestradiol | A measurement of the estradiol in a biological specimen. | Estradiol Measurement | ||
FSH | C74783 | Follicle Stimulating Hormone | A measurement of the follicle stimulating hormone (FSH) in a biological specimen. | Follicle Stimulating Hormone Measurement | ||
PTHFG | C74784 | Parathyroid Hormone, Fragmented | A measurement of the fragmented parathyroid hormone in a biological specimen. | Fragmented Parathyroid Hormone Measurement | ||
TESTOSFR | C74785 | Testosterone, Free | A measurement of the free testosterone in a biological specimen. | Free Testosterone Measurement | ||
T4FR | C74786 | Thyroxine, Free;Free T4 | A measurement of the free thyroxine in a biological specimen. | Free Thyroxine Measurement | ||
T3FR | C74787 | Triiodothyronine, Free;Free T3 | A measurement of the free triiodothyronine in a biological specimen. | Free Triiodothyronine Measurement | ||
INSULIN | C74788 | Insulin | A measurement of the insulin in a biological specimen. | Insulin Measurement | ||
PTHI | C74789 | Parathyroid Hormone, Intact | A measurement of the intact parathyroid hormone in a biological specimen. | Intact Parathyroid Hormone Measurement | ||
LH | C74790 | Luteinizing Hormone | A measurement of the luteinizing hormone in a biological specimen. | Luteinizing Hormone Measurement | ||
PROGEST | C74791 | Progesterone | A measurement of the progesterone hormone in a biological specimen. | Progesterone Measurement | ||
SOMATRO | C80360 | Somatotrophin;Growth Hormone | A measurement of the somatotrophin (growth) hormone in a biological specimen. | Somatotropin Measurement | ||
TESTOS | C74793 | Testosterone;Total Testosterone | A measurement of the total (free and bound) testosterone in a biological specimen. | Total Testosterone Measurement | ||
T4 | C74794 | Thyroxine;Total T4 | A measurement of the total (free and bound) thyroxine in a biological specimen. | Total Thyroxine Measurement | ||
OPIATE | C74796 | Opiate | A measurement of any opiate class drug present in a biological specimen. | Opiate Measurement | ||
LYMMCELY | C74910 | Lymphoma Cells/Lymphocytes | A relative measurement (ratio or percentage) of the malignant lymphocytes to all lymphocytes in a biological specimen. | Lymphoma Cell to Lymphocyte Ratio Measurement | ||
PLSMCELY | C74911 | Mature Plasma Cells/Lymphocytes | A relative measurement (ratio or percentage) of the mature plasma cells (plasmacytes) to all lymphocytes in a biological specimen. | Mature Plasma Cell to Lymphocyte Ratio Measurement | ||
CYACIDU | C74912 | Acid Urate Crystals | A measurement of the ammonium acid urate crystals present in a biological specimen. | Acid Urate Crystal Measurement | ||
ADSDNA | C74913 | Anti-Double Stranded DNA | A measurement of the anti-double stranded DNA antibody in a biological specimen. | Anti-Double Stranded DNA Measurement | ||
ANA | C74916 | Antinuclear Antibodies | A measurement of the antinuclear antibodies (antibodies that attack the body's own tissue) in a biological specimen. | Antinuclear Antibody Measurement | ||
NCTD5P | C79437 | 5 Prime Nucleotidase;5'-Ribonucleotide Phosphohydrolase | A measurement of the 5'-nucleotidase in a biological specimen. | 5 Prime Nucleotidase Measurement | ||
SIXMAM | C74876 | 6-Monoacetylmorphine | A measurement of the 6-monoacetylmorphine present in a biological specimen. | 6-Monoacetylmorphine Measurement | ||
ACH | C74838 | Acetylcholine | A measurement of the acetylcholine hormone in a biological specimen. | Acetylcholine Measurement | ||
ADPNCTN | C74839 | Adiponectin | A measurement of the adiponectin hormone in a biological specimen. | Adiponectin Measurement | ||
ALBGLOB | C74894 | Albumin/Globulin | The ratio of albumin to globulin in a biological specimen. | Albumin to Globulin Ratio Measurement | ||
ALDSTRN | C74841 | Aldosterone | A measurement of the aldosterone hormone in a biological specimen. | Aldosterone Measurement | ||
ALPCREAT | C79438 | Alkaline Phosphatase/Creatinine | A relative measurement (ratio or percentage) of the alkaline phosphatase to creatinine in a biological specimen. | Alkaline Phosphatase to Creatinine Ratio Measurement | ||
GSTAL | C79433 | Alpha Glutathione-S-Transferase | A measurement of the alpha form of glutathione S-transferase in a biological specimen. | Alpha Glutathione-S-Transferase Measurement | ||
AMMONIA | C74799 | Ammonia;NH3 | A measurement of the ammonia in a biological specimen. | Ammonia Measurement | ||
ANDSTNDL | C74842 | Androstenediol | A measurement of the androstenediol metabolite in a biological specimen. | Androstenediol Metabolite Measurement | ||
ANDSTNDN | C74843 | Androstenedione;4-Androstenedione | A measurement of the androstenedione hormone in a biological specimen. | Androstenedione Measurement | ||
ANGTNS1 | C74844 | Angiotensin I | A measurement of the angiotensin I hormone in a biological specimen. | Angiotensin I Measurement | ||
ANGTNS2 | C74845 | Angiotensin II | A measurement of the angiotensin II hormone in a biological specimen. | Angiotensin II Measurement | ||
ANGTNSGN | C74846 | Angiotensinogen;Angiotensin Precursor | A measurement of the angiotensinogen hormone in a biological specimen. | Angiotensinogen Measurement | ||
ANTIDPRS | C74691 | Antidepressants | A measurement of any antidepressant class drug present in a biological specimen. | Antidepressant Measurement | ||
ADH | C74847 | Antidiuretic Hormone;Vasopressin | A measurement of the antidiuretic hormone in a biological specimen. | Antidiuretic Hormone Measurement | ||
ANP | C74886 | Atrial Natriuretic Peptide;Atriopeptin | A measurement of the atrial natriuretic peptide in a biological specimen. | Atrial Natriuretic Peptide Measurement | ||
BNZDZPN | C74692 | Benzodiazepine | A measurement of any benzodiazepine class drug present in a biological specimen. | Benzodiazepine Measurement | ||
BILEAC | C74800 | Bile Acid;Bile Salts;Bile Acids;Bile Salt | A measurement of the total bile acids in a biological specimen. | Bile Acid Measurement | ||
CLCTONN | C74848 | Calcitonin | A measurement of the calcitonin hormone in a biological specimen. | Calcitonin Measurement | ||
CLCTRIOL | C74849 | Calcitriol | A measurement of the calcitriol hormone in a biological specimen. | Calcitriol Measurement | ||
CACREAT | C79439 | Calcium/Creatinine | A relative measurement (ratio or percentage) of the calcium to creatinine in a biological specimen. | Calcium to Creatinine Ratio Measurement | ||
CLCREAT | C79440 | Chloride/Creatinine | A relative measurement (ratio or percentage) of the chloride to creatinine in a biological specimen. | Chloride to Creatinine Ratio Measurement | ||
CCK | C74850 | Cholecystokinin;Pancreozymin | A measurement of the cholecystokinin hormone in a biological specimen. | Cholecystokinin Measurement | ||
CODEINE | C74877 | Codeine | A measurement of the codeine present in a biological specimen. | Codeine Measurement | ||
CRTRONE | C79434 | Corticosterone | A measurement of corticosterone in a biological specimen. | Corticosterone Measurement | ||
CRH | C74851 | Corticotropin Releasing Hormone;Corticotropin Releasing Factor | A measurement of the corticotropin releasing hormone in a biological specimen. | Corticotropin Releasing Hormone Measurement | ||
CKBBCK | C79466 | Creatine Kinase BB/Total Creatine Kinase | A relative measurement (ratio or percentage) of the BB-type creatine kinase to total creatine kinase in a biological specimen. | Creatine Kinase BB to Total Creatine Kinase Ratio Measurement | ||
CKMBCK | C79441 | Creatine Kinase MB/Total Creatine Kinase | A relative measurement (ratio or percentage) of the MB-type creatine kinase to total creatine kinase in a biological specimen. | Creatine Kinase MB to Total Creatine Kinase Ratio Measurement | ||
CKMMCK | C79442 | Creatine Kinase MM/Total Creatine Kinase | A relative measurement (ratio or percentage) of the MM-type creatine kinase to total creatine kinase in a biological specimen. | Creatine Kinase MM to Total Creatine Kinase Ratio Measurement | ||
DHEA | C74852 | Dehydroepiandrosterone;Dehydroisoandrosterone | A measurement of the dehydroepiandrosterone hormone in a biological specimen. | Dehydroepiandrosterone Measurement | ||
DPD | C79443 | Deoxypyridinoline | A measurement of the deoxypyridinoline in a biological specimen. | Deoxypyridinoline Measurement | ||
DPDCREAT | C79444 | Deoxypyridinoline/Creatinine | A relative measurement (ratio or percentage) of the deoxypyridinoline to creatinine in a biological specimen. | Deoxypyridinoline to Creatinine Ratio Measurement | ||
DIHYDCDN | C74878 | Dihydrocodeine | A measurement of the dihydrocodeine present in a biological specimen. | Dihydrocodeine Measurement | ||
DHT | C74853 | Dihydrotestosterone;Androstanalone | A measurement of the dihydrotestosterone hormone in a biological specimen. | Dihydrotestosterone Measurement | ||
DOPAMINE | C74854 | Dopamine | A measurement of the dopamine hormone in a biological specimen. | Dopamine Measurement | ||
EPIN | C79445 | Epinephrine;Adrenaline | A measurement of the epinephrine hormone in a biological specimen. | Epinephrine Measurement | ||
EPO | C74855 | Erythropoietin;Hematopoietin | A measurement of the erythropoietin hormone in a biological specimen. | Erythropoietin Measurement | ||
ESTRIOL | C74856 | Estriol;Oestriol | A measurement of the estriol hormone in a biological specimen. | Estriol Measurement | ||
ESTRONE | C74857 | Estrone;Oestrone | A measurement of the estrone hormone in a biological specimen. | Estrone Measurement | ||
ETHANOL | C74693 | Ethanol;Alcohol | A measurement of the ethanol present in a biological specimen. | Ethanol Measurement | ||
GGTCREAT | C79446 | Gamma Glutamyl Transferase/Creatinine | A relative measurement (ratio or percentage) of the gamma glutamyl transferase to creatinine in a biological specimen. | Gamma Glutamyl Transferase to Creatinine Ratio Measurement | ||
GASTRIN | C74858 | Gastrin | A measurement of the gastrin hormone in a biological specimen. | Gastrin Measurement | ||
GLUCAGON | C74859 | Glucagon | A measurement of the glucagon hormone in a biological specimen. | Glucagon Measurement | ||
GLUCCRT | C79447 | Glucose/Creatinine | A relative measurement (ratio or percentage) of the glucose to creatinine in a biological specimen. | Glucose to Creatinine Ratio Measurement | ||
GLDH | C79448 | Glutamate Dehydrogenase | A measurement of the glutamate dehydrogenase in a biological specimen. | Glutamate Dehydrogenase Measurement | ||
GSTCREAT | C79435 | Glutathione-S-Transferase/Creatinine | A relative measurement (ratio or percentage) of the glutathione S-transferase to creatinine in a biological specimen. | Glutathione-S-Transferase to Creatinine Ratio Measurement | ||
GNRH | C74860 | Gonadotropin Releasing Hormone;Luteinising Hormone Releasing Hormone | A measurement of the gonadotropin releasing hormone in a biological specimen. | Gonadotropin Releasing Hormone Measurement | ||
GRWHIH | C74861 | Growth Hormone Inhibiting Hormone;Somatostatin | A measurement of the growth hormone inhibiting hormone in a biological specimen. | Growth Hormone Inhibiting Hormone Measurement | ||
GRWHRH | C74862 | Growth Hormone Releasing Hormone;Somatocrinin | A measurement of the growth hormone releasing hormone in a biological specimen. | Growth Hormone Releasing Hormone Measurement | ||
HVA | C74863 | Homovanillic Acid | A measurement of the homovanillic acid metabolite in a biological specimen. | Homovanillic Acid Measurement | ||
HYDCDN | C74879 | Hydrocodone | A measurement of the hydrocodone present in a biological specimen. | Hydrocodone Measurement | ||
HYDMRPHN | C74880 | Hydromorphone | A measurement of the hydromorphone present in a biological specimen. | Hydromorphone Measurement | ||
IGF1 | C74864 | Insulin-like Growth Factor-1 | A measurement of the insulin-like growth factor-1 in a biological specimen. | Insulin Like Growth Factor-1 Measurement | ||
IGF2 | C74865 | Insulin-like Growth Factor-2 | A measurement of the insulin-like growth factor-2 in a biological specimen. | Insulin Like Growth Factor-2 Measurement | ||
INTLK1 | C74805 | Interleukin 1 | A measurement of the interleukin 1 in a biological specimen. | Interleukin 1 Measurement | ||
INTLK10 | C74806 | Interleukin 10 | A measurement of the interleukin 10 in a biological specimen. | Interleukin 10 Measurement | ||
INTLK11 | C74807 | Interleukin 11 | A measurement of the interleukin 11 in a biological specimen. | Interleukin 11 Measurement | ||
INTLK12 | C74808 | Interleukin 12 | A measurement of the interleukin 12 in a biological specimen. | Interleukin 12 Measurement | ||
INTLK13 | C74809 | Interleukin 13 | A measurement of the interleukin 13 in a biological specimen. | Interleukin 13 Measurement | ||
INTLK14 | C74810 | Interleukin 14 | A measurement of the interleukin 14 in a biological specimen. | Interleukin 14 Measurement | ||
INTLK15 | C74811 | Interleukin 15 | A measurement of the interleukin 15 in a biological specimen. | Interleukin 15 Measurement | ||
INTLK16 | C74812 | Interleukin 16 | A measurement of the interleukin 16 in a biological specimen. | Interleukin 16 Measurement | ||
INTLK17 | C74813 | Interleukin 17 | A measurement of the interleukin 17 in a biological specimen. | Interleukin 17 Measurement | ||
INTLK18 | C74814 | Interleukin 18 | A measurement of the interleukin 18 in a biological specimen. | Interleukin 18 Measurement | ||
INTLK19 | C74815 | Interleukin 19 | A measurement of the interleukin 19 in a biological specimen. | Interleukin 19 Measurement | ||
INTLK2 | C74816 | Interleukin 2 | A measurement of the interleukin 2 in a biological specimen. | Interleukin 2 Measurement | ||
INTLK20 | C74817 | Interleukin 20 | A measurement of the interleukin 20 in a biological specimen. | Interleukin 20 Measurement | ||
INTLK21 | C74818 | Interleukin 21 | A measurement of the interleukin 21 in a biological specimen. | Interleukin 21 Measurement | ||
INTLK22 | C74819 | Interleukin 22 | A measurement of the interleukin 22 in a biological specimen. | Interleukin 22 Measurement | ||
INTLK23 | C74820 | Interleukin 23 | A measurement of the interleukin 23 in a biological specimen. | Interleukin 23 Measurement | ||
INTLK24 | C74821 | Interleukin 24 | A measurement of the interleukin 24 in a biological specimen. | Interleukin 24 Measurement | ||
INTLK25 | C74822 | Interleukin 25 | A measurement of the interleukin 25 in a biological specimen. | Interleukin 25 Measurement | ||
INTLK26 | C74823 | Interleukin 26 | A measurement of the interleukin 26 in a biological specimen. | Interleukin 26 Measurement | ||
INTLK27 | C74824 | Interleukin 27 | A measurement of the interleukin 27 in a biological specimen. | Interleukin 27 Measurement | ||
INTLK28 | C74825 | Interleukin 28 | A measurement of the interleukin 28 in a biological specimen. | Interleukin 28 Measurement | ||
INTLK29 | C74826 | Interleukin 29 | A measurement of the interleukin 29 in a biological specimen. | Interleukin 29 Measurement | ||
INTLK3 | C74827 | Interleukin 3 | A measurement of the interleukin 3 in a biological specimen. | Interleukin 3 Measurement | ||
INTLK30 | C74828 | Interleukin 30 | A measurement of the interleukin 30 in a biological specimen. | Interleukin 30 Measurement | ||
INTLK31 | C74829 | Interleukin 31 | A measurement of the interleukin 31 in a biological specimen. | Interleukin 31 Measurement | ||
INTLK32 | C74830 | Interleukin 32 | A measurement of the interleukin 32 in a biological specimen. | Interleukin 32 Measurement | ||
INTLK33 | C74831 | Interleukin 33 | A measurement of the interleukin 33 in a biological specimen. | Interleukin 33 Measurement | ||
INTLK4 | C74832 | Interleukin 4 | A measurement of the interleukin 4 in a biological specimen. | Interleukin 4 Measurement | ||
INTLK5 | C74833 | Interleukin 5 | A measurement of the interleukin 5 in a biological specimen. | Interleukin 5 Measurement | ||
INTLK6 | C74834 | Interleukin 6 | A measurement of the interleukin 6 in a biological specimen. | Interleukin 6 Measurement | ||
INTLK7 | C74835 | Interleukin 7 | A measurement of the interleukin 7 in a biological specimen. | Interleukin 7 Measurement | ||
INTLK8 | C74836 | Interleukin 8 | A measurement of the interleukin 8 in a biological specimen. | Interleukin 8 Measurement | ||
INTLK9 | C74837 | Interleukin 9 | A measurement of the interleukin 9 in a biological specimen. | Interleukin 9 Measurement | ||
LDH1 | C74887 | LDH Isoenzyme 1 | A measurement of the lactate dehydrogenase isoenzyme 1 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 1 Measurement | ||
LDH2 | C74888 | LDH Isoenzyme 2 | A measurement of the lactate dehydrogenase isoenzyme 2 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 2 Measurement | ||
LDH3 | C74889 | LDH Isoenzyme 3 | A measurement of the lactate dehydrogenase isoenzyme 3 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 3 Measurement | ||
LDH4 | C74890 | LDH Isoenzyme 4 | A measurement of the lactate dehydrogenase isoenzyme 4 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 4 Measurement | ||
LDH5 | C74891 | LDH Isoenzyme 5 | A measurement of the lactate dehydrogenase isoenzyme 5 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 5 Measurement | ||
LDHCREAT | C79449 | Lactate Dehydrogenase/Creatinine | A relative measurement (ratio or percentage) of the lactate dehydrogenase to creatinine in a biological specimen. | Lactate Dehydrogenase to Creatinine Ratio Measurement | ||
LACTICAC | C79450 | Lactic Acid;2-hydroxypropanoic acid;Lactate | A measurement of the lactic acid in a biological specimen. | Lactic Acid Measurement | ||
LGLUCLE | C79467 | Large Unstained Cells/Leukocytes | A relative measure (ratio or percentage) of the large unstained cells to leukocytes in a biological specimen. | Large Unstained Cells to Leukocytes Ratio Measurement | ||
LDH1LDH | C79451 | LDH Isoenzyme 1/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 1 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 1 to LDH Ratio Measurement | ||
LDH2LDH | C79452 | LDH Isoenzyme 2/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 2 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 2 to LDH Ratio Measurement | ||
LDH3LDH | C79453 | LDH Isoenzyme 3/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 3 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 3 to LDH Ratio Measurement | ||
LDH4LDH | C79454 | LDH Isoenzyme 4/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 4 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 4 to LDH Ratio Measurement | ||
LDH5LDH | C79455 | LDH Isoenzyme 5/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 5 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 5 to LDH Ratio Measurement | ||
LEPTIN | C74866 | Leptin | A measurement of the leptin hormone in a biological specimen. | Leptin Measurement | ||
MGCREAT | C79456 | Magnesium/Creatinine | A relative measurement (ratio or percentage) of the magnesium to creatinine in a biological specimen. | Magnesium to Creatinine Ratio Measurement | ||
MLATONIN | C74867 | Melatonin | A measurement of the melatonin hormone in a biological specimen. | Melatonin Measurement | ||
METHDN | C74881 | Methadone | A measurement of the methadone present in a biological specimen. | Methadone Measurement | ||
METHQLDN | C74882 | Methaqualone | A measurement of the methaqualone present in a biological specimen. | Methaqualone Measurement | ||
MORPHINE | C74883 | Morphine | A measurement of the morphine present in a biological specimen. | Morphine Measurement | ||
GSTMU | C79457 | Mu Glutathione-S-Transferase | A measurement of the mu form of glutathione S-transferase in a biological specimen. | Mu Glutathione-S-Transferase Measurement | ||
GSTMUCRT | C79458 | Mu Glutathione-S-Transferase/Creatinine | A relative measurement (ratio or percentage) of the mu gamma glutamyl transpeptidase to creatinine in a biological specimen. | Mu Glutathione-S-Transferase to Creatinine Ratio Measurement | ||
MGB | C79436 | Myoglobin | A measurement of myoglobin in a biological specimen. | Myoglobin Measurement | ||
NAG | C79459 | N-Acetyl Glucosamide;N-Acetyl Glucosamine | A measurement of N-acetyl glucosamide in a biological specimen. | N-Acetyl Glucosamide Measurement | ||
NAGCREAT | C79460 | N-Acetyl Glucosamide/Creatinine | A relative measurement (ratio or percentage) of the N-acetyl glucosamide to creatinine in a biological specimen. | N-Acetyl Glucosamide to Creatinine Ratio Measurement | ||
NPY | C74892 | Neuropeptide Y | A measurement of the neuropeptide Y in a biological specimen. | Neuropeptide Y Measurement | ||
NOREPIN | C74868 | Noradrenaline;Norepinephrine | A measurement of the norepinephrine hormone in a biological specimen. | Noradrenaline Measurement | ||
OSMLTY | C74801 | Osmolality | A measurement of the osmoles of solute per unit of biological specimen. | Osmolality Measurement | ||
OXYCDN | C74884 | Oxycodone;Oxycontin | A measurement of the oxycodone present in a biological specimen. | Oxycodone Measurement | ||
OXYTOCIN | C74869 | Oxytocin;Oxytoxin | A measurement of the oxytocin hormone in a biological specimen. | Oxytocin Measurement | ||
PCP | C74694 | Phencyclidine;Phenylcyclohexylpiperidine | A measurement of the phencyclidine present in a biological specimen. | Phencyclidine Measurement | ||
PHENTHZ | C74695 | Phenothiazine;Dibenzothiazine | A measurement of the phenothiazine present in a biological specimen. | Phenothiazine Measurement | ||
PHOSCRT | C79461 | Phosphate/Creatinine | A relative measurement (ratio or percentage) of the phosphate to creatinine in a biological specimen. | Phosphate to Creatinine Ratio Measurement | ||
KCREAT | C79462 | Potassium/Creatinine | A relative measurement (ratio or percentage) of the potassium to creatinine in a biological specimen. | Potassium to Creatinine Ratio Measurement | ||
PROLCTN | C74870 | Prolactin | A measurement of the prolactin hormone in a biological specimen. | Prolactin Measurement | ||
PROPOX | C74885 | Propoxyphene | A measurement of the propoxyphene present in a biological specimen. | Propoxyphene Measurement | ||
PROTCRT | C79463 | Protein/Creatinine | A relative measurement (ratio or percentage) of the protein to creatinine in a biological specimen. | Protein to Creatinine Ratio Measurement | ||
PSDEPHD | C74696 | Pseudoephedrine | A measurement of the pseudoephedrine present in a biological specimen. | Pseudoephedrine Measurement | ||
LYMRCT | C74629 | Reactive Lymphocytes | A measurement of the reactive lymphocytes (lymphocytes which have become large due to an antigen reaction) in a biological specimen. | Reactive Lymphocyte Count Measurement | ||
RENIN | C74893 | Renin;Angiotensinogenase | A measurement of the renin in a biological specimen. | Renin Measurement | ||
SECRETIN | C74871 | Secretin | A measurement of the secretin hormone in a biological specimen. | Secretin Measurement | ||
SRTONIN | C74872 | Serotonin | A measurement of the serotonin hormone in a biological specimen. | Serotonin Measurement | ||
NACREAT | C79464 | Sodium/Creatinine | A relative measurement (ratio or percentage) of the sodium to creatinine in a biological specimen. | Sodium to Creatinine Ratio Measurement | ||
SDH | C79465 | Sorbitol Dehydrogenase | A measurement of the sorbitol dehydrogenase in a biological specimen. | Sorbitol Dehydrogenase Measurement | ||
THRMPTN | C74873 | Thrombopoietin | A measurement of the thrombopoietin hormone in a biological specimen. | Thrombopoietin Measurement | ||
TRH | C74874 | Thyrotropin Releasing Hormone;Thyrotropin Releasing Factor | A measurement of the thyrotropin releasing hormone in a biological specimen. | Thyrotropin Releasing Hormone Measurement | ||
VMA | C74875 | Vanillyl Mandelic Acid;Vanilmandelic Acid | A measurement of the vanillyl mandelic acid metabolite in a biological specimen. | Vanillyl Mandelic Acid Measurement | ||
VITA | C74895 | Vitamin A;Retinol | A measurement of the Vitamin A in a biological specimen. | Vitamin A Measurement | ||
VITB1 | C74896 | Thiamine;Vitamin B1 | A measurement of the thiamine in a biological specimen. | Vitamin B1 Measurement | ||
VITB17 | C74897 | Vitamin B17;Amygdalin | A measurement of the Vitamin B17 in a biological specimen. | Vitamin B17 Measurement | ||
VITB2 | C74898 | Riboflavin;Vitamin B2 | A measurement of the riboflavin in a biological specimen. | Vitamin B2 Measurement | ||
VITB3 | C74899 | Niacin;Vitamin B3 | A measurement of the niacin in a biological specimen. | Vitamin B3 Measurement | ||
VITB5 | C74900 | Vitamin B5;Pantothenic Acid | A measurement of the Vitamin B5 in a biological specimen. | Vitamin B5 Measurement | ||
VITB6 | C74901 | Vitamin B6;Pyridoxine | A measurement of the Vitamin B6 in a biological specimen. | Vitamin B6 Measurement | ||
VITB7 | C74902 | Vitamin B7;Biotin | A measurement of the Vitamin B7 in a biological specimen. | Vitamin B7 Measurement | ||
VITC | C74903 | Vitamin C;Ascorbic Acid | A measurement of the Vitamin C in a biological specimen. | Vitamin C Measurement | ||
VITD2 | C74904 | Vitamin D2;Ergocalciferol | A measurement of the Vitamin D2 in a biological specimen. | Vitamin D2 Measurement | ||
VITD3 | C74905 | Vitamin D3;Cholecalciferol | A measurement of the Vitamin D3 in a biological specimen. | Vitamin D3 Measurement | ||
VITE | C74906 | Vitamin E;Tocopherol | A measurement of the Vitamin E in a biological specimen. | Vitamin E Measurement | ||
VITK | C74907 | Vitamin K;Naphthoquinone | A measurement of the Vitamin K in a biological specimen. | Vitamin K Measurement | ||
VOLUME | C74720 | Volume | A measurement of the volume of a biological specimen. | Volume Measurement | ||
A1ANTRYP | C80167 | Alpha-1 Antitrypsin;Serum Trypsin Inhibitor | A measurement of the alpha-1 antitrypsin in a biological specimen. | Alpha-1 Antitrypsin Measurement | ||
A2MACG | C80168 | Alpha-2 Macroglobulin | A measurement of the alpha-2 macroglobulin in a biological specimen. | Alpha-2 Macroglobulin Measurement | ||
ACE | C80169 | Angiotensin Converting Enzyme | A measurement of the angiotensin converting enzyme in a biological specimen. | Angiotensin Converting Enzyme Measurement | ||
ACPHOS | C80163 | Acid Phosphatase | A measurement of the acid phosphatase in a biological specimen. | Acid Phosphatase Measurement | ||
AMA | C81975 | Antimitochondrial Antibodies;Mitochondrial Antibody | A measurement of the antimitochondrial antibodies in a biological specimen. | Antimitochondrial Antibody Measurement | ||
AMYLB42 | C84809 | Amyloid Beta 42;Amyloid Beta 42 Protein | A measurement of the 42 amino acid amyloid beta protein isoform in a biological specimen. | Beta Amyloid 42 Measurement | ||
AMYLOIDB | C81999 | Amyloid, Beta;Beta Amyloid | A measurement of the total amyloid beta in a biological specimen. | Beta Amyloid Measurement | ||
AMYLOIDP | C81998 | Amyloid P | A measurement of the total amyloid P in a biological specimen. | Amyloid P Measurement | ||
ANGLOBDR | C81974 | Antiglobulin Test, Direct;Direct Coombs Test | A measurement of the antibody or complement-coated erythrocytes in a biological specimen in vivo. | Direct Antiglobulin Test | ||
ANTHRM | C81958 | Antithrombin;Antithrombin III;Antithrombin Activity;Antithrombin III Activity | A measurement of the antithrombin activity in a biological specimen. | Antithrombin Measurement | ||
ANTHRMAG | C81977 | Antithrombin Antigen;Antithrombin III Antigen | A measurement of the antithrombin antigen in a biological specimen. | Antithrombin Antigen Measurement | ||
APOA2 | C82000 | Apolipoprotein AII | A measurement of the apolipoprotein AII in a biological specimen. | Apolipoprotein AII Measurement | ||
APOC3 | C82001 | Apolipoprotein CIII | A measurement of the apolipoprotein CIII in a biological specimen. | Apolipoprotein CIII Measurement | ||
APOE | C82002 | Apolipoprotein E | A measurement of the apolipoprotein E in a biological specimen. | Apolipoprotein E Measurement | ||
APOH | C82003 | Apolipoprotein H | A measurement of the apolipoprotein H in a biological specimen. | Apolipoprotein H Measurement | ||
APPEAR | C25377 | Specimen Appearance | The outward or visible aspect of a specimen. | Appearance | ||
ASCAB | C81976 | Anti-Saccharomyces cerevisiae Antibody | A measurement of the anti-Saccharomyces cerevisiae antibody in a biological specimen. | Anti-Saccharomyces cerevisiae Antibody Measurement | ||
ASTAG | C81978 | Aspartate Aminotransferase Antigen;SGOT Antigen | A measurement of the aspartate aminotransferase antigen in a biological specimen. | Aspartate Aminotransferase Antigen Measurement | ||
B2GLYAB | C81979 | Beta-2 Glycoprotein Antibody | A measurement of the beta-2 glycoprotein antibody in a biological specimen. | Beta-2 Glycoprotein Antibody Measurement | ||
B2MICG | C81980 | Beta-2 Microglobulin | A measurement of the beta-2 microglobulin in a biological specimen. | Beta-2 Microglobulin Measurement | ||
BDNF | C82004 | Brain-Derived Neurotrophic Factor | A measurement of the brain-derived neurotrophic factor in a biological specimen. | Brain-Derived Neurotrophic Factor Measurement | ||
BNPPRO | C82032 | ProB-type Natriuretic Peptide;proBNP;Pro-Brain Natriuretic Peptide | A measurement of the proB-type natriuretic peptide in a biological specimen. | ProB-Type Natriuretic Peptide Measurement | ||
C1QAB | C80173 | Complement C1q Antibody | A measurement of the complement C1q antibody in a biological specimen. | Complement C1q Antibody Measurement | ||
C3 | C80174 | Complement C3 | A measurement of the complement C3 in a biological specimen. | Complement C3 Measurement | ||
C3A | C80175 | Complement C3a;ASP, Complement C3 DesArg, Acetylation-stimulating Protein | A measurement of the complement C3a in a biological specimen. | Complement C3a Measurement | ||
C3B | C80176 | Complement C3b | A measurement of the complement C3b in a biological specimen. | Complement C3b Measurement | ||
C4 | C80177 | Complement C4 | A measurement of the complement C4 in a biological specimen. | Complement C4 Measurement | ||
C4A | C80178 | Complement C4a | A measurement of the complement C4a in a biological specimen. | Complement C4a Measurement | ||
C5A | C80179 | Complement C5a | A measurement of the complement C5a in a biological specimen. | Complement C5a Measurement | ||
CA125AG | C81981 | Cancer Antigen 125 | A measurement of the cancer antigen 125 in a biological specimen. | Cancer Antigen 125 Measurement | ||
CA19_9AG | C81982 | Cancer Antigen 19-9 | A measurement of the cancer antigen 19-9 in a biological specimen. | Cancer Antigen 19-9 Measurement | ||
CAION | C81948 | Calcium, Ionized | A measurement of the ionized calcium in a biological specimen. | Ionized Calcium Measurement | ||
CALPRO | C82005 | Calprotectin | A measurement of the calprotectin in a biological specimen. | Calprotectin Measurement | ||
CBB | C80172 | Complement Bb | A measurement of the complement Bb in a biological specimen. | Complement Bb Measurement | ||
CD40 | C82006 | CD40 | A measurement of the CD40 in a biological specimen. | CD40 Measurement | ||
CD40L | C82007 | CD40 Ligand | A measurement of the CD40 ligand in a biological specimen. | CD40 Ligand Measurement | ||
CEA | C81983 | Carcinoembryonic Antigen | A measurement of the carcinoembryonic antigen in a biological specimen. | Carcinoembryonic Antigen Measurement | ||
CHOLHDL | C80171 | Cholesterol/HDL-Cholesterol | A relative measurement (ratio or percentage) of total cholesterol to high-density lipoprotein cholesterol (HDL-C) in a biological specimen. | Cholesterol to HDL-Cholesterol Ratio Measurement | ||
CTOT | C80160 | Complement Total | A measurement of the total complement in a biological specimen. | Complement Measurement | ||
CTXI | C82038 | Type I Collagen C-Telopeptides;Type I Collagen X-linked C-telopeptide | A measurement of the type I collagen C-telopeptides in a biological specimen. | Type I Collagen C-Telopeptide Measurement | ||
CTXII | C82040 | Type II Collagen C-Telopeptides | A measurement of the type II collagen C-telopeptides in a biological specimen. | Type II Collagen C-Telopeptide Measurement | ||
CYSTARCH | C81951 | Starch Crystals | A measurement of the starch crystals in a biological specimen. | Starch Crystal Measurement | ||
DDIMER | C82621 | D-Dimer | A measurement of the d-dimers in a biological specimen. | D-Dimer Measurement | ||
DNAAB | C81973 | Anti-DNA Antibodies;Anti-ds-DNA Antibodies | A measurement of the anti-DNA antibodies in a biological specimen. | Anti-DNA Antibody Measurement | ||
EGF | C82009 | Epidermal Growth Factor | A measurement of the epidermal growth factor in a biological specimen. | Epidermal Growth Factor Measurement | ||
ELA1 | C82028 | Pancreatic Elastase 1 | A measurement of the pancreatic elastase 1 in a biological specimen. | Pancreatic Elastase Measurement | ||
ELA1PMN | C82029 | Pancreatic Elastase 1, Polymorphonuclear | A measurement of the polymorphonuclear pancreatic elastase 1 in a biological specimen. | Polymorphonuclear Pancreatic Elastase Measurement | ||
ELA2 | C82026 | Neutrophil Elastase | A measurement of the neutrophil elastase in a biological specimen. | Neutrophil Elastase Measurement | ||
ELA2PMN | C82027 | Neutrophil Elastase, Polymorphonuclear | A measurement of the polymorphonuclear neutrophil elastase in a biological specimen. | Polymorphonuclear Neutrophil Elastase Measurement | ||
ENA78 | C82010 | Epith Neutrophil-Activating Peptide 78 | A measurement of the epithelial neutrophil-activating peptide in a biological specimen. | Epithelial Neutrophil-Activating Peptide 78 Measurement | ||
ENDOTH1 | C82008 | Endothelin-1 | A measurement of the endothelin-1 in a biological specimen. | Endothelin-1 Measurement | ||
ENRAGE | C82011 | Extracell Newly Ident RAGE Bind Protein;S100 Calcium Binding Protein A12 | A measurement of the extracellular newly identified RAGE (receptor for advanced glycation end products) binding protein in a biological specimen. | Extracell Newly Ident RAGE Bind Protein Measurement | ||
EOSMM | C84819 | Eosinophilic Metamyelocytes | A measurement of the eosinphilic metamyelocytes in a biological specimen. | Eosinophilic Metamyelocyte Count | ||
EOSMYL | C84821 | Eosinophilic Myelocytes | A measurement of the eosinophilic myelocytes in a biological specimen. | Eosinophilic Myelocyte Count | ||
EOTAXIN1 | C81952 | Eotaxin-1;Chemokine Ligand 11 | A measurement of the eotaxin-1 in a biological specimen. | Eotaxin-1 Measurement | ||
EOTAXIN2 | C81953 | Eotaxin-2;Chemokine Ligand 24 | A measurement of the eotaxin-2 in a biological specimen. | Eotaxin-2 Measurement | ||
EOTAXIN3 | C81954 | Eotaxin-3;Chemokine Ligand 26 | A measurement of the eotaxin-3 in a biological specimen. | Eotaxin-3 Measurement | ||
ESTRIOLF | C81963 | Estriol, Free | A measurement of the free estriol in a biological specimen. | Free Estriol Measurement | ||
FABP1 | C82012 | Fatty Acid Binding Protein 1 | A measurement of the fatty acid binding protein 1 in a biological specimen. | Fatty Acid Binding Protein 1 Measurement | ||
FACTIII | C81959 | Factor III;Tissue Factor, CD142 | A measurement of the factor III in a biological specimen. | Factor III Measurement | ||
FACTVII | C81960 | Factor VII | A measurement of the factor VII in a biological specimen. | Factor VII Measurement | ||
FACTVIII | C81961 | Factor VIII | A measurement of the factor VIII in a biological specimen. | Factor VIII Measurement | ||
FATACFR | C80200 | Free Fatty Acid;Non-Esterified Fatty Acid, Free | A measurement of the total non-esterified fatty acids in a biological specimen. | Non-esterified Fatty Acids Measurement | ||
FATACFRS | C80206 | Free Fatty Acid, Saturated;Non-esterified Fatty Acid, Saturated | A measurement of the saturated non-esterified fatty acids in a biological specimen. | Saturated Non-esterified Fatty Acids Measurement | ||
FATACFRU | C80209 | Free Fatty Acid, Unsaturated;Non-esterified Fatty Acid, Unsaturated | A measurement of the unsaturated non-esterified fatty acids in a biological specimen. | Unsaturated Non-esterified Fatty Acids Measurement | ||
FATBODOV | C81947 | Fat Bodies, Oval | A measurement of the oval-shaped fat bodies, usually renal proximal tubular cells with lipid aggregates in the cytoplasm, in a biological specimen. | Oval Fat Body Measurement | ||
FDP | C82013 | Fibrin Degradation Products | A measurement of the fibrin degradation products in a biological specimen. | Fibrin Degradation Products Measurement | ||
FGFBF | C82014 | Fibroblast Growth Factor Basic Form;FGF2 | A measurement of the basic form of fibroblast growth factor in a biological specimen. | Fibroblast Growth Factor Basic Form Measurement | ||
G6PD | C80184 | Glucose-6-Phosphate Dehydrogenase | A measurement of the glucose-6-phosphate dehydrogenase in a biological specimen. | Glucose-6-Phosphate Dehydrogenase Measurement | ||
GAD1 | C82015 | Glutamic Acid Decarboxylase 1;Glutamic Acid Decarboxylase 67 | A measurement of the glutamic acid decarboxylase 1 in a biological specimen. | Glutamic Acid Decarboxylase 1 Measurement | ||
GAD2 | C82016 | Glutamic Acid Decarboxylase 2;Glutamic Acid Decarboxylase 65 | A measurement of the glutamic acid decarboxylase 2 in a biological specimen. | Glutamic Acid Decarboxylase 2 Measurement | ||
GAD2AB | C82017 | Glutamic Acid Decarboxylase 2 Antibody;Glutamic Acid Decarboxylase 65 Antibody | A measurement of the glutamic acid decarboxylase 2 antibody in a biological specimen. | Glutamic Acid Decarboxylase 2 Antibody Measurement | ||
GALANIN | C80182 | Galanin | A measurement of the galanin in a biological specimen. | Galanin Measurement | ||
GCSF | C82018 | Granulocyte Colony Stimulating Factor | A measurement of the granulocyte colony stimulating factor in a biological specimen. | Granulocyte Colony Stimulating Factor Measurement | ||
GLP1 | C80183 | Glucagon-Like Peptide-1;Total Glucagon-Like Peptide-1 | A measurement of the total glucagon-like peptide-1 in a biological specimen. | Glucagon-like Peptide-1 Measurement | ||
GLP1AC | C80164 | Glucagon-Like Peptide-1, Active Form | A measurement of the active form of glucagon-like peptide-1 in a biological specimen. | Active Glucagon-like Peptide-1 Measurement | ||
GMCSF | C82019 | Granulocyte Macrophage Colony Stm Factor | A measurement of the granulocyte macrophage colony stimulating factor in a biological specimen. | Granulocyte Macrophage Colony Stm Factor Measurement | ||
GOLD | C80186 | Gold | A measurement of the gold in a biological specimen. | Gold Measurement | ||
GST | C80185 | Glutathione S-Transferase, Total | A measurement of the total glutathione-s-transferase in a biological specimen. | Glutathione-S-Transferase Measurement | ||
GSTALCRT | C80166 | Glutathione S-Transferase, Alpha/Creat | A relative measurement (ratio or percentage) of the alpha glutathione-S-transferase to creatinine in a biological specimen. | Alpha Glutathione-S-Transferase to Creatinine Ratio Measurement | ||
GSTPI | C80203 | Glutathione S-Transferase, Pi | A measurement of the Pi glutathione-s-transferase in a biological specimen. | Pi Glutathione S-Transferase Measurement | ||
GSTTH | C80207 | Glutathione S-Transferase, Theta | A measurement of the theta glutathione-s-transferase in a biological specimen. | Theta Glutathione S-Transferase Measurement | ||
GUSA | C80165 | Glucuronidase, Alpha | A measurement of the alpha glucuronidase in a biological specimen. | Alpha Glucuronidase Measurement | ||
GUSB | C80170 | Glucuronidase, Beta | A measurement of the beta glucuronidase in a biological specimen. | Beta Glucuronidase Measurement | ||
HDL2 | C80187 | HDL-Cholesterol Subclass 2 | A measurement of the high-density lipoprotein (HDL) cholesterol subclass 2 in a biological specimen. | HDL-Cholesterol Subclass 2 Measurement | ||
HDL3 | C80188 | HDL-Cholesterol Subclass 3 | A measurement of the high-density lipoprotein (HDL) cholesterol subclass 3 in a biological specimen. | HDL-Cholesterol Subclass 3 Measurement | ||
HISTAMIN | C80189 | Histamine | A measurement of the histamine in a biological specimen. | Histamine Measurement | ||
HTPHAB | C81984 | Heterophile Antibodies | A measurement of the heterophile antibodies in a biological specimen. | Heterophile Antibody Measurement | ||
HYPRLN | C80190 | Hydroxyproline | A measurement of the total hydroxyproline in a biological specimen. | Hydroxyproline Measurement | ||
IC512AB | C81985 | Islet Cell 512 Antibody | A measurement of the islet cell 512 antibody in a biological specimen. | Islet Cell 512 Antibody Measurement | ||
IC512AG | C81986 | Islet Cell 512 Antigen | A measurement of the islet cell 512 antigen in a biological specimen. | Islet Cell 512 Antigen Measurement | ||
IFNA | C81994 | Interferon Alpha | A measurement of the interferon alpha in a biological specimen. | Interferon Alpha Measurement | ||
IFNB | C81995 | Interferon Beta | A measurement of the interferon beta in a biological specimen. | Interferon Beta Measurement | ||
IFNG | C81996 | Interferon Gamma | A measurement of the interferon gamma in a biological specimen. | Interferon Gamma Measurement | ||
IGA | C81969 | Immunoglobulin A | A measurement of the Immunoglobulin A in a biological specimen. | Immunoglobulin A Measurement | ||
IGE | C81970 | Immunoglobulin E | A measurement of the Immunoglobulin E in a biological specimen. | Immunoglobulin E Measurement | ||
IGG | C81971 | Immunoglobulin G | A measurement of the Immunoglobulin G in a biological specimen. | Immunoglobulin G Measurement | ||
IGM | C81972 | Immunoglobulin M | A measurement of the Immunoglobulin M in a biological specimen. | Immunoglobulin M Measurement | ||
INDICAN | C82044 | Indican | A measurement of the indican present in a biological specimen. | Indican Measurement | ||
INGAPAB | C81987 | Islet Neogenesis Assoc Protein Antibody | A measurement of the islet neogenesis associated protein antibody in a biological specimen. | Islet Neogenesis Associated Protein Antibody Measurement | ||
INHIBINA | C82020 | Inhibin A | A measurement of the inhibin A in a biological specimen. | Inhibin A Measurement | ||
ISOPRF2 | C80180 | F2-Isoprostane | A measurement of the F2-isoprostane in a biological specimen. | F2 Isoprostane Measurement | ||
LPA | C82022 | Lipoprotein-a | A measurement of the lipoprotein-a in a biological specimen. | Lipoprotein a Measurement | ||
LTF | C82021 | Lactoferrin;Lactotransferrin | A measurement of the lactoferrin in a biological specimen. | Lactoferrin Measurement | ||
LYMPHOTC | C81955 | Lymphotactin;Chemokine Ligand 1 | A measurement of the lymphotactin in a biological specimen. | Lymphotactin Measurement | ||
MCP1 | C82025 | Monocyte Chemotactic Protein 1 | A measurement of the monocyte chemotactic protein 1 in a biological specimen. | Monocyte Chemotactic Protein 1 Measurement | ||
MCSF | C80191 | Macrophage Colony Stimulating Factor | A measurement of the macrophage colony stimulating factor in a biological specimen. | Macrophage Colony Stimulating Factor Measurement | ||
MDC | C81956 | Macrophage-Derived Chemokine;Chemokine Ligand 22 | A measurement of the macrophage-derived chemokine in a biological specimen. | Macrophage-Derived Chemokine Measurement | ||
MIP1A | C82023 | Macrophage Inflammatory Protein 1 Alpha;Chemokine Ligand 3 | A measurement of the macrophage inflammatory protein 1 alpha in a biological specimen. | Macrophage Inflammatory Protein 1 Alpha Measurement | ||
MIP1B | C82024 | Macrophage Inflammatory Protein 1 Beta;Chemokine Ligand 4 | A measurement of the macrophage inflammatory protein 1 beta in a biological specimen. | Macrophage Inflammatory Protein 1 Beta Measurement | ||
MMP1 | C80192 | Matrix Metalloproteinase 1;Interstitial Collagenase | A measurement of the matrix metalloproteinase 1 in a biological specimen. | Matrix Metalloproteinase 1 Measurement | ||
MMP2 | C80193 | Matrix Metalloproteinase 2;Gelatinase A | A measurement of the matrix metalloproteinase 2 in a biological specimen. | Matrix Metalloproteinase 2 Measurement | ||
MMP3 | C80194 | Matrix Metalloproteinase 3;Stromelysin 1 | A measurement of the matrix metalloproteinase 3 in a biological specimen. | Matrix Metalloproteinase 3 Measurement | ||
MMP7 | C80195 | Matrix Metalloproteinase 7;Matrilysin | A measurement of the matrix metalloproteinase 7 in a biological specimen. | Matrix Metalloproteinase 7 Measurement | ||
MMP8 | C80196 | Matrix Metalloproteinase 8;Neutrophil Collagenase | A measurement of the matrix metalloproteinase 8 in a biological specimen. | Matrix Metalloproteinase 8 Measurement | ||
MMP9 | C80197 | Matrix Metalloproteinase 9;Gelatinase B | A measurement of the matrix metalloproteinase 9 in a biological specimen. | Matrix Metalloproteinase 9 Measurement | ||
MPO | C80198 | Myeloperoxidase | A measurement of the myeloperoxidase in a biological specimen. | Myeloperoxidase Measurement | ||
NEOPTERN | C80199 | Neopterin | A measurement of the neopterin in a biological specimen. | Neopterin Measurement | ||
NEUTMM | C84822 | Neutrophilic Metamyelocytes | A measurement of the neutrophilic metamyelocytes in a biological specimen. | Neutrophilic Metamyelocyte Count | ||
NEUTMY | C84823 | Neutrophilic Myelocytes | A measurement of the neutrophilic myelocytes in a biological specimen. | Neutrophilic Myelocyte Count | ||
NEUTSG | C81997 | Neutrophils, Segmented | A measurement of the segmented neutrophils in a biological specimen. | Segmented Neutrophil Count | ||
NEUTSGLE | C82045 | Neutrophils, Segmented/Leukocytes | A relative measurement (ratio or percentage) of segmented neutrophils to leukocytes in a biological specimen. | Segmented Neutrophil to Leukocyte Ratio Measurement | ||
NTXI | C82039 | Type I Collagen N-Telopeptides | A measurement of the type I collagen N-telopeptides in a biological specimen. | Type I Collagen N-Telopeptide Measurement | ||
NTXII | C82041 | Type II Collagen N-Telopeptides | A measurement of the type II collagen N-telopeptides in a biological specimen. | Type II Collagen N-Telopeptide Measurement | ||
PAI1 | C82030 | Plasminogen Activator Inhibitor-1 | A measurement of the plasminogen activator inhibitor-1 in a biological specimen. | Plasminogen Activator Inhibitor-1 Measurement | ||
PAI1AG | C81989 | Plasminogen Activator Inhibitor-1 AG | A measurement of the plasminogen activator inhibitor-1 antigen in a biological specimen. | Plasminogen Activator Inhibitor-1 Antigen Measurement | ||
PAP | C80204 | Prostatic Acid Phosphatase | A measurement of the prostatic acid phosphatase in a biological specimen. | Prostatic Acid Phosphatase Measurement | ||
PAPPA | C82031 | Pregnancy-Associated Plasma Protein-A | A measurement of the pregnancy-associated plasma protein-A in a biological specimen. | Pregnancy-Associated Plasma Protein-A Measurement | ||
PCO2 | C82625 | Partial Pressure Carbon Dioxide | A measurement of the pressure of carbon dioxide in a biological specimen. | Partial Pressure of Carbon Dioxide Measurement | ||
PDW | C81962 | Platelet Distribution Width | A measurement of the range of platelet sizes in a biological specimen. | Platelet Distribution Width | ||
PEMAB | C81988 | Pemphigoid Antibodies | A measurement of the pemphigoid antibodies in a biological specimen. | Pemphigoid Antibody Measurement | ||
PICP | C82033 | Procollagen Type I Carboxy Term Peptide | A measurement of the procollagen-1 carboxy-terminal peptide in a biological specimen. | Procollagen Type I Carboxy Terminal Peptide Measurement | ||
PNCTPP | C80201 | Pancreatic Polypeptide | A measurement of the pancreatic polypeptide in a biological specimen. | Pancreatic Polypeptide Measurement | ||
PO2 | C71251 | Partial Pressure Oxygen | A measurement of the pressure of oxygen in a biological specimen. | Partial Pressure of Oxygen Measurement | ||
PROINSUL | C81967 | Proinsulin | A measurement of the proinsulin in a biological specimen. | Proinsulin Measurement | ||
PTF1_2 | C82034 | Prothrombin Fragments 1 + 2 | A measurement of the prothrombin fragments 1 and 2 in a biological specimen. | Prothrombin Fragments 1 and 2 Measurement | ||
PTHCT | C81964 | Parathyroid Hormone, C-Terminal | A measurement of the C-terminal fragment of parathyroid hormone in a biological specimen. | C-Terminal Parathyroid Hormone Measurement | ||
PTHMM | C81965 | Parathyroid Hormone, Mid-Molecule | A measurement of the mid-molecule fragment of parathyroid hormone in a biological specimen. | Mid-Molecule Parathyroid Hormone Measurement | ||
PTHNT | C81966 | Parathyroid Hormone, N-Terminal | A measurement of the N-terminal fragment of parathyroid hormone in a biological specimen. | N-Terminal Parathyroid Hormone Measurement | ||
PYRIDNLN | C80211 | Pyridinoline | A measurement of the pyridinoline in a biological specimen. | Pyridinoline Measurement | ||
PYY | C80202 | Peptide YY;Peptide Tyrosine Tyrosine | A measurement of the peptide YY in a biological specimen. | Peptide YY Measurement | ||
RANTES | C81957 | Reg upon Act Normal T-cell Exprd Secrtd;Chemokine Ligand 5 | A measurement of the RANTES (regulated on activation, normally, T-cell expressed, and secreted) chemokine in a biological specimen. | Reg upon Act Normal T-cell Exprd Secrtd Measurement | ||
RBCNUCLE | C82046 | Nucleated Erythrocytes/Leukocytes | A relative measurement (ratio or percentage) of nucleated erythrocytes to leukocytes in a biological specimen. | Nucleated Erythrocyte to Leukocyte Ratio Measurement | ||
RESISTIN | C80205 | Resistin | A measurement of the resistin in a biological specimen. | Resistin Measurement | ||
RT3 | C81968 | Triiodothyronine, Reverse | A measurement of the reverse triiodothyronine in a biological specimen. | Reverse Triiodothyronine Measurement | ||
SCF | C82035 | Stem Cell Factor;KIT Ligand | A measurement of the stem cell factor in a biological specimen. | Stem Cell Factor Measurement | ||
TFERRIN | C82037 | Transferrin | A measurement of the transferrin in a biological specimen. | Transferrin Measurement | ||
THYAB | C81990 | Thyroid Antibodies | A measurement of the thyroid antibodies in a biological specimen. | Thyroid Antibody Measurement | ||
THYAMAB | C81991 | Thyroid Antimicrosomal Antibodies | A measurement of the thyroid antimicrosomal antibodies in a biological specimen. | Thyroid Antimicrosomal Antibody Measurement | ||
THYATAB | C81992 | Thyroid Antithyroglobulin Antibodies | A measurement of the thyroid antithyroglobulin antibodies in a biological specimen. | Thyroid Antithyroglobulin Antibody Measurement | ||
TIMP1 | C82036 | Tissue Inhibitor of Metalloproteinase 1 | A measurement of the tissue inhibitor of metalloproteinase 1 in a biological specimen. | Tissue Inhibitor of Metalloproteinase 1 Measurement | ||
TPAAG | C81993 | Tissue Plasminogen Activator Antigen | A measurement of the tissue plasminogen activator antigen in a biological specimen. | Tissue Plasminogen Activator Antigen Measurement | ||
TPRONP | C84811 | Non-Phosphorylated Tau Protein | A measurement of the non-phosphorylated Tau protein in a biological specimen. | Nonphosphorylated Tau Protein Measurement | ||
TPROT | C84810 | Tau Protein;Total Tau Protein | A measurement of the total Tau protein in a biological specimen. | Tau Protein Measurement | ||
TPROTP | C84812 | Phosphorylated Tau Protein | A measurement of the phosphorylated Tau protein in a biological specimen. | Phosphorylated Tau Protein Measurement | ||
TRAP | C80208 | Total Radical-Trap Antioxidant Potential | A measurement of the ability of the antioxidants in a biological specimen to buffer free radicals in a suspension. | Total Radical-Trap Antioxidant Potential Measurement | ||
TT | C80365 | Thrombin Time | A measurement of the time it takes a plasma sample to clot after adding the active enzyme thrombin. (NCI) | Thrombin Time | ||
VCAM1 | C82042 | Vascular Cell Adhesion Molecule 1 | A measurement of the vascular cell adhesion molecule 1 in a biological specimen. | Vascular Cell Adhesion Molecule 1 Measurement | ||
VEGF | C92514 | Vascular Endothelial Growth Factor | A measurement of the vascular endothelial growth factor in a biological specimen. | Vascular Endohelial Growth Factor Measurement | ||
VISC | C75912 | Viscosity | The resistance of a liquid to sheer forces and flow. (NCI) | Viscosity | ||
VITD | C84818 | Vitamin D;Total Vitamin D | A measurement of the total Vitamin D in a biological specimen. | Vitamin D Measurement | ||
ZINC | C80210 | Zinc | A measurement of the zinc in a biological specimen. | Zinc Measurement | ||
CORTFR | C88113 | Cortisol, Free | A measurement of the free, unbound cortisol in a biological specimen. | Free Cortisol Measurement | ||
VITDAT | C92267 | 1, 25-Dihydroxyvitamin D;Active Vitamin D | A measurement of the total active Vitamin D in a biological specimen. | 1, 25-Dihydroxyvitamin D Measurement | ||
VITDIT | C92268 | 25-Hydroxyvitamin D;Inactive Vitamin D | A measurement of the total inactive Vitamin D in a biological specimen. | 25-Hydroxyvitamin D Measurement | ||
ACETOAC | C92247 | Acetoacetic Acid;Acetoacetate | A measurement of the acetoacetic acid in a biological specimen. | Acetoacetic Acid Measurement | ||
ACYLCAOX | C92286 | Acyl Coenzyme A Oxidase;Fatty Acyl Coenzyme A Oxidase;Acyl CoA Oxidase | A measurement of the acyl coenzyme A oxidase in a biological specimen. | Acyl Coenzyme A Oxidase Measurement | ||
GLOBA1 | C92252 | Alpha-1 Globulin;A1-Globulin | A measurement of the proteins contributing to the alpha 1 fraction in a biological specimen. | Alpha-1 Globulin Measurement | ||
GLOBA1PT | C92253 | Alpha-1 Globulin/Total Protein | A relative measurement (ratio or percentage) of alpha-1-fraction proteins to total proteins in a biological specimen. | Alpha-1 Globulin to Total Protein Ratio Measurement | ||
GLOBA2 | C92254 | Alpha-2 Globulin;A2-Globulin | A measurement of the proteins contributing to the alpha 2 fraction in a biological specimen. | Alpha-2 Globulin Measurement | ||
GLOBA2PT | C92255 | Alpha-2 Globulin/Total Protein | A relative measurement (ratio or percentage) of alpha-2-fraction proteins to total proteins in a biological specimen. | Alpha-2 Globulin to Total Protein Ratio Measurement | ||
CYAMPPH | C92243 | Amorphous Phosphate Crystals | A measurement of the amorphous phosphate crystals in a biological specimen. | Amorphous Phosphate Crystals Measurement | ||
CYAMPURT | C92244 | Amorphous Urate Crystals | A measurement of the amorphous urate crystals in a biological specimen. | Amorphous Urate Crystals Measurement | ||
ASSDNA | C92269 | Anti-Single Stranded DNA IgG | A measurement of the anti-single stranded DNA IgG antibody in a biological specimen. | Anti-Single Stranded DNA IgG Measurement | ||
APOE4 | C92293 | Apolipoprotein E4 | A measurement of the apolipoprotein E4 in a biological specimen. | Apolipoprotein E4 Measurement | ||
GLOBB | C92256 | Beta Globulin | A measurement of the proteins contributing to the beta fraction in a biological specimen. | Beta Globulin Measurement | ||
GLOBBPT | C92294 | Beta Globulin/Total Protein | A relative measurement (ratio or percentage) of beta fraction proteins to total proteins in a biological specimen. | Beta Globulin to Total Protein Ratio Measurement | ||
ALPBS | C92287 | Bone Specific Alkaline Phosphatase | A measurement of the bone specific alkaline phosphatase isoform in a biological specimen. | Bone Specific Alkaline Phosphatase Measurement | ||
CARNITAT | C92288 | Carnitine Acetyl Transferase | A measurement of the carnitine acetyl transferase in a biological specimen. | Carnitine Acetyl Transferase Measurement | ||
CPNIGAAB | C92432 | Chlamydia pneumoniae IgA Antibody | A measurement of the Chlamydia pneumoniae IgA antibody in a biological specimen. | Chlamydia pneumoniae IgA Antibody Measurement | ||
CPNIGMAB | C92433 | Chlamydia pneumoniae IgM Antibody | A measurement of the Chlamydia pneumoniae IgM in a biological specimen. | Chlamydia pneumoniae IgM Antibody Measurement | ||
CHOLINES | C92289 | Cholinesterase | A measurement of the cholinesterase in a biological specimen. | Cholinesterase Measurement | ||
CITRATE | C92248 | Citrate | A measurement of the citrate in a biological specimen. | Citrate Measurement | ||
COTININE | C92249 | Cotinine | A measurement of the cotinine in a biological specimen. | Cotinine Measurement | ||
CYSTATC | C92290 | Cystatin C | A measurement of the cystatin C in a biological specimen. | Cystatin C Measurement | ||
RBCCLMP | C92245 | Erythrocyte Cell Clumps;Red Blood Cell Clumps;RBC Clumps | A measurement of red blood cell clumps in a biological specimen. | Erythrocyte Cell Clumps Measurement | ||
RBCMORPH | C92296 | Erythrocyte Cell Morphology;Red Blood Cell Morphology;RBC Morphology | An examination or assessment of the form and structure of red blood cells. | Erythrocyte Cell Morphology | ||
ENAAB | C92270 | Anti-ENA;Extractable Nuclear Antigen Antibody | A measurement of the extractable nuclear antigen antibody in a biological specimen. | Extractable Nuclear Antigen Antibody Measurement | ||
GLOBG | C92257 | Gamma Globulin | A measurement of the proteins contributing to the gamma fraction in a biological specimen. | Gamma Globulin Measurement | ||
GLOBGPT | C92295 | Gamma Globulin/Total Protein | A relative measurement (ratio or percentage) of gamma fraction proteins to total proteins in a biological specimen. | Gamma Globulin to Total Protein Ratio Measurement | ||
GFR | C90505 | Glomerular Filtration Rate | A kidney function test that measures the fluid volume that is filtered from the kidney glomeruli to the Bowman's capsule per unit of time. | Glomerular Filtration Rate | ||
HGBA | C92258 | Hemoglobin A | A measurement of the hemoglobin A in a biological specimen. | Hemoglobin A Measurement | ||
HGBA2 | C92259 | Hemoglobin A2 | A measurement of the hemoglobin A2 in a biological specimen. | Hemoglobin A2 Measurement | ||
HGBB | C92260 | Hemoglobin B | A measurement of the hemoglobin B in a biological specimen. | Hemoglobin B Measurement | ||
HGBC | C92261 | Hemoglobin C | A measurement of the hemoglobin C in a biological specimen. | Hemoglobin C Measurement | ||
HGBF | C92262 | Hemoglobin F;Fetal Hemoglobin | A measurement of the hemoglobin F in a biological specimen. | Hemoglobin F Measurement | ||
HAABIGM | C92271 | Hepatitis A Virus Antibody IgM | A measurement of hepatitis A virus antibody IgM in a biological specimen. | Hepatitis A Virus Antibody IgM Measurement | ||
HGRNA | C92272 | Hepatitis G RNA | A measurement of the Hepatitis G RNA in a biological specimen. | Hepatitis G RNA Measurement | ||
HIVIMONA | C92263 | HIV-1 Group M and O Nucleic Acid | A measurement of the HIV-1 group M and O nucleic acids in a biological specimen. | HIV-1 Group M and O Nucleic Acid Measurement | ||
HIVIOAB | C92264 | HIV-1 Group O Antibody | A measurement of the HIV-1 group O antibody in a biological specimen. | HIV-1 Group O Antibody Measurement | ||
HIVI24AG | C92265 | HIV-1 p24 Antigen | A measurement of the HIV-1 p24 antigen in a biological specimen. | HIV-1 p24 Antigen Measurement | ||
HIV2NUAC | C92266 | HIV-2 Nucleic Acid | A measurement of the HIV-2 nucleic acids in a biological specimen. | HIV-2 Nucleic Acid Measurement | ||
IAH1N1VL | C92273 | Influenza A H1N1 Viral Load | A measurement of the Influenza A H1N1 viral load in a biological specimen. | Influenza A H1N1 Viral Load Measurement | ||
INFAVLD | C92274 | Influenza A Viral Load | A measurement of the Influenza A viral load in a biological specimen. | Influenza A Viral Load Measurement | ||
LPNAG | C92275 | Legionella pneumophila Antigen | A measurement of the Legionella pneumophila antigen in a biological specimen. | Legionella pneumophila Antigen Measurement | ||
LPNIGGAB | C92276 | Legionella pneumophila IgG Antibody | A measurement of the Legionella pneumophila IgG antibody in a biological specimen. | Legionella pneumophila IgG Antibody Measurement | ||
LPNGMAB | C92277 | Legionella pneumophila IgG IgM Antibody | A measurement of the Legionella pneumophila IgG and IgM in a biological specimen. | Legionella pneumophila IgG IgM Antibody Measurement | ||
LPNIGMAB | C92278 | Legionella pneumophila IgM Antibody | A measurement of the Legionella pneumophila IgM antibody in a biological specimen. | Legionella pneumophila IgM Antibody Measurement | ||
WBCMORPH | C92297 | Leukocyte Cell Morphology;White Blood Cell Morphology;WBC Morphology | An examination or assessment of the form and structure of white blood cells. | Leukocyte Cell Morphology | ||
WBCCLMP | C92246 | Leukocyte Cell Clumps;White Blood Cell Clumps;WBC Clumps | A measurement of white blood cell clumps in a biological specimen. | Leukocyte Cell Clumps Measurement | ||
MCPROT | C92291 | Monoclonal Immunoglobulin Protein;Paraprotein | A measurement of homogenous immunoglobulin resulting from the proliferation of a single clone of plasma cells in a biological specimen. | Monoclonal Protein Measurement | ||
MYTBGIR | C92241 | Mycobacterium tuberculosis IFN Gamma Response | A measurement of the amount of interferon gamma that is released when Mycobacterium tuberculosis antigen is incubated with a biological specimen, usually blood. Increased amounts of interferon gamma suggests a prior or existing M. tuberculosis infection. | Mycobacterium tuberculosis Interferon Gamma Response | ||
MYTBNUAC | C92279 | Mycobacterium tuberculosis Nucleic Acid | A measurement of the Mycobacterium tuberculosis nucleic acid in a biological specimen. | Mycobacterium tuberculosis Nucleic Acid Measurement | ||
MYPCERPC | C92242 | Myeloid/Erythroid Ratio | A relative measurement (ratio or percentage) of myeloid progenitor cells to erythrocyte precursor cells in a biological specimen. | Myeloid to Erythroid Ratio Measurement | ||
MPOAB | C92280 | Myeloperoxidase Antibody | A measurement of the myeloperoxidase antibody in a biological specimen. | Myeloperoxidase Antibody Measurement | ||
NGON | C92298 | Neisseria gonorrhoeae Screening | Examination of a biological specimen to detect the presence of Neisseria gonorrhoeae. | Neisseria gonorrhoeae Screening | ||
OSMRTY | C74802 | Osmolarity | A measurement of the osmoles of solute per liter of solution. | Osmolarity Measurement | ||
OXALATE | C92250 | Oxalate;Ethanedioate | A measurement of the oxalate in a biological specimen. | Oxalate Measurement | ||
PROTOSML | C92240 | Protein/Osmolality;Protein/Osmolality Ratio | A relative measurement (ratio or percentage) of total proteins to the osmolality of a biological specimen. | Protein to Osmolality Ratio Measurement | ||
SJSSAAB | C92236 | Ro Antibody;Sjogrens SS-A Antibody | A measurement of the Sjogrens SS-A antibody in a biological specimen. | Sjogren's SS-A Antibody Measurement | ||
SJSSBAB | C92237 | La Antibody;Sjogrens SS-B Antibody | A measurement of the Sjogrens SS-B antibody in a biological specimen. | Sjogren's SS-B Antibody Measurement | ||
SMTHAB | C92281 | Smith Antibody | A measurement of the Smith antibody in a biological specimen. | Smith Antibody Measurement | ||
STRPLOAB | C92282 | Streptolysin O Antibody;Antistreptolysin O | A measurement of Streptolysin O Antibody in a biological specimen. | Streptolysin O Antibody Measurement | ||
EPITCE | C92251 | Transitional Epithelial Cells | A measurement of the transitional epithelial cells present in a biological specimen. | Transitional Epithelial Cells Measurement | ||
TRICH | C92238 | Trichomonas | Examination of a biological specimen to detect the presence of any protozoan belonging to the Trichomonas genus. | Trichomonas Screening | ||
TRYPTASE | C92292 | Tryptase | A measurement of the tryptase in a biological specimen. | Tryptase Measurement | ||
MYBLAT1 | C92283 | Type I Myeloblasts | A measurement of type I myeloblast cells per unit of a biological specimen. | Type I Myeloblasts Measurement | ||
MYBLAT2 | C92284 | Type II Myeloblasts | A measurement of type II myeloblast cells per unit of a biological specimen. | Type II Myeloblasts Measurement | ||
MYBLAT3 | C92285 | Type III Myeloblasts | A measurement of type III myeloblast cells per unit of a biological specimen. | Type III Myeloblasts Measurement | ||
YEASTHYP | C92239 | Yeast Hyphae | Examination of a biological specimen to detect the presence of any yeast cells that are in the long, filamentous and branching phase of growth. | Yeast Hyphae Screening | ||
SVCAM1 | C92533 | Soluble Vascular Cell Adhesion Molecule 1 | A measurement of the soluble vascular cell adhesion molecule 1 in a biological specimen. | Soluble Vascular Cell Adhesion Molecule 1 | ||
AFPL3AFP | C96565 | A Fetoprotein L3/A Fetoprotein | A relative measurement (ratio or percentage) of alpha fetoprotein L3 to total alpha fetoprotein in a biological specimen. | Alpha Fetoprotein L3 to Total Alpha Fetoprotein Ratio Measurement | ||
ACHRAB | C96559 | Acetylcholine Receptor Antibody | A measurement of the acetylcholine receptor antibody in a biological specimen. | Acetylcholine Receptor Antibody Measurement | ||
ACHE | C96560 | Acetylcholinesterase | A measurement of the acetylcholinesterase in a biological specimen. | Acetylcholinesterase Measurement | ||
AFPL1 | C96562 | Alpha Fetoprotein L1 | A measurement of the alpha fetoprotein L1 in a biological specimen. | Alpha Fetoprotein L1 Measurement | ||
AFPL2 | C96563 | Alpha Fetoprotein L2 | A measurement of the alpha fetoprotein L2 in a biological specimen. | Alpha Fetoprotein L2 Measurement | ||
AFPL3 | C96564 | Alpha Fetoprotein L3 | A measurement of the alpha fetoprotein L3 in a biological specimen. | Alpha Fetoprotein L3 Measurement | ||
STIPBASO | C96567 | Basophilic Stippling | A measurement of the basophilic stippling in a biological specimen. | Basophilic Stippling Measurement | ||
BNZLCGN | C75350 | Benzoylecgonine;Cocaine Metabolite | A measurement of the benzoylecgonine in a biological specimen. | Benzoylecgonine Measurement | ||
BHYXBTR | C96568 | Beta-Hydroxybutyrate;B-Hydroxybutyrate;3-Hydroxybutyrate | A measurement of the total Beta-hydroxybutyrate in a biological specimen. | Beta-Hydroxybutyrate Measurement | ||
CSBROAD | C96588 | Broad Casts | A measurement of the broad casts in a biological specimen. | Broad Casts Measurement | ||
CACLR | C96589 | Calcium Clearance | A measurement of the volume of serum or plasma that would be cleared of calcium by excretion of urine for a specified unit of time (e.g. one minute). | Calcium Clearance Measurement | ||
CASULPH | C96590 | Calcium Sulphate | A measurement of the calcium sulphate in a biological specimen. | Calcium Sulphate Measurement | ||
CARBXHGB | C96591 | Carboxyhemoglobin | A measurement of the carboxyhemoglobin in a biological specimen. | Carboxyhemoglobin Measurement | ||
CEC | C96592 | Circulating Endothelial Cells | A measurement of the circulating endothelial cells in a biological specimen. | Circulating Endothelial Cell Count | ||
CTC | C96593 | Circulating Tumor Cells | A measurement of the circulating tumor cells in a biological specimen. | Circulating Tumor Cell Count | ||
CLARITY | C96594 | Clarity | A measurement of the transparency of a biological specimen. | Clarity Measurement | ||
CCPAB | C96595 | Cyclic Citrullinated Peptide Antibody | A measurement of the cyclic citrullinated peptide antibody in a biological specimen. | Cyclic Citrullinated Peptide Antibody Measurement | ||
CMVIGGAB | C96596 | Cytomegalovirus IgG Antibody | A measurement of the cytomegalovirus IgG antibody in a biological specimen. | Cytomegalovirus IgG Antibody Measurement | ||
CMVIGMAB | C96597 | Cytomegalovirus IgM Antibody | A measurement of the cytomegalovirus IgM antibody in a biological specimen. | Cytomegalovirus IgM Antibody Measurement | ||
DHEAS | C96629 | Dehydroepiandrosterone Sulfate;DHEA-S;sDHEA;DHEA Sulfate | A measurement of the sulfated Dehydroepiandrosterone in a biological specimen. | Sulfated DHEA Measurement | ||
DRVVT | C96696 | Dilute Russell's Viper Venom Time | A measurement of the time it takes a plasma sample to clot after adding dilute Russell's viper venom. | Dilute Russell's Viper Venom Time Measurement | ||
ECCENTCY | C96598 | Eccentrocytes | A measurement of the eccentrocytes (erythrocytes in which the hemoglobin is localized to a particular portion of the cell, noticeable as localized staining) in a biological specimen. | Eccentrocyte Count | ||
EBCIGGAB | C96600 | Epstein-Barr Capsid IgG Antibody | A measurement of the Epstein-Barr capsid IgG antibody in a biological specimen. | Epstein-Barr Capsid IgG Antibody Measurement | ||
EBCIGMAB | C96601 | Epstein-Barr Capsid IgM Antibody | A measurement of the Epstein-Barr capsid IgM antibody in a biological specimen. | Epstein-Barr Capsid IgM Antibody Measurement | ||
EBEAG | C96602 | Epstein-Barr Early Antigen | A measurement of the Epstein-Barr early antigen in a biological specimen. | Epstein-Barr Early Antigen Measurement | ||
EBNAB | C96603 | Epstein-Barr Nuclear Antibody | A measurement of the Epstein-Barr nuclear antibody in a biological specimen. | Epstein-Barr Nuclear Antibody Measurement | ||
EBNAG | C96604 | Epstein-Barr Nuclear Antigen | A measurement of the Epstein-Barr nuclear antigen in a biological specimen. | Epstein-Barr Nuclear Antigen Measurement | ||
RBCGHOST | C96605 | Erythrocyte Ghosts;RBC Ghosts | A measurement of the erythrocyte ghosts (erythrocytes in which hemoglobin has been removed through hemolysis) in a biological specimen. | Erythrocyte Ghost Count | ||
FACTII | C96626 | Factor II;Prothrombin | A measurement of the Factor II in a biological specimen. | Prothrombin Measurement | ||
FAT | C96648 | Fat | A measurement of the fat in a biological specimen. | Fat Measurement | ||
FGF23 | C96650 | Fibroblast Growth Factor 23;Phosphatonin | A measurement of the fibroblast growth factor 23 in a biological specimen. | Fibroblast Growth Factor 23 Measurement | ||
NEUTGT | C96651 | Giant Neutrophils | A measurement of the giant neutrophils in a biological specimen. | Giant Neutrophil Count | ||
GLUCCLR | C96652 | Glucose Clearance | A measurement of the glucose clearance in a biological specimen. | Glucose Clearance Measurement | ||
GADAB | C96653 | Glutamic Acid Decarboxylase Antibody;GAD Antibody | A measurement of the glutamic acid decarboxylase antibody in a biological specimen. | Glutamic Acid Decarboxylase Antibody Measurement | ||
GRAN | C96654 | Granulocytes | A measurement of the granulocytes in a biological specimen. | Granulocyte Count | ||
HBCAB | C96660 | Hepatitis B Virus Core Antibody | A measurement of the hepatitis B virus core antibody in a biological specimen. | Hepatitis B Virus Core Antibody Measurement | ||
HBCIGMAB | C96661 | Hepatitis B Virus Core IgM Antibody | A measurement of the hepatitis B virus core IgM antibody in a biological specimen. | Hepatitis B Virus Core IgM Antibody Measurement | ||
HBEAB | C96662 | Hepatitis B Virus e Antibody | A measurement of the hepatitis B e antibody in a biological specimen. | Hepatitis B Virus e Antibody Measurement | ||
HBEAG | C96663 | Hepatitis B Virus e Antigen | A measurement of the hepatitis B e antigen in a biological specimen. | Hepatitis B Virus e Antigen Measurement | ||
HDAB | C96664 | Hepatitis D Virus Antibody;Hepatitis Delta Antibody | A measurement of the hepatitis D virus antibody in a biological specimen. | Hepatitis D Virus Antibody Measurement | ||
HEIGMAB | C96665 | Hepatitis E Virus IgM Antibody | A measurement of the hepatitis E virus IgM antibody in a biological specimen. | Hepatitis E Virus IgM Antibody Measurement | ||
HS1IGGAB | C96697 | Herpes Simplex Virus 1 IgG Antibody;HSV-1 IgG Antibody | A measurement of the herpes simplex virus 1 IgG antibody in a biological specimen. | Herpes Simplex Virus 1 IgG Antibody Measurement | ||
HS12GGAB | C96698 | Herpes Simplex Virus 1/2 IgG Antibody;HSV-1/2 IgG Ab | A measurement of the herpes simplex virus 1 and 2 IgG antibody in a biological specimen. | Herpes Simplex Virus 1/2 IgG Antibody Measurement | ||
HS12GMAB | C96666 | Herpes Simplex Virus 1/2 IgM Antibody;HSV-1/2 IgM Ab | A measurement of the herpes simplex virus 1 and 2 IgM antibody in a biological specimen. | Herpes Simplex Virus 1/2 IgM Antibody Measurement | ||
HS2IGGAB | C96667 | Herpes Simplex Virus 2 IgG Antibody;HSV-2 IgG Antibody | A measurement of the herpes simplex virus 2 IgG antibody in a biological specimen. | Herpes Simplex Virus 2 IgG Antibody Measurement | ||
HEXK | C96668 | Hexokinase | A measurement of the hexokinase in a biological specimen. | Hexokinase Measurement | ||
HYPERCHR | C96669 | Hyperchromia | A measurement of the prevalence of the erthrocytes with an elevated hemoglobin concentration. | Hyperchromia Measurement | ||
BASOIM | C96670 | Immature Basophils | A measurement of the immature basophils in a biological specimen. | Immature Basophil Count | ||
BASOIMLE | C96671 | Immature Basophils/Leukocytes | A relative measurement (ratio or percentage) of immature basophils to total leukocytes in a biological specimen. | Immature Basophil to Leukocyte Ratio Measurement | ||
CELLSIM | C96672 | Immature Cells | A measurement of the total immature cells in a blood specimen. | Immature Cell Count | ||
EOSIM | C96673 | Immature Eosinophils | A measurement of the immature eosinophils in a biological specimen. | Immature Eosinophil Count | ||
EOSIMLE | C96674 | Immature Eosinophils/Leukocytes | A relative measurement (ratio or percentage) of immature eosinophils to total leukocytes in a biological specimen. | Immature Eosinophil to Leukocyte Ratio Measurement | ||
GRANIM | C96675 | Immature Granulocytes | A measurement of the total immature granulocytes in a biological specimen. | Immature Granulocyte Count | ||
MONOIM | C96676 | Immature Monocytes | A measurement of the immature monocytes in a biological specimen. | Immature Monocyte Count | ||
MONOIMLE | C96677 | Immature Monocytes/Leukocytes | A relative measurement (ratio or percentage) of immature monocytes to total leukocytes in a biological specimen. | Immature Monocyte to Leukocyte Ratio Measurement | ||
NEUTIM | C96678 | Immature Neutrophils | A measurement of the total immature neutrophils in a biological specimen. | Immature Neutrophil Count | ||
PLSIMCE | C96679 | Immature Plasma Cells | A measurement of the immature plasma cells in a biological specimen. | Immature Plasma Cell Count | ||
PLSIMCLY | C96680 | Immature Plasma Cells/Lymphocytes | A relative measurement (ratio or percentage) of immature plasma cells to total lymphocytes in a biological specimen. | Immature Plasma Cell to Lymphocyte Ratio Measurement | ||
INHIBINB | C96681 | Inhibin B | A measurement of the inhibin B in a biological specimen. | Inhibin B Measurement | ||
KURLOFCE | C96682 | Kurloff Cells | A measurement of the large secretory granule-containing immune cells in a biological specimen taken from members of certain genera of the Caviidae family. | Kurloff Cells Measurement | ||
LKM1AB | C96683 | Liver Kidney Microsomal Type 1 Antibody;LKM-1 | A measurement of the liver kidney microsomal type 1 antibody in a biological specimen. | Liver Kidney Microsomal Type 1 Antibody Measurement | ||
MPC | C96686 | Mean Platelet Component | A measurement of the mean platelet component (platelet activity) in a blood specimen. | Mean Platelet Component Measurement | ||
KRCYMG | C96688 | Megakaryocytes | A measurement of the megakaryocytes per unit of a biological specimen. | Megakaryocyte Count | ||
HGBMET | C96689 | Methemoglobin | A measurement of the methemoglobin in a biological specimen. | Methemoglobin Measurement | ||
MMA | C96690 | Methylmalonic Acid | A measurement of the methylmalonic acid in a biological specimen. | Methylmalonic Acid Measurement | ||
BNPPRONT | C96610 | N-Terminal ProB-type Natriuretic Peptide;NT proBNP II;N-terminal pro-Brain Natriuretic Peptide | A measurement of the N-terminal proB-type natriuretic peptide in a biological specimen. | N-Terminal ProB-type Natriuretic Peptide Measurement | ||
OXYCAP | C96614 | Oxygen Capacity | A measurement of the maximum amount of oxygen that can be combined chemically with hemoglobin in a volume of blood. | Oxygen Capacity Measurement | ||
OXYSAT | C68032 | Oxygen Saturation | A measurement of the oxygen-hemoglobin saturation of a volume of blood. | Oxygen Saturation Measurement | ||
HGBOXY | C96616 | Oxyhemoglobin | A measurement of the oxyhemoglobin in a biological specimen. | Oxyhemoglobin Measurement | ||
PB19GGAB | C96617 | Parvovirus B19 IgG Antibody | A measurement of the Parvovirus B19 IgG antibody in a biological specimen. | Parvovirus B19 IgG Antibody Measurement | ||
PB19GMAB | C96618 | Parvovirus B19 IgM Antibody | A measurement of the Parvovirus B19 IgM antibody in a biological specimen. | Parvovirus B19 IgM Antibody Measurement | ||
PHOSLPD | C96623 | Phospholipid | A measurement of the phospholipids in a biological specimen. | Phospholipid Measurement | ||
PLATCLMP | C96624 | Platelet Clumps;PLT Clumps | A measurement of the platelet clumps in a biological specimen. | Platelet Clumps Count | ||
P1NP | C96625 | Procollagen 1 N-Terminal Propeptide;Amino-terminal propeptide of type 1 procollagen;P1NP Aminoterm Type 1 | A measurement of the procollagen 1 N-terminal propeptide in a biological specimen. | Procollagen 1 N-Terminal Propeptide Measurement | ||
RPTLTIME | C96628 | Reptilase Time | A measurement of the time it takes a plasma sample to clot after adding the active enzyme reptilase. | Reptilase Time Measurement | ||
TRGTCE | C96636 | Leptocytes;Target Cells | A measurement of the target cells in a biological specimen. | Target Cell Count | ||
THYPXD | C96639 | Thyroperoxidase;Thyroid Peroxidase | A measurement of the thyroperoxidase in a biological specimen. | Thyroperoxidase Measurement | ||
THYPXDAB | C96638 | Thyroperoxidase Antibody | A measurement of the thyroperoxidase antibody in a biological specimen. | Thyroperoxidase Antibody Measurement | ||
TOXGRAN | C96641 | Toxic Granulation | A measurement of the toxic granulation in neutrophilic blood cells. | Toxic Granulation Measurement | ||
UREACRT | C96645 | Urea/Creatinine | A relative measurement (ratio or percentage) of the urea to creatinine in a biological specimen. | Urea to Creatinine Ratio Measurement | ||
ADVVLD | C98705 | ADV Viral Load | A measurement of the adenovirus viral load in a biological specimen. | Adenovirus Viral Load Measurement | ||
AFACTXAA | C98706 | Anti-Factor Xa Activity | A measurement of the anti-activated Factor X in a biological specimen. This test is used to monitor low molecular weight or unfractionated heparin levels in a biological specimen. | Anti-Factor Xa Activity Measurement | ||
AMYLASEP | C98767 | Amylase, Pancreatic | A measurement of the pancreatic enzyme amylase in a biological specimen. | Pancreatic Amylase Measurement | ||
AMYLASES | C98780 | Amylase, Salivary | A measurement of the salivary enzyme amylase in a biological specimen. | Salivary Amylase Measurement | ||
APTTSTND | C98862 | Activated PTT/Standard | A relative measurement (ratio or percentage) of the subject's partial thromboplastin time to a standard or control partial thromboplastin time. | Activated PTT/Standard Ratio Measurement | ||
BASOCE | C98865 | Basophils/Total Cells | A relative measurement (ratio or percentage) of the basophils to total cells in a biological specimen (for example a bone marrow specimen). | Basophil to Total CellRatio Measurement | ||
BKVVLD | C98710 | BKV Viral Load | A measurement of the BK virus viral load in a biological specimen. | BK Virus Viral Load Measurement | ||
BLSTMBCE | C98761 | Myeloblasts/Total Cells | A relative measurement (ratio or percentage) of the myeloblasts to total cells in a biological specimen (for example a bone marrow specimen). | Myeloblast to Total Cell Ratio Measurement | ||
BLSTMGK | C98752 | Megakaryoblasts | A measurement of the megakaryoblasts in a biological specimen. | Megakaryoblast Cell Count | ||
BLSTMKCE | C98753 | Megakaryoblasts/Total Cells | A relative measurement (ratio or percentage) of the megakaryoblasts to total cells in a biological specimen (for example a bone marrow specimen). | Megakaryoblast to Total Cell Ratio Measurement | ||
BLSTNMCE | C98764 | Normoblasts/Total Cells | A relative measurement (ratio or percentage) of the normoblasts to total cells in a biological specimen (for example a bone marrow specimen). | Normoblast to Total Cell Ratio Measurement | ||
BLSTPNCE | C98870 | Pronormoblasts/Total Cells | A relative measurement (ratio or percentage) of the pronormoblasts to total cells in a biological specimen (for example a bone marrow specimen). | Pronormoblast to Total CellRatio Measurement | ||
CMVVLD | C98716 | CMV Viral Load | A measurement of the cytomegalovirus viral load in a biological specimen. | Cytomegalovirus Viral Load Measurement | ||
EBVVLD | C98721 | EBV Viral Load | A measurement of the Epstein-Barr virus viral load in a biological specimen. | Epstein-Barr Virus Viral Load Measurement | ||
EOSCE | C98720 | Eosinophils/Total Cells | A relative measurement (ratio or percentage) of the eosinophils to total cells in a biological specimen (for example a bone marrow specimen). | Eosinophils to Total Cell Ratio Measurement | ||
FACTIX | C98725 | Factor IX | A measurement of the factor IX in a biological specimen. | Factor IX Measurement | ||
FACTV | C98726 | Factor V | A measurement of the factor V in a biological specimen. | Factor V Measurement | ||
FACTVW | C98799 | von Willebrand Factor | A measurement of the von Willebrand factor in a biological specimen. | von Willebrand Factor Measurement | ||
FACTX | C98727 | Factor X | A measurement of the factor X in a biological specimen. | Factor X Measurement | ||
FATDROP | C98728 | Fat Droplet | A measurement of the triglyceride aggregates within a biological specimen. | Fat Droplet Measurement | ||
GFRBSA | C98734 | Glomerular Filtration Rate Adj for BSA | A measurement of the glomerular filtration rate adjusted for body size. | Glomerular Filtration Rate Adjusted for BSA | ||
GFRBSCRT | C98735 | GFR from Creatinine Adjusted for BSA | An estimation of the glomerular filtration rate adjusted for body size based on creatinine. | Glomerular Filtration Rate from Creatinine Adjusted for BSA | ||
GFRBSCYC | C98736 | GFR from Cystatin C Adjusted for BSA | An estimation of the glomerular filtration rate adjusted for body size based on cystatin C. | Glomerular Filtration Rate from Cystatin C Adjusted for BSA | ||
GRANCE | C98866 | Granulocytes/Total Cells | A relative measurement (ratio or percentage) of the granulocytes to total cells in a biological specimen (for example a bone marrow specimen). | Granulocyte to Total CellRatio Measurement | ||
HASIGEAB | C98740 | Human Anti-Sheep IgE Antibody | A measurement of the human anti-sheep IgE antibodies in a biological specimen. | Human Anti-Sheep IgE Antibody Measurement | ||
HASIGGAB | C98741 | Human Anti-Sheep IgG Antibody | A measurement of the human anti-sheep IgG antibodies in a biological specimen. | Human Anti-Sheep IgG Antibody Measurement | ||
HASIGMAB | C98742 | Human Anti-Sheep IgM Antibody | A measurement of the human anti-sheep IgM antibodies in a biological specimen. | Human Anti-Sheep IgM Antibody Measurement | ||
HMOSIDRN | C96659 | Hemosiderin | A measurement of the hemosiderin complex in a biological specimen. | - - - | ||
HS1IGMAB | C98738 | Herpes Simplex Virus 1 IgM Antibody | A measurement of the Herpes Simplex virus 1 IgM antibodies in a biological specimen. | Herpes Simplex Virus 1 IgM Antibody Measurement | ||
HS2IGMAB | C98739 | Herpes Simplex Virus 2 IgM Antibody | A measurement of the Herpes Simplex virus 2 IgM antibodies in a biological specimen. | Herpes Simplex Virus 2 IgM Antibody Measurement | ||
IGD | C98745 | Immunoglobulin D | A measurement of the Immunoglobulin D in a biological specimen. | Immunoglobulin D Measurement | ||
INLCLR | C98748 | Inulin Clearance | A measurement of the volume of serum or plasma that would be cleared of inulin by excretion of urine for a specified unit of time (e.g. one minute). | Inulin Clearance | ||
IOTCLR | C98749 | Iothalamate Clearance | A measurement of the volume of serum or plasma that would be cleared of iothalamate by excretion of urine for a specified unit of time (e.g. one minute). | Iothalamate Clearance | ||
IOTCLRBS | C98750 | Iothalamate Clearance Adjusted for BSA | A measurement of the volume of serum or plasma that would be cleared of iothalamate by excretion of urine for a specified unit of time (e.g. one minute), adjusted for body size. | Iothalamate Clearance Adjusted for BSA | ||
KLCFR | C98730 | Kappa Light Chain, Free | A measurement of the free kappa light chain in a biological specimen. | Free Kappa Light Chain Measurement | ||
KLCLLCFR | C98731 | Kappa Lt Chain,Free/Lambda Lt Chain,Free | A relative measurement (ratio or percentage) of the free kappa light chain to the free lambda light chain in a biological specimen. | Free Kappa Light Chain to Free Lambda Light Chain Ratio Measurement | ||
KRCYMGCE | C98867 | Megakaryocytes/Total Cells | A relative measurement (ratio or percentage) of the megakaryocytes to total cells in a biological specimen (for example a bone marrow specimen). | Megakaryocyte to Total CellRatio Measurement | ||
LLCFR | C98732 | Lambda Light Chain, Free | A measurement of the free lambda light chain in a biological specimen. | Free Lambda Light Chain Measurement | ||
LYMCE | C98751 | Lymphocytes/Total Cells | A relative measurement (ratio or percentage) of the lymphocytes to total cells in a biological specimen (for example a bone marrow specimen). | Lymphocyte to Total Cell Ratio Measurement | ||
METAMYCE | C98754 | Metamyelocytes/Total Cells | A relative measurement (ratio or percentage ) of the metamyelocytes (small, myelocytic neutrophils with an indented nucleus) to total cells in a biological specimen (for example a bone marrow specimen). | Metamyelocyte to Total Cell Ratio Measurement | ||
MONOCE | C98872 | Monocytes/Total Cells | A relative measurement (ratio or percentage) of the monocytes to total cells in a biological specimen (for example a bone marrow specimen). | Monocytes to Total CellRatioMeasurement | ||
MYCYCE | C98868 | Myelocytes/Total Cells | A relative measurement (ratio or percentage) of the myelocytes to total cells in a biological specimen (for example a bone marrow specimen). | Myelocyte to Total CellRatio Measurement | ||
NEUTCE | C98763 | Neutrophils/Total Cells | A relative measurement (ratio or percentage) of the neutrophils to total cells in a biological specimen (for example a bone marrow specimen). | Neutrophil to Total Cell Ratio Measurement | ||
NKCE | C98762 | Natural Killer Cells | A measurement of the total natural killer cells in a biological specimen. | Natural Killer Cell Count | ||
PLSMCECE | C98869 | Plasma Cells/Total Cells | A relative measurement (ratio or percentage) of the mature plasma cells (plasmacytes) to total cells in a biological specimen (for example a bone marrow specimen). | Plasma Cell to Total CellRatio Measurement | ||
PROMYCE | C98773 | Promyelocytes/Total Cells | A relative measurement (ratio or percentage) of the promyelocytes (immature myelocytes) to total cells in a biological specimen (for example a bone marrow specimen). | Promyelocyte to Total Cell Ratio Measurement | ||
PTA | C98774 | Prothrombin Activity | A measurement of the biological activity of prothrombin in a biological specimen. | Prothrombin Activity Measurement | ||
RETIHGB | C98776 | Reticulocyte Hemoglobin | A measurement of the amount of hemoglobin in reticulocytes. | Reticulocyte Hemoglobin Measurement | ||
TFRRNSAT | C98792 | Transferrin Saturation | A measurement of the iron bound to transferrin in a biological specimen. | Transferrin Saturation Measurement | ||
VZVIGAAB | C98795 | Varicella Zoster Virus IgA Antibody | A measurement of the Varicella Zoster virus IgA antibodies in a biological specimen. | Varicella Zoster Virus IgA Antibody Measurement | ||
VZVIGGAB | C98796 | Varicella Zoster Virus IgG Antibody | A measurement of the Varicella Zoster virus IgG antibodies in a biological specimen. | Varicella Zoster Virus IgG Antibody Measurement | ||
VZVIGMAB | C98797 | Varicella Zoster Virus IgM Antibody | A measurement of the Varicella Zoster virus IgM antibodies in a biological specimen. | Varicella Zoster Virus IgM Antibody Measurement | ||
DHPG | C101017 | 3,4-Dihydroxyphenylglycol;3.4 Dihydroxyphenylglycol | A measurement of the catecholamine metabolite, 3,4-Dihydroxyphenylglycol in a biological specimen. | 3,4-Dihydroxyphenylglycol Measurement | ||
APROTCRS | C100471 | Activated Protein C Resistance;Factor V Leiden Screen | A measurement of the resistance in the anticoagulation response to activated protein C in a biological specimen. | Activated Protein C Resistance Measurement | ||
APTTSPTT | C100421 | Activated PTT/Standard PTT;Activated Partial Thromboplastin Time/Standard Thromboplastin Time | A relative measurement (ratio or percentage) of the subject's activated partial thromboplastin time to a standard or control partial thromboplastin time. | Activated PTT to Standard PTT Ratio Measurement | ||
AAP | C100430 | Alanine Aminopeptidase | A measurement of the alanine aminopeptidase in a biological specimen. | Alanine Aminopeptidase Measurement | ||
A1AGLP | C100429 | Alpha-1 Acid Glycoprotein | A measurement of the alpha-1 acid glycoprotein in a biological specimen. | Alpha-1 Acid Glycoprotein Measurement | ||
A1MICG | C100461 | Alpha-1 Microglobulin;Protein HC | A measurement of the alpha-1 microglobulin in a biological specimen. | Alpha-1 Microglobulin Measurement | ||
A1MCREAT | C100462 | Alpha-1 Microglobulin/Creatinine | A relative measurement (ratio or percentage) of the alpha-1 microglobulin to creatinine in a biological specimen. | Alpha-1 Microglobulin to Creatinine Ratio Measurement | ||
APOC2 | C100427 | Apolipoprotein C2;Apolipoprotein CII | A measurement of the apolipoprotein C2 in a biological specimen. | Apolipoprotein C2 Measurement | ||
APOJ | C100428 | Apolipoprotein J;Clusterin | A measurement of the apolipoprotein J in a biological specimen. | Apolipoprotein J Measurement | ||
BETACRTN | C100472 | Beta Carotene;b-Carotene;Beta Carotin | A measurement of the beta carotene in a biological specimen. | Beta Carotene Measurement | ||
BTP | C100426 | Beta-Trace Protein | A measurement of the beta-trace protein in a biological specimen. | Beta-Trace Protein Measurement | ||
CDT | C101016 | Carbohydrate-Deficient Transferrin | A measurement of transferrin with a reduced number of carbohydrate moieties in a biological specimen. | Carbohydrate-Deficient Transferrin Measurement | ||
CRLPLSMN | C100432 | Ceruloplasmin;Caeruloplasmin | A measurement of ceruloplasmin in a biological specimen. | Ceruloplasmin Measurement | ||
CH50 | C100423 | Complement CH50;Total Hemolytic Complement;CH50 | A measurement of the complement required to lyse 50 percent of red blood cells in a biological specimen. | CH50 Measurement | ||
CXCR3 | C100431 | Chemokine (C-X-C Motif) Receptor 3;GPR9, CD183, CXCR3 | A measurement of the CXCR3, chemokine (C-X-C motif) receptor 3, in a biological specimen. | Chemokine Receptor CXCR3 Measurement | ||
CTRIGAAB | C100464 | Chlamydia trachomatis IgA Antibody | A measurement of the Chlamydia trachomatis IgA antibody in a biological specimen. | Chlamydia trachomatis IgA Antibody Measurement | ||
CTRIGGAB | C100466 | Chlamydia trachomatis IgG Antibody | A measurement of the Chlamydia trachomatis IgG antibody in a biological specimen. | Chlamydia trachomatis IgG Antibody Measurement | ||
CTRIGMAB | C100465 | Chlamydia trachomatis IgM Antibody | A measurement of the Chlamydia trachomatis IgM antibody in a biological specimen. | Chlamydia trachomatis IgM Antibody Measurement | ||
DTPACLR | C100441 | DTPA Clearance | A measurement of the volume of serum or plasma that would be cleared of Diethylenetriamine pentaacetate (DTPA) through its excretion for a specified unit of time. | Diethylene Triamine Pentaacetic Acid Clearance | ||
DNASEBAB | C100463 | DNase-B Antibody;Anti-Dnase B | A measurement of Dnase-B antibody in a biological specimen. | DNase-B Antibody Measurement | ||
ECT | C100422 | Ecarin Clotting Time | A measurement of the activity of thrombin inhibitors in a biological specimen based on the generation of meizothrombin. | Ecarin Clotting Time Measurement | ||
EDTACLR | C100440 | EDTA Clearance | A measurement of the volume of serum or plasma that would be cleared of Ethylenediamine tetraacetic acid (EDTA) through its excretion for a specified unit of time. | EDTA Clearance | ||
GLYCRLFR | C100448 | Free Glycerol;Free Glycerin | A measurement of the amount of unbound glycerol in a biological specimen. | Free Glycerol Measurement | ||
GFRBSB2M | C100450 | GFR from B-2 Microglobulin Adj for BSA | A measurement of the glomerular filtration rate (GFR) based on the clearance of beta-2 microglobulin after adjusting it for the body surface area. | Glomerular Filtration Rate from B-2 Microglobulin Adjusted for BSA Measurement | ||
GFRBSBTP | C100449 | GFR from Beta-Trace Protein Adj for BSA | A measurement of the glomerular filtration rate (GFR) based on the clearance of beta-trace protein after adjusting it for the body surface area. | Glomerular Filtration Rate from Beta-Trace Protein Adjusted for BSA Measurement | ||
HDLCLDLC | C100425 | HDL Cholesterol/LDL Cholesterol Ratio | A relative measurement (ratio or percentage) of the amount of HDL cholesterol compared to LDL cholesterol in a biological specimen. | HDL Cholesterol to LDL Cholesterol Ratio Measurement | ||
HLAB27AG | C100460 | HLA-B27 Antigen;Human Leukocyte Antigen B27 | A measurement of the human leukocyte antigen B27 (HLA-B27) in a biological specimen. | HLA-B27 Antigen Measurement | ||
HOMAIR | C100447 | Homostat Model Assess of Insulin Rstn;Homeostatic Model Assessment of Insulin Resistance | An assessment of beta-cell function and insulin resistance based on fasting blood glucose and insulin concentrations. | Homeostatic Model Assessment of Insulin Resistance | ||
GRANIMLE | C100445 | Immature Granulocytes/Leukocytes | A relative measurement (ratio or percentage) of the immature granulocytes to leukocytes in a biological specimen (for example a bone marrow specimen). | Immature Granulocytes to Leukocytes Ratio Measurement | ||
LYMIM | C100444 | Immature Lymphocytes | A measurement of the immature lymphocytes in a biological specimen. | Immature Lymphocytes Measurement | ||
LYMIMLE | C100443 | Immature Lymphocytes/Leukocytes | A relative measurement (ratio or percentage) of the immature lymphocytes to leukocytes in a biological specimen. | Immature Lymphocytes to Leukocytes Ratio Measurement | ||
NEUTIMLE | C100442 | Immature Neutrophils/Leukocytes | A relative measurement (ratio or percentage) of the immature neutrophils to leukocytes in a biological specimen. | Immature Neutrophils to Leukocytes Ratio Measurement | ||
IOHEXCLR | C100439 | Iohexol Clearance | A measurement of the volume of serum or plasma that would be cleared of Iohexol through excretion for a specified unit of time. | Iohexol Clearance | ||
JO1AB | C100459 | Jo-1 Antibody | A measurement of the Jo-1 antibody in a biological specimen. | Jo-1 Antibody Measurement | ||
KIM1 | C100433 | Kidney Injury Molecule-1;KIM-1;Hepatitis A Virus Cellular Receptor 1 | A measurement of the kidney injury molecule-1 (Kim-1) in a biological specimen. | Kidney Injury Molecule-1 Measurement | ||
LKM1IAAB | C100456 | Liver Kidney Microsomal Type 1 IgA Ab | A measurement of the liver kidney microsomal type 1 IgA antibodies in a biological specimen. | Liver Kidney Microsomal Type 1 IgA Antibody Measurement | ||
LKM1IGAB | C100454 | Liver Kidney Microsomal Type 1 IgG Ab | A measurement of the liver kidney microsomal type 1 IgG antibodies in a biological specimen. | Liver Kidney Microsomal Type 1 IgG Antibody Measurement | ||
LKM1IMAB | C100455 | Liver Kidney Microsomal Type 1 IgM Ab | A measurement of the liver kidney microsomal type 1 IgM antibodies in a biological specimen. | Liver Kidney Microsomal Type 1 IgM Antibody Measurement | ||
NPAP | C100434 | Non-Prostatic Acid Phosphatase | A measurement of the non-prostatic acid phosphatase in a biological specimen. | Non-Prostatic Acid Phosphatase Measurement | ||
OVAPARS | C100452 | Ova and Parasite | A measurement of the parasites and ova in a biological specimen. | Ova and Parasite Measurement | ||
PEPSNGA | C100469 | Pepsinogen A;PGA | A measurement of the pepsinogen A in a biological specimen. | Pepsinogen A Measurement | ||
PEPSNGC | C100470 | Pepsinogen C;PGC | A measurement of the pepsinogen C in a biological specimen. | Pepsinogen C Measurement | ||
PEPSNGI | C100467 | Pepsinogen I;PGI | A measurement of the pepsinogen I in a biological specimen. | Pepsinogen I Measurement | ||
PEPSNGII | C100468 | Pepsinogen II;PGII | A measurement of the pepsinogen II in a biological specimen. | Pepsinogen II Measurement | ||
PEPSNG | C100122 | Pepsinogen | A measurement of the pepsinogen in a biological specimen. | Pepsinogen Measurement | ||
PLSMDM | C100453 | Plasmodium | Examination of a biological specimen to detect the presence of any protozoan belonging to the Plasmodium genus. | Plasmodium Measurement | ||
PLATHCT | C100424 | Platelet Hematocrit;Thrombocytocrit | A relative measurement (ratio or percentage) of the proportion of the volume of blood taken up by platelets. | Platelet Hematocrit Measurement | ||
PREALB | C100435 | Prealbumin | A measurement of the prealbumin in a biological specimen. | Prealbumin Measurement | ||
PERTHRBL | C100446 | Proerythroblast | A measurement of the proerythroblasts in a biological specimen. | Proerythroblast Measurement | ||
PROTS | C100436 | Protein S | A measurement of the protein S in a biological specimen. | Protein S Measurement | ||
RBP | C100437 | Retinol Binding Protein | A measurement of the total retinol binding protein in a biological specimen. | Retinol Binding Protein Measurement | ||
RNPAB | C100457 | Ribonucleoprotein Antibody;RNP Antibody | A measurement of the ribonucleoprotein antibody in a biological specimen. | Ribonucleoprotein Antibody Measurement | ||
BLSTRSID | C100419 | Ringed Sideroblasts | A measurement of the ringed sideroblasts (abnormal nucleated erythroblasts with a large number of iron deposits in the perinuclear mitochondria, forming a ring around the nucleus) in a biological specimen. | Ringed Sideroblast Measurement | ||
SCL70AB | C100458 | Scl-70 Antibody;Scleroderma-70 Antibody | A measurement of the Scl-70 antibody in a biological specimen. | Scl-70 Antibody Measurement | ||
BLSTSID | C100418 | Sideroblast | A measurement of the sideroblasts (nucleated erythroblasts with iron granules in the cytoplasm) in a biological specimen. | Sideroblast Measurement | ||
SLTFRNRC | C100438 | Soluble Transferrin Receptor | A measurement of the soluble transferrin receptor in a biological specimen. | Soluble Transferrin Receptor Measurement | ||
TRCYANDP | C100420 | Tricyclic Antidepressants | A measurement of tricyclic antidepressants in a biological specimen. | Tricyclic Antidepressant Measurement | ||
Back to top | ||||||
CL.C67154.LBTEST | Laboratory Test Name (LBTEST) | text Extensible: Yes | C67154 | Laboratory Test Name | Terminology used for Laboratory Tests of the CDISC Standard Data Tabulation Model. | CDISC SDTM Laboratory Test Terminology by Name |
Anisocytes | C74797 | Anisocytes | A measurement of the inequality in the size of the red blood cells in a whole blood specimen. | Anisocyte Measurement | ||
Poikilocytes | C79602 | Poikilocytes | A measurement of the odd-shaped erythrocytes in a whole blood specimen. | Poikilocyte Measurement | ||
Bilirubin | C38037 | Bilirubin;Total Bilirubin | A measurement of the total bilirubin in a biological specimen. | Total Bilirubin Measurement | ||
Activated Partial Thromboplastin Time | C38462 | Activated Partial Thromboplastin Time | A measurement of the length of time that it takes for clotting to occur when reagents are added to a plasma specimen. The test is partial due to the absence of tissue factor (Factor III) from the reaction mixture. | Partial Thromboplastin Time | ||
Glucose | C41376 | Glucose | A measurement of the glucose in a biological specimen. | Plasma Glucose Measurement | ||
pH | C45997 | pH | A measure of the acidity or alkalinity of a fluid on a scale of 0 to 14. | pH | ||
Erythrocytes | C51946 | Erythrocytes;Red Blood Cells | A measurement of the total erythrocytes in a biological specimen. | Erythrocyte Count | ||
Reticulocytes | C51947 | Reticulocytes | A measurement of the reticulocytes in a biological specimen. | Reticulocyte Count | ||
Leukocytes | C51948 | Leukocytes;White Blood Cells | A measurement of the leukocytes in a biological specimen. | Leukocyte Count | ||
Lymphocytes | C51949 | Lymphocytes | A measurement of the lymphocytes in a biological specimen. | Lymphocyte Count | ||
Platelets | C51951 | Platelets | A measurement of the platelets in a biological specimen. | Platelet Count | ||
Blood Urea Nitrogen | C61019 | Blood Urea Nitrogen | A measurement of the urea nitrogen in a blood specimen. | Blood Urea Nitrogen Measurement | ||
Cholesterol | C61032 | Cholesterol;Total Cholesterol | A measurement of the cholesterol in a biological specimen. | Serum Total Cholesterol Measurement | ||
HDL Cholesterol | C61041 | HDL Cholesterol | A measurement of the high density lipoprotein cholesterol in a biological specimen. | Serum HDL Cholesterol Measurement | ||
LDL Cholesterol | C61042 | LDL Cholesterol | A measurement of the low density lipoprotein cholesterol in a biological specimen. | Serum LDL Cholesterol Measurement | ||
Prothrombin Time | C62656 | Prothrombin Time | A blood clotting measurement that evaluates the extrinsic pathway of coagulation. | Prothrombin Time | ||
Neutrophils | C63321 | Neutrophils | A measurement of the neutrophils in a biological specimen. | Absolute Neutrophil Count | ||
Albumin | C64431 | Albumin;Microalbumin | A measurement of the albumin protein in a biological specimen. | Albumin Measurement | ||
Alkaline Phosphatase | C64432 | Alkaline Phosphatase | A measurement of the alkaline phosphatase in a biological specimen. | Alkaline Phosphatase Measurement | ||
Alanine Aminotransferase | C64433 | Alanine Aminotransferase;SGPT | A measurement of the alanine aminotransferase in a biological specimen. | Alanine Aminotransferase Measurement | ||
Amylase | C64434 | Amylase | A measurement of the total enzyme amylase in a biological specimen. | Amylase Measurement | ||
Aspartate Aminotransferase | C64467 | Aspartate Aminotransferase;SGOT | A measurement of the aspartate aminotransferase in a biological specimen. | Aspartate Aminotransferase Measurement | ||
Bacteria | C64469 | Bacteria | A measurement of the bacteria in a biological specimen. | Bacterial Count | ||
Basophils | C64470 | Basophils | A measurement of the basophils in a biological specimen. | Total Basophil Count | ||
Basophils/Leukocytes | C64471 | Basophils/Leukocytes | A relative measurement (ratio or percentage) of the basophils to leukocytes in a biological specimen. | Basophil To Leukocyte Ratio | ||
Direct Bilirubin | C64481 | Direct Bilirubin | A measurement of the conjugated or water-soluble bilirubin in a biological specimen. | Direct Bilirubin Measurement | ||
Indirect Bilirubin | C64483 | Indirect Bilirubin | A measurement of the unconjugated or non-water-soluble bilirubin in a biological specimen. | Indirect Bilirubin Measurement | ||
Blasts/Leukocytes | C64487 | Blasts/Leukocytes | A relative measurement (ratio or percentage) of the blasts to leukocytes in a biological specimen. | Blast To Leukocyte Ratio | ||
Calcium | C64488 | Calcium | A measurement of the calcium in a biological specimen. | Calcium Measurement | ||
Creatine Kinase | C64489 | Creatine Kinase | A measurement of the total creatine kinase in a biological specimen. | Creatine Kinase Measurement | ||
Creatine Kinase BB | C64490 | Creatine Kinase BB | A measurement of the homozygous B-type creatine kinase in a biological specimen. | Creatine Kinase BB Measurement | ||
Creatine Kinase MB | C64491 | Creatine Kinase MB | A measurement of the heterozygous MB-type creatine kinase in a biological specimen. | Creatine Kinase MB Measurement | ||
Creatine Kinase MM | C64494 | Creatine Kinase MM | A measurement of the homozygous M-type creatine kinase in a biological specimen. | Creatine Kinase MM Measurement | ||
Chloride | C64495 | Chloride | A measurement of the chloride in a biological specimen. | Chloride Measurement | ||
Carbon Dioxide | C64545 | Carbon Dioxide | A measurement of the carbon dioxide gas in a biological specimen. | Carbon Dioxide Measurement | ||
Color | C64546 | Color | A measurement of the color of a biological specimen. | Color Assessment | ||
Creatinine | C64547 | Creatinine | A measurement of the creatinine in a biological specimen. | Creatinine Measurement | ||
C Reactive Protein | C64548 | C Reactive Protein | A measurement of the C reactive protein in a biological specimen. | C-Reactive Protein Measurement | ||
Elliptocytes | C64549 | Elliptocytes;Ovalocytes | A measurement of the elliptically shaped erythrocytes in a biological specimen. | Elliptocyte Count | ||
Eosinophils | C64550 | Eosinophils | A measurement of the eosinophils in a biological specimen. | Eosinophil Count | ||
Eosinophils/Leukocytes | C64604 | Eosinophils/Leukocytes | A relative measurement (ratio or percentage) of the eosinophils to leukocytes in a biological specimen. | Eosinophil To Leukocyte Ratio | ||
Epithelial Cells | C64605 | Epithelial Cells | A measurement of the epithelial cells in a biological specimen. | Epithelial Cell Count | ||
Fibrinogen | C64606 | Fibrinogen | A measurement of the fibrinogen in a biological specimen. | Fibrinogen Measurement | ||
Hematocrit | C64796 | Hematocrit | The percentage of a whole blood specimen that is composed of red blood cells (erythrocytes). | Hematocrit | ||
Ery. Mean Corpuscular Hemoglobin | C64797 | Ery. Mean Corpuscular Hemoglobin | A quantitative measurement of the mean amount of hemoglobin per erythrocyte in a biological specimen. | Erythrocyte Mean Corpuscular Hemoglobin | ||
Ery. Mean Corpuscular HGB Concentration | C64798 | Ery. Mean Corpuscular HGB Concentration | A quantitative measurement of the mean amount of hemoglobin per erythrocytes in a specified volume of a biological specimen. | Erythrocyte Mean Corpuscular Hemoglobin Concentration | ||
Ery. Mean Corpuscular Volume | C64799 | Ery. Mean Corpuscular Volume | A quantitative measurement of the mean volume of erythrocytes in a biological specimen. | Erythrocyte Mean Corpuscular Volume | ||
Erythrocytes Distribution Width | C64800 | Erythrocytes Distribution Width | A value derived from mean corpuscular volume and the standard deviation of the red blood cell volume in a whole blood specimen. | Erythrocyte Distribution Width Measurement | ||
Dacryocytes | C64801 | Dacryocytes;Tear Shaped Erythrocytes;Teardrop Cells | A measurement of dacryocytes in a biological specimen. | Dacryocyte Analysis | ||
Hypochromia | C64802 | Hypochromia | An observation which indicates that the hemoglobin concentration in a red blood cell specimen has fallen below a specified level. | Hypochromia | ||
Polychromasia | C64803 | Polychromasia | A measurement of the blue-staining characteristic of newly generated erythrocytes. | Polychromasia | ||
Prothrombin Intl. Normalized Ratio | C64805 | Prothrombin Intl. Normalized Ratio | A ratio that represents the prothrombin time for a plasma specimen, divided by the result for a control plasma specimen, further standardized for the International Sensitivity Index of the tissue factor (thromboplastin) used in the test. | International Normalized Ratio of Prothrombin Time | ||
VLDL Cholesterol | C64806 | VLDL Cholesterol | A measurement of the very low density lipoprotein cholesterol in a biological specimen. | Serum VLDL Cholesterol Measurement | ||
Triacylglycerol Lipase | C64807 | Triacylglycerol Lipase | A measurement of the pancreatic lipase in a biological specimen. | Triacylglycerol Lipase Measurement | ||
Sodium | C64809 | Sodium | A measurement of the sodium in a biological specimen. | Sodium Measurement | ||
Nitrite | C64810 | Nitrite | A measurement of the nitrite in a urine specimen. | Nitrite Measurement | ||
Triglycerides | C64812 | Triglycerides | A measurement of the triglycerides in a biological specimen. | Triglyceride Measurement | ||
Thyrotropin | C64813 | Thyrotropin | A measurement of the thyrotropin in a biological specimen. | Thyrotropin Measurement | ||
Urate | C64814 | Urate;Uric Acid | A measurement of the urate in a biological specimen. | Urate Measurement | ||
Urea | C64815 | Urea | A measurement of the urea in a biological specimen. | Urea Measurement | ||
Urobilinogen | C64816 | Urobilinogen | A measurement of the urobilinogen in a biological specimen. | Urobilinogen Measurement | ||
Vitamin B12 | C64817 | Vitamin B12 | A measurement of the Vitamin B12 in a serum specimen. | Vitamin B12 Measurement | ||
Lymphocytes Atypical | C64818 | Lymphocytes Atypical | A measurement of the atypical lymphocytes in a biological specimen. | Atypical Lymphocyte Count | ||
Lymphocytes Atypical/Leukocytes | C64819 | Lymphocytes Atypical/Leukocytes | A relative measurement (ratio or percentage) of the atypical lymphocytes to leukocytes in a biological specimen. | Atypical Lymphocyte To Leukocyte Ratio | ||
Lymphocytes/Leukocytes | C64820 | Lymphocytes/Leukocytes | A relative measurement (ratio or percentage) of the lymphocytes to leukocytes in a biological specimen. | Lymphocyte To Leukocyte Ratio | ||
Macrocytes | C64821 | Macrocytes | A measurement of the macrocytes in a biological specimen. | Macrocyte Count | ||
Microcytes | C64822 | Microcytes | A measurement of the microcytes in a biological specimen. | Microcyte Count | ||
Monocytes | C64823 | Monocytes | A measurement of the monocytes in a biological specimen. | Monocyte Count | ||
Monocytes/Leukocytes | C64824 | Monocytes/Leukocytes | A relative measurement (ratio or percentage) of the monocytes to leukocytes in a biological specimen. | Monocyte To Leukocyte Ratio | ||
Myeloblasts/Leukocytes | C64825 | Myeloblasts/Leukocytes | A relative measure (ratio or percentage) of the myeloblasts to leukocytes in a biological specimen. | Myeloblast To Leukocyte Ratio | ||
Myelocytes/Leukocytes | C64826 | Myelocytes/Leukocytes | A relative measurement (ratio or percentage) of the myelocytes to leukocytes in a biological specimen. | Myelocyte To Leukocyte Ratio | ||
Neutrophils/Leukocytes | C64827 | Neutrophils/Leukocytes | A relative measurement (ratio or percentage) of the neutrophils to leukocytes in a biological specimen. | Neutrophil To Leukocyte Ratio | ||
Reticulocytes/Erythrocytes | C64828 | Reticulocytes/Erythrocytes | A relative measurement (ratio or percentage) of reticulocytes to erythrocytes in a biological specimen. | Reticulocyte To Erythrocyte Ratio | ||
Prolymphocytes/Leukocytes | C64829 | Prolymphocytes/Leukocytes | A relative measurement (ratio or percentage) of prolymphocytes to leukocytes in a biological specimen. | Prolymphocyte To Leukocyte Ratio | ||
Neutrophils Band Form | C64830 | Neutrophils Band Form | A measurement of the banded neutrophils in a biological specimen. | Neutrophil Band Form Count | ||
Neutrophils Band Form/Leukocytes | C64831 | Neutrophils Band Form/Leukocytes | A relative measurement (ratio or percentage) of the banded neutrophils to leukocytes in a biological specimen. | Neutrophil Band Form To Leukocyte Ratio | ||
Specific Gravity | C64832 | Specific Gravity | A ratio of the density of a fluid to the density of water. | Specific Gravity | ||
Magnesium | C64840 | Magnesium | A measurement of the magnesium in a biological specimen. | Magnesium Measurement | ||
Gamma Glutamyl Transferase | C64847 | Gamma Glutamyl Transferase | A measurement of the gamma glutamyl transferase in a biological specimen. | Gamma Glutamyl Transpeptidase Measurement | ||
Hemoglobin | C64848 | Hemoglobin | A measurement of the hemoglobin in a biological specimen. | Hemoglobin Measurement | ||
Hemoglobin A1C | C64849 | Hemoglobin A1C | A measurement of the glycosylated hemoglobin in a biological specimen. | Glycosylated Hemoglobin Measurement | ||
Hepatitis B Virus Surface Antigen | C64850 | HBsAg;Hepatitis B Virus Surface Antigen | A measurement of the surface antigen reaction of a biological specimen to the Hepatitis B virus. | Hepatitis B Virus Surface Antigen Measurement | ||
Choriogonadotropin Beta | C64851 | Choriogonadotropin Beta;Pregnancy Test | A measurement of the Choriogonadotropin Beta in a biological specimen. | Choriogonadotropin Beta Measurement | ||
Potassium | C64853 | Potassium | A measurement of the potassium in a biological specimen. | Potassium Measurement | ||
Ketones | C64854 | Ketones | A measurement of the ketones in a biological specimen. | Ketone Measurement | ||
Lactate Dehydrogenase | C64855 | Lactate Dehydrogenase | A measurement of the lactate dehydrogenase in a biological specimen. | Lactate Dehydrogenase Measurement | ||
Leukocyte Esterase | C64856 | Leukocyte Esterase | A measurement of the enzyme which indicates the presence of white blood cells in a biological specimen. | Leukocyte Esterase Measurement | ||
Phosphate | C64857 | Phosphate;Phosphorus;Inorganic Phosphate | A measurement of the phosphate in a biological specimen. | Phosphate Measurement | ||
Protein | C64858 | Protein | A measurement of a group of complex organic macromolecules composed of one or more alpha-L-amino acid chains in a biological specimen. | Total Protein Measurement | ||
Prostate Specific Antigen | C17634 | Prostate Specific Antigen | A measurement of the prostate specific antigen in a biological specimen. | Prostate Specific Antigen Measurement | ||
Creatinine Clearance | C25747 | Creatinine Clearance | A measurement of the volume of serum or plasma that would be cleared of creatinine by excretion of urine for a specified unit of time (e.g. one minute). | Creatinine Clearance | ||
Hairy Cells | C74604 | Hairy Cells | A measurement of the hairy cells (b-cell lymphocytes with hairy projections from the cytoplasm) in a biological specimen. | Hairy Cell Count | ||
Blasts | C74605 | Blasts | A measurement of the blast cells in a biological specimen. | Blast Count | ||
CD19 | C74606 | CD19 | A measurement of the CD19 B cells in a biological specimen. | CD19 Expressing B Cell Count | ||
CD3 | C74607 | CD3 | A measurement of the CD3 T cells in a biological specimen. | CD3 Expressing T Cell Count | ||
CD4 | C74608 | CD4 | A measurement of the CD4 T cells in a biological specimen. | CD4 Expressing T Cell Count | ||
CD8 | C74609 | CD8 | A measurement of the CD8 T cells in a biological specimen. | CD8 Expressing T Cell Count | ||
Dohle Bodies | C74610 | Dohle Bodies | A measurement of the Dohle bodies (blue-gray, basophilic, leukocyte inclusions located in the peripheral cytoplasm of neutrophils) in a biological specimen. | Dohle Body Measurement | ||
Erythrocyte Sedimentation Rate | C74611 | Erythrocyte Sedimentation Rate;Biernacki Reaction | The distance (e.g. millimeters) that red blood cells settle in unclotted blood over a specified unit of time (e.g. one hour). | Erythrocyte Sedimentation Rate Measurement | ||
Hypersegmented Cells | C74612 | Hypersegmented Cells | A measurement of the hypersegmented (more than five lobes) neutrophils in a biological specimen. | Hypersegmented Neutrophil Measurement | ||
Lymphoma Cells | C74613 | Lymphoma Cells | A measurement of the malignant lymphocytes in a biological specimen. | Lymphoma Cell Count | ||
May-Hegglin Anomaly | C74614 | May-Hegglin Anomaly | A measurement of the May-Hegglin anomaly in a blood sample. This anomaly is characterized by large, misshapen platelets and the presence of Dohle bodies in leukocytes. | May-Hegglin Anomaly Measurement | ||
Metamyelocytes | C74615 | Metamyelocytes | A measurement of the metamyelocytes (small, myelocytic neutrophils with an indented nucleus) in a biological specimen. | Metamyelocyte Count | ||
Pappenheimer Bodies | C74616 | Pappenheimer Bodies | A measurement of the cells containing Pappenheimer Bodies (violet or blue staining ferritin granules usually found along the periphery of the red blood cells) in a biological specimen. | Pappenheimer Body Count | ||
Pelger Huet Anomaly | C74617 | Pelger Huet Anomaly | A measurement of the Pelger Huet Anomaly (nuclei of neutrophils and eosinophils appear rod-like, spherical or dumbbell shaped) in a biological specimen. | Pelger Huet Anomaly Measurement | ||
Plasmacytoid Lymphocytes | C74618 | Plasmacytoid Lymphocytes;Plymphocytes | A measurement of the plasmacytoid lymphocytes (lymphocytes with peripherally clumped chromatin and often deep blue cytoplasm, and that appear similar to plasma cells) in a biological specimen. | Plasmacytoid Lymphocyte Count | ||
Precursor Plasma Cells | C74619 | Precursor Plasma Cells;Plasmablast | A measurement of the precursor (blast stage) plasma cells (antibody secreting cells derived from B cells via antigen stimulation) in a biological specimen. | Precursor Plasma Cell Count | ||
Prolymphocytes | C74620 | Prolymphocytes | A measurement of the prolymphocytes in a biological specimen. | Prolymphocyte Count | ||
Promonocytes | C74621 | Promonocytes | A measurement of the promonocytes in a biological specimen. | Promonocyte Count | ||
Promyelocytes | C74622 | Promyelocytes | A measurement of the promyelocytes (immature myelocytes) in a biological specimen. | Promyelocyte Count | ||
Rouleaux Formation | C74624 | Rouleaux Formation | A measurement of the number of stacking red blood cells within a biological specimen. | Rouleaux Formation Count | ||
Sezary Cells | C74625 | Sezary Cells | A measurement of the Sezary cells (atypical lymphocytes with cerebriform nuclei) in a biological specimen. | Sezary Cell Count | ||
Sickle Cells | C74626 | Sickle Cells | A measurement of the sickle cells (sickle shaped red blood cells) in a biological specimen. | Sickle Cell Count | ||
Smudge Cells | C74627 | Smudge Cells;Basket Cells | A measurement of the smudge cells (the nuclear remnant of a ruptured white blood cell) in a biological specimen. | Smudge Cell Count | ||
Vacuolated Neutrophils | C74628 | Vacuolated Neutrophils | A measurement of the neutrophils containing small vacuoles in a biological specimen. | Vacuolated Neutrophil Count | ||
Leukemic Blasts | C74630 | Leukemic Blasts;Leukemic Lymphoblasts;Immunoblastic Lymphocytes | A measurement of the leukemic blasts (lymphoblasts that remain in an immature state even when outside the bone marrow) in a biological specimen. | Leukemic Blast Count | ||
Monoblasts | C74631 | Monoblasts | A measurement of the monoblast cells in a biological specimen. | Monoblast Count | ||
Myeloblasts | C74632 | Myeloblasts | A measurement of the myeloblast cells in a biological specimen. | Myeloblast Count | ||
Acanthocytes/Erythrocytes | C74633 | Acanthocytes/Erythrocytes | A relative measurement (ratio or percentage) of acanthocytes to all erythrocytes in a biological specimen. | Acanthocyte to Erythrocyte Ratio Measurement | ||
Bite Cells/Erythrocytes | C74634 | Bite Cells/Erythrocytes | A relative measurement (ratio or percentage) of bite cells (erythrocytes with the appearance of a bite having been removed, due to oxidative hemolysis) to all erythrocytes in a biological specimen . | Bite Cell to Erythrocyte Ratio Measurement | ||
CD19/Lymphocytes | C74635 | CD19/Lymphocytes | A relative measurement (ratio or percentage) of CD19 B cells to all lymphocytes in a biological specimen. | CD19 B Cell to Lymphocyte Ratio Measurement | ||
CD3/Lymphocytes | C74636 | CD3/Lymphocytes | A relative measurement (ratio or percentage) of CD3 T cells to all lymphocytes in a biological specimen. | CD3 T Cell to Lymphocyte Ratio Measurement | ||
CD4/CD8 | C74637 | CD4/CD8 | A relative measurement (ratio or percentage) of CD4 T cells to the CD8 T cells in a biological specimen. | CD4 T Cell to CD8 T Cell Ratio Measurement | ||
CD4/Lymphocytes | C74638 | CD4/Lymphocytes | A relative measurement (ratio or percentage) of CD4 T cells to all lymphocytes in a biological specimen. | CD4 T Cell to Lymphocyte Ratio Measurement | ||
CD8/Lymphocytes | C74639 | CD8/Lymphocytes | A relative measurement (ratio or percentage) of CD8 T cells to all lymphocytes in a biological specimen. | CD8 T Cell to Lymphocyte Ratio Measurement | ||
Hairy Cells/Lymphocytes | C74640 | Hairy Cells/Lymphocytes | A relative measurement (ratio or percentage) of the hairy cells (b-cell lymphocytes with hairy projections from the cytoplasm) to all lymphocytes in a biological specimen . | Hairy Cell to Lymphocyte Ratio Measurement | ||
Leukemic Blasts/Lymphocytes | C74641 | Leukemic Blasts/Lymphocytes | A relative measurement (ratio or percentage) of the leukemic blasts (immature lymphoblasts) to mature lymphocytes in a biological specimen. | Leukemic Blast to Lymphocyte Ratio Measurement | ||
Malignant Cells, NOS/Blood Cells | C74643 | Malignant Cells, NOS/Blood Cells | A relative measurement (ratio or percentage) of the malignant cells of all types to all blood cells in a biological specimen. | Malignant Cell to Blood Cell Ratio Measurement | ||
Metamyelocytes/Leukocytes | C74645 | Metamyelocytes/Leukocytes | A relative measurement (ratio or percentage) of the metamyelocytes (small, myelocytic neutrophils with an indented nucleus) to all leukocytes in a biological specimen. | Metamyelocyte to Leukocyte Ratio Measurement | ||
Monoblasts/Leukocytes | C74646 | Monoblasts/Leukocytes | A relative measurement (ratio or percentage) of the monoblasts to leukocytes in a biological specimen. | Monoblast to Leukocyte Ratio Measurement | ||
Nucleated Erythrocytes/Erythrocytes | C74647 | Nucleated Erythrocytes/Erythrocytes;Nucleated Red Blood Cells/Erythrocytes | A relative measurement (ratio or percentage) of the nucleated erythrocytes (large, immature nucleated erythrocytes) to all erythrocytes in a biological specimen. | Nucleated Red Blood Cell to Erythrocyte Ratio Measurement | ||
Plasmacytoid Lymphocytes/Lymphocytes | C74648 | Plasmacytoid Lymphocytes/Lymphocytes | A relative measurement (ratio or percentage) of the plasmacytoid lymphocytes (lymphocytes with peripherally clumped chromatin and often deep blue cytoplasm, and that appear similar to plasma cells) to all lymphocytes in a biological specimen. | Plasmacytoid Lymphocyte to Lymphocyte Ratio Measurement | ||
Poikilocytes/Erythrocytes | C74649 | Poikilocytes/Erythrocytes | A relative measurement (ratio or percentage) of the poikilocytes, or irregularly shaped erythrocytes, to all erythrocytes in a biological specimen. | Poikilocyte to Erythrocyte Ratio Measurement | ||
Precursor Plasma Cells/Lymphocytes | C74650 | Precursor Plasma Cells/Lymphocytes | A relative measurement (ratio or percentage) of the precursor (blast stage) plasma cells (antibody secreting cells derived from B cells via antigen stimulation) to all lymphocytes in a biological specimen. | Precursor Plasma Cell to Lymphocyte Ratio Measurement | ||
Prolymphocytes/Lymphocytes | C74651 | Prolymphocytes/Lymphocytes | A relative measurement (ratio or percentage) of the prolymphocytes to all lymphocytes in a biological specimen. | Prolymphocyte to Lymphocyte Ratio Measurement | ||
Promonocytes/Leukocytes | C74652 | Promonocytes/Leukocytes | A relative measurement (ratio or percentage) of the promonocytes to all leukocytes in a biological specimen. | Promonocyte to Lymphocyte Ratio Measurement | ||
Promyelocytes/Leukocytes | C74653 | Promyelocytes/Leukocytes | A relative measurement (ratio or percentage) of the promyelocytes (immature myelocytes) to all leukocytes in a biological specimen. | Promyelocyte to Lymphocyte Ratio Measurement | ||
Reactive Lymphocytes/Lymphocytes | C74654 | Reactive Lymphocytes/Lymphocytes | A relative measurement (ratio or percentage) of the reactive lymphocytes (lymphocytes which have become large due to an antigen reaction) to all lymphocytes in a biological specimen. | Reactive Lymphocyte to Lymphocyte Ratio Measurement | ||
Sezary Cells/Lymphocytes | C74655 | Sezary Cells/Lymphocytes | A relative measurement (ratio or percentage of the Sezary cells (atypical lymphocytes with cerebriform nuclei) to all lymphocytes in a biological specimen. | Sezary Cell to Lymphocyte Ratio Measurement | ||
Sickle Cells/Erythrocytes | C74656 | Sickle Cells/Erythrocytes | A relative measurement (ratio or percentage) of the sickle cells (sickle shaped red blood cells) to all erythrocytes in a biological specimen. | Sickle Cell to Erythrocyte Ratio Measurement | ||
Auer Rods | C74657 | Auer Rods | A measurement of the Auer rods (elongated needle structures that are found in the cytoplasm of leukemic blasts and are formed by clumps of azurophilic granular material) in a biological specimen. | Auer Rod Measurement | ||
Helmet Cells | C74658 | Helmet Cells | A measurement of the Helmet cells (specialized Keratocytes with two projections on either end that are tapered and hornlike) in a biological specimen. | Helmet Cell Count | ||
Large Unstained Cells | C74659 | Large Unstained Cells | A measurement of the large, peroxidase-negative cells which cannot be further characterized (i.e. as large lymphocytes, virocytes, or stem cells) present in a biological specimen. | Large Unstained Cell Count | ||
Malignant Cells, NOS | C74660 | Malignant Cells, NOS | A measurement of the malignant cells of all types in a biological specimen. | Malignant Cell Count | ||
Mature Plasma Cells | C74661 | Mature Plasma Cells;Plasmacytes | A measurement of the mature plasma cells (plasmacytes) in a biological specimen. | Mature Plasma Cell Count | ||
Myelocytes | C74662 | Myelocytes | A measurement of the myelocytes in a biological specimen. | Myelocyte Count | ||
Spermatozoa | C74663 | Spermatozoa | A measurement of the spermatozoa cells present in a biological specimen. | Spermatozoa Cell Count | ||
Yeast Cells | C74664 | Yeast Cells | A measurement of the yeast cells present in a biological specimen. | Yeast Cell Measurement | ||
Amorphous Crystals | C74665 | Amorphous Crystals | A measurement of the amorphous (Note: phosphate or urate, depending on pH) crystals present in a biological specimen. | Amorphous Crystal Measurement | ||
Amorphous Sediment | C74666 | Amorphous Sediment;Amorphous Debris | A measurement of the amorphous sediment present in a biological specimen. | Amorphous Sediment Measurement | ||
Bicarbonate | C74667 | Bicarbonate;HCO3 | A measurement of the bicarbonate in a biological specimen. | Bicarbonate Measurement | ||
Bilirubin Crystals | C74668 | Bilirubin Crystals | A measurement of the bilirubin crystals present in a biological specimen. | Bilirubin Crystal Measurement | ||
Calcium Carbonate Crystals | C74669 | Calcium Carbonate Crystals | A measurement of the calcium carbonate crystals present in a biological specimen. | Calcium Carbonate Crystal Measurement | ||
Calcium Oxalate Crystals | C74670 | Calcium Oxalate Crystals | A measurement of the calcium oxalate crystals present in a biological specimen. | Calcium Oxalate Crystal Measurement | ||
Calcium Phosphate Crystals | C74671 | Calcium Phosphate Crystals | A measurement of the calcium phosphate crystals present in a biological specimen. | Calcium Phosphate Crystal Measurement | ||
Cholesterol Crystals | C74672 | Cholesterol Crystals | A measurement of the cholesterol crystals present in a biological specimen. | Cholesterol Crystal Measurement | ||
Crystals | C74673 | Crystals | A statement that indicates crystals were looked for and not found in a biological specimen. | Crystal Present Or Absent | ||
Cystine Crystals | C74674 | Cystine Crystals | A measurement of the cystine crystals present in a biological specimen. | Cystine Crystal Measurement | ||
Vitamin B9 | C74676 | Folic Acid;Vitamin B9 | A measurement of the folic acid in a biological specimen. | Folic Acid Measurement | ||
Carnitine, Free | C74677 | Carnitine, Free | A measurement of the free carnitine in a biological specimen. | Free Carnitine Measurement | ||
Fructosamine | C74678 | Fructosamine;Glycated Serum Protein | A measurement of the fructosamine in a biological specimen. | Fructosamine Measurement | ||
Iron | C74679 | Iron;FE | A measurement of the iron in a biological specimen. | Iron Measurement | ||
Leucine Crystals | C74680 | Leucine Crystals | A measurement of the leucine crystals present in a biological specimen. | Leucine Crystal Measurement | ||
Monosodium Urate Crystals | C74681 | Monosodium Urate Crystals | A measurement of the monosodium urate crystals present in a biological specimen. | Monosodium Urate Crystal Measurement | ||
Carnitine | C74682 | Carnitine | A measurement of the total carnitine in a biological specimen. | Total Carnitine Measurement | ||
Tyrosine Crystals | C74683 | Tyrosine Crystals | A measurement of the triple phosphate crystals present in a biological specimen. | Tyrosine Crystal Measurement | ||
Uric Acid Crystals | C74684 | Uric Acid Crystals | A measurement of the uric acid crystals present in a biological specimen. | Uric Acid Crystal Measurement | ||
Anion Gap | C74685 | Anion Gap | A computed estimate of the unmeasured anions (those other than the chloride and bicarbonate anions) in a biological specimen. | Anion Gap Measurement | ||
Occult Blood | C74686 | Occult Blood | A measurement of the blood in body products such as a stool sample, not detectable on gross examination. | Occult Blood Measurement | ||
Amphetamine | C74687 | Amphetamine | A measurement of any amphetamine class drug present in a biological specimen. | Amphetamine Drug Class Measurement | ||
Barbiturates | C74688 | Barbiturates | A measurement of any barbiturate class drug present in a biological specimen. | Barbiturate Drug Class Measurement | ||
Cannabinoids | C74689 | Cannabinoids | A measurement of any cannabinoid class drug present in a biological specimen. | Cannabinoid Drug Class Measurement | ||
Cocaine | C74690 | Cocaine | A measurement of the cocaine present in a biological specimen. | Cocaine Measurement | ||
Round Epithelial Cells | C74698 | Round Epithelial Cells | A measurement of the round epithelial cells present in a biological specimen. | Round Epithelial Cell Count | ||
Acanthocytes | C74699 | Acanthocytes | A measurement of the acanthocytes in a biological specimen. | Acanthocyte Count | ||
Bite Cells | C74700 | Bite Cells | A measurement of the bite cells (erythrocytes with the appearance of a bite having been removed, due to oxidative hemolysis) in a biological specimen . | Bite Cell Count | ||
Burr Cells | C74701 | Burr Cells;Keratocytes | A measurement of the Burr cells (erythrocytes characterized by the presence of small, blunt projections evenly distributed across the cell surface) in a biological specimen. | Burr Cell Count | ||
Cabot Rings | C74702 | Cabot Rings | A measurement of the Cabot rings (red-purple staining, threadlike, ring or figure 8 shaped filaments in an erythrocyte) in a biological specimen. | Cabot Ring Count | ||
Crenated Cells | C74703 | Crenated Cells;Echinocytes | A measurement of the Burr cells (erythrocytes characterized by the presence of multiple small, sharp projections evenly distributed across the cell surface) in a biological specimen. | Crenated Cell Measurement | ||
Howell-Jolly Bodies | C74704 | Howell-Jolly Bodies | A measurement of the Howell-Jolly bodies (spherical, blue-black condensed DNA inclusions within the body of a red blood cell that appear under Wright-stain) in a biological specimen. | Howell-Jolly Body Measurement | ||
Nucleated Erythrocytes | C74705 | Nucleated Erythrocytes;Nucleated Red Blood Cells | A measurement of the nucleated erythrocytes (large, immature nucleated erythrocytes) in a biological specimen. | Nucleated Red Blood Cell Count | ||
Schistocytes | C74706 | Schistocytes | A measurement of the schistocytes (fragmented red blood cells) in a biological specimen. | Schistocyte Count | ||
Spherocytes | C74707 | Spherocytes | A measurement of the spherocytes (small, sphere-shaped red blood cells) in a biological specimen. | Spherocyte Count | ||
Stomatocytes | C74708 | Stomatocytes | A measurement of the stomatocytes (red blood cells with an oval or rectangular area of central pallor, producing the appearance of a cell mouth) in a biological specimen. | Stomatocyte Count | ||
Heinz Bodies | C74709 | Heinz Bodies;Heinz-Erhlich Bodies | A measurement of the Heinz bodies (small round inclusions within the body of a red blood cell) in a biological specimen. | Heinz-Ehrlich Body Measurement | ||
Hepatitis A Virus Antibody | C92534 | Hepatitis A Virus Antibody | A measurement of the antibody reaction of a biological specimen to the Hepatitis A virus. | Hepatitis A Antibody Measurement | ||
Hepatitis B Virus Surface Antibody | C74711 | Anti-HBs;HBsAb;Hepatitis B Virus Surface Antibody | A measurement of the surface antibody reaction of a biological specimen to the Hepatitis B virus. | Hepatitis B Surface Antibody Measurement | ||
Hepatitis C Virus Antibody | C92535 | Hepatitis C Virus Antibody | A measurement of the antibody reaction of a biological specimen to the Hepatitis C virus. | Hepatitis C Antibody Measurement | ||
HIV-1 Antibody | C74713 | HIV-1 Antibody | A measurement of the antibody reaction of a biological specimen to the HIV-1 virus. | HIV-1 Antibody Measurement | ||
HIV-1/2 Antibody | C74714 | HIV-1/2 Antibody | A measurement of the antibody reaction of a biological specimen to the either the HIV-1 or HIV-2 virus. | HIV-1 HIV-2 Antibody Measurement | ||
HIV-2 Antibody | C74715 | HIV-2 Antibody | A measurement of the antibody reaction of a biological specimen to the HIV-2 virus. | HIV-2 Antibody Measurement | ||
Rapid Plasma Reagin | C74716 | Rapid Plasma Reagin | A measurement of the antibodies produced by cellular damage caused by Treponema pallidum (syphilis) in a biological specimen. | Rapid Plasma Reagin Measurement | ||
Rheumatoid Factor | C74717 | Rheumatoid Factor | A measurement of the rheumatoid factor antibody in a biological specimen. | Rheumatoid Factor Measurement | ||
Total Iron Binding Capacity | C74718 | Total Iron Binding Capacity | A measurement of the amount of iron needed to fully saturate the transferrin in a biological specimen. | Total Iron Binding Capacity | ||
Unsaturated Iron Binding Capacity | C74719 | Unsaturated Iron Binding Capacity | A measurement of the binding capacity of unsaturated iron in a biological specimen. | Unsaturated Iron Binding Capacity Measurement | ||
Mucous Threads | C74721 | Mucous Threads | A measurement of the mucous threads present in a biological specimen. | Mucous Thread Measurement | ||
Turbidity | C74723 | Turbidity | A measurement of the opacity of a biological specimen. | Turbidity Measurement | ||
HAV Viral Load | C92541 | HAV Viral Load | A measurement of the hepatitis A viral load in a biological specimen. | Hepatitis A Viral Load Measurement | ||
HBV Viral Load | C92542 | HBV Viral Load | A measurement of the hepatitis B viral load in a biological specimen. | Hepatitis B Viral Load Measurement | ||
HCV Viral Load | C92543 | HCV Viral Load | A measurement of the hepatitis C viral load in a biological specimen. | Hepatitis C Viral Load Measurement | ||
HIV Viral Load | C92544 | HIV Viral Load | A measurement of the HIV viral load in a biological specimen. | HIV Viral Load Measurement | ||
Giant Platelets | C74728 | Giant Platelets | A measurement of the giant (larger than 7um in diameter) platelets in a biological specimen. | Giant Platelet Count | ||
Large Platelets | C74729 | Large Platelets | A measurement of the large (between 4 um and 7um in diameter) platelets in a biological specimen. | Large Platelet Count | ||
Mean Platelet Volume | C74730 | Mean Platelet Volume | A measurement of the average size of the platelets present in a blood sample. | Mean Platelet Volume Measurement | ||
Aldolase | C74731 | Aldolase | A measurement of the aldolase enzyme in a biological specimen. | Aldolase Measurement | ||
Alpha Fetoprotein | C74732 | Alpha Fetoprotein | A measurement of the alpha fetoprotein in a biological specimen. | Alpha-fetoprotein Measurement | ||
Apolipoprotein A1 | C74733 | Apolipoprotein A1 | A measurement of the apolipoprotein A1 in the high density lipoproteins of a biological specimen. | Apolipoprotein A1 Measurement | ||
Apolipoprotein B | C74734 | Apolipoprotein B | A measurement of the apolipoprotein B in the low density lipoproteins of a biological specimen. | Apolipoprotein B Measurement | ||
Brain Natriuretic Peptide | C74735 | Brain Natriuretic Peptide;B-Type Natriuretic Peptide | A measurement of the brain (B-type) natriuretic peptide in a biological specimen. | Brain Natriuretic Peptide Measurement | ||
C-peptide | C74736 | C-peptide | A measurement of the C (connecting) peptide of insulin in a biological specimen. | C-peptide Measurement | ||
Ferritin | C74737 | Ferritin | A measurement of the ferritin in a biological specimen. | Ferritin Measurement | ||
Globulin | C74738 | Globulin | A measurement of the globulin protein in a biological specimen. | Globulin Protein Measurement | ||
Glutamate | C74739 | Glutamate;Glutamic Acid | A measurement of the glutamate in a biological specimen. | Glutamate Measurement | ||
Haptoglobin | C74740 | Haptoglobin | A measurement of the haptoglobin protein in a biological specimen. | Haptoglobin Protein Measurement | ||
Homocysteine | C74741 | Homocysteine | A measurement of the homocysteine amino acid in a biological specimen. | Homocysteine Acid Measurement | ||
N-telopeptide | C74743 | N-telopeptide | A measurement of the N-telopeptide in a biological specimen. | N-telopeptide Measurement | ||
Osteocalcin | C74744 | Osteocalcin | A measurement of the osteocalcin in a biological specimen. | Osteocalcin Measurement | ||
Sex Hormone Binding Globulin | C74745 | Sex Hormone Binding Globulin;Sex Hormone Binding Protein | A measurement of the sex hormone binding (globulin) protein in a biological specimen. | Sex Hormone Binding Protein Measurement | ||
Thyroxine Binding Globulin | C74746 | Thyroxine Binding Globulin | A measurement of the thyroxine binding globulin protein in a biological specimen. | Thyroxine Binding Globulin Protein Measurement | ||
Triiodothyronine | C74747 | Triiodothyronine;Total T3 | A measurement of the total (free and bound) triiodothyronine in a biological specimen. | Triiodothyronine Measurement | ||
Triiodothyronine Uptake | C74748 | Triiodothyronine Uptake | A measurement of the binding of triiodothyonine to thyroxine binding globulin protein in a biological specimen. | Triiodothyronine Uptake Measurement | ||
Troponin I | C74749 | Troponin I | A measurement of the actin binding troponin in a biological specimen. | Troponin I Measurement | ||
Troponin T | C74750 | Troponin T | A measurement of the tropomyosin binding troponin in a biological specimen. | Troponin T Measurement | ||
Tumor Necrosis Factor | C74751 | Tumor Necrosis Factor;Tumor Necrosis Factor alpha | A measurement of the total tumor necrosis factor (cachexin) cytokine in a biological specimen. | Tumor Necrosis Factor Measurement | ||
BUN/Creatinine | C74753 | BUN/Creatinine | A relative measurement (ratio or percentage) (ratio) of the blood urea nitrogen (BUN) to the creatinine in a biological specimen. | Blood Urea Nitrogen To Creatinine Ratio Measurement | ||
Hippuric Acid Crystals | C74754 | Hippuric Acid Crystals | A measurement of the hippuric acid crystals present in a biological specimen. | Hippuric Acid Crystal Measurement | ||
Sulfa Crystals | C74755 | Sulfa Crystals | A measurement of the sulfa crystals present in a biological specimen. | Sulfa Crystal Measurement | ||
Triple Phosphate Crystals | C74756 | Triple Phosphate Crystals | A measurement of the triple phosphate crystals present in a biological specimen. | Triple Phosphate Crystal Measurement | ||
Unclassified Crystals | C74757 | Unclassified Crystals | A measurement of the unclassifiable crystals present in a biological specimen. | Unclassified Crystal Measurement | ||
Ammonium Biurate Crystals | C74758 | Ammonium Biurate Crystals | A measurement of the ammonium biurate crystals present in a biological specimen. | Urine Ammonium Biurate Crystal Measurement | ||
Ammonium Oxalate Crystals | C74759 | Ammonium Oxalate Crystals | A measurement of the ammonium oxalate crystals present in a urine specimen. | Urine Ammonium Oxalate Crystal Measurement | ||
Albumin/Creatinine | C74761 | Albumin/Creatinine;Microalbumin/Creatinine Ratio | A relative measurement (ratio or percentage) of the albumin to the creatinine in a biological specimen. | Albumin To Creatinine Protein Ratio Measurement | ||
Bacterial Casts | C74762 | Bacterial Casts | A measurement of the bacterial casts present in a biological specimen. | Bacterial Cast Measurement | ||
Casts | C74763 | Casts | A statement that indicates casts were looked for and not found in a biological specimen. | Cast Present Or Absent | ||
Cellular Casts | C74764 | Cellular Casts | A measurement of the cellular (white blood cell, red blood cell, epithelial and bacterial) casts present in a biological specimen. | Cellular Cast Measurement | ||
Granular Coarse Casts | C74765 | Granular Coarse Casts | A measurement of the coarse granular casts present in a biological specimen. | Coarse Granular Cast Measurement | ||
Fatty Casts | C74766 | Fatty Casts | A measurement of the fatty casts present in a biological specimen. | Fatty Cast Measurement | ||
Granular Casts | C74768 | Granular Casts | A measurement of the granular (coarse and fine) casts present in a biological specimen. | Granular Cast Measurement | ||
Granular Fine Casts | C74769 | Granular Fine Casts | A measurement of the fine granular casts present in a biological specimen. | Granular Fine Cast Measurement | ||
Hyaline Casts | C74770 | Hyaline Casts | A measurement of the hyaline casts present in a biological specimen. | Hyaline Cast Measurement | ||
Mixed Casts | C74771 | Mixed Casts | A measurement of the mixed (the cast contains a mixture of cell types) casts present in a biological specimen. | Mixed Cast Count | ||
RBC Casts | C74772 | RBC Casts | A measurement of the red blood cell casts present in a biological specimen. | Red Blood Cell Cast Measurement | ||
Squamous Epithelial Cells | C74773 | Squamous Epithelial Cells | A measurement of the squamous epithelial cells present in a biological specimen. | Squamous Epithelial Cell Count | ||
Squamous Transitional Epithelial Cells | C74774 | Squamous Transitional Epithelial Cells;Epithelial Cells | A measurement of the squamous transitional epithelial cells present in a biological specimen. | Squamous Transitional Epithelial Cell Count | ||
Tubular Epithelial Cells | C74775 | Tubular Epithelial Cells;Renal Tubular Epithelial Cells | A measurement of the tubular epithelial cells present in a biological specimen. | Tubular Epithelial Cell Count | ||
Unclassified Casts | C74776 | Unclassified Casts | A measurement of the unclassifiable casts present in a biological specimen. | Unclassified Cast Measurement | ||
Waxy Casts | C74777 | Waxy Casts | A measurement of the waxy casts present in a biological specimen. | Waxy Cell Cast Measurement | ||
WBC Casts | C74778 | WBC Casts | A measurement of the white blood cell casts present in a biological specimen. | White Blood Cell Cast Measurement | ||
Epithelial Casts | C74779 | Epithelial Casts | A measurement of the epithelial cell casts present in a biological specimen. | Epithelial-Cast Measurement | ||
Adrenocorticotropic Hormone | C74780 | Adrenocorticotropic Hormone | A measurement of the adrenocorticotropic hormone in a biological specimen. | Adrenocorticotropic Hormone Measurement | ||
Cortisol | C74781 | Cortisol;Total Cortisol | A measurement of the cortisol in a biological specimen. | Cortisol Measurement | ||
Estradiol | C74782 | Estradiol;Oestradiol | A measurement of the estradiol in a biological specimen. | Estradiol Measurement | ||
Follicle Stimulating Hormone | C74783 | Follicle Stimulating Hormone | A measurement of the follicle stimulating hormone (FSH) in a biological specimen. | Follicle Stimulating Hormone Measurement | ||
Parathyroid Hormone, Fragmented | C74784 | Parathyroid Hormone, Fragmented | A measurement of the fragmented parathyroid hormone in a biological specimen. | Fragmented Parathyroid Hormone Measurement | ||
Testosterone, Free | C74785 | Testosterone, Free | A measurement of the free testosterone in a biological specimen. | Free Testosterone Measurement | ||
Thyroxine, Free | C74786 | Thyroxine, Free;Free T4 | A measurement of the free thyroxine in a biological specimen. | Free Thyroxine Measurement | ||
Triiodothyronine, Free | C74787 | Triiodothyronine, Free;Free T3 | A measurement of the free triiodothyronine in a biological specimen. | Free Triiodothyronine Measurement | ||
Insulin | C74788 | Insulin | A measurement of the insulin in a biological specimen. | Insulin Measurement | ||
Parathyroid Hormone, Intact | C74789 | Parathyroid Hormone, Intact | A measurement of the intact parathyroid hormone in a biological specimen. | Intact Parathyroid Hormone Measurement | ||
Luteinizing Hormone | C74790 | Luteinizing Hormone | A measurement of the luteinizing hormone in a biological specimen. | Luteinizing Hormone Measurement | ||
Progesterone | C74791 | Progesterone | A measurement of the progesterone hormone in a biological specimen. | Progesterone Measurement | ||
Somatotrophin | C80360 | Somatotrophin;Growth Hormone | A measurement of the somatotrophin (growth) hormone in a biological specimen. | Somatotropin Measurement | ||
Testosterone | C74793 | Testosterone;Total Testosterone | A measurement of the total (free and bound) testosterone in a biological specimen. | Total Testosterone Measurement | ||
Thyroxine | C74794 | Thyroxine;Total T4 | A measurement of the total (free and bound) thyroxine in a biological specimen. | Total Thyroxine Measurement | ||
Opiate | C74796 | Opiate | A measurement of any opiate class drug present in a biological specimen. | Opiate Measurement | ||
Lymphoma Cells/Lymphocytes | C74910 | Lymphoma Cells/Lymphocytes | A relative measurement (ratio or percentage) of the malignant lymphocytes to all lymphocytes in a biological specimen. | Lymphoma Cell to Lymphocyte Ratio Measurement | ||
Mature Plasma Cells/Lymphocytes | C74911 | Mature Plasma Cells/Lymphocytes | A relative measurement (ratio or percentage) of the mature plasma cells (plasmacytes) to all lymphocytes in a biological specimen. | Mature Plasma Cell to Lymphocyte Ratio Measurement | ||
Acid Urate Crystals | C74912 | Acid Urate Crystals | A measurement of the ammonium acid urate crystals present in a biological specimen. | Acid Urate Crystal Measurement | ||
Anti-Double Stranded DNA | C74913 | Anti-Double Stranded DNA | A measurement of the anti-double stranded DNA antibody in a biological specimen. | Anti-Double Stranded DNA Measurement | ||
Antinuclear Antibodies | C74916 | Antinuclear Antibodies | A measurement of the antinuclear antibodies (antibodies that attack the body's own tissue) in a biological specimen. | Antinuclear Antibody Measurement | ||
5 Prime Nucleotidase | C79437 | 5 Prime Nucleotidase;5'-Ribonucleotide Phosphohydrolase | A measurement of the 5'-nucleotidase in a biological specimen. | 5 Prime Nucleotidase Measurement | ||
6-Monoacetylmorphine | C74876 | 6-Monoacetylmorphine | A measurement of the 6-monoacetylmorphine present in a biological specimen. | 6-Monoacetylmorphine Measurement | ||
Acetylcholine | C74838 | Acetylcholine | A measurement of the acetylcholine hormone in a biological specimen. | Acetylcholine Measurement | ||
Adiponectin | C74839 | Adiponectin | A measurement of the adiponectin hormone in a biological specimen. | Adiponectin Measurement | ||
Albumin/Globulin | C74894 | Albumin/Globulin | The ratio of albumin to globulin in a biological specimen. | Albumin to Globulin Ratio Measurement | ||
Aldosterone | C74841 | Aldosterone | A measurement of the aldosterone hormone in a biological specimen. | Aldosterone Measurement | ||
Alkaline Phosphatase/Creatinine | C79438 | Alkaline Phosphatase/Creatinine | A relative measurement (ratio or percentage) of the alkaline phosphatase to creatinine in a biological specimen. | Alkaline Phosphatase to Creatinine Ratio Measurement | ||
Alpha Glutathione-S-Transferase | C79433 | Alpha Glutathione-S-Transferase | A measurement of the alpha form of glutathione S-transferase in a biological specimen. | Alpha Glutathione-S-Transferase Measurement | ||
Ammonia | C74799 | Ammonia;NH3 | A measurement of the ammonia in a biological specimen. | Ammonia Measurement | ||
Androstenediol | C74842 | Androstenediol | A measurement of the androstenediol metabolite in a biological specimen. | Androstenediol Metabolite Measurement | ||
Androstenedione | C74843 | Androstenedione;4-Androstenedione | A measurement of the androstenedione hormone in a biological specimen. | Androstenedione Measurement | ||
Angiotensin I | C74844 | Angiotensin I | A measurement of the angiotensin I hormone in a biological specimen. | Angiotensin I Measurement | ||
Angiotensin II | C74845 | Angiotensin II | A measurement of the angiotensin II hormone in a biological specimen. | Angiotensin II Measurement | ||
Angiotensinogen | C74846 | Angiotensinogen;Angiotensin Precursor | A measurement of the angiotensinogen hormone in a biological specimen. | Angiotensinogen Measurement | ||
Antidepressants | C74691 | Antidepressants | A measurement of any antidepressant class drug present in a biological specimen. | Antidepressant Measurement | ||
Antidiuretic Hormone | C74847 | Antidiuretic Hormone;Vasopressin | A measurement of the antidiuretic hormone in a biological specimen. | Antidiuretic Hormone Measurement | ||
Atrial Natriuretic Peptide | C74886 | Atrial Natriuretic Peptide;Atriopeptin | A measurement of the atrial natriuretic peptide in a biological specimen. | Atrial Natriuretic Peptide Measurement | ||
Benzodiazepine | C74692 | Benzodiazepine | A measurement of any benzodiazepine class drug present in a biological specimen. | Benzodiazepine Measurement | ||
Bile Acid | C74800 | Bile Acid;Bile Salts;Bile Acids;Bile Salt | A measurement of the total bile acids in a biological specimen. | Bile Acid Measurement | ||
Calcitonin | C74848 | Calcitonin | A measurement of the calcitonin hormone in a biological specimen. | Calcitonin Measurement | ||
Calcitriol | C74849 | Calcitriol | A measurement of the calcitriol hormone in a biological specimen. | Calcitriol Measurement | ||
Calcium/Creatinine | C79439 | Calcium/Creatinine | A relative measurement (ratio or percentage) of the calcium to creatinine in a biological specimen. | Calcium to Creatinine Ratio Measurement | ||
Chloride/Creatinine | C79440 | Chloride/Creatinine | A relative measurement (ratio or percentage) of the chloride to creatinine in a biological specimen. | Chloride to Creatinine Ratio Measurement | ||
Cholecystokinin | C74850 | Cholecystokinin;Pancreozymin | A measurement of the cholecystokinin hormone in a biological specimen. | Cholecystokinin Measurement | ||
Codeine | C74877 | Codeine | A measurement of the codeine present in a biological specimen. | Codeine Measurement | ||
Corticosterone | C79434 | Corticosterone | A measurement of corticosterone in a biological specimen. | Corticosterone Measurement | ||
Corticotropin Releasing Hormone | C74851 | Corticotropin Releasing Hormone;Corticotropin Releasing Factor | A measurement of the corticotropin releasing hormone in a biological specimen. | Corticotropin Releasing Hormone Measurement | ||
Creatine Kinase BB/Total Creatine Kinase | C79466 | Creatine Kinase BB/Total Creatine Kinase | A relative measurement (ratio or percentage) of the BB-type creatine kinase to total creatine kinase in a biological specimen. | Creatine Kinase BB to Total Creatine Kinase Ratio Measurement | ||
Creatine Kinase MB/Total Creatine Kinase | C79441 | Creatine Kinase MB/Total Creatine Kinase | A relative measurement (ratio or percentage) of the MB-type creatine kinase to total creatine kinase in a biological specimen. | Creatine Kinase MB to Total Creatine Kinase Ratio Measurement | ||
Creatine Kinase MM/Total Creatine Kinase | C79442 | Creatine Kinase MM/Total Creatine Kinase | A relative measurement (ratio or percentage) of the MM-type creatine kinase to total creatine kinase in a biological specimen. | Creatine Kinase MM to Total Creatine Kinase Ratio Measurement | ||
Dehydroepiandrosterone | C74852 | Dehydroepiandrosterone;Dehydroisoandrosterone | A measurement of the dehydroepiandrosterone hormone in a biological specimen. | Dehydroepiandrosterone Measurement | ||
Deoxypyridinoline | C79443 | Deoxypyridinoline | A measurement of the deoxypyridinoline in a biological specimen. | Deoxypyridinoline Measurement | ||
Deoxypyridinoline/Creatinine | C79444 | Deoxypyridinoline/Creatinine | A relative measurement (ratio or percentage) of the deoxypyridinoline to creatinine in a biological specimen. | Deoxypyridinoline to Creatinine Ratio Measurement | ||
Dihydrocodeine | C74878 | Dihydrocodeine | A measurement of the dihydrocodeine present in a biological specimen. | Dihydrocodeine Measurement | ||
Dihydrotestosterone | C74853 | Dihydrotestosterone;Androstanalone | A measurement of the dihydrotestosterone hormone in a biological specimen. | Dihydrotestosterone Measurement | ||
Dopamine | C74854 | Dopamine | A measurement of the dopamine hormone in a biological specimen. | Dopamine Measurement | ||
Epinephrine | C79445 | Epinephrine;Adrenaline | A measurement of the epinephrine hormone in a biological specimen. | Epinephrine Measurement | ||
Erythropoietin | C74855 | Erythropoietin;Hematopoietin | A measurement of the erythropoietin hormone in a biological specimen. | Erythropoietin Measurement | ||
Estriol | C74856 | Estriol;Oestriol | A measurement of the estriol hormone in a biological specimen. | Estriol Measurement | ||
Estrone | C74857 | Estrone;Oestrone | A measurement of the estrone hormone in a biological specimen. | Estrone Measurement | ||
Ethanol | C74693 | Ethanol;Alcohol | A measurement of the ethanol present in a biological specimen. | Ethanol Measurement | ||
Gamma Glutamyl Transferase/Creatinine | C79446 | Gamma Glutamyl Transferase/Creatinine | A relative measurement (ratio or percentage) of the gamma glutamyl transferase to creatinine in a biological specimen. | Gamma Glutamyl Transferase to Creatinine Ratio Measurement | ||
Gastrin | C74858 | Gastrin | A measurement of the gastrin hormone in a biological specimen. | Gastrin Measurement | ||
Glucagon | C74859 | Glucagon | A measurement of the glucagon hormone in a biological specimen. | Glucagon Measurement | ||
Glucose/Creatinine | C79447 | Glucose/Creatinine | A relative measurement (ratio or percentage) of the glucose to creatinine in a biological specimen. | Glucose to Creatinine Ratio Measurement | ||
Glutamate Dehydrogenase | C79448 | Glutamate Dehydrogenase | A measurement of the glutamate dehydrogenase in a biological specimen. | Glutamate Dehydrogenase Measurement | ||
Glutathione-S-Transferase/Creatinine | C79435 | Glutathione-S-Transferase/Creatinine | A relative measurement (ratio or percentage) of the glutathione S-transferase to creatinine in a biological specimen. | Glutathione-S-Transferase to Creatinine Ratio Measurement | ||
Gonadotropin Releasing Hormone | C74860 | Gonadotropin Releasing Hormone;Luteinising Hormone Releasing Hormone | A measurement of the gonadotropin releasing hormone in a biological specimen. | Gonadotropin Releasing Hormone Measurement | ||
Growth Hormone Inhibiting Hormone | C74861 | Growth Hormone Inhibiting Hormone;Somatostatin | A measurement of the growth hormone inhibiting hormone in a biological specimen. | Growth Hormone Inhibiting Hormone Measurement | ||
Growth Hormone Releasing Hormone | C74862 | Growth Hormone Releasing Hormone;Somatocrinin | A measurement of the growth hormone releasing hormone in a biological specimen. | Growth Hormone Releasing Hormone Measurement | ||
Homovanillic Acid | C74863 | Homovanillic Acid | A measurement of the homovanillic acid metabolite in a biological specimen. | Homovanillic Acid Measurement | ||
Hydrocodone | C74879 | Hydrocodone | A measurement of the hydrocodone present in a biological specimen. | Hydrocodone Measurement | ||
Hydromorphone | C74880 | Hydromorphone | A measurement of the hydromorphone present in a biological specimen. | Hydromorphone Measurement | ||
Insulin-like Growth Factor-1 | C74864 | Insulin-like Growth Factor-1 | A measurement of the insulin-like growth factor-1 in a biological specimen. | Insulin Like Growth Factor-1 Measurement | ||
Insulin-like Growth Factor-2 | C74865 | Insulin-like Growth Factor-2 | A measurement of the insulin-like growth factor-2 in a biological specimen. | Insulin Like Growth Factor-2 Measurement | ||
Interleukin 1 | C74805 | Interleukin 1 | A measurement of the interleukin 1 in a biological specimen. | Interleukin 1 Measurement | ||
Interleukin 10 | C74806 | Interleukin 10 | A measurement of the interleukin 10 in a biological specimen. | Interleukin 10 Measurement | ||
Interleukin 11 | C74807 | Interleukin 11 | A measurement of the interleukin 11 in a biological specimen. | Interleukin 11 Measurement | ||
Interleukin 12 | C74808 | Interleukin 12 | A measurement of the interleukin 12 in a biological specimen. | Interleukin 12 Measurement | ||
Interleukin 13 | C74809 | Interleukin 13 | A measurement of the interleukin 13 in a biological specimen. | Interleukin 13 Measurement | ||
Interleukin 14 | C74810 | Interleukin 14 | A measurement of the interleukin 14 in a biological specimen. | Interleukin 14 Measurement | ||
Interleukin 15 | C74811 | Interleukin 15 | A measurement of the interleukin 15 in a biological specimen. | Interleukin 15 Measurement | ||
Interleukin 16 | C74812 | Interleukin 16 | A measurement of the interleukin 16 in a biological specimen. | Interleukin 16 Measurement | ||
Interleukin 17 | C74813 | Interleukin 17 | A measurement of the interleukin 17 in a biological specimen. | Interleukin 17 Measurement | ||
Interleukin 18 | C74814 | Interleukin 18 | A measurement of the interleukin 18 in a biological specimen. | Interleukin 18 Measurement | ||
Interleukin 19 | C74815 | Interleukin 19 | A measurement of the interleukin 19 in a biological specimen. | Interleukin 19 Measurement | ||
Interleukin 2 | C74816 | Interleukin 2 | A measurement of the interleukin 2 in a biological specimen. | Interleukin 2 Measurement | ||
Interleukin 20 | C74817 | Interleukin 20 | A measurement of the interleukin 20 in a biological specimen. | Interleukin 20 Measurement | ||
Interleukin 21 | C74818 | Interleukin 21 | A measurement of the interleukin 21 in a biological specimen. | Interleukin 21 Measurement | ||
Interleukin 22 | C74819 | Interleukin 22 | A measurement of the interleukin 22 in a biological specimen. | Interleukin 22 Measurement | ||
Interleukin 23 | C74820 | Interleukin 23 | A measurement of the interleukin 23 in a biological specimen. | Interleukin 23 Measurement | ||
Interleukin 24 | C74821 | Interleukin 24 | A measurement of the interleukin 24 in a biological specimen. | Interleukin 24 Measurement | ||
Interleukin 25 | C74822 | Interleukin 25 | A measurement of the interleukin 25 in a biological specimen. | Interleukin 25 Measurement | ||
Interleukin 26 | C74823 | Interleukin 26 | A measurement of the interleukin 26 in a biological specimen. | Interleukin 26 Measurement | ||
Interleukin 27 | C74824 | Interleukin 27 | A measurement of the interleukin 27 in a biological specimen. | Interleukin 27 Measurement | ||
Interleukin 28 | C74825 | Interleukin 28 | A measurement of the interleukin 28 in a biological specimen. | Interleukin 28 Measurement | ||
Interleukin 29 | C74826 | Interleukin 29 | A measurement of the interleukin 29 in a biological specimen. | Interleukin 29 Measurement | ||
Interleukin 3 | C74827 | Interleukin 3 | A measurement of the interleukin 3 in a biological specimen. | Interleukin 3 Measurement | ||
Interleukin 30 | C74828 | Interleukin 30 | A measurement of the interleukin 30 in a biological specimen. | Interleukin 30 Measurement | ||
Interleukin 31 | C74829 | Interleukin 31 | A measurement of the interleukin 31 in a biological specimen. | Interleukin 31 Measurement | ||
Interleukin 32 | C74830 | Interleukin 32 | A measurement of the interleukin 32 in a biological specimen. | Interleukin 32 Measurement | ||
Interleukin 33 | C74831 | Interleukin 33 | A measurement of the interleukin 33 in a biological specimen. | Interleukin 33 Measurement | ||
Interleukin 4 | C74832 | Interleukin 4 | A measurement of the interleukin 4 in a biological specimen. | Interleukin 4 Measurement | ||
Interleukin 5 | C74833 | Interleukin 5 | A measurement of the interleukin 5 in a biological specimen. | Interleukin 5 Measurement | ||
Interleukin 6 | C74834 | Interleukin 6 | A measurement of the interleukin 6 in a biological specimen. | Interleukin 6 Measurement | ||
Interleukin 7 | C74835 | Interleukin 7 | A measurement of the interleukin 7 in a biological specimen. | Interleukin 7 Measurement | ||
Interleukin 8 | C74836 | Interleukin 8 | A measurement of the interleukin 8 in a biological specimen. | Interleukin 8 Measurement | ||
Interleukin 9 | C74837 | Interleukin 9 | A measurement of the interleukin 9 in a biological specimen. | Interleukin 9 Measurement | ||
LDH Isoenzyme 1 | C74887 | LDH Isoenzyme 1 | A measurement of the lactate dehydrogenase isoenzyme 1 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 1 Measurement | ||
LDH Isoenzyme 2 | C74888 | LDH Isoenzyme 2 | A measurement of the lactate dehydrogenase isoenzyme 2 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 2 Measurement | ||
LDH Isoenzyme 3 | C74889 | LDH Isoenzyme 3 | A measurement of the lactate dehydrogenase isoenzyme 3 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 3 Measurement | ||
LDH Isoenzyme 4 | C74890 | LDH Isoenzyme 4 | A measurement of the lactate dehydrogenase isoenzyme 4 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 4 Measurement | ||
LDH Isoenzyme 5 | C74891 | LDH Isoenzyme 5 | A measurement of the lactate dehydrogenase isoenzyme 5 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 5 Measurement | ||
Lactate Dehydrogenase/Creatinine | C79449 | Lactate Dehydrogenase/Creatinine | A relative measurement (ratio or percentage) of the lactate dehydrogenase to creatinine in a biological specimen. | Lactate Dehydrogenase to Creatinine Ratio Measurement | ||
Lactic Acid | C79450 | Lactic Acid;2-hydroxypropanoic acid;Lactate | A measurement of the lactic acid in a biological specimen. | Lactic Acid Measurement | ||
Large Unstained Cells/Leukocytes | C79467 | Large Unstained Cells/Leukocytes | A relative measure (ratio or percentage) of the large unstained cells to leukocytes in a biological specimen. | Large Unstained Cells to Leukocytes Ratio Measurement | ||
LDH Isoenzyme 1/LDH | C79451 | LDH Isoenzyme 1/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 1 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 1 to LDH Ratio Measurement | ||
LDH Isoenzyme 2/LDH | C79452 | LDH Isoenzyme 2/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 2 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 2 to LDH Ratio Measurement | ||
LDH Isoenzyme 3/LDH | C79453 | LDH Isoenzyme 3/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 3 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 3 to LDH Ratio Measurement | ||
LDH Isoenzyme 4/LDH | C79454 | LDH Isoenzyme 4/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 4 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 4 to LDH Ratio Measurement | ||
LDH Isoenzyme 5/LDH | C79455 | LDH Isoenzyme 5/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 5 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 5 to LDH Ratio Measurement | ||
Leptin | C74866 | Leptin | A measurement of the leptin hormone in a biological specimen. | Leptin Measurement | ||
Magnesium/Creatinine | C79456 | Magnesium/Creatinine | A relative measurement (ratio or percentage) of the magnesium to creatinine in a biological specimen. | Magnesium to Creatinine Ratio Measurement | ||
Melatonin | C74867 | Melatonin | A measurement of the melatonin hormone in a biological specimen. | Melatonin Measurement | ||
Methadone | C74881 | Methadone | A measurement of the methadone present in a biological specimen. | Methadone Measurement | ||
Methaqualone | C74882 | Methaqualone | A measurement of the methaqualone present in a biological specimen. | Methaqualone Measurement | ||
Morphine | C74883 | Morphine | A measurement of the morphine present in a biological specimen. | Morphine Measurement | ||
Mu Glutathione-S-Transferase | C79457 | Mu Glutathione-S-Transferase | A measurement of the mu form of glutathione S-transferase in a biological specimen. | Mu Glutathione-S-Transferase Measurement | ||
Mu Glutathione-S-Transferase/Creatinine | C79458 | Mu Glutathione-S-Transferase/Creatinine | A relative measurement (ratio or percentage) of the mu gamma glutamyl transpeptidase to creatinine in a biological specimen. | Mu Glutathione-S-Transferase to Creatinine Ratio Measurement | ||
Myoglobin | C79436 | Myoglobin | A measurement of myoglobin in a biological specimen. | Myoglobin Measurement | ||
N-Acetyl Glucosamide | C79459 | N-Acetyl Glucosamide;N-Acetyl Glucosamine | A measurement of N-acetyl glucosamide in a biological specimen. | N-Acetyl Glucosamide Measurement | ||
N-Acetyl Glucosamide/Creatinine | C79460 | N-Acetyl Glucosamide/Creatinine | A relative measurement (ratio or percentage) of the N-acetyl glucosamide to creatinine in a biological specimen. | N-Acetyl Glucosamide to Creatinine Ratio Measurement | ||
Neuropeptide Y | C74892 | Neuropeptide Y | A measurement of the neuropeptide Y in a biological specimen. | Neuropeptide Y Measurement | ||
Norepinephrine | C74868 | Noradrenaline;Norepinephrine | A measurement of the norepinephrine hormone in a biological specimen. | Noradrenaline Measurement | ||
Osmolality | C74801 | Osmolality | A measurement of the osmoles of solute per unit of biological specimen. | Osmolality Measurement | ||
Oxycodone | C74884 | Oxycodone;Oxycontin | A measurement of the oxycodone present in a biological specimen. | Oxycodone Measurement | ||
Oxytocin | C74869 | Oxytocin;Oxytoxin | A measurement of the oxytocin hormone in a biological specimen. | Oxytocin Measurement | ||
Phencyclidine | C74694 | Phencyclidine;Phenylcyclohexylpiperidine | A measurement of the phencyclidine present in a biological specimen. | Phencyclidine Measurement | ||
Phenothiazine | C74695 | Phenothiazine;Dibenzothiazine | A measurement of the phenothiazine present in a biological specimen. | Phenothiazine Measurement | ||
Phosphate/Creatinine | C79461 | Phosphate/Creatinine | A relative measurement (ratio or percentage) of the phosphate to creatinine in a biological specimen. | Phosphate to Creatinine Ratio Measurement | ||
Potassium/Creatinine | C79462 | Potassium/Creatinine | A relative measurement (ratio or percentage) of the potassium to creatinine in a biological specimen. | Potassium to Creatinine Ratio Measurement | ||
Prolactin | C74870 | Prolactin | A measurement of the prolactin hormone in a biological specimen. | Prolactin Measurement | ||
Propoxyphene | C74885 | Propoxyphene | A measurement of the propoxyphene present in a biological specimen. | Propoxyphene Measurement | ||
Protein/Creatinine | C79463 | Protein/Creatinine | A relative measurement (ratio or percentage) of the protein to creatinine in a biological specimen. | Protein to Creatinine Ratio Measurement | ||
Pseudoephedrine | C74696 | Pseudoephedrine | A measurement of the pseudoephedrine present in a biological specimen. | Pseudoephedrine Measurement | ||
Reactive Lymphocytes | C74629 | Reactive Lymphocytes | A measurement of the reactive lymphocytes (lymphocytes which have become large due to an antigen reaction) in a biological specimen. | Reactive Lymphocyte Count Measurement | ||
Renin | C74893 | Renin;Angiotensinogenase | A measurement of the renin in a biological specimen. | Renin Measurement | ||
Secretin | C74871 | Secretin | A measurement of the secretin hormone in a biological specimen. | Secretin Measurement | ||
Serotonin | C74872 | Serotonin | A measurement of the serotonin hormone in a biological specimen. | Serotonin Measurement | ||
Sodium/Creatinine | C79464 | Sodium/Creatinine | A relative measurement (ratio or percentage) of the sodium to creatinine in a biological specimen. | Sodium to Creatinine Ratio Measurement | ||
Sorbitol Dehydrogenase | C79465 | Sorbitol Dehydrogenase | A measurement of the sorbitol dehydrogenase in a biological specimen. | Sorbitol Dehydrogenase Measurement | ||
Thrombopoietin | C74873 | Thrombopoietin | A measurement of the thrombopoietin hormone in a biological specimen. | Thrombopoietin Measurement | ||
Thyrotropin Releasing Hormone | C74874 | Thyrotropin Releasing Hormone;Thyrotropin Releasing Factor | A measurement of the thyrotropin releasing hormone in a biological specimen. | Thyrotropin Releasing Hormone Measurement | ||
Vanillyl Mandelic Acid | C74875 | Vanillyl Mandelic Acid;Vanilmandelic Acid | A measurement of the vanillyl mandelic acid metabolite in a biological specimen. | Vanillyl Mandelic Acid Measurement | ||
Vitamin A | C74895 | Vitamin A;Retinol | A measurement of the Vitamin A in a biological specimen. | Vitamin A Measurement | ||
Thiamine | C74896 | Thiamine;Vitamin B1 | A measurement of the thiamine in a biological specimen. | Vitamin B1 Measurement | ||
Vitamin B17 | C74897 | Vitamin B17;Amygdalin | A measurement of the Vitamin B17 in a biological specimen. | Vitamin B17 Measurement | ||
Riboflavin | C74898 | Riboflavin;Vitamin B2 | A measurement of the riboflavin in a biological specimen. | Vitamin B2 Measurement | ||
Niacin | C74899 | Niacin;Vitamin B3 | A measurement of the niacin in a biological specimen. | Vitamin B3 Measurement | ||
Vitamin B5 | C74900 | Vitamin B5;Pantothenic Acid | A measurement of the Vitamin B5 in a biological specimen. | Vitamin B5 Measurement | ||
Vitamin B6 | C74901 | Vitamin B6;Pyridoxine | A measurement of the Vitamin B6 in a biological specimen. | Vitamin B6 Measurement | ||
Vitamin B7 | C74902 | Vitamin B7;Biotin | A measurement of the Vitamin B7 in a biological specimen. | Vitamin B7 Measurement | ||
Vitamin C | C74903 | Vitamin C;Ascorbic Acid | A measurement of the Vitamin C in a biological specimen. | Vitamin C Measurement | ||
Vitamin D2 | C74904 | Vitamin D2;Ergocalciferol | A measurement of the Vitamin D2 in a biological specimen. | Vitamin D2 Measurement | ||
Vitamin D3 | C74905 | Vitamin D3;Cholecalciferol | A measurement of the Vitamin D3 in a biological specimen. | Vitamin D3 Measurement | ||
Vitamin E | C74906 | Vitamin E;Tocopherol | A measurement of the Vitamin E in a biological specimen. | Vitamin E Measurement | ||
Vitamin K | C74907 | Vitamin K;Naphthoquinone | A measurement of the Vitamin K in a biological specimen. | Vitamin K Measurement | ||
Volume | C74720 | Volume | A measurement of the volume of a biological specimen. | Volume Measurement | ||
Alpha-1 Antitrypsin | C80167 | Alpha-1 Antitrypsin;Serum Trypsin Inhibitor | A measurement of the alpha-1 antitrypsin in a biological specimen. | Alpha-1 Antitrypsin Measurement | ||
Alpha-2 Macroglobulin | C80168 | Alpha-2 Macroglobulin | A measurement of the alpha-2 macroglobulin in a biological specimen. | Alpha-2 Macroglobulin Measurement | ||
Angiotensin Converting Enzyme | C80169 | Angiotensin Converting Enzyme | A measurement of the angiotensin converting enzyme in a biological specimen. | Angiotensin Converting Enzyme Measurement | ||
Acid Phosphatase | C80163 | Acid Phosphatase | A measurement of the acid phosphatase in a biological specimen. | Acid Phosphatase Measurement | ||
Antimitochondrial Antibodies | C81975 | Antimitochondrial Antibodies;Mitochondrial Antibody | A measurement of the antimitochondrial antibodies in a biological specimen. | Antimitochondrial Antibody Measurement | ||
Amyloid Beta 42 | C84809 | Amyloid Beta 42;Amyloid Beta 42 Protein | A measurement of the 42 amino acid amyloid beta protein isoform in a biological specimen. | Beta Amyloid 42 Measurement | ||
Amyloid, Beta | C81999 | Amyloid, Beta;Beta Amyloid | A measurement of the total amyloid beta in a biological specimen. | Beta Amyloid Measurement | ||
Amyloid P | C81998 | Amyloid P | A measurement of the total amyloid P in a biological specimen. | Amyloid P Measurement | ||
Antiglobulin Test, Direct | C81974 | Antiglobulin Test, Direct;Direct Coombs Test | A measurement of the antibody or complement-coated erythrocytes in a biological specimen in vivo. | Direct Antiglobulin Test | ||
Antithrombin | C81958 | Antithrombin;Antithrombin III;Antithrombin Activity;Antithrombin III Activity | A measurement of the antithrombin activity in a biological specimen. | Antithrombin Measurement | ||
Antithrombin Antigen | C81977 | Antithrombin Antigen;Antithrombin III Antigen | A measurement of the antithrombin antigen in a biological specimen. | Antithrombin Antigen Measurement | ||
Apolipoprotein AII | C82000 | Apolipoprotein AII | A measurement of the apolipoprotein AII in a biological specimen. | Apolipoprotein AII Measurement | ||
Apolipoprotein CIII | C82001 | Apolipoprotein CIII | A measurement of the apolipoprotein CIII in a biological specimen. | Apolipoprotein CIII Measurement | ||
Apolipoprotein E | C82002 | Apolipoprotein E | A measurement of the apolipoprotein E in a biological specimen. | Apolipoprotein E Measurement | ||
Apolipoprotein H | C82003 | Apolipoprotein H | A measurement of the apolipoprotein H in a biological specimen. | Apolipoprotein H Measurement | ||
Specimen Appearance | C25377 | Specimen Appearance | The outward or visible aspect of a specimen. | Appearance | ||
Anti-Saccharomyces cerevisiae Antibody | C81976 | Anti-Saccharomyces cerevisiae Antibody | A measurement of the anti-Saccharomyces cerevisiae antibody in a biological specimen. | Anti-Saccharomyces cerevisiae Antibody Measurement | ||
Aspartate Aminotransferase Antigen | C81978 | Aspartate Aminotransferase Antigen;SGOT Antigen | A measurement of the aspartate aminotransferase antigen in a biological specimen. | Aspartate Aminotransferase Antigen Measurement | ||
Beta-2 Glycoprotein Antibody | C81979 | Beta-2 Glycoprotein Antibody | A measurement of the beta-2 glycoprotein antibody in a biological specimen. | Beta-2 Glycoprotein Antibody Measurement | ||
Beta-2 Microglobulin | C81980 | Beta-2 Microglobulin | A measurement of the beta-2 microglobulin in a biological specimen. | Beta-2 Microglobulin Measurement | ||
Brain-Derived Neurotrophic Factor | C82004 | Brain-Derived Neurotrophic Factor | A measurement of the brain-derived neurotrophic factor in a biological specimen. | Brain-Derived Neurotrophic Factor Measurement | ||
ProB-type Natriuretic Peptide | C82032 | ProB-type Natriuretic Peptide;proBNP;Pro-Brain Natriuretic Peptide | A measurement of the proB-type natriuretic peptide in a biological specimen. | ProB-Type Natriuretic Peptide Measurement | ||
Complement C1q Antibody | C80173 | Complement C1q Antibody | A measurement of the complement C1q antibody in a biological specimen. | Complement C1q Antibody Measurement | ||
Complement C3 | C80174 | Complement C3 | A measurement of the complement C3 in a biological specimen. | Complement C3 Measurement | ||
Complement C3a | C80175 | Complement C3a;ASP, Complement C3 DesArg, Acetylation-stimulating Protein | A measurement of the complement C3a in a biological specimen. | Complement C3a Measurement | ||
Complement C3b | C80176 | Complement C3b | A measurement of the complement C3b in a biological specimen. | Complement C3b Measurement | ||
Complement C4 | C80177 | Complement C4 | A measurement of the complement C4 in a biological specimen. | Complement C4 Measurement | ||
Complement C4a | C80178 | Complement C4a | A measurement of the complement C4a in a biological specimen. | Complement C4a Measurement | ||
Complement C5a | C80179 | Complement C5a | A measurement of the complement C5a in a biological specimen. | Complement C5a Measurement | ||
Cancer Antigen 125 | C81981 | Cancer Antigen 125 | A measurement of the cancer antigen 125 in a biological specimen. | Cancer Antigen 125 Measurement | ||
Cancer Antigen 19-9 | C81982 | Cancer Antigen 19-9 | A measurement of the cancer antigen 19-9 in a biological specimen. | Cancer Antigen 19-9 Measurement | ||
Calcium, Ionized | C81948 | Calcium, Ionized | A measurement of the ionized calcium in a biological specimen. | Ionized Calcium Measurement | ||
Calprotectin | C82005 | Calprotectin | A measurement of the calprotectin in a biological specimen. | Calprotectin Measurement | ||
Complement Bb | C80172 | Complement Bb | A measurement of the complement Bb in a biological specimen. | Complement Bb Measurement | ||
CD40 | C82006 | CD40 | A measurement of the CD40 in a biological specimen. | CD40 Measurement | ||
CD40 Ligand | C82007 | CD40 Ligand | A measurement of the CD40 ligand in a biological specimen. | CD40 Ligand Measurement | ||
Carcinoembryonic Antigen | C81983 | Carcinoembryonic Antigen | A measurement of the carcinoembryonic antigen in a biological specimen. | Carcinoembryonic Antigen Measurement | ||
Cholesterol/HDL-Cholesterol | C80171 | Cholesterol/HDL-Cholesterol | A relative measurement (ratio or percentage) of total cholesterol to high-density lipoprotein cholesterol (HDL-C) in a biological specimen. | Cholesterol to HDL-Cholesterol Ratio Measurement | ||
Complement Total | C80160 | Complement Total | A measurement of the total complement in a biological specimen. | Complement Measurement | ||
Type I Collagen C-Telopeptides | C82038 | Type I Collagen C-Telopeptides;Type I Collagen X-linked C-telopeptide | A measurement of the type I collagen C-telopeptides in a biological specimen. | Type I Collagen C-Telopeptide Measurement | ||
Type II Collagen C-Telopeptides | C82040 | Type II Collagen C-Telopeptides | A measurement of the type II collagen C-telopeptides in a biological specimen. | Type II Collagen C-Telopeptide Measurement | ||
Starch Crystals | C81951 | Starch Crystals | A measurement of the starch crystals in a biological specimen. | Starch Crystal Measurement | ||
D-Dimer | C82621 | D-Dimer | A measurement of the d-dimers in a biological specimen. | D-Dimer Measurement | ||
Anti-DNA Antibodies | C81973 | Anti-DNA Antibodies;Anti-ds-DNA Antibodies | A measurement of the anti-DNA antibodies in a biological specimen. | Anti-DNA Antibody Measurement | ||
Epidermal Growth Factor | C82009 | Epidermal Growth Factor | A measurement of the epidermal growth factor in a biological specimen. | Epidermal Growth Factor Measurement | ||
Pancreatic Elastase 1 | C82028 | Pancreatic Elastase 1 | A measurement of the pancreatic elastase 1 in a biological specimen. | Pancreatic Elastase Measurement | ||
Pancreatic Elastase 1, Polymorphonuclear | C82029 | Pancreatic Elastase 1, Polymorphonuclear | A measurement of the polymorphonuclear pancreatic elastase 1 in a biological specimen. | Polymorphonuclear Pancreatic Elastase Measurement | ||
Neutrophil Elastase | C82026 | Neutrophil Elastase | A measurement of the neutrophil elastase in a biological specimen. | Neutrophil Elastase Measurement | ||
Neutrophil Elastase, Polymorphonuclear | C82027 | Neutrophil Elastase, Polymorphonuclear | A measurement of the polymorphonuclear neutrophil elastase in a biological specimen. | Polymorphonuclear Neutrophil Elastase Measurement | ||
Epith Neutrophil-Activating Peptide 78 | C82010 | Epith Neutrophil-Activating Peptide 78 | A measurement of the epithelial neutrophil-activating peptide in a biological specimen. | Epithelial Neutrophil-Activating Peptide 78 Measurement | ||
Endothelin-1 | C82008 | Endothelin-1 | A measurement of the endothelin-1 in a biological specimen. | Endothelin-1 Measurement | ||
Extracell Newly Ident RAGE Bind Protein | C82011 | Extracell Newly Ident RAGE Bind Protein;S100 Calcium Binding Protein A12 | A measurement of the extracellular newly identified RAGE (receptor for advanced glycation end products) binding protein in a biological specimen. | Extracell Newly Ident RAGE Bind Protein Measurement | ||
Eosinophilic Metamyelocytes | C84819 | Eosinophilic Metamyelocytes | A measurement of the eosinphilic metamyelocytes in a biological specimen. | Eosinophilic Metamyelocyte Count | ||
Eosinophilic Myelocytes | C84821 | Eosinophilic Myelocytes | A measurement of the eosinophilic myelocytes in a biological specimen. | Eosinophilic Myelocyte Count | ||
Eotaxin-1 | C81952 | Eotaxin-1;Chemokine Ligand 11 | A measurement of the eotaxin-1 in a biological specimen. | Eotaxin-1 Measurement | ||
Eotaxin-2 | C81953 | Eotaxin-2;Chemokine Ligand 24 | A measurement of the eotaxin-2 in a biological specimen. | Eotaxin-2 Measurement | ||
Eotaxin-3 | C81954 | Eotaxin-3;Chemokine Ligand 26 | A measurement of the eotaxin-3 in a biological specimen. | Eotaxin-3 Measurement | ||
Estriol, Free | C81963 | Estriol, Free | A measurement of the free estriol in a biological specimen. | Free Estriol Measurement | ||
Fatty Acid Binding Protein 1 | C82012 | Fatty Acid Binding Protein 1 | A measurement of the fatty acid binding protein 1 in a biological specimen. | Fatty Acid Binding Protein 1 Measurement | ||
Factor III | C81959 | Factor III;Tissue Factor, CD142 | A measurement of the factor III in a biological specimen. | Factor III Measurement | ||
Factor VII | C81960 | Factor VII | A measurement of the factor VII in a biological specimen. | Factor VII Measurement | ||
Factor VIII | C81961 | Factor VIII | A measurement of the factor VIII in a biological specimen. | Factor VIII Measurement | ||
Free Fatty Acid | C80200 | Free Fatty Acid;Non-Esterified Fatty Acid, Free | A measurement of the total non-esterified fatty acids in a biological specimen. | Non-esterified Fatty Acids Measurement | ||
Free Fatty Acid, Saturated | C80206 | Free Fatty Acid, Saturated;Non-esterified Fatty Acid, Saturated | A measurement of the saturated non-esterified fatty acids in a biological specimen. | Saturated Non-esterified Fatty Acids Measurement | ||
Free Fatty Acid, Unsaturated | C80209 | Free Fatty Acid, Unsaturated;Non-esterified Fatty Acid, Unsaturated | A measurement of the unsaturated non-esterified fatty acids in a biological specimen. | Unsaturated Non-esterified Fatty Acids Measurement | ||
Fat Bodies, Oval | C81947 | Fat Bodies, Oval | A measurement of the oval-shaped fat bodies, usually renal proximal tubular cells with lipid aggregates in the cytoplasm, in a biological specimen. | Oval Fat Body Measurement | ||
Fibrin Degradation Products | C82013 | Fibrin Degradation Products | A measurement of the fibrin degradation products in a biological specimen. | Fibrin Degradation Products Measurement | ||
Fibroblast Growth Factor Basic Form | C82014 | Fibroblast Growth Factor Basic Form;FGF2 | A measurement of the basic form of fibroblast growth factor in a biological specimen. | Fibroblast Growth Factor Basic Form Measurement | ||
Glucose-6-Phosphate Dehydrogenase | C80184 | Glucose-6-Phosphate Dehydrogenase | A measurement of the glucose-6-phosphate dehydrogenase in a biological specimen. | Glucose-6-Phosphate Dehydrogenase Measurement | ||
Glutamic Acid Decarboxylase 1 | C82015 | Glutamic Acid Decarboxylase 1;Glutamic Acid Decarboxylase 67 | A measurement of the glutamic acid decarboxylase 1 in a biological specimen. | Glutamic Acid Decarboxylase 1 Measurement | ||
Glutamic Acid Decarboxylase 2 | C82016 | Glutamic Acid Decarboxylase 2;Glutamic Acid Decarboxylase 65 | A measurement of the glutamic acid decarboxylase 2 in a biological specimen. | Glutamic Acid Decarboxylase 2 Measurement | ||
Glutamic Acid Decarboxylase 2 Antibody | C82017 | Glutamic Acid Decarboxylase 2 Antibody;Glutamic Acid Decarboxylase 65 Antibody | A measurement of the glutamic acid decarboxylase 2 antibody in a biological specimen. | Glutamic Acid Decarboxylase 2 Antibody Measurement | ||
Galanin | C80182 | Galanin | A measurement of the galanin in a biological specimen. | Galanin Measurement | ||
Granulocyte Colony Stimulating Factor | C82018 | Granulocyte Colony Stimulating Factor | A measurement of the granulocyte colony stimulating factor in a biological specimen. | Granulocyte Colony Stimulating Factor Measurement | ||
Glucagon-Like Peptide-1 | C80183 | Glucagon-Like Peptide-1;Total Glucagon-Like Peptide-1 | A measurement of the total glucagon-like peptide-1 in a biological specimen. | Glucagon-like Peptide-1 Measurement | ||
Glucagon-Like Peptide-1, Active Form | C80164 | Glucagon-Like Peptide-1, Active Form | A measurement of the active form of glucagon-like peptide-1 in a biological specimen. | Active Glucagon-like Peptide-1 Measurement | ||
Granulocyte Macrophage Colony Stm Factor | C82019 | Granulocyte Macrophage Colony Stm Factor | A measurement of the granulocyte macrophage colony stimulating factor in a biological specimen. | Granulocyte Macrophage Colony Stm Factor Measurement | ||
Gold | C80186 | Gold | A measurement of the gold in a biological specimen. | Gold Measurement | ||
Glutathione S-Transferase, Total | C80185 | Glutathione S-Transferase, Total | A measurement of the total glutathione-s-transferase in a biological specimen. | Glutathione-S-Transferase Measurement | ||
Glutathione S-Transferase, Alpha/Creat | C80166 | Glutathione S-Transferase, Alpha/Creat | A relative measurement (ratio or percentage) of the alpha glutathione-S-transferase to creatinine in a biological specimen. | Alpha Glutathione-S-Transferase to Creatinine Ratio Measurement | ||
Glutathione S-Transferase, Pi | C80203 | Glutathione S-Transferase, Pi | A measurement of the Pi glutathione-s-transferase in a biological specimen. | Pi Glutathione S-Transferase Measurement | ||
Glutathione S-Transferase, Theta | C80207 | Glutathione S-Transferase, Theta | A measurement of the theta glutathione-s-transferase in a biological specimen. | Theta Glutathione S-Transferase Measurement | ||
Glucuronidase, Alpha | C80165 | Glucuronidase, Alpha | A measurement of the alpha glucuronidase in a biological specimen. | Alpha Glucuronidase Measurement | ||
Glucuronidase, Beta | C80170 | Glucuronidase, Beta | A measurement of the beta glucuronidase in a biological specimen. | Beta Glucuronidase Measurement | ||
HDL-Cholesterol Subclass 2 | C80187 | HDL-Cholesterol Subclass 2 | A measurement of the high-density lipoprotein (HDL) cholesterol subclass 2 in a biological specimen. | HDL-Cholesterol Subclass 2 Measurement | ||
HDL-Cholesterol Subclass 3 | C80188 | HDL-Cholesterol Subclass 3 | A measurement of the high-density lipoprotein (HDL) cholesterol subclass 3 in a biological specimen. | HDL-Cholesterol Subclass 3 Measurement | ||
Histamine | C80189 | Histamine | A measurement of the histamine in a biological specimen. | Histamine Measurement | ||
Heterophile Antibodies | C81984 | Heterophile Antibodies | A measurement of the heterophile antibodies in a biological specimen. | Heterophile Antibody Measurement | ||
Hydroxyproline | C80190 | Hydroxyproline | A measurement of the total hydroxyproline in a biological specimen. | Hydroxyproline Measurement | ||
Islet Cell 512 Antibody | C81985 | Islet Cell 512 Antibody | A measurement of the islet cell 512 antibody in a biological specimen. | Islet Cell 512 Antibody Measurement | ||
Islet Cell 512 Antigen | C81986 | Islet Cell 512 Antigen | A measurement of the islet cell 512 antigen in a biological specimen. | Islet Cell 512 Antigen Measurement | ||
Interferon Alpha | C81994 | Interferon Alpha | A measurement of the interferon alpha in a biological specimen. | Interferon Alpha Measurement | ||
Interferon Beta | C81995 | Interferon Beta | A measurement of the interferon beta in a biological specimen. | Interferon Beta Measurement | ||
Interferon Gamma | C81996 | Interferon Gamma | A measurement of the interferon gamma in a biological specimen. | Interferon Gamma Measurement | ||
Immunoglobulin A | C81969 | Immunoglobulin A | A measurement of the Immunoglobulin A in a biological specimen. | Immunoglobulin A Measurement | ||
Immunoglobulin E | C81970 | Immunoglobulin E | A measurement of the Immunoglobulin E in a biological specimen. | Immunoglobulin E Measurement | ||
Immunoglobulin G | C81971 | Immunoglobulin G | A measurement of the Immunoglobulin G in a biological specimen. | Immunoglobulin G Measurement | ||
Immunoglobulin M | C81972 | Immunoglobulin M | A measurement of the Immunoglobulin M in a biological specimen. | Immunoglobulin M Measurement | ||
Indican | C82044 | Indican | A measurement of the indican present in a biological specimen. | Indican Measurement | ||
Islet Neogenesis Assoc Protein Antibody | C81987 | Islet Neogenesis Assoc Protein Antibody | A measurement of the islet neogenesis associated protein antibody in a biological specimen. | Islet Neogenesis Associated Protein Antibody Measurement | ||
Inhibin A | C82020 | Inhibin A | A measurement of the inhibin A in a biological specimen. | Inhibin A Measurement | ||
F2-Isoprostane | C80180 | F2-Isoprostane | A measurement of the F2-isoprostane in a biological specimen. | F2 Isoprostane Measurement | ||
Lipoprotein-a | C82022 | Lipoprotein-a | A measurement of the lipoprotein-a in a biological specimen. | Lipoprotein a Measurement | ||
Lactoferrin | C82021 | Lactoferrin;Lactotransferrin | A measurement of the lactoferrin in a biological specimen. | Lactoferrin Measurement | ||
Lymphotactin | C81955 | Lymphotactin;Chemokine Ligand 1 | A measurement of the lymphotactin in a biological specimen. | Lymphotactin Measurement | ||
Monocyte Chemotactic Protein 1 | C82025 | Monocyte Chemotactic Protein 1 | A measurement of the monocyte chemotactic protein 1 in a biological specimen. | Monocyte Chemotactic Protein 1 Measurement | ||
Macrophage Colony Stimulating Factor | C80191 | Macrophage Colony Stimulating Factor | A measurement of the macrophage colony stimulating factor in a biological specimen. | Macrophage Colony Stimulating Factor Measurement | ||
Macrophage-Derived Chemokine | C81956 | Macrophage-Derived Chemokine;Chemokine Ligand 22 | A measurement of the macrophage-derived chemokine in a biological specimen. | Macrophage-Derived Chemokine Measurement | ||
Macrophage Inflammatory Protein 1 Alpha | C82023 | Macrophage Inflammatory Protein 1 Alpha;Chemokine Ligand 3 | A measurement of the macrophage inflammatory protein 1 alpha in a biological specimen. | Macrophage Inflammatory Protein 1 Alpha Measurement | ||
Macrophage Inflammatory Protein 1 Beta | C82024 | Macrophage Inflammatory Protein 1 Beta;Chemokine Ligand 4 | A measurement of the macrophage inflammatory protein 1 beta in a biological specimen. | Macrophage Inflammatory Protein 1 Beta Measurement | ||
Matrix Metalloproteinase 1 | C80192 | Matrix Metalloproteinase 1;Interstitial Collagenase | A measurement of the matrix metalloproteinase 1 in a biological specimen. | Matrix Metalloproteinase 1 Measurement | ||
Matrix Metalloproteinase 2 | C80193 | Matrix Metalloproteinase 2;Gelatinase A | A measurement of the matrix metalloproteinase 2 in a biological specimen. | Matrix Metalloproteinase 2 Measurement | ||
Matrix Metalloproteinase 3 | C80194 | Matrix Metalloproteinase 3;Stromelysin 1 | A measurement of the matrix metalloproteinase 3 in a biological specimen. | Matrix Metalloproteinase 3 Measurement | ||
Matrix Metalloproteinase 7 | C80195 | Matrix Metalloproteinase 7;Matrilysin | A measurement of the matrix metalloproteinase 7 in a biological specimen. | Matrix Metalloproteinase 7 Measurement | ||
Matrix Metalloproteinase 8 | C80196 | Matrix Metalloproteinase 8;Neutrophil Collagenase | A measurement of the matrix metalloproteinase 8 in a biological specimen. | Matrix Metalloproteinase 8 Measurement | ||
Matrix Metalloproteinase 9 | C80197 | Matrix Metalloproteinase 9;Gelatinase B | A measurement of the matrix metalloproteinase 9 in a biological specimen. | Matrix Metalloproteinase 9 Measurement | ||
Myeloperoxidase | C80198 | Myeloperoxidase | A measurement of the myeloperoxidase in a biological specimen. | Myeloperoxidase Measurement | ||
Neopterin | C80199 | Neopterin | A measurement of the neopterin in a biological specimen. | Neopterin Measurement | ||
Neutrophilic Metamyelocytes | C84822 | Neutrophilic Metamyelocytes | A measurement of the neutrophilic metamyelocytes in a biological specimen. | Neutrophilic Metamyelocyte Count | ||
Neutrophilic Myelocytes | C84823 | Neutrophilic Myelocytes | A measurement of the neutrophilic myelocytes in a biological specimen. | Neutrophilic Myelocyte Count | ||
Neutrophils, Segmented | C81997 | Neutrophils, Segmented | A measurement of the segmented neutrophils in a biological specimen. | Segmented Neutrophil Count | ||
Neutrophils, Segmented/Leukocytes | C82045 | Neutrophils, Segmented/Leukocytes | A relative measurement (ratio or percentage) of segmented neutrophils to leukocytes in a biological specimen. | Segmented Neutrophil to Leukocyte Ratio Measurement | ||
Type I Collagen N-Telopeptides | C82039 | Type I Collagen N-Telopeptides | A measurement of the type I collagen N-telopeptides in a biological specimen. | Type I Collagen N-Telopeptide Measurement | ||
Type II Collagen N-Telopeptides | C82041 | Type II Collagen N-Telopeptides | A measurement of the type II collagen N-telopeptides in a biological specimen. | Type II Collagen N-Telopeptide Measurement | ||
Plasminogen Activator Inhibitor-1 | C82030 | Plasminogen Activator Inhibitor-1 | A measurement of the plasminogen activator inhibitor-1 in a biological specimen. | Plasminogen Activator Inhibitor-1 Measurement | ||
Plasminogen Activator Inhibitor-1 AG | C81989 | Plasminogen Activator Inhibitor-1 AG | A measurement of the plasminogen activator inhibitor-1 antigen in a biological specimen. | Plasminogen Activator Inhibitor-1 Antigen Measurement | ||
Prostatic Acid Phosphatase | C80204 | Prostatic Acid Phosphatase | A measurement of the prostatic acid phosphatase in a biological specimen. | Prostatic Acid Phosphatase Measurement | ||
Pregnancy-Associated Plasma Protein-A | C82031 | Pregnancy-Associated Plasma Protein-A | A measurement of the pregnancy-associated plasma protein-A in a biological specimen. | Pregnancy-Associated Plasma Protein-A Measurement | ||
Partial Pressure Carbon Dioxide | C82625 | Partial Pressure Carbon Dioxide | A measurement of the pressure of carbon dioxide in a biological specimen. | Partial Pressure of Carbon Dioxide Measurement | ||
Platelet Distribution Width | C81962 | Platelet Distribution Width | A measurement of the range of platelet sizes in a biological specimen. | Platelet Distribution Width | ||
Pemphigoid Antibodies | C81988 | Pemphigoid Antibodies | A measurement of the pemphigoid antibodies in a biological specimen. | Pemphigoid Antibody Measurement | ||
Procollagen Type I Carboxy Term Peptide | C82033 | Procollagen Type I Carboxy Term Peptide | A measurement of the procollagen-1 carboxy-terminal peptide in a biological specimen. | Procollagen Type I Carboxy Terminal Peptide Measurement | ||
Pancreatic Polypeptide | C80201 | Pancreatic Polypeptide | A measurement of the pancreatic polypeptide in a biological specimen. | Pancreatic Polypeptide Measurement | ||
Partial Pressure Oxygen | C71251 | Partial Pressure Oxygen | A measurement of the pressure of oxygen in a biological specimen. | Partial Pressure of Oxygen Measurement | ||
Proinsulin | C81967 | Proinsulin | A measurement of the proinsulin in a biological specimen. | Proinsulin Measurement | ||
Prothrombin Fragments 1 + 2 | C82034 | Prothrombin Fragments 1 + 2 | A measurement of the prothrombin fragments 1 and 2 in a biological specimen. | Prothrombin Fragments 1 and 2 Measurement | ||
Parathyroid Hormone, C-Terminal | C81964 | Parathyroid Hormone, C-Terminal | A measurement of the C-terminal fragment of parathyroid hormone in a biological specimen. | C-Terminal Parathyroid Hormone Measurement | ||
Parathyroid Hormone, Mid-Molecule | C81965 | Parathyroid Hormone, Mid-Molecule | A measurement of the mid-molecule fragment of parathyroid hormone in a biological specimen. | Mid-Molecule Parathyroid Hormone Measurement | ||
Parathyroid Hormone, N-Terminal | C81966 | Parathyroid Hormone, N-Terminal | A measurement of the N-terminal fragment of parathyroid hormone in a biological specimen. | N-Terminal Parathyroid Hormone Measurement | ||
Pyridinoline | C80211 | Pyridinoline | A measurement of the pyridinoline in a biological specimen. | Pyridinoline Measurement | ||
Peptide YY | C80202 | Peptide YY;Peptide Tyrosine Tyrosine | A measurement of the peptide YY in a biological specimen. | Peptide YY Measurement | ||
Reg upon Act Normal T-cell Exprd Secrtd | C81957 | Reg upon Act Normal T-cell Exprd Secrtd;Chemokine Ligand 5 | A measurement of the RANTES (regulated on activation, normally, T-cell expressed, and secreted) chemokine in a biological specimen. | Reg upon Act Normal T-cell Exprd Secrtd Measurement | ||
Nucleated Erythrocytes/Leukocytes | C82046 | Nucleated Erythrocytes/Leukocytes | A relative measurement (ratio or percentage) of nucleated erythrocytes to leukocytes in a biological specimen. | Nucleated Erythrocyte to Leukocyte Ratio Measurement | ||
Resistin | C80205 | Resistin | A measurement of the resistin in a biological specimen. | Resistin Measurement | ||
Triiodothyronine, Reverse | C81968 | Triiodothyronine, Reverse | A measurement of the reverse triiodothyronine in a biological specimen. | Reverse Triiodothyronine Measurement | ||
Stem Cell Factor | C82035 | Stem Cell Factor;KIT Ligand | A measurement of the stem cell factor in a biological specimen. | Stem Cell Factor Measurement | ||
Transferrin | C82037 | Transferrin | A measurement of the transferrin in a biological specimen. | Transferrin Measurement | ||
Thyroid Antibodies | C81990 | Thyroid Antibodies | A measurement of the thyroid antibodies in a biological specimen. | Thyroid Antibody Measurement | ||
Thyroid Antimicrosomal Antibodies | C81991 | Thyroid Antimicrosomal Antibodies | A measurement of the thyroid antimicrosomal antibodies in a biological specimen. | Thyroid Antimicrosomal Antibody Measurement | ||
Thyroid Antithyroglobulin Antibodies | C81992 | Thyroid Antithyroglobulin Antibodies | A measurement of the thyroid antithyroglobulin antibodies in a biological specimen. | Thyroid Antithyroglobulin Antibody Measurement | ||
Tissue Inhibitor of Metalloproteinase 1 | C82036 | Tissue Inhibitor of Metalloproteinase 1 | A measurement of the tissue inhibitor of metalloproteinase 1 in a biological specimen. | Tissue Inhibitor of Metalloproteinase 1 Measurement | ||
Tissue Plasminogen Activator Antigen | C81993 | Tissue Plasminogen Activator Antigen | A measurement of the tissue plasminogen activator antigen in a biological specimen. | Tissue Plasminogen Activator Antigen Measurement | ||
Non-Phosphorylated Tau Protein | C84811 | Non-Phosphorylated Tau Protein | A measurement of the non-phosphorylated Tau protein in a biological specimen. | Nonphosphorylated Tau Protein Measurement | ||
Tau Protein | C84810 | Tau Protein;Total Tau Protein | A measurement of the total Tau protein in a biological specimen. | Tau Protein Measurement | ||
Phosphorylated Tau Protein | C84812 | Phosphorylated Tau Protein | A measurement of the phosphorylated Tau protein in a biological specimen. | Phosphorylated Tau Protein Measurement | ||
Total Radical-Trap Antioxidant Potential | C80208 | Total Radical-Trap Antioxidant Potential | A measurement of the ability of the antioxidants in a biological specimen to buffer free radicals in a suspension. | Total Radical-Trap Antioxidant Potential Measurement | ||
Thrombin Time | C80365 | Thrombin Time | A measurement of the time it takes a plasma sample to clot after adding the active enzyme thrombin. (NCI) | Thrombin Time | ||
Vascular Cell Adhesion Molecule 1 | C82042 | Vascular Cell Adhesion Molecule 1 | A measurement of the vascular cell adhesion molecule 1 in a biological specimen. | Vascular Cell Adhesion Molecule 1 Measurement | ||
Vascular Endothelial Growth Factor | C92514 | Vascular Endothelial Growth Factor | A measurement of the vascular endothelial growth factor in a biological specimen. | Vascular Endohelial Growth Factor Measurement | ||
Viscosity | C75912 | Viscosity | The resistance of a liquid to sheer forces and flow. (NCI) | Viscosity | ||
Vitamin D | C84818 | Vitamin D;Total Vitamin D | A measurement of the total Vitamin D in a biological specimen. | Vitamin D Measurement | ||
Zinc | C80210 | Zinc | A measurement of the zinc in a biological specimen. | Zinc Measurement | ||
Cortisol, Free | C88113 | Cortisol, Free | A measurement of the free, unbound cortisol in a biological specimen. | Free Cortisol Measurement | ||
1, 25-Dihydroxyvitamin D | C92267 | 1, 25-Dihydroxyvitamin D;Active Vitamin D | A measurement of the total active Vitamin D in a biological specimen. | 1, 25-Dihydroxyvitamin D Measurement | ||
25-Hydroxyvitamin D | C92268 | 25-Hydroxyvitamin D;Inactive Vitamin D | A measurement of the total inactive Vitamin D in a biological specimen. | 25-Hydroxyvitamin D Measurement | ||
Acetoacetic Acid | C92247 | Acetoacetic Acid;Acetoacetate | A measurement of the acetoacetic acid in a biological specimen. | Acetoacetic Acid Measurement | ||
Acyl Coenzyme A Oxidase | C92286 | Acyl Coenzyme A Oxidase;Fatty Acyl Coenzyme A Oxidase;Acyl CoA Oxidase | A measurement of the acyl coenzyme A oxidase in a biological specimen. | Acyl Coenzyme A Oxidase Measurement | ||
Alpha-1 Globulin | C92252 | Alpha-1 Globulin;A1-Globulin | A measurement of the proteins contributing to the alpha 1 fraction in a biological specimen. | Alpha-1 Globulin Measurement | ||
Alpha-1 Globulin/Total Protein | C92253 | Alpha-1 Globulin/Total Protein | A relative measurement (ratio or percentage) of alpha-1-fraction proteins to total proteins in a biological specimen. | Alpha-1 Globulin to Total Protein Ratio Measurement | ||
Alpha-2 Globulin | C92254 | Alpha-2 Globulin;A2-Globulin | A measurement of the proteins contributing to the alpha 2 fraction in a biological specimen. | Alpha-2 Globulin Measurement | ||
Alpha-2 Globulin/Total Protein | C92255 | Alpha-2 Globulin/Total Protein | A relative measurement (ratio or percentage) of alpha-2-fraction proteins to total proteins in a biological specimen. | Alpha-2 Globulin to Total Protein Ratio Measurement | ||
Amorphous Phosphate Crystals | C92243 | Amorphous Phosphate Crystals | A measurement of the amorphous phosphate crystals in a biological specimen. | Amorphous Phosphate Crystals Measurement | ||
Amorphous Urate Crystals | C92244 | Amorphous Urate Crystals | A measurement of the amorphous urate crystals in a biological specimen. | Amorphous Urate Crystals Measurement | ||
Anti-Single Stranded DNA IgG | C92269 | Anti-Single Stranded DNA IgG | A measurement of the anti-single stranded DNA IgG antibody in a biological specimen. | Anti-Single Stranded DNA IgG Measurement | ||
Apolipoprotein E4 | C92293 | Apolipoprotein E4 | A measurement of the apolipoprotein E4 in a biological specimen. | Apolipoprotein E4 Measurement | ||
Beta Globulin | C92256 | Beta Globulin | A measurement of the proteins contributing to the beta fraction in a biological specimen. | Beta Globulin Measurement | ||
Beta Globulin/Total Protein | C92294 | Beta Globulin/Total Protein | A relative measurement (ratio or percentage) of beta fraction proteins to total proteins in a biological specimen. | Beta Globulin to Total Protein Ratio Measurement | ||
Bone Specific Alkaline Phosphatase | C92287 | Bone Specific Alkaline Phosphatase | A measurement of the bone specific alkaline phosphatase isoform in a biological specimen. | Bone Specific Alkaline Phosphatase Measurement | ||
Carnitine Acetyl Transferase | C92288 | Carnitine Acetyl Transferase | A measurement of the carnitine acetyl transferase in a biological specimen. | Carnitine Acetyl Transferase Measurement | ||
Chlamydia pneumoniae IgA Antibody | C92432 | Chlamydia pneumoniae IgA Antibody | A measurement of the Chlamydia pneumoniae IgA antibody in a biological specimen. | Chlamydia pneumoniae IgA Antibody Measurement | ||
Chlamydia pneumoniae IgM Antibody | C92433 | Chlamydia pneumoniae IgM Antibody | A measurement of the Chlamydia pneumoniae IgM in a biological specimen. | Chlamydia pneumoniae IgM Antibody Measurement | ||
Cholinesterase | C92289 | Cholinesterase | A measurement of the cholinesterase in a biological specimen. | Cholinesterase Measurement | ||
Citrate | C92248 | Citrate | A measurement of the citrate in a biological specimen. | Citrate Measurement | ||
Cotinine | C92249 | Cotinine | A measurement of the cotinine in a biological specimen. | Cotinine Measurement | ||
Cystatin C | C92290 | Cystatin C | A measurement of the cystatin C in a biological specimen. | Cystatin C Measurement | ||
Erythrocyte Cell Clumps | C92245 | Erythrocyte Cell Clumps;Red Blood Cell Clumps;RBC Clumps | A measurement of red blood cell clumps in a biological specimen. | Erythrocyte Cell Clumps Measurement | ||
Erythrocyte Cell Morphology | C92296 | Erythrocyte Cell Morphology;Red Blood Cell Morphology;RBC Morphology | An examination or assessment of the form and structure of red blood cells. | Erythrocyte Cell Morphology | ||
Extractable Nuclear Antigen Antibody | C92270 | Anti-ENA;Extractable Nuclear Antigen Antibody | A measurement of the extractable nuclear antigen antibody in a biological specimen. | Extractable Nuclear Antigen Antibody Measurement | ||
Gamma Globulin | C92257 | Gamma Globulin | A measurement of the proteins contributing to the gamma fraction in a biological specimen. | Gamma Globulin Measurement | ||
Gamma Globulin/Total Protein | C92295 | Gamma Globulin/Total Protein | A relative measurement (ratio or percentage) of gamma fraction proteins to total proteins in a biological specimen. | Gamma Globulin to Total Protein Ratio Measurement | ||
Glomerular Filtration Rate | C90505 | Glomerular Filtration Rate | A kidney function test that measures the fluid volume that is filtered from the kidney glomeruli to the Bowman's capsule per unit of time. | Glomerular Filtration Rate | ||
Hemoglobin A | C92258 | Hemoglobin A | A measurement of the hemoglobin A in a biological specimen. | Hemoglobin A Measurement | ||
Hemoglobin A2 | C92259 | Hemoglobin A2 | A measurement of the hemoglobin A2 in a biological specimen. | Hemoglobin A2 Measurement | ||
Hemoglobin B | C92260 | Hemoglobin B | A measurement of the hemoglobin B in a biological specimen. | Hemoglobin B Measurement | ||
Hemoglobin C | C92261 | Hemoglobin C | A measurement of the hemoglobin C in a biological specimen. | Hemoglobin C Measurement | ||
Hemoglobin F | C92262 | Hemoglobin F;Fetal Hemoglobin | A measurement of the hemoglobin F in a biological specimen. | Hemoglobin F Measurement | ||
Hepatitis A Virus Antibody IgM | C92271 | Hepatitis A Virus Antibody IgM | A measurement of hepatitis A virus antibody IgM in a biological specimen. | Hepatitis A Virus Antibody IgM Measurement | ||
Hepatitis G RNA | C92272 | Hepatitis G RNA | A measurement of the Hepatitis G RNA in a biological specimen. | Hepatitis G RNA Measurement | ||
HIV-1 Group M and O Nucleic Acid | C92263 | HIV-1 Group M and O Nucleic Acid | A measurement of the HIV-1 group M and O nucleic acids in a biological specimen. | HIV-1 Group M and O Nucleic Acid Measurement | ||
HIV-1 Group O Antibody | C92264 | HIV-1 Group O Antibody | A measurement of the HIV-1 group O antibody in a biological specimen. | HIV-1 Group O Antibody Measurement | ||
HIV-1 p24 Antigen | C92265 | HIV-1 p24 Antigen | A measurement of the HIV-1 p24 antigen in a biological specimen. | HIV-1 p24 Antigen Measurement | ||
HIV-2 Nucleic Acid | C92266 | HIV-2 Nucleic Acid | A measurement of the HIV-2 nucleic acids in a biological specimen. | HIV-2 Nucleic Acid Measurement | ||
Influenza A H1N1 Viral Load | C92273 | Influenza A H1N1 Viral Load | A measurement of the Influenza A H1N1 viral load in a biological specimen. | Influenza A H1N1 Viral Load Measurement | ||
Influenza A Viral Load | C92274 | Influenza A Viral Load | A measurement of the Influenza A viral load in a biological specimen. | Influenza A Viral Load Measurement | ||
Legionella pneumophila Antigen | C92275 | Legionella pneumophila Antigen | A measurement of the Legionella pneumophila antigen in a biological specimen. | Legionella pneumophila Antigen Measurement | ||
Legionella pneumophila IgG Antibody | C92276 | Legionella pneumophila IgG Antibody | A measurement of the Legionella pneumophila IgG antibody in a biological specimen. | Legionella pneumophila IgG Antibody Measurement | ||
Legionella pneumophila IgG IgM Antibody | C92277 | Legionella pneumophila IgG IgM Antibody | A measurement of the Legionella pneumophila IgG and IgM in a biological specimen. | Legionella pneumophila IgG IgM Antibody Measurement | ||
Legionella pneumophila IgM Antibody | C92278 | Legionella pneumophila IgM Antibody | A measurement of the Legionella pneumophila IgM antibody in a biological specimen. | Legionella pneumophila IgM Antibody Measurement | ||
Leukocyte Cell Morphology | C92297 | Leukocyte Cell Morphology;White Blood Cell Morphology;WBC Morphology | An examination or assessment of the form and structure of white blood cells. | Leukocyte Cell Morphology | ||
Leukocyte Cell Clumps | C92246 | Leukocyte Cell Clumps;White Blood Cell Clumps;WBC Clumps | A measurement of white blood cell clumps in a biological specimen. | Leukocyte Cell Clumps Measurement | ||
Monoclonal Protein | C92291 | Monoclonal Immunoglobulin Protein;Paraprotein | A measurement of homogenous immunoglobulin resulting from the proliferation of a single clone of plasma cells in a biological specimen. | Monoclonal Protein Measurement | ||
M. tuberculosis IFN Gamma Response | C92241 | Mycobacterium tuberculosis IFN Gamma Response | A measurement of the amount of interferon gamma that is released when Mycobacterium tuberculosis antigen is incubated with a biological specimen, usually blood. Increased amounts of interferon gamma suggests a prior or existing M. tuberculosis infection. | Mycobacterium tuberculosis Interferon Gamma Response | ||
Mycobacterium tuberculosis Nucleic Acid | C92279 | Mycobacterium tuberculosis Nucleic Acid | A measurement of the Mycobacterium tuberculosis nucleic acid in a biological specimen. | Mycobacterium tuberculosis Nucleic Acid Measurement | ||
Myeloid/Erythroid Ratio | C92242 | Myeloid/Erythroid Ratio | A relative measurement (ratio or percentage) of myeloid progenitor cells to erythrocyte precursor cells in a biological specimen. | Myeloid to Erythroid Ratio Measurement | ||
Myeloperoxidase Antibody | C92280 | Myeloperoxidase Antibody | A measurement of the myeloperoxidase antibody in a biological specimen. | Myeloperoxidase Antibody Measurement | ||
Neisseria gonorrhoeae Screening | C92298 | Neisseria gonorrhoeae Screening | Examination of a biological specimen to detect the presence of Neisseria gonorrhoeae. | Neisseria gonorrhoeae Screening | ||
Osmolarity | C74802 | Osmolarity | A measurement of the osmoles of solute per liter of solution. | Osmolarity Measurement | ||
Oxalate | C92250 | Oxalate;Ethanedioate | A measurement of the oxalate in a biological specimen. | Oxalate Measurement | ||
Protein/Osmolality | C92240 | Protein/Osmolality;Protein/Osmolality Ratio | A relative measurement (ratio or percentage) of total proteins to the osmolality of a biological specimen. | Protein to Osmolality Ratio Measurement | ||
Sjogrens SS-A Antibody | C92236 | Ro Antibody;Sjogrens SS-A Antibody | A measurement of the Sjogrens SS-A antibody in a biological specimen. | Sjogren's SS-A Antibody Measurement | ||
Sjogrens SS-B Antibody | C92237 | La Antibody;Sjogrens SS-B Antibody | A measurement of the Sjogrens SS-B antibody in a biological specimen. | Sjogren's SS-B Antibody Measurement | ||
Smith Antibody | C92281 | Smith Antibody | A measurement of the Smith antibody in a biological specimen. | Smith Antibody Measurement | ||
Streptolysin O Antibody | C92282 | Streptolysin O Antibody;Antistreptolysin O | A measurement of Streptolysin O Antibody in a biological specimen. | Streptolysin O Antibody Measurement | ||
Transitional Epithelial Cells | C92251 | Transitional Epithelial Cells | A measurement of the transitional epithelial cells present in a biological specimen. | Transitional Epithelial Cells Measurement | ||
Trichomonas | C92238 | Trichomonas | Examination of a biological specimen to detect the presence of any protozoan belonging to the Trichomonas genus. | Trichomonas Screening | ||
Tryptase | C92292 | Tryptase | A measurement of the tryptase in a biological specimen. | Tryptase Measurement | ||
Type I Myeloblasts | C92283 | Type I Myeloblasts | A measurement of type I myeloblast cells per unit of a biological specimen. | Type I Myeloblasts Measurement | ||
Type II Myeloblasts | C92284 | Type II Myeloblasts | A measurement of type II myeloblast cells per unit of a biological specimen. | Type II Myeloblasts Measurement | ||
Type III Myeloblasts | C92285 | Type III Myeloblasts | A measurement of type III myeloblast cells per unit of a biological specimen. | Type III Myeloblasts Measurement | ||
Yeast Hyphae | C92239 | Yeast Hyphae | Examination of a biological specimen to detect the presence of any yeast cells that are in the long, filamentous and branching phase of growth. | Yeast Hyphae Screening | ||
Soluble Vasc Cell Adhesion Molecule 1 | C92533 | Soluble Vascular Cell Adhesion Molecule 1 | A measurement of the soluble vascular cell adhesion molecule 1 in a biological specimen. | Soluble Vascular Cell Adhesion Molecule 1 | ||
A Fetoprotein L3/A Fetoprotein | C96565 | A Fetoprotein L3/A Fetoprotein | A relative measurement (ratio or percentage) of alpha fetoprotein L3 to total alpha fetoprotein in a biological specimen. | Alpha Fetoprotein L3 to Total Alpha Fetoprotein Ratio Measurement | ||
Acetylcholine Receptor Antibody | C96559 | Acetylcholine Receptor Antibody | A measurement of the acetylcholine receptor antibody in a biological specimen. | Acetylcholine Receptor Antibody Measurement | ||
Acetylcholinesterase | C96560 | Acetylcholinesterase | A measurement of the acetylcholinesterase in a biological specimen. | Acetylcholinesterase Measurement | ||
Alpha Fetoprotein L1 | C96562 | Alpha Fetoprotein L1 | A measurement of the alpha fetoprotein L1 in a biological specimen. | Alpha Fetoprotein L1 Measurement | ||
Alpha Fetoprotein L2 | C96563 | Alpha Fetoprotein L2 | A measurement of the alpha fetoprotein L2 in a biological specimen. | Alpha Fetoprotein L2 Measurement | ||
Alpha Fetoprotein L3 | C96564 | Alpha Fetoprotein L3 | A measurement of the alpha fetoprotein L3 in a biological specimen. | Alpha Fetoprotein L3 Measurement | ||
Basophilic Stippling | C96567 | Basophilic Stippling | A measurement of the basophilic stippling in a biological specimen. | Basophilic Stippling Measurement | ||
Benzoylecgonine | C75350 | Benzoylecgonine;Cocaine Metabolite | A measurement of the benzoylecgonine in a biological specimen. | Benzoylecgonine Measurement | ||
Beta-Hydroxybutyrate | C96568 | Beta-Hydroxybutyrate;B-Hydroxybutyrate;3-Hydroxybutyrate | A measurement of the total Beta-hydroxybutyrate in a biological specimen. | Beta-Hydroxybutyrate Measurement | ||
Broad Casts | C96588 | Broad Casts | A measurement of the broad casts in a biological specimen. | Broad Casts Measurement | ||
Calcium Clearance | C96589 | Calcium Clearance | A measurement of the volume of serum or plasma that would be cleared of calcium by excretion of urine for a specified unit of time (e.g. one minute). | Calcium Clearance Measurement | ||
Calcium Sulphate | C96590 | Calcium Sulphate | A measurement of the calcium sulphate in a biological specimen. | Calcium Sulphate Measurement | ||
Carboxyhemoglobin | C96591 | Carboxyhemoglobin | A measurement of the carboxyhemoglobin in a biological specimen. | Carboxyhemoglobin Measurement | ||
Circulating Endothelial Cells | C96592 | Circulating Endothelial Cells | A measurement of the circulating endothelial cells in a biological specimen. | Circulating Endothelial Cell Count | ||
Circulating Tumor Cells | C96593 | Circulating Tumor Cells | A measurement of the circulating tumor cells in a biological specimen. | Circulating Tumor Cell Count | ||
Clarity | C96594 | Clarity | A measurement of the transparency of a biological specimen. | Clarity Measurement | ||
Cyclic Citrullinated Peptide Antibody | C96595 | Cyclic Citrullinated Peptide Antibody | A measurement of the cyclic citrullinated peptide antibody in a biological specimen. | Cyclic Citrullinated Peptide Antibody Measurement | ||
Cytomegalovirus IgG Antibody | C96596 | Cytomegalovirus IgG Antibody | A measurement of the cytomegalovirus IgG antibody in a biological specimen. | Cytomegalovirus IgG Antibody Measurement | ||
Cytomegalovirus IgM Antibody | C96597 | Cytomegalovirus IgM Antibody | A measurement of the cytomegalovirus IgM antibody in a biological specimen. | Cytomegalovirus IgM Antibody Measurement | ||
Dehydroepiandrosterone Sulfate | C96629 | Dehydroepiandrosterone Sulfate;DHEA-S;sDHEA;DHEA Sulfate | A measurement of the sulfated Dehydroepiandrosterone in a biological specimen. | Sulfated DHEA Measurement | ||
Dilute Russell's Viper Venom Time | C96696 | Dilute Russell's Viper Venom Time | A measurement of the time it takes a plasma sample to clot after adding dilute Russell's viper venom. | Dilute Russell's Viper Venom Time Measurement | ||
Eccentrocytes | C96598 | Eccentrocytes | A measurement of the eccentrocytes (erythrocytes in which the hemoglobin is localized to a particular portion of the cell, noticeable as localized staining) in a biological specimen. | Eccentrocyte Count | ||
Epstein-Barr Capsid IgG Antibody | C96600 | Epstein-Barr Capsid IgG Antibody | A measurement of the Epstein-Barr capsid IgG antibody in a biological specimen. | Epstein-Barr Capsid IgG Antibody Measurement | ||
Epstein-Barr Capsid IgM Antibody | C96601 | Epstein-Barr Capsid IgM Antibody | A measurement of the Epstein-Barr capsid IgM antibody in a biological specimen. | Epstein-Barr Capsid IgM Antibody Measurement | ||
Epstein-Barr Early Antigen | C96602 | Epstein-Barr Early Antigen | A measurement of the Epstein-Barr early antigen in a biological specimen. | Epstein-Barr Early Antigen Measurement | ||
Epstein-Barr Nuclear Antibody | C96603 | Epstein-Barr Nuclear Antibody | A measurement of the Epstein-Barr nuclear antibody in a biological specimen. | Epstein-Barr Nuclear Antibody Measurement | ||
Epstein-Barr Nuclear Antigen | C96604 | Epstein-Barr Nuclear Antigen | A measurement of the Epstein-Barr nuclear antigen in a biological specimen. | Epstein-Barr Nuclear Antigen Measurement | ||
Erythrocyte Ghosts | C96605 | Erythrocyte Ghosts;RBC Ghosts | A measurement of the erythrocyte ghosts (erythrocytes in which hemoglobin has been removed through hemolysis) in a biological specimen. | Erythrocyte Ghost Count | ||
Factor II | C96626 | Factor II;Prothrombin | A measurement of the Factor II in a biological specimen. | Prothrombin Measurement | ||
Fat | C96648 | Fat | A measurement of the fat in a biological specimen. | Fat Measurement | ||
Fibroblast Growth Factor 23 | C96650 | Fibroblast Growth Factor 23;Phosphatonin | A measurement of the fibroblast growth factor 23 in a biological specimen. | Fibroblast Growth Factor 23 Measurement | ||
Giant Neutrophils | C96651 | Giant Neutrophils | A measurement of the giant neutrophils in a biological specimen. | Giant Neutrophil Count | ||
Glucose Clearance | C96652 | Glucose Clearance | A measurement of the glucose clearance in a biological specimen. | Glucose Clearance Measurement | ||
Glutamic Acid Decarboxylase Antibody | C96653 | Glutamic Acid Decarboxylase Antibody;GAD Antibody | A measurement of the glutamic acid decarboxylase antibody in a biological specimen. | Glutamic Acid Decarboxylase Antibody Measurement | ||
Granulocytes | C96654 | Granulocytes | A measurement of the granulocytes in a biological specimen. | Granulocyte Count | ||
Hepatitis B Virus Core Antibody | C96660 | Hepatitis B Virus Core Antibody | A measurement of the hepatitis B virus core antibody in a biological specimen. | Hepatitis B Virus Core Antibody Measurement | ||
Hepatitis B Virus Core IgM Antibody | C96661 | Hepatitis B Virus Core IgM Antibody | A measurement of the hepatitis B virus core IgM antibody in a biological specimen. | Hepatitis B Virus Core IgM Antibody Measurement | ||
Hepatitis B Virus e Antibody | C96662 | Hepatitis B Virus e Antibody | A measurement of the hepatitis B e antibody in a biological specimen. | Hepatitis B Virus e Antibody Measurement | ||
Hepatitis B Virus e Antigen | C96663 | Hepatitis B Virus e Antigen | A measurement of the hepatitis B e antigen in a biological specimen. | Hepatitis B Virus e Antigen Measurement | ||
Hepatitis D Virus Antibody | C96664 | Hepatitis D Virus Antibody;Hepatitis Delta Antibody | A measurement of the hepatitis D virus antibody in a biological specimen. | Hepatitis D Virus Antibody Measurement | ||
Hepatitis E Virus IgM Antibody | C96665 | Hepatitis E Virus IgM Antibody | A measurement of the hepatitis E virus IgM antibody in a biological specimen. | Hepatitis E Virus IgM Antibody Measurement | ||
Herpes Simplex Virus 1 IgG Antibody | C96697 | Herpes Simplex Virus 1 IgG Antibody;HSV-1 IgG Antibody | A measurement of the herpes simplex virus 1 IgG antibody in a biological specimen. | Herpes Simplex Virus 1 IgG Antibody Measurement | ||
Herpes Simplex Virus 1/2 IgG Antibody | C96698 | Herpes Simplex Virus 1/2 IgG Antibody;HSV-1/2 IgG Ab | A measurement of the herpes simplex virus 1 and 2 IgG antibody in a biological specimen. | Herpes Simplex Virus 1/2 IgG Antibody Measurement | ||
Herpes Simplex Virus 1/2 IgM Antibody | C96666 | Herpes Simplex Virus 1/2 IgM Antibody;HSV-1/2 IgM Ab | A measurement of the herpes simplex virus 1 and 2 IgM antibody in a biological specimen. | Herpes Simplex Virus 1/2 IgM Antibody Measurement | ||
Herpes Simplex Virus 2 IgG Antibody | C96667 | Herpes Simplex Virus 2 IgG Antibody;HSV-2 IgG Antibody | A measurement of the herpes simplex virus 2 IgG antibody in a biological specimen. | Herpes Simplex Virus 2 IgG Antibody Measurement | ||
Hexokinase | C96668 | Hexokinase | A measurement of the hexokinase in a biological specimen. | Hexokinase Measurement | ||
Hyperchromia | C96669 | Hyperchromia | A measurement of the prevalence of the erthrocytes with an elevated hemoglobin concentration. | Hyperchromia Measurement | ||
Immature Basophils | C96670 | Immature Basophils | A measurement of the immature basophils in a biological specimen. | Immature Basophil Count | ||
Immature Basophils/Leukocytes | C96671 | Immature Basophils/Leukocytes | A relative measurement (ratio or percentage) of immature basophils to total leukocytes in a biological specimen. | Immature Basophil to Leukocyte Ratio Measurement | ||
Immature Cells | C96672 | Immature Cells | A measurement of the total immature cells in a blood specimen. | Immature Cell Count | ||
Immature Eosinophils | C96673 | Immature Eosinophils | A measurement of the immature eosinophils in a biological specimen. | Immature Eosinophil Count | ||
Immature Eosinophils/Leukocytes | C96674 | Immature Eosinophils/Leukocytes | A relative measurement (ratio or percentage) of immature eosinophils to total leukocytes in a biological specimen. | Immature Eosinophil to Leukocyte Ratio Measurement | ||
Immature Granulocytes | C96675 | Immature Granulocytes | A measurement of the total immature granulocytes in a biological specimen. | Immature Granulocyte Count | ||
Immature Monocytes | C96676 | Immature Monocytes | A measurement of the immature monocytes in a biological specimen. | Immature Monocyte Count | ||
Immature Monocytes/Leukocytes | C96677 | Immature Monocytes/Leukocytes | A relative measurement (ratio or percentage) of immature monocytes to total leukocytes in a biological specimen. | Immature Monocyte to Leukocyte Ratio Measurement | ||
Immature Neutrophils | C96678 | Immature Neutrophils | A measurement of the total immature neutrophils in a biological specimen. | Immature Neutrophil Count | ||
Immature Plasma Cells | C96679 | Immature Plasma Cells | A measurement of the immature plasma cells in a biological specimen. | Immature Plasma Cell Count | ||
Immature Plasma Cells/Lymphocytes | C96680 | Immature Plasma Cells/Lymphocytes | A relative measurement (ratio or percentage) of immature plasma cells to total lymphocytes in a biological specimen. | Immature Plasma Cell to Lymphocyte Ratio Measurement | ||
Inhibin B | C96681 | Inhibin B | A measurement of the inhibin B in a biological specimen. | Inhibin B Measurement | ||
Kurloff Cells | C96682 | Kurloff Cells | A measurement of the large secretory granule-containing immune cells in a biological specimen taken from members of certain genera of the Caviidae family. | Kurloff Cells Measurement | ||
Liver Kidney Microsomal Type 1 Antibody | C96683 | Liver Kidney Microsomal Type 1 Antibody;LKM-1 | A measurement of the liver kidney microsomal type 1 antibody in a biological specimen. | Liver Kidney Microsomal Type 1 Antibody Measurement | ||
Mean Platelet Component | C96686 | Mean Platelet Component | A measurement of the mean platelet component (platelet activity) in a blood specimen. | Mean Platelet Component Measurement | ||
Megakaryocytes | C96688 | Megakaryocytes | A measurement of the megakaryocytes per unit of a biological specimen. | Megakaryocyte Count | ||
Methemoglobin | C96689 | Methemoglobin | A measurement of the methemoglobin in a biological specimen. | Methemoglobin Measurement | ||
Methylmalonic Acid | C96690 | Methylmalonic Acid | A measurement of the methylmalonic acid in a biological specimen. | Methylmalonic Acid Measurement | ||
N-Terminal ProB-type Natriuretic Peptide | C96610 | N-Terminal ProB-type Natriuretic Peptide;NT proBNP II;N-terminal pro-Brain Natriuretic Peptide | A measurement of the N-terminal proB-type natriuretic peptide in a biological specimen. | N-Terminal ProB-type Natriuretic Peptide Measurement | ||
Oxygen Capacity | C96614 | Oxygen Capacity | A measurement of the maximum amount of oxygen that can be combined chemically with hemoglobin in a volume of blood. | Oxygen Capacity Measurement | ||
Oxygen Saturation | C68032 | Oxygen Saturation | A measurement of the oxygen-hemoglobin saturation of a volume of blood. | Oxygen Saturation Measurement | ||
Oxyhemoglobin | C96616 | Oxyhemoglobin | A measurement of the oxyhemoglobin in a biological specimen. | Oxyhemoglobin Measurement | ||
Parvovirus B19 IgG Antibody | C96617 | Parvovirus B19 IgG Antibody | A measurement of the Parvovirus B19 IgG antibody in a biological specimen. | Parvovirus B19 IgG Antibody Measurement | ||
Parvovirus B19 IgM Antibody | C96618 | Parvovirus B19 IgM Antibody | A measurement of the Parvovirus B19 IgM antibody in a biological specimen. | Parvovirus B19 IgM Antibody Measurement | ||
Phospholipid | C96623 | Phospholipid | A measurement of the phospholipids in a biological specimen. | Phospholipid Measurement | ||
Platelet Clumps | C96624 | Platelet Clumps;PLT Clumps | A measurement of the platelet clumps in a biological specimen. | Platelet Clumps Count | ||
Procollagen 1 N-Terminal Propeptide | C96625 | Procollagen 1 N-Terminal Propeptide;Amino-terminal propeptide of type 1 procollagen;P1NP Aminoterm Type 1 | A measurement of the procollagen 1 N-terminal propeptide in a biological specimen. | Procollagen 1 N-Terminal Propeptide Measurement | ||
Reptilase Time | C96628 | Reptilase Time | A measurement of the time it takes a plasma sample to clot after adding the active enzyme reptilase. | Reptilase Time Measurement | ||
Target Cells | C96636 | Leptocytes;Target Cells | A measurement of the target cells in a biological specimen. | Target Cell Count | ||
Thyroperoxidase | C96639 | Thyroperoxidase;Thyroid Peroxidase | A measurement of the thyroperoxidase in a biological specimen. | Thyroperoxidase Measurement | ||
Thyroperoxidase Antibody | C96638 | Thyroperoxidase Antibody | A measurement of the thyroperoxidase antibody in a biological specimen. | Thyroperoxidase Antibody Measurement | ||
Toxic Granulation | C96641 | Toxic Granulation | A measurement of the toxic granulation in neutrophilic blood cells. | Toxic Granulation Measurement | ||
Urea/Creatinine | C96645 | Urea/Creatinine | A relative measurement (ratio or percentage) of the urea to creatinine in a biological specimen. | Urea to Creatinine Ratio Measurement | ||
ADV Viral Load | C98705 | ADV Viral Load | A measurement of the adenovirus viral load in a biological specimen. | Adenovirus Viral Load Measurement | ||
Anti-Factor Xa Activity | C98706 | Anti-Factor Xa Activity | A measurement of the anti-activated Factor X in a biological specimen. This test is used to monitor low molecular weight or unfractionated heparin levels in a biological specimen. | Anti-Factor Xa Activity Measurement | ||
Amylase, Pancreatic | C98767 | Amylase, Pancreatic | A measurement of the pancreatic enzyme amylase in a biological specimen. | Pancreatic Amylase Measurement | ||
Amylase, Salivary | C98780 | Amylase, Salivary | A measurement of the salivary enzyme amylase in a biological specimen. | Salivary Amylase Measurement | ||
Activated PTT/Standard | C98862 | Activated PTT/Standard | A relative measurement (ratio or percentage) of the subject's partial thromboplastin time to a standard or control partial thromboplastin time. | Activated PTT/Standard Ratio Measurement | ||
Basophils/Total Cells | C98865 | Basophils/Total Cells | A relative measurement (ratio or percentage) of the basophils to total cells in a biological specimen (for example a bone marrow specimen). | Basophil to Total CellRatio Measurement | ||
BKV Viral Load | C98710 | BKV Viral Load | A measurement of the BK virus viral load in a biological specimen. | BK Virus Viral Load Measurement | ||
Myeloblasts/Total Cells | C98761 | Myeloblasts/Total Cells | A relative measurement (ratio or percentage) of the myeloblasts to total cells in a biological specimen (for example a bone marrow specimen). | Myeloblast to Total Cell Ratio Measurement | ||
Megakaryoblasts | C98752 | Megakaryoblasts | A measurement of the megakaryoblasts in a biological specimen. | Megakaryoblast Cell Count | ||
Megakaryoblasts/Total Cells | C98753 | Megakaryoblasts/Total Cells | A relative measurement (ratio or percentage) of the megakaryoblasts to total cells in a biological specimen (for example a bone marrow specimen). | Megakaryoblast to Total Cell Ratio Measurement | ||
Normoblasts/Total Cells | C98764 | Normoblasts/Total Cells | A relative measurement (ratio or percentage) of the normoblasts to total cells in a biological specimen (for example a bone marrow specimen). | Normoblast to Total Cell Ratio Measurement | ||
Pronormoblasts/Total Cells | C98870 | Pronormoblasts/Total Cells | A relative measurement (ratio or percentage) of the pronormoblasts to total cells in a biological specimen (for example a bone marrow specimen). | Pronormoblast to Total CellRatio Measurement | ||
CMV Viral Load | C98716 | CMV Viral Load | A measurement of the cytomegalovirus viral load in a biological specimen. | Cytomegalovirus Viral Load Measurement | ||
EBV Viral Load | C98721 | EBV Viral Load | A measurement of the Epstein-Barr virus viral load in a biological specimen. | Epstein-Barr Virus Viral Load Measurement | ||
Eosinophils/Total Cells | C98720 | Eosinophils/Total Cells | A relative measurement (ratio or percentage) of the eosinophils to total cells in a biological specimen (for example a bone marrow specimen). | Eosinophils to Total Cell Ratio Measurement | ||
Factor IX | C98725 | Factor IX | A measurement of the factor IX in a biological specimen. | Factor IX Measurement | ||
Factor V | C98726 | Factor V | A measurement of the factor V in a biological specimen. | Factor V Measurement | ||
von Willebrand Factor | C98799 | von Willebrand Factor | A measurement of the von Willebrand factor in a biological specimen. | von Willebrand Factor Measurement | ||
Factor X | C98727 | Factor X | A measurement of the factor X in a biological specimen. | Factor X Measurement | ||
Fat Droplet | C98728 | Fat Droplet | A measurement of the triglyceride aggregates within a biological specimen. | Fat Droplet Measurement | ||
Glomerular Filtration Rate Adj for BSA | C98734 | Glomerular Filtration Rate Adj for BSA | A measurement of the glomerular filtration rate adjusted for body size. | Glomerular Filtration Rate Adjusted for BSA | ||
GFR from Creatinine Adjusted for BSA | C98735 | GFR from Creatinine Adjusted for BSA | An estimation of the glomerular filtration rate adjusted for body size based on creatinine. | Glomerular Filtration Rate from Creatinine Adjusted for BSA | ||
GFR from Cystatin C Adjusted for BSA | C98736 | GFR from Cystatin C Adjusted for BSA | An estimation of the glomerular filtration rate adjusted for body size based on cystatin C. | Glomerular Filtration Rate from Cystatin C Adjusted for BSA | ||
Granulocytes/Total Cells | C98866 | Granulocytes/Total Cells | A relative measurement (ratio or percentage) of the granulocytes to total cells in a biological specimen (for example a bone marrow specimen). | Granulocyte to Total CellRatio Measurement | ||
Human Anti-Sheep IgE Antibody | C98740 | Human Anti-Sheep IgE Antibody | A measurement of the human anti-sheep IgE antibodies in a biological specimen. | Human Anti-Sheep IgE Antibody Measurement | ||
Human Anti-Sheep IgG Antibody | C98741 | Human Anti-Sheep IgG Antibody | A measurement of the human anti-sheep IgG antibodies in a biological specimen. | Human Anti-Sheep IgG Antibody Measurement | ||
Human Anti-Sheep IgM Antibody | C98742 | Human Anti-Sheep IgM Antibody | A measurement of the human anti-sheep IgM antibodies in a biological specimen. | Human Anti-Sheep IgM Antibody Measurement | ||
Hemosiderin | C96659 | Hemosiderin | A measurement of the hemosiderin complex in a biological specimen. | - - - | ||
Herpes Simplex Virus 1 IgM Antibody | C98738 | Herpes Simplex Virus 1 IgM Antibody | A measurement of the Herpes Simplex virus 1 IgM antibodies in a biological specimen. | Herpes Simplex Virus 1 IgM Antibody Measurement | ||
Herpes Simplex Virus 2 IgM Antibody | C98739 | Herpes Simplex Virus 2 IgM Antibody | A measurement of the Herpes Simplex virus 2 IgM antibodies in a biological specimen. | Herpes Simplex Virus 2 IgM Antibody Measurement | ||
Immunoglobulin D | C98745 | Immunoglobulin D | A measurement of the Immunoglobulin D in a biological specimen. | Immunoglobulin D Measurement | ||
Inulin Clearance | C98748 | Inulin Clearance | A measurement of the volume of serum or plasma that would be cleared of inulin by excretion of urine for a specified unit of time (e.g. one minute). | Inulin Clearance | ||
Iothalamate Clearance | C98749 | Iothalamate Clearance | A measurement of the volume of serum or plasma that would be cleared of iothalamate by excretion of urine for a specified unit of time (e.g. one minute). | Iothalamate Clearance | ||
Iothalamate Clearance Adjusted for BSA | C98750 | Iothalamate Clearance Adjusted for BSA | A measurement of the volume of serum or plasma that would be cleared of iothalamate by excretion of urine for a specified unit of time (e.g. one minute), adjusted for body size. | Iothalamate Clearance Adjusted for BSA | ||
Kappa Light Chain, Free | C98730 | Kappa Light Chain, Free | A measurement of the free kappa light chain in a biological specimen. | Free Kappa Light Chain Measurement | ||
Kappa Lt Chain,Free/Lambda Lt Chain,Free | C98731 | Kappa Lt Chain,Free/Lambda Lt Chain,Free | A relative measurement (ratio or percentage) of the free kappa light chain to the free lambda light chain in a biological specimen. | Free Kappa Light Chain to Free Lambda Light Chain Ratio Measurement | ||
Megakaryocytes/Total Cells | C98867 | Megakaryocytes/Total Cells | A relative measurement (ratio or percentage) of the megakaryocytes to total cells in a biological specimen (for example a bone marrow specimen). | Megakaryocyte to Total CellRatio Measurement | ||
Lambda Light Chain, Free | C98732 | Lambda Light Chain, Free | A measurement of the free lambda light chain in a biological specimen. | Free Lambda Light Chain Measurement | ||
Lymphocytes/Total Cells | C98751 | Lymphocytes/Total Cells | A relative measurement (ratio or percentage) of the lymphocytes to total cells in a biological specimen (for example a bone marrow specimen). | Lymphocyte to Total Cell Ratio Measurement | ||
Metamyelocytes/Total Cells | C98754 | Metamyelocytes/Total Cells | A relative measurement (ratio or percentage ) of the metamyelocytes (small, myelocytic neutrophils with an indented nucleus) to total cells in a biological specimen (for example a bone marrow specimen). | Metamyelocyte to Total Cell Ratio Measurement | ||
Monocytes/Total Cells | C98872 | Monocytes/Total Cells | A relative measurement (ratio or percentage) of the monocytes to total cells in a biological specimen (for example a bone marrow specimen). | Monocytes to Total CellRatioMeasurement | ||
Myelocytes/Total Cells | C98868 | Myelocytes/Total Cells | A relative measurement (ratio or percentage) of the myelocytes to total cells in a biological specimen (for example a bone marrow specimen). | Myelocyte to Total CellRatio Measurement | ||
Neutrophils/Total Cells | C98763 | Neutrophils/Total Cells | A relative measurement (ratio or percentage) of the neutrophils to total cells in a biological specimen (for example a bone marrow specimen). | Neutrophil to Total Cell Ratio Measurement | ||
Natural Killer Cells | C98762 | Natural Killer Cells | A measurement of the total natural killer cells in a biological specimen. | Natural Killer Cell Count | ||
Plasma Cells/Total Cells | C98869 | Plasma Cells/Total Cells | A relative measurement (ratio or percentage) of the mature plasma cells (plasmacytes) to total cells in a biological specimen (for example a bone marrow specimen). | Plasma Cell to Total CellRatio Measurement | ||
Promyelocytes/Total Cells | C98773 | Promyelocytes/Total Cells | A relative measurement (ratio or percentage) of the promyelocytes (immature myelocytes) to total cells in a biological specimen (for example a bone marrow specimen). | Promyelocyte to Total Cell Ratio Measurement | ||
Prothrombin Activity | C98774 | Prothrombin Activity | A measurement of the biological activity of prothrombin in a biological specimen. | Prothrombin Activity Measurement | ||
Reticulocyte Hemoglobin | C98776 | Reticulocyte Hemoglobin | A measurement of the amount of hemoglobin in reticulocytes. | Reticulocyte Hemoglobin Measurement | ||
Transferrin Saturation | C98792 | Transferrin Saturation | A measurement of the iron bound to transferrin in a biological specimen. | Transferrin Saturation Measurement | ||
Varicella Zoster Virus IgA Antibody | C98795 | Varicella Zoster Virus IgA Antibody | A measurement of the Varicella Zoster virus IgA antibodies in a biological specimen. | Varicella Zoster Virus IgA Antibody Measurement | ||
Varicella Zoster Virus IgG Antibody | C98796 | Varicella Zoster Virus IgG Antibody | A measurement of the Varicella Zoster virus IgG antibodies in a biological specimen. | Varicella Zoster Virus IgG Antibody Measurement | ||
Varicella Zoster Virus IgM Antibody | C98797 | Varicella Zoster Virus IgM Antibody | A measurement of the Varicella Zoster virus IgM antibodies in a biological specimen. | Varicella Zoster Virus IgM Antibody Measurement | ||
3,4-Dihydroxyphenylglycol | C101017 | 3,4-Dihydroxyphenylglycol;3.4 Dihydroxyphenylglycol | A measurement of the catecholamine metabolite, 3,4-Dihydroxyphenylglycol in a biological specimen. | 3,4-Dihydroxyphenylglycol Measurement | ||
Activated Protein C Resistance | C100471 | Activated Protein C Resistance;Factor V Leiden Screen | A measurement of the resistance in the anticoagulation response to activated protein C in a biological specimen. | Activated Protein C Resistance Measurement | ||
Activated PTT/Standard PTT | C100421 | Activated PTT/Standard PTT;Activated Partial Thromboplastin Time/Standard Thromboplastin Time | A relative measurement (ratio or percentage) of the subject's activated partial thromboplastin time to a standard or control partial thromboplastin time. | Activated PTT to Standard PTT Ratio Measurement | ||
Alanine Aminopeptidase | C100430 | Alanine Aminopeptidase | A measurement of the alanine aminopeptidase in a biological specimen. | Alanine Aminopeptidase Measurement | ||
Alpha-1 Acid Glycoprotein | C100429 | Alpha-1 Acid Glycoprotein | A measurement of the alpha-1 acid glycoprotein in a biological specimen. | Alpha-1 Acid Glycoprotein Measurement | ||
Alpha-1 Microglobulin | C100461 | Alpha-1 Microglobulin;Protein HC | A measurement of the alpha-1 microglobulin in a biological specimen. | Alpha-1 Microglobulin Measurement | ||
Alpha-1 Microglobulin/Creatinine | C100462 | Alpha-1 Microglobulin/Creatinine | A relative measurement (ratio or percentage) of the alpha-1 microglobulin to creatinine in a biological specimen. | Alpha-1 Microglobulin to Creatinine Ratio Measurement | ||
Apolipoprotein C2 | C100427 | Apolipoprotein C2;Apolipoprotein CII | A measurement of the apolipoprotein C2 in a biological specimen. | Apolipoprotein C2 Measurement | ||
Apolipoprotein J | C100428 | Apolipoprotein J;Clusterin | A measurement of the apolipoprotein J in a biological specimen. | Apolipoprotein J Measurement | ||
Beta Carotene | C100472 | Beta Carotene;b-Carotene;Beta Carotin | A measurement of the beta carotene in a biological specimen. | Beta Carotene Measurement | ||
Beta-Trace Protein | C100426 | Beta-Trace Protein | A measurement of the beta-trace protein in a biological specimen. | Beta-Trace Protein Measurement | ||
Carbohydrate-Deficient Transferrin | C101016 | Carbohydrate-Deficient Transferrin | A measurement of transferrin with a reduced number of carbohydrate moieties in a biological specimen. | Carbohydrate-Deficient Transferrin Measurement | ||
Ceruloplasmin | C100432 | Ceruloplasmin;Caeruloplasmin | A measurement of ceruloplasmin in a biological specimen. | Ceruloplasmin Measurement | ||
Complement CH50 | C100423 | Complement CH50;Total Hemolytic Complement;CH50 | A measurement of the complement required to lyse 50 percent of red blood cells in a biological specimen. | CH50 Measurement | ||
Chemokine (C-X-C Motif) Receptor 3 | C100431 | Chemokine (C-X-C Motif) Receptor 3;GPR9, CD183, CXCR3 | A measurement of the CXCR3, chemokine (C-X-C motif) receptor 3, in a biological specimen. | Chemokine Receptor CXCR3 Measurement | ||
Chlamydia trachomatis IgA Antibody | C100464 | Chlamydia trachomatis IgA Antibody | A measurement of the Chlamydia trachomatis IgA antibody in a biological specimen. | Chlamydia trachomatis IgA Antibody Measurement | ||
Chlamydia trachomatis IgG Antibody | C100466 | Chlamydia trachomatis IgG Antibody | A measurement of the Chlamydia trachomatis IgG antibody in a biological specimen. | Chlamydia trachomatis IgG Antibody Measurement | ||
Chlamydia trachomatis IgM Antibody | C100465 | Chlamydia trachomatis IgM Antibody | A measurement of the Chlamydia trachomatis IgM antibody in a biological specimen. | Chlamydia trachomatis IgM Antibody Measurement | ||
DTPA Clearance | C100441 | DTPA Clearance | A measurement of the volume of serum or plasma that would be cleared of Diethylenetriamine pentaacetate (DTPA) through its excretion for a specified unit of time. | Diethylene Triamine Pentaacetic Acid Clearance | ||
DNase-B Antibody | C100463 | DNase-B Antibody;Anti-Dnase B | A measurement of Dnase-B antibody in a biological specimen. | DNase-B Antibody Measurement | ||
Ecarin Clotting Time | C100422 | Ecarin Clotting Time | A measurement of the activity of thrombin inhibitors in a biological specimen based on the generation of meizothrombin. | Ecarin Clotting Time Measurement | ||
EDTA Clearance | C100440 | EDTA Clearance | A measurement of the volume of serum or plasma that would be cleared of Ethylenediamine tetraacetic acid (EDTA) through its excretion for a specified unit of time. | EDTA Clearance | ||
Free Glycerol | C100448 | Free Glycerol;Free Glycerin | A measurement of the amount of unbound glycerol in a biological specimen. | Free Glycerol Measurement | ||
GFR from B-2 Microglobulin Adj for BSA | C100450 | GFR from B-2 Microglobulin Adj for BSA | A measurement of the glomerular filtration rate (GFR) based on the clearance of beta-2 microglobulin after adjusting it for the body surface area. | Glomerular Filtration Rate from B-2 Microglobulin Adjusted for BSA Measurement | ||
GFR from Beta-Trace Protein Adj for BSA | C100449 | GFR from Beta-Trace Protein Adj for BSA | A measurement of the glomerular filtration rate (GFR) based on the clearance of beta-trace protein after adjusting it for the body surface area. | Glomerular Filtration Rate from Beta-Trace Protein Adjusted for BSA Measurement | ||
HDL Cholesterol/LDL Cholesterol Ratio | C100425 | HDL Cholesterol/LDL Cholesterol Ratio | A relative measurement (ratio or percentage) of the amount of HDL cholesterol compared to LDL cholesterol in a biological specimen. | HDL Cholesterol to LDL Cholesterol Ratio Measurement | ||
HLA-B27 Antigen | C100460 | HLA-B27 Antigen;Human Leukocyte Antigen B27 | A measurement of the human leukocyte antigen B27 (HLA-B27) in a biological specimen. | HLA-B27 Antigen Measurement | ||
Homostat Model Assess of Insulin Rstn | C100447 | Homostat Model Assess of Insulin Rstn;Homeostatic Model Assessment of Insulin Resistance | An assessment of beta-cell function and insulin resistance based on fasting blood glucose and insulin concentrations. | Homeostatic Model Assessment of Insulin Resistance | ||
Immature Granulocytes/Leukocytes | C100445 | Immature Granulocytes/Leukocytes | A relative measurement (ratio or percentage) of the immature granulocytes to leukocytes in a biological specimen (for example a bone marrow specimen). | Immature Granulocytes to Leukocytes Ratio Measurement | ||
Immature Lymphocytes | C100444 | Immature Lymphocytes | A measurement of the immature lymphocytes in a biological specimen. | Immature Lymphocytes Measurement | ||
Immature Lymphocytes/Leukocytes | C100443 | Immature Lymphocytes/Leukocytes | A relative measurement (ratio or percentage) of the immature lymphocytes to leukocytes in a biological specimen. | Immature Lymphocytes to Leukocytes Ratio Measurement | ||
Immature Neutrophils/Leukocytes | C100442 | Immature Neutrophils/Leukocytes | A relative measurement (ratio or percentage) of the immature neutrophils to leukocytes in a biological specimen. | Immature Neutrophils to Leukocytes Ratio Measurement | ||
Iohexol Clearance | C100439 | Iohexol Clearance | A measurement of the volume of serum or plasma that would be cleared of Iohexol through excretion for a specified unit of time. | Iohexol Clearance | ||
Jo-1 Antibody | C100459 | Jo-1 Antibody | A measurement of the Jo-1 antibody in a biological specimen. | Jo-1 Antibody Measurement | ||
Kidney Injury Molecule-1 | C100433 | Kidney Injury Molecule-1;KIM-1;Hepatitis A Virus Cellular Receptor 1 | A measurement of the kidney injury molecule-1 (Kim-1) in a biological specimen. | Kidney Injury Molecule-1 Measurement | ||
Liver Kidney Microsomal Type 1 IgA Ab | C100456 | Liver Kidney Microsomal Type 1 IgA Ab | A measurement of the liver kidney microsomal type 1 IgA antibodies in a biological specimen. | Liver Kidney Microsomal Type 1 IgA Antibody Measurement | ||
Liver Kidney Microsomal Type 1 IgG Ab | C100454 | Liver Kidney Microsomal Type 1 IgG Ab | A measurement of the liver kidney microsomal type 1 IgG antibodies in a biological specimen. | Liver Kidney Microsomal Type 1 IgG Antibody Measurement | ||
Liver Kidney Microsomal Type 1 IgM Ab | C100455 | Liver Kidney Microsomal Type 1 IgM Ab | A measurement of the liver kidney microsomal type 1 IgM antibodies in a biological specimen. | Liver Kidney Microsomal Type 1 IgM Antibody Measurement | ||
Non-Prostatic Acid Phosphatase | C100434 | Non-Prostatic Acid Phosphatase | A measurement of the non-prostatic acid phosphatase in a biological specimen. | Non-Prostatic Acid Phosphatase Measurement | ||
Ova and Parasite | C100452 | Ova and Parasite | A measurement of the parasites and ova in a biological specimen. | Ova and Parasite Measurement | ||
Pepsinogen A | C100469 | Pepsinogen A;PGA | A measurement of the pepsinogen A in a biological specimen. | Pepsinogen A Measurement | ||
Pepsinogen C | C100470 | Pepsinogen C;PGC | A measurement of the pepsinogen C in a biological specimen. | Pepsinogen C Measurement | ||
Pepsinogen I | C100467 | Pepsinogen I;PGI | A measurement of the pepsinogen I in a biological specimen. | Pepsinogen I Measurement | ||
Pepsinogen II | C100468 | Pepsinogen II;PGII | A measurement of the pepsinogen II in a biological specimen. | Pepsinogen II Measurement | ||
Pepsinogen | C100122 | Pepsinogen | A measurement of the pepsinogen in a biological specimen. | Pepsinogen Measurement | ||
Plasmodium | C100453 | Plasmodium | Examination of a biological specimen to detect the presence of any protozoan belonging to the Plasmodium genus. | Plasmodium Measurement | ||
Platelet Hematocrit | C100424 | Platelet Hematocrit;Thrombocytocrit | A relative measurement (ratio or percentage) of the proportion of the volume of blood taken up by platelets. | Platelet Hematocrit Measurement | ||
Prealbumin | C100435 | Prealbumin | A measurement of the prealbumin in a biological specimen. | Prealbumin Measurement | ||
Proerythroblast | C100446 | Proerythroblast | A measurement of the proerythroblasts in a biological specimen. | Proerythroblast Measurement | ||
Protein S | C100436 | Protein S | A measurement of the protein S in a biological specimen. | Protein S Measurement | ||
Retinol Binding Protein | C100437 | Retinol Binding Protein | A measurement of the total retinol binding protein in a biological specimen. | Retinol Binding Protein Measurement | ||
Ribonucleoprotein Antibody | C100457 | Ribonucleoprotein Antibody;RNP Antibody | A measurement of the ribonucleoprotein antibody in a biological specimen. | Ribonucleoprotein Antibody Measurement | ||
Ringed Sideroblasts | C100419 | Ringed Sideroblasts | A measurement of the ringed sideroblasts (abnormal nucleated erythroblasts with a large number of iron deposits in the perinuclear mitochondria, forming a ring around the nucleus) in a biological specimen. | Ringed Sideroblast Measurement | ||
Scl-70 Antibody | C100458 | Scl-70 Antibody;Scleroderma-70 Antibody | A measurement of the Scl-70 antibody in a biological specimen. | Scl-70 Antibody Measurement | ||
Sideroblast | C100418 | Sideroblast | A measurement of the sideroblasts (nucleated erythroblasts with iron granules in the cytoplasm) in a biological specimen. | Sideroblast Measurement | ||
Soluble Transferrin Receptor | C100438 | Soluble Transferrin Receptor | A measurement of the soluble transferrin receptor in a biological specimen. | Soluble Transferrin Receptor Measurement | ||
Tricyclic Antidepressants | C100420 | Tricyclic Antidepressants | A measurement of tricyclic antidepressants in a biological specimen. | Tricyclic Antidepressant Measurement | ||
Back to top | ||||||
CL.C71113.FREQ | Frequency (FREQ) | text Extensible: Yes | C71113 | Frequency | The terminology that includes terms pertaining to frequency within CDISC. | CDISC SDTM Frequency Terminology |
OTHER | C17649 | Other | Different than the one(s) previously specified or mentioned. (NCI) | Other | ||
UNKNOWN | C17998 | U;Unknown | Not known, not observed, not recorded, or refused. (NCI) | Unknown | ||
CONTINUOUS | C53279 | Continuous | Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption. (NCI) | Continue | ||
BID | C64496 | BD;Twice per day | Two times per day, at unspecified times. (NCI) | Twice Daily | ||
BIS | C64497 | Twice per week | Two times per week. (NCI) | Twice Weekly | ||
QM | C64498 | Every Month | Every month. (NCI) | Monthly | ||
PRN | C64499 | As needed | As needed. (NCI) | As Necessary | ||
Q10H | C64500 | Every 10 hours | Every ten hours. (NCI) | Every Ten Hours | ||
Q11H | C64501 | Every 11 hours | Every eleven hours. (NCI) | Every Eleven Hours | ||
Q12H | C64502 | Every 12 hours | Every twelve hours. (NCI) | Every Twelve Hours | ||
Q13H | C64503 | Every 13 hours | Every thirteen hours. (NCI) | Every Thirteen Hours | ||
Q14H | C64504 | Every 14 hours | Every fourteen hours. (NCI) | Every Fourteen Hours | ||
Q15H | C64505 | Every 15 hours | Every fifteen hours. (NCI) | Every Fifteen Hours | ||
Q16H | C64506 | Every 16 hours | Every sixteen hours. (NCI) | Every Sixteen Hours | ||
Q17H | C64507 | Every 17 hours | Every seventeen hours. (NCI) | Every Seventeen Hours | ||
Q18H | C64508 | Every 18 hours | Every eighteen hours. (NCI) | Every Eighteen Hours | ||
Q19H | C64509 | Every 19 hours | Every nineteen hours. (NCI) | Every Nineteen Hours | ||
QH | C64510 | Every hour | Every hour. (NCI) | Every Hour | ||
Q20H | C64511 | Every 20 hours | Every twenty hours. (NCI) | Every Twenty Hours | ||
Q21H | C64512 | Every 21 hours | Every twenty-one hours. (NCI) | Every Twenty-One Hours | ||
Q22H | C64513 | Every 22 hours | Every twenty-two hours. (NCI) | Every Twenty-Two Hours | ||
Q23H | C64514 | Every 23 hours | Every twenty-three hours. (NCI) | Every Twenty-Three Hours | ||
Q24H | C64515 | Every 24 hours | Every twenty-four hours. (NCI) | Every Twenty-Four Hours | ||
Q2H | C64516 | Every 2 hours | Every two hours. (NCI) | Every Two Hours | ||
Q3H | C64517 | Every 3 hours | Every three hours. (NCI) | Every Three Hours | ||
Q4H | C64518 | Every 4 hours | Every four hours. (NCI) | Every Four Hours | ||
Q5H | C64519 | Every 5 hours | Every five hours. (NCI) | Every Five Hours | ||
Q6H | C64520 | Every 6 hours | Every six hours. (NCI) | Every Six Hours | ||
Q7H | C64521 | Every 7 hours | Every seven hours. (NCI) | Every Seven Hours | ||
Q8H | C64523 | Every 8 hours | Every eight hours. (NCI) | Every Eight Hours | ||
Q9H | C64524 | Every 9 hours | Every nine hours. (NCI) | Every Nine Hours | ||
QOD | C64525 | Every other day | Every other day. (NCI) | Every Other Day | ||
TID | C64527 | 3 times per day | Three times per day. (NCI) | Three Times Daily | ||
TIS | C64528 | Three times a week | Three times per week. (NCI) | Three Times Weekly | ||
Q4S | C64529 | Every 4 weeks | Every four weeks. (NCI) | Every Four Weeks | ||
QID | C64530 | 4 times per day | Four times per day. (NCI) | Four Times Daily | ||
QIS | C64531 | 4 times per week | Four times per week. (NCI) | Four Times Weekly | ||
Q3D | C64533 | Every 3 days | Every three days. (NCI) | Every Three Days | ||
Q4D | C64534 | Every 4 days | Every four days. (NCI) | Every Four Days | ||
Q3S | C64535 | Every 3 weeks | Every three weeks. (NCI) | Every Three Weeks | ||
Q2M | C64536 | Every two months | Every two months. (NCI) | Every Two Months | ||
Q3M | C64537 | Every 3 months | Every three months. (NCI) | Every Three Months | ||
Q4M | C64538 | Every 4 months | Every four months. (NCI) | Every Four Months | ||
ONCE | C64576 | Once | A one time intervention. (NCI) | Once | ||
QS | C67069 | Every week;Per Week | Every week. (NCI) | Weekly | ||
Q5D | C71124 | Every 5 days | Every five days. (NCI) | Every Five Days | ||
Q2S | C71127 | Every 2 weeks | Every two weeks. (NCI) | Every Two Weeks | ||
BIM | C71129 | Twice per month | Twice per month. (NCI) | Twice Per Month | ||
INTERMITTENT | C71325 | Intermittent | Periodically stopping and starting. (NCI) | Intermittent | ||
QD | C25473 | Daily | Occurring or done each day. | Daily | ||
OCCASIONAL | C64954 | Occasional | Not occurring regularly or at short intervals. | Infrequent | ||
AD LIBITUM | C64636 | Ad Libitum | As much as desired. | As Much as Desired | ||
1 TIME PER WEEK | C64526 | One Time Per Week | One time per week. (NCI) | Once Weekly | ||
2 TIMES PER YEAR | C98861 | 2 Times Per Year | Two times per year. (NCI) | Two Times Yearly | ||
3 TIMES PER MONTH | C98859 | 3 Times Per Month | Three times per month. (NCI) | Three Times Monthly | ||
3 TIMES PER YEAR | C98860 | 3 Times Per Year | Three times per year. (NCI) | Three Times Yearly | ||
4 TIMES PER MONTH | C98852 | 4 Times Per Month | Four times per month. (NCI) | Four Times Monthly | ||
4 TIMES PER YEAR | C98853 | 4 Times Per Year | Four times per year. (NCI) | Four Times Yearly | ||
5 TIMES PER DAY | C98849 | 5 Times Daily | Five times per day. (NCI) | Five Times Daily | ||
5 TIMES PER MONTH | C98850 | 5 Times Per Month | Five times per month. (NCI) | Five Times Monthly | ||
5 TIMES PER WEEK | C85552 | 5 Times Per Week | Five times per week. (NCI) | Five Times Weekly | ||
5 TIMES PER YEAR | C98851 | 5 Times Per Year | Five times per year. (NCI) | Five Times Yearly | ||
6 TIMES PER DAY | C98855 | 6 Times Daily | Six times per day. (NCI) | Six Times Daily | ||
6 TIMES PER MONTH | C98856 | 6 Times Per Month | Six times per month. (NCI) | Six Times Monthly | ||
6 TIMES PER WEEK | C98857 | 6 Times Per Week | Six times per week. (NCI) | Six Times Weekly | ||
6 TIMES PER YEAR | C98858 | 6 Times Per Year | Six times per year. (NCI) | Six Times Yearly | ||
7 TIMES PER WEEK | C98854 | 7 Times Per Week | Seven times per week. (NCI) | Seven Times Weekly | ||
PA | C74924 | Per Annum;Per Year | A frequency rate of occurrences of something within a period of time equal to three hundred sixty-five days. | Per Year | ||
Q6S | C89788 | Every 6 Weeks | Every six weeks. (NCI) | Every Six Weeks | ||
Back to top | ||||||
CL.C71148.POSITION | Position (POSITION) | text Extensible: Yes | C71148 | Position | Terminology codelist used with Body Position within CDISC. | CDISC SDTM Body Position Terminology |
SITTING | C62122 | Sitting | The state or act of one who sits; the posture of one who occupies a seat. (NCI) | Sitting | ||
PRONE | C62165 | Prone | An anterior recumbent body position whereby the person lies on its stomach and faces downward. (NCI) | Prone Position | ||
STANDING | C62166 | Standing | The act of assuming or maintaining an erect upright position. (NCI) | Standing | ||
SUPINE | C62167 | Supine | A posterior recumbent body position whereby the person lies on its back and faces upward. (NCI) | Supine Position | ||
TRENDELENBURG | C62168 | Trendelenburg | A supine position with the person inclined at an angle of 45 degrees so that the pelvis is higher than the head. (NCI) | Trendelenburg | ||
REVERSE TRENDELENBURG | C62169 | Reverse Trendelenburg | A supine position with the person inclined at an angle of 45 degrees so that the head is higher than the pelvis. (NCI) | Reverse Trendelenburg | ||
RIGHT LATERAL DECUBITUS | C62171 | Right lateral decubitus | A recumbent right lateral side position. (NCI) | Right Lateral Decubitus Position | ||
LEFT LATERAL DECUBITUS | C62172 | Left lateral decubitus | A recumbent left lateral side position. (NCI) | Left Lateral Decubitus Position | ||
FOWLERS | C62173 | Fowlers | A semi-sitting position whereby the head of an adjustable bed is elevated to the desired height, about 60-90 cm, to produce angulation of the body, usually 45 degrees to 60 degrees. Knees may or may not be bent. (NCI) | Fowler's Position | ||
SEMI-FOWLERS | C62174 | Semi-Fowlers | A semi-sitting or semi-reclined body position whereby the head is elevated on an angle of approximately 30 degrees. (NCI) | Semi-Fowler's Position | ||
UNCONSTRAINED | C90480 | Unconstrained | The ability to move body parts and limbs without physical restriction. (NCI) | Unconstrained Body Movement | ||
SLING | C92604 | Sling | A position in which the subject's body is supported by a sling. | Patient in Body Sling | ||
LATERAL DECUBITUS | C100758 | Lateral Decubitus | Lying down on one side. | Lateral Decubitus Position | ||
Back to top | ||||||
CL.C71150.EGSTRESC | ECG Result (EGSTRESC) | text Extensible: Yes | C71150 | ECG Result | Terminology codelist used with ECG Findings and Abnormalities within CDISC. | CDISC SDTM ECG Finding Terminology |
SINUS TACHYCARDIA | C26889 | Sinus tachycardia | A heart rate of more than 100 beats per minute, with its origin in the sinus node. (NCI) | Sinus Tachycardia | ||
SINUS BRADYCARDIA | C26923 | Sinus bradycardia | A heart rate of less than 60 beats per minute, with its origin in the sinus node. (NCI) | Sinus Bradycardia | ||
VENTRICULAR ARRHYTHMIA ASSOCIATED WITH LONG QT SYNDROME | C34786 | Ventricular arrhythmia associated with long QT syndrome | A ventricular arrhythmia characterized by syncopal episodes and a long QT interval, sometimes leading to sudden death due to paroxysmal ventricular arrhythmia. This arrhythmia is associated with a prolongation of repolarization following depolarization of the cardiac ventricles. The prolongation of the Q-T interval combined with torsades de pointes manifests as several different forms; some may be acquired or congenital; some may lead to serious arrhythmia and sudden cardiac death. (NCI) | Long QT Syndrome | ||
PRE-EXCITATION | C34940 | Pre-excitation | A condition characterized by the activation of the whole or some part of the ventricle by the transmission of an atrial impulse along an accessory pathway rather than by way of the normal specific conduction system which includes a delay at the atrioventricular node. (NCI) | Pre-Excitation Syndrome | ||
AV NODE RE-ENTRY | C35058 | AV node re-entry | A supraventricular tachycardia due to reentry along a circuit contained within the AV node. AVNRT is the most common form of supraventricular tachycardia and usually presents as a narrow QRS complex tachycardia at a rate between 150 and 250 beats per minute. (NCI) | Atrioventricular Nodal Reentry Tachycardia | ||
JUNCTIONAL TACHYCARDIA | C35059 | Junctional tachycardia | An automatic tachycardia originating in the atrioventricular junction, typically arising in the conduction tissues surrounding the atrioventricular node. A junctional tachycardia tends to be a regular, narrow complex tachycardia and usually occurs during myocardial infarction, after heart surgery, or in digitalis intoxication. The rate may range from 140 to 250 beats per minute. (NCI) | Junctional Tachycardia | ||
SUPRAVENTRICULAR TACHYCARDIA | C35061 | Supraventricular tachycardia | A generic expression for any tachycardia that originates in the atria or the atrioventricular node. (NCI) | Supraventricular Tachycardia | ||
WOLFF-PARKINSON-WHITE SYNDROME | C35132 | Wolff-Parkinson-White syndrome | A type of ventricular pre-excitation resulting from the activation of an accessory pathway known as the Bundle of Kent. This pathway presents an abnormal electrical communication from the atria to the ventricles. Wolff-Parkinson-White syndrome is characterized by a short PR interval and a long QRS interval with a delta wave. (NCI) | Wolff-Parkinson-White Syndrome | ||
ATRIAL TACHYCARDIA | C35481 | Atrial tachycardia | Any rapid heart rhythm originating in the atria. Atrial fibrillation and atrial flutter are varieties of atrial tachycardia. Atrial tachycardia is an electrical circuit originating in the upper or atrial chambers. This electrical circuit or focus takes over and generates rapid impulses across the atrial chambers. These impulses are transmitted to the ventricular chambers resulting in a rapid rate. These arrhythmias may originate from a variety of places across the atria. They may exist as an isolated problem or be related to an ongoing structural problem within the heart. (NCI) | Atrial Tachycardia | ||
ATRIAL FIBRILLATION | C50466 | Atrial fibrillation | A supraventricular arrhythmia characterized by uncoordinated atrial myocardium activation due to multiple reentry circuits with consequent deterioration of atrial mechanical function. Instead of intermittently contracting, the atria quiver continuously in a chaotic pattern, causing a totally irregular, often tachycardia ventricular rate. On the ECG it is described by the replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in size, shape, and timing, associated with an irregular, frequently rapid ventricular response when atrioventricular conduction is intact. (NCI) | Atrial Fibrillation | ||
3RD DEGREE AV BLOCK | C50501 | 3rd degree AV block | Complete failure of atrial electrical impulse conduction through the AV node to the ventricles. (NCI) | AV Block Third Degree | ||
TORSADES DE POINTES | C50779 | Torsades de pointes | An atypical rapid polymorphic ventricular tachycardia with a characteristic rotation of the QRS complex around the isoelectric baseline. In addition the QRS complex displays a periodic waxing and waning of amplitude on the electrogram. (NCI) | Torsades De Pointes | ||
VENTRICULAR FIBRILLATION | C50799 | Ventricular fibrillation | An arrhythmia characterized by an irregular pattern of high or low-amplitude waves that cannot be differentiated into QRS complexes or T waves. These electrocardiographic waves occur as a result of fibrillary contractions of the ventricular muscle due to rapid repetitive excitation of myocardial fibers without coordinated contraction of the ventricle. (NCI) | Ventricular Fibrillation | ||
VENTRICULAR FLUTTER | C50800 | Ventricular flutter | A ventricular tachyarrhythmia characterized by a high ventricular rate (180 and 250 beats per minute) with a regular rhythm. The electrocardiogram shows large oscillating sine wave-like complexes occurring as a result of QRS complexes and T waves being merged. The P wave is not visible. (NCI) | Ventricular Flutter | ||
VENTRICULAR TACHYCARDIA | C50802 | Ventricular tachycardia | A tachycardia arising distal to bundle of His, with a rate greater than 100 beats per minute. (NCI) | Ventricular Tachycardia | ||
ATRIAL FLUTTER | C51224 | Atrial flutter | An electrocardiographic finding of an organized rhythmic contraction of the atria which is generally at a rate of 200-300 beats per minute. (NCI) | Atrial Flutter | ||
R ON T PHENOMENON | C61395 | R on T phenomenon | An electrocardiographic finding phenomena in which the R wave occurs on top of the T wave; this can trigger ventricular fibrillation or ventricular tachycardia. (NCI) | R On T Phenomenon | ||
1ST DEGREE AV BLOCK | C62015 | 1st degree AV block | A delay in the time required for the conduction of an electrical impulse through the atrioventricular (AV) node beyond 0.2 seconds; prolongation of the PR interval beyond 200 milliseconds. (NCI) | AV Block First Degree | ||
2ND DEGREE AV BLOCK | C62016 | 2nd degree AV block | Intermittent failure of atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles. (NCI) | AV Block Second Degree | ||
VENTRICULAR TACHYCARDIA, MONOMORPHIC | C62234 | Ventricular tachycardia, monomorphic | A ventricular tachycardia in which the ventricular activation sequence is constant. The morphology of the electrocardiographic waveform is unchanging and is referred to as monomorphic. (NCI) | Monomorphic Ventricular Tachycardia | ||
VENTRICULAR TACHYCARDIA, POLYMORPHIC | C62236 | Ventricular tachycardia, polymorphic | A ventricular tachycardia in which the ventricular activation sequence is variable. The morphology of the electrocardiographic waveform is variable and is referred to as polymorphic. (NCI) | Polymorphic Ventricular Tachycardia | ||
SINUS ARRHYTHMIA | C62239 | Sinus arrhythmia | Irregularity of the heartbeat due to a variation in the sinus rhythm resulting in cyclic changes in the heart rate during breathing. This rhythm is most commonly seen with breathing due to fluctuations in parasympathetic vagal tone. During inspiration stretch receptors in the lungs stimulate the cardioinhibitory centers in the medulla via fibers in the vagus nerve. Irregularity of the heartbeat due to a variation in the sinus rhythm resulting in cyclic changes in the heart rate during breathing. This rhythm is most commonly seen with breathing due to fluctuations in parasympathetic vagal tone. During inspiration stretch receptors in the lungs stimulate the cardioinhibitory centers in the medulla via fibers in the vagus nerve. (NCI) | Sinus Arrhythmia | ||
WANDERING ATRIAL PACEMAKER | C62240 | Wandering atrial pacemaker | A condition characterized by the site of origin of impulses, controlling the heart rate, changing within the atria, including the sinus node. Variations within P waves and PR intervals occur and an irregular rate of impulse formation is observed. (NCI) | Wandering Atrial Pacemaker | ||
SINUS ARREST/PAUSE | C62242 | Sinus arrest/pause | A failure of impulse formation in the sinus node. Sinus arrest is indistinguishable from third degree sinoatrial exit block on the standard ECG. (NCI) | Sinus Arrest | ||
SINUS NODE DYSFUNCTION (BRADYCARDIA) | C62243 | Sinus node dysfunction (bradycardia) | A derangement in the normal functioning of the sinoatrial node. Typically, SA node dysfunction is manifest as sinoatrial exit block or sinus arrest, but may present as an absolute or relative bradycardia in the presence of a stressor. It may be associated with bradycardia-tachycardia syndrome. (NCI) | Sinus Node Dysfunction | ||
SICK SINUS SYNDROME | C62244 | Sick sinus syndrome | A constellation of signs and symptoms which may include syncope, fatigue, dizziness, and alternating periods of bradycardia and atrial tachycardia, which is caused by sinoatrial node dysfunction. (NCI) | Sick Sinus Syndrome | ||
ECTOPIC ATRIAL RHYTHM | C62245 | Ectopic atrial rhythm | A cardiac rhythm resulting from either an abnormal electrical focus in the atria or intra-atrial reentry. Atrial ectopic beats (AEB) refer to a contraction of the upper heart chamber which occurs before it would be expected. Atrial ectopic beats are also known as premature atrial beats, premature atrial complex (PAC), or atrial extrasystole. (NCI) | Ectopic Atrial Rhythm | ||
SHORT PR INTERVAL | C62246 | Short PR interval | A PR interval of less than 0.12 seconds. (NCI) | Short PR Interval | ||
PR PROLONGATION | C62247 | PR prolongation | A PR interval of more than 0.20 seconds in adults. (NCI) | Prolonged PR Interval | ||
ISORHYTHMIC DISSOCIATION | C62248 | Isorhythmic dissociation | A type of atrioventricular dissociation characterized by atria and ventricles beating at similar rates, although independently. (NCI) | Isorhythmic Atrioventricular Dissociation | ||
PAROXYSMAL AV BLOCK | C62250 | Paroxysmal AV block | Sudden onset AV block, often associated with preexisting conduction disorders. (NCI) | Paroxysmal Atrioventricular Block | ||
INAPPROPRIATE SINUS TACHYCARDIA | C62253 | Inappropriate sinus tachycardia | Inappropriate sinus tachycardia (IST) is a rare form of supraventricular tachycardia involving the sinus node, in which a patient has an abnormally high heart rate, occurring both at rest and in response to stressors (such as physical activity). (NCI) | Inappropriate Sinus Tachycardia | ||
PREMATURE VENTRICULAR COMPLEX | C62256 | PVC | Ectopic impulses originating in the ventricles. (NCI) | Ventricular Premature Complex | ||
PREMATURE ATRIAL COMPLEXES | C62257 | Premature atrial complexes | Ectopic impulses originating in the atria. (NCI) | Atrial Premature Complex | ||
DELTA WAVE | C62258 | Delta wave | An initial slurring (delta wave) of the QRS complex due to the presence of an accessory pathway. This characteristic EKG pattern is typically seen in Wolff-Parkinson-White syndrome. (NCI) | EKG Delta Wave | ||
VENTRICULAR COUPLET | C62259 | Ventricular couplet | Two sequential ventricular premature complexes. An otherwise normal finding, but possibly indicative of electrical heart disease particularly in comparison with a single ventricular premature complexes. (NCI) | Ventricular Couplet | ||
AV RE-ENTRANT TACHYCARDIA | C62261 | AV re-entrant tachycardia | A supraventricular tachycardia due to reentry along a circuit including a concealed AV nodal bypass tract. This tachycardia circuit proceeds in an antegrade fashion through the AV node and then is conducted retrograde through the bypass tract into the atria. (NCI) | Atrioventricular Reentrant Tachycardia | ||
ACCELERATED IDIOVENTRICULAR RHYTHM | C62266 | Accelerated idioventricular rhythm | The term accelerated idioventricular rhythm describes an ectopic ventricular rhythm with 3 or more consecutive ventricular premature beats with a rate faster than the normal ventricular intrinsic escape rate of 30 to 40 beats per minute, but slower than ventricular tachycardia. Accelerated idioventricular rhythm differs from ventricular tachycardia by additional features such as the onset with a long coupling interval and the end by a gradual decrease of the ventricular rate or increase of the sinus rate. (NCI) | Accelerated Idioventricular Rhythm | ||
LEFT ANTERIOR FASCICULAR BLOCK | C62267 | Left anterior fascicular block | An impairment of transmission of the cardiac electrical impulse along the fibers of the left anterior fascicle. In left anterior fascicular block (LAFB) the posteroinferior regions of the left ventricular endocardium are activated abnormally before the anterosuperior left ventricular area. After emerging from the posteroinferior division of the left bundle branch, the impulse first propagates in an inferior, rightward, and usually anterior direction for a short period of time. This orientation is responsible for the small Q waves in leads 1 and aVL and for the R waves in leads II, III, and aVF. (NCI) | Left Anterior Fascicular Block | ||
LEFT POSTERIOR FASCICULAR BLOCK | C62268 | Left posterior fascicular block | An impairment of transmission of the cardiac electrical impulse along the fibers of the left posterior fascicle. In pure left posterior fascicular block (LPFB), the impulse emerges from the unblocked anterosuperior division, thus producing small q waves in leads II, III, and aVF. Thereafter, the impulse moves through the electrically predominant left ventricle in an inferior and rightward direction, thus explaining the S waves in leads I and aVL as well as the R waves in leads II, III, and aVF. (NCI) | Left Posterior Fascicular Block | ||
LEFT BUNDLE BRANCH BLOCK | C62269 | Left bundle branch block | An impairment of transmission of the cardiac electrical impulse along the fibers of the left main bundle branch, or both the left anterior fascicle and left posterior fascicle. This conduction disturbance is characterized by wide (greater than 0.11s) QRS complexes. The diagnostic criteria consist of prolongation of the QRS complexes (over 0.11s) with neither a Q wave nor an S wave in lead V1 and in the properly placed V6. A wide R wave with a notch on its top (plateau) is seen in these leads. In hearts with an electrical (and anatomic) vertical position a small Q wave may be seen in AVL in the absence of MI. Right chest lead V1 may or may not show an initial R wave, but the latter should be present in lead V2. (NCI) | Left Bundle Branch Block | ||
RIGHT BUNDLE BRANCH BLOCK | C62270 | Right Bundle Branch Block | An impairment of transmission of the cardiac electrical impulse along the fibers of the right bundle branch. A "complete RBBB pattern" (with QRS duration > 0.11s) does not necessarily reflect the existence of a total conduction block in the right branch. This pattern only indicates that the entire or major parts of both ventricles are activated by the impulse emerging from the left branch. Thus, a significant degree of conduction delay ("high-grade" or "incomplete RBBB") can produce a similar pattern. (NCI) | Right Bundle Branch Block | ||
INTRAVENTRICULAR CONDUCTION DELAY, NONSPECIFIC | C62271 | Intraventricular conduction delay, nonspecific | A delay in transmission of cardiac electrical impulses in the His-Purkinje system, diagnosed when the QRS is modestly prolonged (< 120 msec) and the QRS pattern and axis are not typical of a hemiblock. The conduction delay is considered to occur beyond the Purkinje's myocardial gates and arises from slow cell-to-cell conduction. The phenomenon is common in patients with acute MI. (NCI) | Nonspecific Intraventricular Conduction Delay | ||
ST SEGMENT ABNORMALITY | C71026 | ST segment abnormality | An electrocardiographic finding of the ST segment elevation or depression which is not indicative of ischemia or infarction. (NCI) | ST Segment Abnormality | ||
ST DEPRESSION | C71027 | ST depression | An electrocardiographic finding of ST segment depression below the baseline, often described as up sloping, down sloping or horizontal. (NCI) | ST Depression | ||
ST ELEVATION | C71028 | ST elevation | An electrocardiographic finding of ST segment elevation above the baseline. (NCI) | ST Elevation | ||
ST ELEVATION PERICARDITIS | C71029 | ST elevation pericarditis | An electrocardiographic finding of ST changes consistent with pericarditis. (NCI) | ST Elevation Pericarditis | ||
J POINT ELEVATION | C71030 | J point elevation | Elevation of the J point above the baseline; the J point represents the end of ventricular depolarization and located at the terminus of the QRS complex. (NCI) | J Point Elevation | ||
NON-SPECIFIC ST-T CHANGES | C71031 | Non-specific ST-T changes | An electrocardiographic finding of changes in the ST segment and T wave that do not meet criteria for ischemia or infarction. (NCI) | Non-Specific ST-T Changes | ||
NOTCHED T-WAVES | C71032 | Notched T-waves | Any depression occurring in a positive t wave. (NCI) | Notched T-Waves | ||
POOR R WAVE PROGRESSION | C71033 | Poor R Wave Progression | Lack of progression of R wave height across precordial leads. (NCI) | Poor R Wave Progression | ||
PROLONGED QT | C71034 | Prolonged QT | A QT interval that is prolonged. The length of the QT interval varies with the heart rate. (NCI) | Prolonged QT Interval | ||
ELECTRICAL ALTERNANS | C71035 | Electrical alternans | An electrocardiographic finding in which there is an alternating pattern of any of the waveform components. (NCI) | Electrical Alternans | ||
SINOATRIAL EXIT BLOCK | C50553 | Sinoatrial exit block | A blockage of electrical conduction within the sinoatrial node resulting in the failure of impulse transmission from the sinoatrial node. (NCI) | Sinoatrial Node Exit Block | ||
ATRIAL ENLARGEMENT | C71039 | Atrial Enlargement | An electrocardiographic finding which comprises left, right or bilateral atrial enlargement. (NCI) | EKG Finding Atrial Enlargement | ||
LEFT ATRIAL ENLARGEMENT | C71040 | P-mitrale | An electrocardiographic finding suggesting underlying hypertrophy or dilatation of the left atrium. Electrocardiographic criteria used for the diagnosis of left atrial abnormality may include a bifid p wave, a biphasic p wave and/or a p wave duration of greater than 0.12 seconds. (NCI) | P-mitrale | ||
RIGHT ATRIAL ABNORMALITY | C71041 | P-pulmonale | An electrocardiographic finding suggesting underlying hypertrophy or dilatation of the right atrium. Electrocardiographic criteria used for the diagnosis of right atrial abnormality may include a peaked p wave greater than 2.5 millimeters in amplitude in the inferior leads. (NCI) | P-pulmonale | ||
ECTOPIC VENTRICULAR RHYTHM | C71042 | Ectopic ventricular rhythm | A cardiac rhythm resulting from either an abnormal electrical focus in the ventricle. Ventricular ectopic beats (VEB) refer to a contraction of the lower heart chamber which occurs before it would be expected. Ventricular ectopic beats are also known as premature ventricular beats, premature ventricular complex (PVC), or ventricular extrasystole. (NCI) | Ectopic Ventricular Rhythm | ||
ECTOPIC SUPRAVENTRICULAR RHYTHM | C71043 | Ectopic supraventricular rhythm | An electrocardiographic finding of a rhythm originating at a site other than the sinoatrial node, which is also above the atrioventricular node. (NCI) | Ectopic Supraventricular Rhythm | ||
2:1 AV BLOCK | C71044 | 2:1 AV block | A electrocardiographic finding of an electrical phenomenon in which the ratio of electrical impulse generated above the atrioventricular node to the number of impulses conducted through to the ventricles is 2:1. (NCI) | 2:1 Atrioventricular Block | ||
ATRIOVENTRICULAR DISSOCIATION | C71045 | Atrioventricular dissociation | An electrocardiographic finding in which the electrical activity of the atria and ventricles are causally independent of one another. (NCI) | Atrioventricular Dissociation | ||
BIFASCICULAR BLOCK | C71046 | Bifascicular block | An electrocardiographic finding comprising right bundle branch block and left anterior fascicular block, or right bundle branch block and left posterior fascicular block. Defects occurring in two of the three divisions of the conduction system of the heart are considered bifascicular blocks. Technically left bundle branch block may be considered a bifascicular block. (NCI) | Bifascicular Block | ||
INCOMPLETE LEFT BUNDLE BRANCH BLOCK | C71047 | Incomplete left bundle branch block | An partial impairment of transmission of the cardiac electrical impulse along the fibers of the left bundle branch. (NCI) | Incomplete Left Bundle Branch Block | ||
INCOMPLETE RIGHT BUNDLE BRANCH BLOCK | C71048 | Incomplete right bundle branch block | Various mechanisms may result in a pattern showing an incomplete right bundle branch block (RBBB). These include different degrees of conduction delay through the main trunk of the right bundle branch; increased conduction time through an elongated right bundle branch; diffuse Purkinje-myocardial delay due to right ventricular stretch or dilatation; surgical trauma or disease-related interruption of the major ramifications of the right branch (distal RBBB or right fascicular blocks); congenital variations of the distribution of the major ramifications resulting in a slight delay in the activation of the crista supraventricularis. (NCI) | Incomplete Right Bundle Branch Block | ||
INCOMPLETE BUNDLE BRANCH BLOCK | C71049 | Incomplete bundle branch block | An electrocardiographic finding of bundle branch block which does not meet the criteria for a more specific bundle branch block. (NCI) | Incomplete Bundle Branch Block | ||
MULTIFOCAL ATRIAL TACHYCARDIA | C71050 | Multifocal atrial tachycardia | An electrocardiographic finding in which the electrical axis of the p wave is variable and the rate is greater than 100 beats per minute. To meet criteria for multifocal atrial tachycardia, the p wave must exhibit three distinct morphologies on the rhythm strip. (NCI) | Multifocal Atrial Tachycardia | ||
JUNCTIONAL RHYTHM | C71051 | Junctional rhythm | An electrocardiographic finding in which the pacer of the heart is located in the AV junction, normally presenting with a narrow QRS complex and a rate of 60-100 beats per minute. (NCI) | Junctional Rhythm | ||
SUSTAINED VENTRICULAR TACHYCARDIA | C71052 | Sustained ventricular tachycardia | An electrocardiographic finding of ventricular tachycardia greater than 30 seconds in duration. (NCI) | Sustained Ventricular Tachycardia | ||
NON-SUSTAINED VENTRICULAR TACHYCARDIA | C71053 | Non-sustained ventricular tachycardia | An electrocardiographic finding of ventricular tachycardia less than 30 seconds in duration. (NCI) | Non-Sustained Ventricular Tachycardia | ||
BIGEMINY | C71054 | Bigeminy | An electrocardiographic finding of a normal QRS followed by a premature ventricular contraction; a rhythmic pairing of normal and abnormal beats originating in the ventricles in a 1-1 ratio. (NCI) | Bigeminy | ||
TRIGEMINY | C71055 | Trigeminy | An electrocardiographic finding of normal QRS followed by a premature ventricular contraction; a rhythmic pairing of normal and abnormal beats originating from the ventricles in a 1-2 ratio. (NCI) | Trigeminy | ||
VENTRICULAR TACHYCARDIA STORM | C71056 | Ventricular tachycardia storm | Multiple, temporally related, episodes of ventricular tachycardia or fibrillation, occurring three or more times in a 24 hour period. (NCI) | Ventricular Tachycardia Storm | ||
ADENOSINE-SENSITIVE VENTRICULAR TACHYCARDIA | C71057 | Adenosine-sensitive ventricular tachycardia | A condition that occurs as a result of cAMP-mediated triggered activity and typically originates from the right ventricular outflow tract (RVOT). This type of tachycardia occurs in patients with apparently normal hearts. (NCI) | Adenosine-Sensitive Ventricular Tachycardia | ||
VERAPAMIL-SENSITIVE VENTRICULAR TACHYCARDIA | C71058 | Verapamil-sensitive ventricular tachycardia | A well-recognized condition that is believed to result from triggered activity. Despite its uniform response to verapamil, however, this uncommon form of ventricular tachycardia may not be as homogeneous a condition as first believed. (NCI) | Verapamil-Sensitive Ventricular Tachycardia | ||
VENTRICULAR ARRHYTHMIA ASSOCIATED WITH BRUGADA SYNDROME | C71059 | Ventricular arrhythmia associated with Brugada syndrome | A condition characterized by a pattern of right bundle branch block (RBBB) and ST-segment elevation within electrocardiogram (ECG) leads V1-V3 . This pattern emerges as a result of a defect in ion channel genes, resulting in abnormal electrophysiological activity in the right ventricle and a propensity to malignant tachyarrhythmias. (NCI) | Brugada Syndrome | ||
VENTRICULAR ARRHYTHMIA ASSOCIATED WITH SHORT QT SYNDROME | C71060 | Ventricular arrhythmia associated with short QT syndrome | Ventricular tachyarrhythmias occurring in association with short QT syndrome. (NCI) | Short QT Syndrome | ||
FASCICULAR TACHYCARDIA | C71061 | Fascicular tachycardia | A distinct subgroup of idiopathic ventricular tachycardia (VT) that may be confused with either typical VT or supraventricular tachycardia (SVT). It is characterized by the absence of structural heart disease and classic electrocardiographic and electrophysiological features. It originates from the region of the posterior fascicle (or occasionally the anterior fascicle) of the left bundle branch and is partly propagated by the His-Purkinje network. It therefore produces QRS complexes of relatively short duration (0.11-0.14)s. (NCI) | Fascicular Tachycardia | ||
BUNDLE BRANCH REENTRANT TACHYCARDIA | C71062 | Bundle branch reentrant tachycardia | An uncommon form of ventricular tachycardia (VT) incorporating both bundle branches into the reentry circuit. Surface electrocardiogram (ECG) of sinus rhythm (SR) characteristically shows intraventricular conduction defects. Patients typically present with presyncope, syncope or sudden death because of VT with fast rates frequently above 200 beats per minute. The QRS morphology during VT is a typical bundle branch block pattern, usually left bundle branch block, and may be identical to that in SR. (NCI) | Bundle Branch Re-Entrant Ventricular Tachycardia | ||
IDIOPATHIC RIGHT BUNDLE BRANCH BLOCK VENTRICULAR TACHYCARDIA | C71063 | Idiopathic right bundle branch block ventricular tachycardia | Idiopathic ventricular tachycardia (VT) is a type of ventricular tachycardia occurring unrelated to any organic cardiac disease. The abnormality is probably congenital, be it a focus of abnormal automaticity or myocardial tissue that can sustain re-entry. The clinical presentation for idiopathic VT can be very much like a paroxysmal supraventricular tachycardia. That is, most patients are generally younger without overt cardiac disease and present with paroxysmal palpitations. Idiopathic ventricular tachycardia is not generally life-threatening. (NCI) | Idiopathic Right Bundle Branch Block | ||
OUTFLOW TRACT VENTRICULAR TACHYCARDIA | C71064 | Outflow tract ventricular tachycardia | Right ventricular outflow tract tachycardia (RVOT) is the most common with a female predominance. It is often exercise induced or enhanced. The site of origin is the right ventricular outflow tract and hence the electrocardiographic appearance is that of left bundle branch block and inferior axis. The mechanism is thought to be abnormal automaticity that is sensitive to adenosine. (NCI) | Right Ventricular Outflow Tract Tachycardia | ||
ACUTE ANTERIOR WALL MI | C71065 | Acute Anterior Wall Myocardial Infarction | Electrocardiographic finding showing a current of injury in leads corresponding to the anatomic region of the anterior wall of the heart. (NCI) | Acute Anterior Wall Myocardial Infarction | ||
ACUTE INFERIOR WALL MI | C71066 | Acute Inferior Wall Myocardial Infarction | Electrocardiographic finding showing a current of injury in leads corresponding to the anatomic region of the inferior wall of the heart. (NCI) | Acute Inferior Wall Myocardial Infarction | ||
ACUTE LATERAL WALL MI | C71067 | Acute Lateral Wall Myocardial Infarction | Electrocardiographic finding showing a current of injury in leads corresponding to the anatomic region of the lateral wall of the heart. (NCI) | Acute Lateral Wall Myocardial Infarction | ||
ACUTE POSTERIOR WALL MI | C71068 | Acute Posterior Wall Myocardial Infarction | Electrocardiographic finding showing a current of injury in leads corresponding to the anatomic region of the posterior wall of the heart. (NCI) | Acute Posterior Wall Myocardial Infarction | ||
ANTERIOR WALL MYOCARDIAL INFARCTION | C71069 | Anterior Wall Myocardial Infarction | Electrocardiographic finding showing an injury in leads corresponding to the anatomic region of the anterior wall of the heart. (NCI) | Anterior Wall Myocardial Infarction | ||
INFERIOR WALL MYOCARDIAL INFARCTION | C71070 | Inferior Wall Myocardial Infarction | Electrocardiographic finding showing an injury in leads corresponding to the anatomic region of the inferior wall of the heart. (NCI) | Inferior Wall Myocardial Infarction | ||
INTRAATRIAL CONDUCTION DELAY | C71073 | Intraatrial Conduction Delay | A delay in impulse propagation through the atria. (NCI) | Intra-Atrial Conduction Delay | ||
JUNCTIONAL BRADYCARDIA | C71074 | Junctional bradycardia | An electrocardiographic finding in which the pacer of the heart is located in the AV junction, normally presenting with a narrow QRS complex at a rate less than 60 beats per minute. (NCI) | Junctional Bradycardia | ||
LATERAL WALL MYOCARDIAL INFARCTION | C71075 | Lateral Wall Myocardial Infarction | Electrocardiographic finding showing an injury in leads corresponding to the anatomic region of the lateral wall of the heart. (NCI) | Lateral Wall Myocardial Infarction | ||
LEFT VENTRICULAR HYPERTROPHY | C71076 | Left Ventricular Hypertrophy | Electrocardiographic findings suggestive of a hypertrophic left ventricle. (NCI) | EKG Finding Left Ventricular Hypertrophy | ||
RIGHT VENTRICULAR HYPERTROPHY | C71077 | Right ventricular Hypertrophy | Electrocardiographic findings suggestive of an enlarged right ventricle. (NCI) | EKG Finding Right Ventricular Hypertrophy | ||
LOW QRS VOLTAGE | C71078 | Low QRS voltage | An electrocardiographic finding of a QRS amplitude less than or equal to 5mm in the limb leads or QRS amplitude less than or equal to 10mm in the precordial leads. (NCI) | Low QRS Voltage | ||
NON Q WAVE MYOCARDIAL INFARCTION | C71080 | Non Q Wave Myocardial Infarction | A myocardial infarction in the absence of observable Q wave abnormalities in the ECG. (NCI) | Non Q Wave Myocardial Infarction | ||
POSTERIOR WALL MYOCARDIAL INFARCTION | C71081 | Posterior Wall Myocardial Infarction | Electrocardiographic finding showing an injury in leads corresponding to the anatomic region of the posterior wall of the heart. (NCI) | Posterior Wall Myocardial Infarction | ||
SEPTAL MYOCARDIAL INFARCTION | C71082 | Septal myocardial infarction | Electrocardiographic findings suggesting an infarction in the anatomic location of the cardiac septum. (NCI) | Septal Myocardial Infarction | ||
T WAVE ABNORMALITY | C71083 | T wave abnormality | An electrocardiographic finding of a T wave which appears peaked, inverted, flattened or biphasic. (NCI) | T Wave Abnormality | ||
VENTRICULAR HYPERTROPHY | C71084 | Ventricular Hypertrophy | Electrocardiographic findings suggestive of enlarged cardiac ventricles. (NCI) | Ventricular Hypertrophy | ||
T WAVE INVERSION | C71085 | T Wave Inversion | An electrocardiographic finding of an inversion of the T wave from the expected axis. (NCI) | T Wave Inversion | ||
T WAVE PEAKED | C71086 | T wave peaked | An electrocardiographic finding in which the T wave appears increased in amplitude and cresting at a point. (NCI) | T Wave Peaked | ||
T WAVES BIPHASIC | C71087 | T waves biphasic | An electrocardiographic finding in which the T wave is asymmetric. (NCI) | T Waves Biphasic | ||
T WAVES FLAT | C71088 | T waves flat | An electrocardiographic finding in which the T wave appears decreased in amplitude. (NCI) | T Waves Flat | ||
U WAVES | C71089 | U waves | An electrocardiographic finding of a small hump following the T wave occurring during the final phase of Purkinje repolarization. (NCI) | U Waves | ||
WIDE QRS TACHYCARDIA | C71090 | Wide QRS tachycardia | An electrocardiographic finding of a QRS complex. (NCI) | Wide QRS Tachycardia | ||
Q AXIS, LEFT AXIS DEVIATION | C71094 | Q Axis, Left axis deviation | Q axis from -30 to -90 degrees. (NCI) | Q Axis Left Axis Deviation | ||
Q AXIS, RIGHT AXIS DEVIATION | C71095 | Q Axis, Right axis deviation | Q axis from +90 to +180 degrees. (NCI) | Q Axis Right Axis Deviation | ||
QTCB PROLONGATION >500 MSEC | C71096 | QTcB prolongation >500 msec | Corrected QT interval longer than 500 msec, in accordance with Bazett's correction formula. (NCI) | QTcB Prolongation Greater Than 500 msec | ||
QTCF PROLONGATION >500 MSEC | C71097 | QTcF prolongation >500 msec | Corrected QT interval greater than 500 msec, in accordance with Fridericia's correction formula. (NCI) | QTcF Prolongation Greater Than 500 msec | ||
AV MOBITZ I | C83811 | AV Mobitz I | Intermittent failure of atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles, characterized by a progressively lengthening PR interval prior to the block of an atrial impulse. | AV Mobitz I | ||
AV MOBITZ II | C83812 | AV Mobitz II | Intermittent failure of atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles, characterized by a relatively constant PR interval prior to the block of an atrial impulse. | AV Mobitz II | ||
PACED RHYTHM | C88140 | Paced Rhythm;Atrial and/or Ventricular Paced Rhythm | An electrocardiographic finding in which the cardiac rhythm is controlled by an electrical impulse from a mechanical cardiac pacemaker. | Paced Rhythm | ||
BORDERLINE QTcB | C92228 | Borderline QTcB | An electrocardiographic finding in which the QTcB is approximately 430-470 msec. There is variation among subpopulations. | Borderline QTcB | ||
BORDERLINE QTcF | C92229 | Borderline QTcF | An electrocardiographic finding in which the QTcF is approximately 430-470 msec. There is variation among subpopulations. | Borderline QTcF | ||
EARLY R WAVE PROGRESSION | C92230 | Early R Wave Progression | An electrocardiographic finding in which the amplitude of the R wave is abnormally increased in the anterior precordial leads. | Early R Wave Progression | ||
LEFT VENTRICULAR CONDUCTION DELAY | C92231 | Left Ventricular Conduction Delay | An electrocardiographic finding in which there is evidence that electrical transmission through the left ventricle is impaired. | Left Ventricular Conduction Delay | ||
PACED ATRIAL AND VENTRICULAR RHYTHM | C92232 | Paced Atrial And Ventricular Rhythm | An electrocardiographic finding in which both the atrial and ventricular rhythm is controlled by an electrical impulse from a mechanical cardiac pacemaker. | Paced Atrial And Ventricular Rhythm | ||
PACED ATRIAL RHYTHM | C92233 | Paced Atrial Rhythm | An electrocardiographic finding in which the atrial rhythm is controlled by an electrical impulse from a mechanical cardiac pacemaker. | Paced Atrial Rhythm | ||
PACED VENTRICULAR RHYTHM | C92234 | Paced Ventricular Rhythm | An electrocardiographic finding in which the ventricular rhythm is controlled by an electrical impulse from a mechanical cardiac pacemaker. | Paced Ventricular Rhythm | ||
RIGHT VENTRICULAR CONDUCTION DELAY | C92235 | Right Ventricular Conduction Delay;Right Ventricular Delay | An electrocardiographic finding in which there is evidence that electrical transmission through the right ventricle is impaired. | Right Ventricular Conduction Delay | ||
RSR PRIME | C92227 | RSR' | An electrocardiographic finding in which there are two R waves, which are two deflections above the baseline resulting from a single ventricular depolarization. The first upward deflection in the complex is the R wave. The S is the first downward deflection. A second upward deflection is called the R-prime wave. | RSR' | ||
BRADYCARDIA | C37920 | Bradycardia | Non-sinus origin slow heart rate. | Bradycardia | ||
P WAVE ABNORMALITY | C90430 | P Wave Abnormality | An electrocardiographic finding for the P wave that is atypical either for the shape, duration, amplitude, axis or polarity. Abnormality of the P wave signifies aberrant propagation of the electrical impulse through the atria. (NCI) | P Wave Abnormality | ||
P WAVE NOTCHED | C90431 | P Wave Notched | P waves with two peaks longer in duration than normal and amplitude greater than normal. (NCI) | P Wave Notched | ||
PAROXYSMAL VENTRICULAR TACHYCARDIA | C34902 | Paroxysmal Ventricular Tachycardia | An episodic form of ventricular tachycardia, with abrupt onset and termination. (NCI) | Paroxysmal Ventricular Tachycardia | ||
QRS COMPLEX ABNORMALITY | C90440 | QRS Complex Abnormality | An electrocardiographic finding for the QRS complex that is atypical either for the shape, duration, amplitude, axis or polarity. (NCI) | QRS Complex Abnormality | ||
QRS COMPLEX ABSENT | C90441 | QRS Complex Absent | A disturbance in the depolarization of the ventricular myocardium which leads to an absence of the QRS complex in the electrocardiogram tracing. (NCI) | QRS Complex Absent | ||
R WAVE ABNORMALITY | C90443 | R Wave Abnormality | An abnormal R wave that is part of the QRS complex in an electrocardiographic recording, which occurs due to a disturbance in the depolarization mechanism of the ventricular myocardium. (NCI) | R Wave Abnormality | ||
R WAVE NOTCHED | C90444 | R Wave Notched | An R wave variant in which there is a small deflection of the R wave, with changing polarity, within the QRS complex. (NCI) | R Wave Notched | ||
RESPIRATORY SINUS ARRHYTHMIA | C90450 | Respiratory Sinus Arrhythmia | The inherent change of a subject's heart rate associated with each excursion of breath, which can be traced in an electrocardiographic recording. (NCI) | Respiratory Sinus Arrhythmia | ||
S WAVE ABNORMALITY | C90451 | S Wave Abnormality | An abnormal S wave that is part of the QRS complex in an electrocardiographic recording, which occurs due to a disturbance in the depolarization of the ventricular myocardium. (NCI) | S Wave Abnormality | ||
TACHYCARDIA | C38029 | Tachycardia | An abnormally rapid heartbeat, usually applied to a heart rate above 100 per minute. | Tachycardia | ||
VENTRICULAR ESCAPE BEAT | C90483 | Ventricular Escape Beat | A compensatory ectopic beat that occurs in the ventricle after a pause in the ventricular rhythm, which is due to an absence in electrical activity to the ventricles. (NCI) | Ventricular Escape Beat | ||
Back to top | ||||||
CL.C71153.EGTESTCD | ECG Test Code (EGTESTCD) | text Extensible: Yes | C71153 | ECG Test Code | Terminology codelist used with ECG Tests within CDISC. | CDISC SDTM ECG Test Terminology by Code |
HRMAX | C39779 | Summary (Max) Heart Rate | The minimum time between successive cycles of contraction and subsequent relaxation of the heart, usually expressed as beats per minute, obtained from a set of measurements of the heart rate. (NCI) | Maximum Heart Rate | ||
PRMEAN | C62086 | Summary (Mean) PR Duration | The average (mean) duration (time) of the PR interval, obtained from a set of measurements of the PR interval. The PR interval is defined as the time from the beginning of the P wave (representing the onset of atrial depolarization) to the beginning of the R wave (representing the onset of ventricular depolarization). In some cases, a Q wave will precede the R wave, in which case the PR interval is measured from the beginning of the P wave to the beginning of the Q wave. (NCI) | EKG Mean PR Duration | ||
QRSDUR | C62087 | Summary (Mean) QRS Duration | The average (mean) duration (time) of the QRS interval, obtained from a set of measurements of the QRS interval. The QRS interval is defined as the time from the beginning of the QRS complex to the end of the QRS complex, representing the time it takes for the ventricles to depolarize. (NCI) | EKG Mean QRS Duration | ||
QTMEAN | C62089 | Summary (Mean) QT Duration | The average (mean) duration (time) of the QT interval, obtained from a set of measurements of the QT interval. The QT interval is defined as the time from the beginning of the QRS complex to the end of the T wave, representing the time it takes for the ventricles to depolarize and subsequently repolarize. In some cases, the Q wave will be absent, in which case the QT interval is measured from the beginning of the R wave to the end of the T wave. (NCI) | EKG Mean QT Duration | ||
RRMEAN | C62090 | Summary (Mean) RR Duration | The average (mean) duration (time) of the RR interval, obtained from a set of measurements of the RR interval. The RR interval is defined as the time between successive peaks of the R wave and can be used to measure the ventricular rate. (NCI) | EKG Mean RR Duration | ||
RRMIN | C62093 | Summary (Min) RR Duration | The minimum duration (time) between successive peaks of R waves in a particular set of RR intervals. (NCI) | EKG Minimum RR Duration | ||
RRMAX | C62094 | Summary (Max) RR Duration | The maximum duration (time) between successive peaks of R waves in a particular set of RR intervals. (NCI) | EKG Maximum RR Duration | ||
HRMEAN | C62095 | Summary (Mean) Heart Rate | The average (mean) number of cycles of contraction and subsequent relaxation of the heart, usually expressed as beats per minute, obtained from a set of measurements of the heart rate. (NCI) | Mean Heart Rate | ||
HRMIN | C62096 | Summary (Min) Heart Rate | The maximum time between successive cycles of contraction and subsequent relaxation of the heart, usually expressed as beats per minute, obtained from a set of measurements of the heart rate. (NCI) | Minimum Heart Rate | ||
QTCB | C62112 | QTcB - Bazett's Correction Formula | A formula which takes into account the physiologic shortening of the QT interval which occurs as the heart rate increases, permitting comparison of the QT interval across a range of rates. It is mathematically defined as: QTcB = QT/SqRootRR(seconds) and theoretically corrects the QT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | QTcB-Bazett's Correction Formula | ||
QTCF | C62113 | QTcF - Fridericia's Correction Formula | A formula which takes into account the physiologic shortening of the QT interval which occurs as the heart rate increases, permitting comparison of the QT interval across a range of rates. It is mathematically defined as: QTcF = QT/CubeRootRR(seconds) and theoretically corrects the QT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | QTcF-Fridericia's Correction Formula | ||
QTCLC | C62114 | QTcLC - Linear Correction Formula | A formula which takes into account the physiologic shortening of the QT interval which occurs as the heart rate increases, permitting comparison of the QT interval across a range of rates. The linear correction formula uses population-based data obtained and validated using a large cohort of subjects. This method theoretically corrects the QT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | QTcLC-Linear Correction Formula | ||
JTMEAN | C62115 | Summary (Mean) JT Interval | The average (mean) duration (time) of the JT interval, obtained from a set of measurements of the JT interval. The JT interval is defined as the time from the J point (end of ventricular depolarization, the point at which the QRS meets the ST segment) to the end of the T wave (representing the end of ventricular repolarization). (NCI) | EKG Mean JT Duration | ||
JTMIN | C62116 | Summary (Min) JT Interval | The minimum duration (time) of the JT interval, obtained from a set of measurements of the JT interval. The JT interval is defined as the time from the J point (end of ventricular depolarization, the point at which the QRS meets the ST segment) to the end of the T wave (representing the end of ventricular repolarization). (NCI) | EKG Minimum JT Duration | ||
JTMAX | C62117 | Summary (Max) JT Interval | The maximum duration (time) of the JT interval, obtained from a set of measurements of the JT interval. The JT interval is defined as the time from the J point (end of ventricular depolarization, the point at which the QRS meets the ST segment) to the end of the T wave (representing the end of ventricular repolarization). (NCI) | EKG Maximum JT Duration | ||
JTCB | C62118 | JTcB - Bazett's Correction Formula | A formula which takes into account the physiologic shortening of the JT interval which occurs as the heart rate increases, permitting comparison of the JT interval across a range of rates. It is mathematically defined as: JTcB = JT/SqRootRR(seconds) and theoretically corrects the JT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | JTcB-Bazett's Correction Formula | ||
JTCF | C62119 | JTcF - Fridericia's Correction Formula | A formula which takes into account the physiologic shortening of the JT interval which occurs as the heart rate increases, permitting comparison of the JT interval across a range of rates. It is mathematically defined as: JTcF = JT/CubeRootRR(seconds) and theoretically corrects the JT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | JTcF-Fridericia's Correction Formula | ||
JTCLC | C62120 | JTcLC - Linear Correction Formula | A formula which takes into account the physiologic shortening of the JT interval which occurs as the heart rate increases, permitting comparison of the JT interval across a range of rates. The linear correction formula uses population-based data obtained and validated using a large cohort of subjects. Using this method, the corrected JT interval is independent of the ventricular rate. (NCI) | JTcLC-Linear Correction Formula | ||
PAXIS | C62121 | Summary (Mean) P Axis | The mean (average) direction (range -180 degrees to 180 degrees) of the electrical potential generated by atrial depolarization in a particular plane (usually the frontal plane). (NCI) | EKG Mean P Axis | ||
PWAVEDUR | C62123 | Summary (Mean) P Wave Duration | The average (mean) duration (time) from the onset of atrial depolarization to the completion of atrial depolarization (length of the P wave), obtained from a set of measurements of the time from beginning to end of atrial depolarization. (NCI) | EKG Mean P Wave Duration | ||
PWAVEHT | C62124 | Summary (Mean) P Wave Height | The average (mean) height (usually measured in mm) of the maximum deflection from baseline of the P wave (representing atrial depolarization), obtained from a set of measurements of the P wave, from a single lead or set of leads. Typically this measurement is obtained by analysis of Lead II. (NCI) | EKG Mean P Wave Height | ||
PRMIN | C62125 | Summary (Min) PR Duration | The minimum duration (time) of the PR interval, obtained from a set of measurements of the PR interval. The PR interval is defined as the time from the beginning of the P wave (representing the onset of atrial depolarization) to the beginning of the R wave (representing the onset of ventricular depolarization). In some cases, a Q wave will precede the R wave, in which case the PR interval is measured from the beginning of the P wave to the beginning of the Q wave. (NCI) | EKG Minimum PR Duration | ||
PRMAX | C62131 | Summary (Max) PR Duration | The maximum duration (time) of the PR interval, obtained from a set of measurements of the PR interval. The PR interval is defined as the time from the beginning of the P wave (representing the onset of atrial depolarization) to the beginning of the R wave (representing the onset of ventricular depolarization). In some cases, a Q wave will precede the R wave, in which case the PR interval is measured from the beginning of the P wave to the beginning of the Q wave. (NCI) | EKG Maximum PR Duration | ||
QRSAXIS | C62132 | Summary (Mean) QRS Axis | The mean (average) direction of the electrical potential generated by ventricular depolarization. (NCI) | Mean QRS Axis | ||
QTMIN | C62133 | Summary (Min) QT Duration | The minimum duration (time) of the QT interval, obtained from a set of measurements of the QT interval. The QT interval is defined as the time from the beginning of the QRS complex to the end of the T wave, representing the time it takes for the ventricles to depolarize and subsequently repolarize. In some cases, the Q wave will be absent, in which case the QT interval is measured from the beginning of the R wave to the end of the T wave. (NCI) | Minimum QT Duration | ||
QTMAX | C62135 | Summary (Max) QT Duration | The maximum duration (time) of the QT interval, obtained from a set of measurements of the QT interval. The QT interval is defined as the time from the beginning of the QRS complex to the end of the T wave, representing the time it takes for the ventricles to depolarize and subsequently repolarize. In some cases, the Q wave will be absent, in which case the QT interval is measured from the beginning of the R wave to the end of the T wave. (NCI) | EKG Maximum QT Duration | ||
RWAVEAMP | C62136 | Summary (Mean) R Wave Amplitude | The average (mean) amplitude (usually in mm) of the R wave, obtained from a set of measurements of the R wave, in a particular lead or set of leads. (NCI) | EKG Mean R Wave Amplitude | ||
SWAVEAMP | C62137 | Summary (Mean) S Wave Amplitude | The average (mean) amplitude (usually in mm) of the S wave, obtained from a set of measurements of the S wave, in a particular lead or set of leads. (NCI) | EKG Mean S Wave Amplitude | ||
RSAMP | C62144 | Summary (Mean) R+S Amplitude | The average (mean) amplitude (usually in mm) of the summation of the R and S waves, obtained from a set of measurements of the R and S waves, in a particular lead or set of leads. (NCI) | EKG Mean R+S Amplitude | ||
STSEGDUR | C62145 | Summary (Mean) ST Segment Duration | The duration (time) of the ST segment, measured from the J point at the end of the QRS complex to the beginning of the T wave. (NCI) | EKG Mean ST Segment Duration | ||
TAXIS | C62146 | Summary (Mean) T Wave Axis | The mean (average) direction of the electrical potential generated by ventricular repolarization. (NCI) | EKG Mean T Wave Axis | ||
TWAVEDUR | C62147 | Summary (Mean) T Wave Duration | The average (mean) duration (time) from the onset of ventricular repolarization to the completion of ventricular repolarization (length of the T wave), obtained from a set of measurements of the time from beginning to end of ventricular repolarization. (NCI) | EKG Mean T Wave Duration | ||
TWAVAREA | C62148 | Summary (Mean) T Wave Area | The average (mean) area under the curve of the deflection from baseline of the T wave (representing ventricular repolarization), obtained from a set of measurements of the T wave, from a single lead or set of leads. (NCI) | EKG Mean T Wave Area | ||
TWAVEHT | C62149 | Summary (Mean) T Wave Height | The average (mean) height (usually measured in mm) of the maximum deflection from baseline of the T wave (representing ventricular repolarization), obtained from a set of measurements of the T wave, from a single lead or set of leads. (NCI) | EKG Mean T Wave Height | ||
VRMEAN | C62152 | Summary (Mean) Ventricular Rate | The average (mean) number of cycles of contraction and subsequent relaxation of the ventricles, usually expressed as beats per minute, obtained from a set of measurements of the ventricular rate. (NCI) | Mean Ventricular Heart Rate | ||
VRMIN | C62153 | Summary (Min) Ventricular Rate | The minimum time between successive cycles of contraction and subsequent relaxation of the ventricles, usually expressed as beats per minute, obtained from a set of measurements of the ventricular rate. (NCI) | Minimum Ventricular Heart Rate | ||
VRMAX | C62154 | Summary (Max) Ventricular Rate | The maximum time between successive cycles of contraction and subsequent relaxation of the ventricles, usually expressed as beats per minute, obtained from a set of measurements of the ventricular rate. (NCI) | Maximum Ventricular Heart Rate | ||
STDVMEAN | C62155 | Summary (Mean) ST Deviation | The average (mean) deviation (distance from baseline, positive or negative, usually measured in mm) of the ST segment, obtained from a set of measurements of the deviation of the ST segment. (NCI) | EKG Mean ST Deviation | ||
STDVMIN | C62156 | Summary (Min) ST Deviation | The minimum deviation (distance from baseline, positive or negative, usually measured in mm) of the ST segment, obtained from a set of measurements of the deviation of the ST segment. (NCI) | EKG Minimum ST Deviation | ||
STDVMAX | C62157 | Summary (Max) ST Deviation | The maximum deviation (distance from baseline, positive or negative, usually measured in mm) of the ST segment, obtained from a set of measurements of the deviation of the ST segment. (NCI) | EKG Maximum ST Deviation | ||
STELMEAN | C62158 | Summary (Mean) ST Elevation | The average (mean) elevation (positive deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the elevation of the ST segment. (NCI) | EKG Mean ST Segment Elevation | ||
STELMIN | C62159 | Summary (Min) ST Elevation | The minimum elevation (positive deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the elevation of the ST segment. (NCI) | EKG Minimum ST Segment Elevation | ||
STELMAX | C62160 | Summary (Max) ST Elevation | The maximum elevation (positive deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the elevation of the ST segment. (NCI) | EKG Maximum ST Segment Elevation | ||
STDPMEAN | C62161 | Summary (Mean) ST Depression | The average (mean) depression (negative deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the depression of the ST segment. (NCI) | EKG Mean ST Segment Depression | ||
STDPMIN | C62162 | Summary (Min) ST Depression | The minimum depression (negative deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the depression of the ST segment. (NCI) | EKG Minimum ST Segment Depression | ||
STDPMAX | C62163 | Summary (Max) ST Depression | The maximum depression (negative deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the depression of the ST segment. (NCI) | EKG Maximum ST Segment Depression | ||
QTCV | C90442 | QTcV - Van de Water's Correction Formula | A mathematic formula defined as: QTcV = QT-0.087[(60/Heart Rate)-1](seconds). It permits comparison of the QT interval across a range of rates, while accounting for the progressive shortening of the QT interval which occurs as the heart rate increases. (NCI) | QTcV Van de Water's Correction Formula | ||
INTP | C41255 | Interpretation | An act or process of elucidation; explication, or explanation of the meaning of the event or thing via the assignment of objects from the domain to the constants of a formal language, truth-values to the proposition symbols, truth-functions to the connectives, other functions to the function symbols, and extensions to the predicates, if any. The assignments are result of human logic application and are not native to the symbols of the formal language. | Interpretation | ||
QRSDURVP | C100390 | QRS Duration Ventricular Paced | The average (mean) duration (time) of the QRS interval, obtained from a set of measurements of the QRS interval while the ventricle rhythm is controlled by an electrical impulse from a mechanical cardiac pacemaker. The QRS interval is defined as the time from the beginning of the QRS complex to the end of the QRS complex, representing the time it takes for the ventricles to depolarize. | EKG Mean QRS Duration Ventricular Paced | ||
QTC | C100391 | QT Interval, Corrected | The time interval between the start of the Q wave and the end of the T wave in the cardiac cycle as corrected with a non-specified correction formula. | Corrected QT Interval | ||
Back to top | ||||||
CL.C71152.EGTEST | ECG Test Name (EGTEST) | text Extensible: Yes | C71152 | ECG Test Name | Terminology codelist used with ECG Test Names within CDISC. | CDISC SDTM ECG Test Name Terminology |
Summary (Max) Heart Rate | C39779 | Summary (Max) Heart Rate | The minimum time between successive cycles of contraction and subsequent relaxation of the heart, usually expressed as beats per minute, obtained from a set of measurements of the heart rate. (NCI) | Maximum Heart Rate | ||
Summary (Mean) PR Duration | C62086 | Summary (Mean) PR Duration | The average (mean) duration (time) of the PR interval, obtained from a set of measurements of the PR interval. The PR interval is defined as the time from the beginning of the P wave (representing the onset of atrial depolarization) to the beginning of the R wave (representing the onset of ventricular depolarization). In some cases, a Q wave will precede the R wave, in which case the PR interval is measured from the beginning of the P wave to the beginning of the Q wave. (NCI) | EKG Mean PR Duration | ||
Summary (Mean) QRS Duration | C62087 | Summary (Mean) QRS Duration | The average (mean) duration (time) of the QRS interval, obtained from a set of measurements of the QRS interval. The QRS interval is defined as the time from the beginning of the QRS complex to the end of the QRS complex, representing the time it takes for the ventricles to depolarize. (NCI) | EKG Mean QRS Duration | ||
Summary (Mean) QT Duration | C62089 | Summary (Mean) QT Duration | The average (mean) duration (time) of the QT interval, obtained from a set of measurements of the QT interval. The QT interval is defined as the time from the beginning of the QRS complex to the end of the T wave, representing the time it takes for the ventricles to depolarize and subsequently repolarize. In some cases, the Q wave will be absent, in which case the QT interval is measured from the beginning of the R wave to the end of the T wave. (NCI) | EKG Mean QT Duration | ||
Summary (Mean) RR Duration | C62090 | Summary (Mean) RR Duration | The average (mean) duration (time) of the RR interval, obtained from a set of measurements of the RR interval. The RR interval is defined as the time between successive peaks of the R wave and can be used to measure the ventricular rate. (NCI) | EKG Mean RR Duration | ||
Summary (Min) RR Duration | C62093 | Summary (Min) RR Duration | The minimum duration (time) between successive peaks of R waves in a particular set of RR intervals. (NCI) | EKG Minimum RR Duration | ||
Summary (Max) RR Duration | C62094 | Summary (Max) RR Duration | The maximum duration (time) between successive peaks of R waves in a particular set of RR intervals. (NCI) | EKG Maximum RR Duration | ||
Summary (Mean) Heart Rate | C62095 | Summary (Mean) Heart Rate | The average (mean) number of cycles of contraction and subsequent relaxation of the heart, usually expressed as beats per minute, obtained from a set of measurements of the heart rate. (NCI) | Mean Heart Rate | ||
Summary (Min) Heart Rate | C62096 | Summary (Min) Heart Rate | The maximum time between successive cycles of contraction and subsequent relaxation of the heart, usually expressed as beats per minute, obtained from a set of measurements of the heart rate. (NCI) | Minimum Heart Rate | ||
QTcB - Bazett's Correction Formula | C62112 | QTcB - Bazett's Correction Formula | A formula which takes into account the physiologic shortening of the QT interval which occurs as the heart rate increases, permitting comparison of the QT interval across a range of rates. It is mathematically defined as: QTcB = QT/SqRootRR(seconds) and theoretically corrects the QT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | QTcB-Bazett's Correction Formula | ||
QTcF - Fridericia's Correction Formula | C62113 | QTcF - Fridericia's Correction Formula | A formula which takes into account the physiologic shortening of the QT interval which occurs as the heart rate increases, permitting comparison of the QT interval across a range of rates. It is mathematically defined as: QTcF = QT/CubeRootRR(seconds) and theoretically corrects the QT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | QTcF-Fridericia's Correction Formula | ||
QTcLC - Linear Correction Formula | C62114 | QTcLC - Linear Correction Formula | A formula which takes into account the physiologic shortening of the QT interval which occurs as the heart rate increases, permitting comparison of the QT interval across a range of rates. The linear correction formula uses population-based data obtained and validated using a large cohort of subjects. This method theoretically corrects the QT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | QTcLC-Linear Correction Formula | ||
Summary (Mean) JT Interval | C62115 | Summary (Mean) JT Interval | The average (mean) duration (time) of the JT interval, obtained from a set of measurements of the JT interval. The JT interval is defined as the time from the J point (end of ventricular depolarization, the point at which the QRS meets the ST segment) to the end of the T wave (representing the end of ventricular repolarization). (NCI) | EKG Mean JT Duration | ||
Summary (Min) JT Interval | C62116 | Summary (Min) JT Interval | The minimum duration (time) of the JT interval, obtained from a set of measurements of the JT interval. The JT interval is defined as the time from the J point (end of ventricular depolarization, the point at which the QRS meets the ST segment) to the end of the T wave (representing the end of ventricular repolarization). (NCI) | EKG Minimum JT Duration | ||
Summary (Max) JT Interval | C62117 | Summary (Max) JT Interval | The maximum duration (time) of the JT interval, obtained from a set of measurements of the JT interval. The JT interval is defined as the time from the J point (end of ventricular depolarization, the point at which the QRS meets the ST segment) to the end of the T wave (representing the end of ventricular repolarization). (NCI) | EKG Maximum JT Duration | ||
JTcB - Bazett's Correction Formula | C62118 | JTcB - Bazett's Correction Formula | A formula which takes into account the physiologic shortening of the JT interval which occurs as the heart rate increases, permitting comparison of the JT interval across a range of rates. It is mathematically defined as: JTcB = JT/SqRootRR(seconds) and theoretically corrects the JT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | JTcB-Bazett's Correction Formula | ||
JTcF - Fridericia's Correction Formula | C62119 | JTcF - Fridericia's Correction Formula | A formula which takes into account the physiologic shortening of the JT interval which occurs as the heart rate increases, permitting comparison of the JT interval across a range of rates. It is mathematically defined as: JTcF = JT/CubeRootRR(seconds) and theoretically corrects the JT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | JTcF-Fridericia's Correction Formula | ||
JTcLC - Linear Correction Formula | C62120 | JTcLC - Linear Correction Formula | A formula which takes into account the physiologic shortening of the JT interval which occurs as the heart rate increases, permitting comparison of the JT interval across a range of rates. The linear correction formula uses population-based data obtained and validated using a large cohort of subjects. Using this method, the corrected JT interval is independent of the ventricular rate. (NCI) | JTcLC-Linear Correction Formula | ||
Summary (Mean) P Axis | C62121 | Summary (Mean) P Axis | The mean (average) direction (range -180 degrees to 180 degrees) of the electrical potential generated by atrial depolarization in a particular plane (usually the frontal plane). (NCI) | EKG Mean P Axis | ||
Summary (Mean) P Wave Duration | C62123 | Summary (Mean) P Wave Duration | The average (mean) duration (time) from the onset of atrial depolarization to the completion of atrial depolarization (length of the P wave), obtained from a set of measurements of the time from beginning to end of atrial depolarization. (NCI) | EKG Mean P Wave Duration | ||
Summary (Mean) P Wave Height | C62124 | Summary (Mean) P Wave Height | The average (mean) height (usually measured in mm) of the maximum deflection from baseline of the P wave (representing atrial depolarization), obtained from a set of measurements of the P wave, from a single lead or set of leads. Typically this measurement is obtained by analysis of Lead II. (NCI) | EKG Mean P Wave Height | ||
Summary (Min) PR Duration | C62125 | Summary (Min) PR Duration | The minimum duration (time) of the PR interval, obtained from a set of measurements of the PR interval. The PR interval is defined as the time from the beginning of the P wave (representing the onset of atrial depolarization) to the beginning of the R wave (representing the onset of ventricular depolarization). In some cases, a Q wave will precede the R wave, in which case the PR interval is measured from the beginning of the P wave to the beginning of the Q wave. (NCI) | EKG Minimum PR Duration | ||
Summary (Max) PR Duration | C62131 | Summary (Max) PR Duration | The maximum duration (time) of the PR interval, obtained from a set of measurements of the PR interval. The PR interval is defined as the time from the beginning of the P wave (representing the onset of atrial depolarization) to the beginning of the R wave (representing the onset of ventricular depolarization). In some cases, a Q wave will precede the R wave, in which case the PR interval is measured from the beginning of the P wave to the beginning of the Q wave. (NCI) | EKG Maximum PR Duration | ||
Summary (Mean) QRS Axis | C62132 | Summary (Mean) QRS Axis | The mean (average) direction of the electrical potential generated by ventricular depolarization. (NCI) | Mean QRS Axis | ||
Summary (Min) QT Duration | C62133 | Summary (Min) QT Duration | The minimum duration (time) of the QT interval, obtained from a set of measurements of the QT interval. The QT interval is defined as the time from the beginning of the QRS complex to the end of the T wave, representing the time it takes for the ventricles to depolarize and subsequently repolarize. In some cases, the Q wave will be absent, in which case the QT interval is measured from the beginning of the R wave to the end of the T wave. (NCI) | Minimum QT Duration | ||
Summary (Max) QT Duration | C62135 | Summary (Max) QT Duration | The maximum duration (time) of the QT interval, obtained from a set of measurements of the QT interval. The QT interval is defined as the time from the beginning of the QRS complex to the end of the T wave, representing the time it takes for the ventricles to depolarize and subsequently repolarize. In some cases, the Q wave will be absent, in which case the QT interval is measured from the beginning of the R wave to the end of the T wave. (NCI) | EKG Maximum QT Duration | ||
Summary (Mean) R Wave Amplitude | C62136 | Summary (Mean) R Wave Amplitude | The average (mean) amplitude (usually in mm) of the R wave, obtained from a set of measurements of the R wave, in a particular lead or set of leads. (NCI) | EKG Mean R Wave Amplitude | ||
Summary (Mean) S Wave Amplitude | C62137 | Summary (Mean) S Wave Amplitude | The average (mean) amplitude (usually in mm) of the S wave, obtained from a set of measurements of the S wave, in a particular lead or set of leads. (NCI) | EKG Mean S Wave Amplitude | ||
Summary (Mean) R+S Amplitude | C62144 | Summary (Mean) R+S Amplitude | The average (mean) amplitude (usually in mm) of the summation of the R and S waves, obtained from a set of measurements of the R and S waves, in a particular lead or set of leads. (NCI) | EKG Mean R+S Amplitude | ||
Summary (Mean) ST Segment Duration | C62145 | Summary (Mean) ST Segment Duration | The average (mean) duration (time) from the end of ventricular depolarization (end of QRS complex) to the end of ventricular repolarization (end of the T wave). (NCI) | EKG Mean ST Segment Duration | ||
Summary (Mean) T Wave Axis | C62146 | Summary (Mean) T Wave Axis | The mean (average) direction of the electrical potential generated by ventricular repolarization. (NCI) | EKG Mean T Wave Axis | ||
Summary (Mean) T Wave Duration | C62147 | Summary (Mean) T Wave Duration | The average (mean) duration (time) from the onset of ventricular repolarization to the completion of ventricular repolarization (length of the T wave), obtained from a set of measurements of the time from beginning to end of ventricular repolarization. (NCI) | EKG Mean T Wave Duration | ||
Summary (Mean) T Wave Area | C62148 | Summary (Mean) T Wave Area | The average (mean) area under the curve of the deflection from baseline of the T wave (representing ventricular repolarization), obtained from a set of measurements of the T wave, from a single lead or set of leads. (NCI) | EKG Mean T Wave Area | ||
Summary (Mean) T Wave Height | C62149 | Summary (Mean) T Wave Height | The average (mean) height (usually measured in mm) of the maximum deflection from baseline of the T wave (representing ventricular repolarization), obtained from a set of measurements of the T wave, from a single lead or set of leads. (NCI) | EKG Mean T Wave Height | ||
Summary (Mean) Ventricular Rate | C62152 | Summary (Mean) Ventricular Rate | The average (mean) number of cycles of contraction and subsequent relaxation of the ventricles, usually expressed as beats per minute, obtained from a set of measurements of the ventricular rate. (NCI) | Mean Ventricular Heart Rate | ||
Summary (Min) Ventricular Rate | C62153 | Summary (Min) Ventricular Rate | The minimum time between successive cycles of contraction and subsequent relaxation of the ventricles, usually expressed as beats per minute, obtained from a set of measurements of the ventricular rate. (NCI) | Minimum Ventricular Heart Rate | ||
Summary (Max) Ventricular Rate | C62154 | Summary (Max) Ventricular Rate | The maximum time between successive cycles of contraction and subsequent relaxation of the ventricles, usually expressed as beats per minute, obtained from a set of measurements of the ventricular rate. (NCI) | Maximum Ventricular Heart Rate | ||
Summary (Mean) ST Deviation | C62155 | Summary (Mean) ST Deviation | The average (mean) deviation (distance from baseline, positive or negative, usually measured in mm) of the ST segment, obtained from a set of measurements of the deviation of the ST segment. (NCI) | EKG Mean ST Deviation | ||
Summary (Min) ST Deviation | C62156 | Summary (Min) ST Deviation | The minimum deviation (distance from baseline, positive or negative, usually measured in mm) of the ST segment, obtained from a set of measurements of the deviation of the ST segment. (NCI) | EKG Minimum ST Deviation | ||
Summary (Max) ST Deviation | C62157 | Summary (Max) ST Deviation | The maximum deviation (distance from baseline, positive or negative, usually measured in mm) of the ST segment, obtained from a set of measurements of the deviation of the ST segment. (NCI) | EKG Maximum ST Deviation | ||
Summary (Mean) ST Elevation | C62158 | Summary (Mean) ST Elevation | The average (mean) elevation (positive deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the elevation of the ST segment. (NCI) | EKG Mean ST Segment Elevation | ||
Summary (Min) ST Elevation | C62159 | Summary (Min) ST Elevation | The minimum elevation (positive deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the elevation of the ST segment. (NCI) | EKG Minimum ST Segment Elevation | ||
Summary (Max) ST Elevation | C62160 | Summary (Max) ST Elevation | The maximum elevation (positive deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the elevation of the ST segment. (NCI) | EKG Maximum ST Segment Elevation | ||
Summary (Mean) ST Depression | C62161 | Summary (Mean) ST Depression | The average (mean) depression (negative deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the depression of the ST segment. (NCI) | EKG Mean ST Segment Depression | ||
Summary (Min) ST Depression | C62162 | Summary (Min) ST Depression | The minimum depression (negative deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the depression of the ST segment. (NCI) | EKG Minimum ST Segment Depression | ||
Summary (Max) ST Depression | C62163 | Summary (Max) ST Depression | The maximum depression (negative deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the depression of the ST segment. (NCI) | EKG Maximum ST Segment Depression | ||
QTcV - Van de Water's Correction Formula | C90442 | QTcV - Van de Water's Correction Formula | A mathematic formula defined as: QTcV = QT-0.087[(60/Heart Rate)-1](seconds). It permits comparison of the QT interval across a range of rates, while accounting for the progressive shortening of the QT interval which occurs as the heart rate increases. (NCI) | QTcV Van de Water's Correction Formula | ||
Interpretation | C41255 | Interpretation | An act or process of elucidation; explication, or explanation of the meaning of the event or thing via the assignment of objects from the domain to the constants of a formal language, truth-values to the proposition symbols, truth-functions to the connectives, other functions to the function symbols, and extensions to the predicates, if any. The assignments are result of human logic application and are not native to the symbols of the formal language. | Interpretation | ||
QRS Duration Ventricular Paced | C100390 | QRS Duration Ventricular Paced | The average (mean) duration (time) of the QRS interval, obtained from a set of measurements of the QRS interval while the ventricle rhythm is controlled by an electrical impulse from a mechanical cardiac pacemaker. The QRS interval is defined as the time from the beginning of the QRS complex to the end of the QRS complex, representing the time it takes for the ventricles to depolarize. | EKG Mean QRS Duration Ventricular Paced | ||
QT Interval, Corrected | C100391 | QT Interval, Corrected | The time interval between the start of the Q wave and the end of the T wave in the cardiac cycle as corrected with a non-specified correction formula. | Corrected QT Interval | ||
Back to top | ||||||
CL.C71151.EGMETHOD | ECG Test Method (EGMETHOD) | text Extensible: Yes | C71151 | ECG Test Method | Terminology codelist used with ECG Test Methods within CDISC. | CDISC SDTM ECG Test Method Terminology |
12 LEAD UNSPECIFIED | C71101 | 12 Lead Unspecified | An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but the position of the leads is unspecified. (NCI) | 12 Lead Placement Unspecified | ||
12 LEAD STANDARD | C71102 | 12 Lead Standard | An electrocardiogram (ECG) lead placement whereby 12 leads are recorded, with each lead representing an electrical view of the heart. The six leads recorded in the frontal plane are derived from the placement of 3 electrodes (RA or Right Arm, LA, or Left Arm, and LL or Left Leg). These bipolar frontal leads form the basis of Einthoven's triangle, and are represented by leads I, II, and III. Three other derived (or augmented) bipolar frontal vectors are also recorded on a standard 12-lead EKG, aVR, aVF, and aVL. 6 unipolar leads, corresponding to V1 - V6 measure the electrical activity in the horizontal plane. The placement for the V leads is as follows: V1: right 4th intercostal space,V2: left 4th intercostal space, V3: halfway between V2 and V4, V4: left 5th intercostal space, mid-clavicular line, V5: horizontal to V4, anterior axillary line, V6: horizontal to V5, mid-axillary line. (NCI) | 12 Lead Placement Standard | ||
12 LEAD MASON LIKAR | C71103 | 12 Lead Mason Likar | An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but the standard lead positions have been modified for ECG recording during exercise. Exercise stress testing requires moving the limb electrodes to more central positions on the thorax. The electrodes are placed in bony prominences close to the bases of the respective limbs in order to avoid skeletal muscle artifact, provide stability for recording electrodes and to record waveforms similar to the standard limb sites. (NCI) | 12 Lead Placement Mason Likar | ||
12 LEAD MODIFIED MASON LIKAR | C71110 | 12 Lead Modified Mason Likar | An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but the Mason Likar lead positions have been modified so that V1 to V6 on the chest are part of a single electrode pad. In addition, lead CM5 is substituted for lead aVR. (NCI) | 12 Lead Placement Mason Likar Modified | ||
12 LEAD SINGLE PAD | C71112 | 12 Lead Single Pad | An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but the standard lead positions have been modified so that all leads on the chest are part of a single electrode pad. (NCI) | 12 Lead Placement Chest | ||
12 LEAD NON-STANDARD | C71114 | 12 Lead Non-Standard | An electrocardiogram (ECG) lead placement whereby the limb leads are placed on the torso for easier and faster application in emergency situations. (NCI) | 12 Lead Placement Non-Standard | ||
STANDARD LEADS FOR BICYCLE EXERCISE | C71115 | Standard leads for bicycle exercise. Limb leads on the back (shoulder and on the hips) | Limb leads on the back (shoulder and on the hips). (NCI) | Lead Placement Bicycle | ||
12 LEAD CABRERA | C71116 | 12 Lead Cabrera | An electrocardiogram (ECG) lead placement whereby the display of the 12 standard ECG leads is in an orderly sequence in a single horizontal display of: aVL, I, -aVR, II, aVF, III, V1 to V6. In the Cabrera display the limb lead aVR is inverted (-aVR) to obtain the same positive leftward orientation as the other 5 limbs. (NCI) | 12 Lead Placement Cabrera | ||
STANDARD LEADS ONE INTERCOSTAL SPACE HIGHER | C71117 | Standard leads one intercostal space higher | An electrocardiographic lead placement schema in which the V leads are placed one intercostal space cephalad to the position they would have in the standard lead placement schema. (NCI) | Lead Placement Standard Intercostal Space Higher | ||
FRANK LEAD SYSTEM | C71118 | Frank lead system | An electrocardiogram (ECG) lead placement for determining 3 orthogonal components X (right to left direction), Y (foot to head direction) and Z (back to front direction) of the heart. For this method a minimum of 4 electrodes are needed that represent the right arm, left arm, left leg and back. However, usually 7 electrodes are used to avoid dependence on the dipole location and facilitate interpretation. (NCI) | Lead Placement Frank | ||
MCFEE-PARUNGAO LEAD SYSTEM | C71119 | McFee-Parungao lead system | An electrocardiogram (ECG) lead placement for determining 3 orthogonal components X (back to front), Y (right to left) and Z (foot to head) of the heart. This system places the electrodes closer to the heart to achieve better orthogonality and a homogeneous lead field. (NCI) | Lead Placement McFee-Parungao | ||
CUBE LEAD SYSTEM | C71120 | Cube lead system | An electrocardiogram (ECG) lead placement that is a type of uncorrected vectorcardiograph. This lead system is based on a rectangular body axis. It uses an extra number of electrodes to make it three-dimensional. (NCI) | Lead Placement Cube | ||
BIPOLAR UNCORRECTED XYZ LEAD SYSTEM | C71121 | Bipolar uncorrected XYZ lead system | An electrocardiogram (ECG) lead placement whereby the X+ lead is placed at the right mid-axillary line ate the 4th intercostal space, X- at the left mid-axillary line at he 4th intercostal space, Y+ at the proximal left leg, Y- at the superior aspect of the manubrium, Z+ at the direct posterior to Z- and Z- at the 4th intercostal space at the left sternal margin. (NCI) | Lead Placement Bipolar Uncorrected XYZ | ||
PSEUDO-ORTHOGONAL XYZ LEAD SYSTEM | C71122 | Pseudo-orthogonal XYZ lead system | An electrocardiogram (ECG) lead placement that allows monitoring and recording of cardiac electrical activity. A V1-type lead is used whose positive electrode is localized in the 4th intercostal space, 2.5cm from the sternum. Its negative electrode is placed below the left clavicle. An addition of lead V5 and aVF can be made to facilitate interpretation. (NCI) | Lead Placement Pseudo Orthogonal XYZ | ||
12 LEAD EASI DOWER TRANSFORMATION | C71123 | 12 Lead EASI Dower Transformation | An electrocardiogram (ECG) lead placement whereby 4 chest electrodes and 1 reference electrode are used to allow for continuous monitoring at the clinical level. This placement creates a 12 lead ECG that allows the acquisition of simultaneous events in the frontal, horizontal and sagittal heart planes with the linear transformation of vectors. This system provides a three-dimensional portrayal of the heart and uses mathematical and fixed coefficients for each lead. (NCI) | Lead Placement EASI Dower Transformation | ||
12 LEAD 1 LEAD MISSING | C71125 | 12 Lead 1 Lead Missing | An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but one standard lead position is missing therefore requiring a Mortara source consistency filter. (NCI) | 12 Lead Placement 1 Lead Missing | ||
STANDARD 12-LEAD AND CM5-CC5-CH5 | C71126 | Standard 12-lead and CM5-CC5-CH5 | An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but the standard lead positions have been modified so that the bipolar lead groups place the negative of the reference electrode over the manubrium (CM5), the right scapula (CB5), V5R (CC5) or on the forehead (CH5) and the active electrode at V5. (NCI) | 12 Lead Placement Standard And CC5-CM5-CH5 | ||
STANDARD 12-LEAD AND CC5-CM5-ML | C71128 | Standard 12-lead and CC5-CM5-ML | An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but the standard lead positions have been modified so that the negative reference is at CM5 and the active electrode is at the left leg position. (NCI) | 12 Lead Placement Standard And CC5-CM5-ML | ||
STANDARD 12-LEAD EXTENDED RIGHT | C71130 | Standard 12-lead extended to the right by V5R, V4R, V3R | An electrocardiogram (ECG) lead placement whereby the rightward oriented V leads progress from V1R, placed instead of the standard V2, to V6R. The V3 lead in the standard placement is replaced by V4R. (NCI) | 12 Lead Placement Standard Extended Right | ||
STANDARD 12-LEAD EXTENDED LEFT | C71131 | Standard 12-lead extended to the left by V7, V8, V9 | An electrocardiogram (ECG) lead placement whereby the standard lead placement is modified by having leads V7, V8 and V9. (NCI) | 12 Lead Placement Standard Extended Left | ||
VECTORCARDIOGRAPH CORRECTED | C71092 | Vectorcardiograph Corrected | A recording of the electrical activity of the heart displayed in the form of a vector loop, corrected for anatomic inconsistencies. (NCI) | Vectorcardiograph Corrected | ||
VECTORCARDIOGRAPH UNCORRECTED | C71093 | Vectorcardiograph Uncorrected | A recording of the electrical activity of the heart displayed in the form of a vector loop, uncorrected for anatomic inconsistencies. (NCI) | Vectorcardiograph Uncorrected | ||
6 LEAD STANDARD | C90350 | 6 Lead Standard | An electrocardiogram lead placement on the subject using a six electrode lead set with three standard leads and three augmented derived leads to elicit an electrical view of the heart. | 6 Lead Standard | ||
10 LEAD STANDARD | C90349 | 10 Lead Standard | An electrocardiogram lead placement on the subject using a ten electrod |